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1.1 Organocatalysis 
Asymmetric catalysis has seen enormous growth over the last two decades and has found many 
applications in the synthesis of pharmaceuticals, polymers, fine chemicals and pesticides. Indeed, 
an impressive selection of enantioselective catalytic reactions has become readily available which 
covers a wide spectrum of synthetically useful transformations. In general, a catalyst acts by 
lowering the activation energy barrier of a chemical process, which results in the initiation or 
acceleration of a chemical reaction. In asymmetric synthesis chiral catalysts are used to induce 
some level of enantioselectivity. In the beginning metal-based catalysts were typically applied for 
effecting asymmetric transformations.[1] Years later, when the field of organocatalysis emerged, 
small, organic molecules lacking a metal-center were exploited as chiral catalysts.[2] Although the 
concept of organocatalysis has been known for more than 150 years after the discovery of the 
synthesis of oxamide from cyanogen and water by Liebig[3], the major breakthrough did not occur 
until 2000 (see Scheme 1 for seminal examples).[4–6] Since that time, more than 7500 scientific 
reports which describe the use of organocatalysts in 130 different reaction types have been 
published, indicating the importance of this research area. 
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Scheme 1: Seminal examples by Hajos and Parrish,[6] MacMillan[5] and List and Barbas.[4]  
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The reason why many chemists are interested in this research field is because of the advantages 
that organocatalysts offer over classical transition metal types such as better stability against 
oxygen or moisture. Moreover, enantiopure organocatalysts are often cheap and easily available 
in large quantities due to their derivation from chiral naturally occurring precursors. Furthermore, 
small molecules are typically less toxic than metal catalysts and therefore have a positive impact 
on environmental compatibility. Lastly, metallic impurities in pharmaceuticals intermediates can 
be eliminated when organocatalysts are employed.[7,8]  
In organocatalysis, different activation modes by the catalyst are known. One possible mode is 
enamine catalysis. An enolizable carbonyl group is converted to a nucleophilic enamine 
intermediate by condensation with a secondary amine catalyst.[9] This allows the organocatalytic 
enantioselective functionalization of carbonyl compounds at the α-position by reaction with an 
electrophile. In the last decades, many different chiral secondary amines have been developed 
for the reaction of aldehydes and ketones with various electrophiles. For example, the aldol 
reaction is a powerful method for the formation of chiral β-hydroxy-carbonyl compounds starting 
from simple ketones and aldehydes (Scheme 2). In the proline-catalyzed aldol addition, the 
stereoselectivity is controlled via a six-membered transition state in which the aromatic aldehyde 
is preferably attacked by the enamine intermediate from the re-face.[10,11]  
+
R2 H
O
HOMO activation
O H
NR1
R2
O O
R1
 = aryl, alkyl
Me
O
R1
R2
 = aryl, alkyl
N
H
O
OH
L-Pro
Me
O
R1
R2
OH
 
Scheme 2: HOMO activation mode in the aldol reaction. 
A different activation mode is used in iminium catalysis, which is comparable to Lewis acid or 
Brønsted catalysis. Herein, the energy of the lowest unoccupied molecular orbital (LUMO) of the 
electrophile is lowered by iminium ion formation. For example, when an α,β-unsaturated carbonyl 
compound is treated with a secondary amine catalyst the resulting iminium ion intermediate is 
formed. In this intermediate, both C2 and C4 positions are activated, however the higher orbital 
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coefficient in C4 facilitates the occurrence of conjugated additions or pericyclic reactions into this 
iminium intermediate (Scheme 3). Since 2000, several secondary chiral imidazole-based 
organocatalysts by MacMillan or proline-derived catalysts by Jørgensen and Hayashi have been 
developed and established for several reaction types. These include asymmetric epoxidations, 
cyclopropanation and conjugate reductions.[8,12] 
+
R
∗
LUMO activation
N
N
O
R
Nu
NuH
Nu
NuH = malonates,            
nitroalkanes,            
indols
O
HH
O
R
R = aryl, alkyl
N
N
H
O
 
Scheme 3: LUMO activation mode in iminium catalysis. 
In nature, many enzymes use hydrogen-bonding interactions between the amino acids residues 
of the protein and the substrate for biocatalytic transformations.[13] Inspired by these observations, 
small molecules containing hydrogen bond donators such as urea, thiourea and squaramides 
were developed as catalyst for asymmetric organocatalysis. These H-bond donors can interact 
with the substrate via non-covalent dualistic H-bond interactions and increase its reactivity by 
lowering the LUMO energy. Moreover, H-bond interactions may help in the orientation of the 
substrate or can stabilize the transition state to have an impact on the stereoselectivity of the 
reaction. Since this concept has proved to be useful for many organocatalytic transformations,[14] 
bifunctional organocatalysts are often developed. For example, the Michael addition of malonates 
to nitroolefins is catalyzed by a thiourea containing tertiary amine catalyst (Scheme 4).[15] The 
nitroolefin is activated by H-bonding and the tertiary-amine group is acting as a Brønsted base. 
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Scheme 4: Bifunctional catalyst for the Michael addition of malonates to nitroolefins.   
When enantioselectivity is induced by a chiral ion-pair intermediate, this process is defined as 
asymmetric counterion-directed catalysis (ACDC). In this ion pair intermediate, the cationic 
species is non-covalently bound to a chiral anion. In the approach of Jacobsen, thiourea groups 
are used for anion-binding and this concept was successfully applied for a wide variety of chemical 
transformations.[14] In 2006, Benjamin List introduced the usage of chiral phosphoric acids in 
ACDC.[16] One example is the asymmetric transfer hydrogenation of unsaturated aldehydes. In 
this protocol, the aldehyde is transferred into a reactive iminium ion intermediate which can then 
form a chiral ion pair with the (R)-TRIP anion. In this chiral environment, the hydride transfer from 
NADH derivative 1 to unsaturated iminium ion intermediate can occur enantioselectively to form 
the corresponding chiral saturated aldehydes (Scheme 5).[16] 
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Scheme 5: Asymmetric counterion-directed catalysis.   
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1.2 Back Reaction Screening of Quasi-Enantiomeric Products 
The ESI-MS screening, which was originally developed in our laboratory for the evaluation of chiral 
catalysts and catalyst mixtures, is based on monitoring the back reaction of mass-labelled quasi-
enantiomeric products by electrospray ionization mass spectrometry (ESI-MS). In this way, the 
intrinsic enantioselectivity of a chiral catalyst can be determined directly by quantification of 
catalytically relevant intermediates. In contrast to conventional screening methods based on 
product analysis, the results are not affected by catalytically active impurities or a non-catalytic 
background reaction. Moreover, mixtures of chiral catalysts with different molecular masses can 
be screened simultaneously, which is not possible by product analysis. By multi-catalyst screening 
of combinatorial catalyst libraries, catalyst discovery and optimization can be considerably 
accelerated. This screening protocol is fast and operationally simple, as it does not require any 
work-up or purification steps.[17,18] Although application of this method is limited to reactions that 
show some degree of reversibility and proceed via catalytic intermediates that are detectable by 
ESI-MS, screening protocols have been developed for many synthetically useful reactions in 
recent years. Examples are Pd-catalyzed allylic substitutions,[19,20] Cu- and organocatalyzed Diels-
Alder reactions,[21] organocatalytic aldol and Michael reactions[22] (Scheme 6). 
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Scheme 6: Overview of previous screening protocols by the Pfaltz group.  
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The basic concept of our back reaction screening method is displayed in Scheme 7. Starting from 
a 1:1 mixture of mass-labelled quasi-enantiomeric reaction products (R)-P and (S)-P' a back 
reaction leading to components AL1, AL2 and B is induced by addition of a chiral catalyst. Shortly 
after, a sample is taken and analyzed by ESI-MS. From the signals of the mass-labelled fragment-
catalyst adducts AL1-cat and AL2-cat their ratio can be determined, which is equivalent to the ratio 
of the rates of conversion of (R)-P and (S)-P' to AL1 and AL2. Although the concentration of catalytic 
intermediates is generally very low, charged signals can be reliably detected and the relative 
intensities quantified with sufficient accuracy, due to the high sensitivity of ESI-MS. Because the 
steps interconnecting the reactants AL1 and AL2 with products (R)-P and (S)-P' are reversible, 
sampling has to be done in the initial phase of the reaction (typically after ≤1 turnover), in order to 
avoid problems caused by racemization of (R)-P and (S)-P. 
−
B
AL1 B
(R)-P
B AL2
(S)-P'
cat
AL1 B
(R)-P-cat
cat
(S)-P'-cat
catB AL2
AL1cat catAL2
cat
AL1 AL2
+B −B +B
 
Scheme 7: Basic principle of back reaction screening. 
If the step, in which the substrate-catalyst complex A-cat reacts with B, is rate-determining in the 
forward reaction, the enantioselectivity of the overall reaction will be determined by the energy 
difference of the transition states of this step leading to (R)- and (S)-P-cat. In this case, the same 
transition states also control the enantioselectivity of the back reaction, according to the principle 
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of microscopic reversibility. Under this kinetic regime, formation of the catalyst-product adducts 
(R)-P-cat and (S)-P'-cat from (R)-P and (S)-P' in the back reaction is fast and reversible, followed 
by a slow rate-determining bond cleavage leading to AL1-cat and AL2-cat (Curtin-Hammet 
conditions). Consequently, the ratio AL1-cat/AL2-cat determined by back reaction screening should 
be identical to the enantiomeric ratio (R)-P/(S)-P observed for the preparative reaction in the 
forward direction. 
A close match between the enantiomeric ratio produced in the forward reaction and the ratio AL1-
cat/AL2-cat measured for the back reaction also provides strong evidence that the substrate-
catalyst complex A-cat is involved in the rate- and enantioselectivity-determining step. If the 
selectivities of the forward and back reaction differ, this would imply that a different step in the 
catalytic cycle is responsible for the observed enantioselectivity. In this way, mechanistic insights 
into the enantioselective step of a catalytic process can be obtained, which are not directly 
available by other methods.  
As an example, this methodology was used for mechanistic investigations of the conjugate 
addition of aldehydes to nitroolefins.[23] The most widely accepted mechanism for reactions of this 
type involves an enamine as the central intermediate which undergoes α-functionalization with the 
electrophile (Scheme 8, left cycle). As an alternative, a catalytic cycle has been proposed that 
proceeds via an enol that interacts with the catalyst through hydrogen bonding (Scheme 8, right 
cycle). The back reaction screening approach helped to resolve this controversy based on the 
detection of the ratio of quasi-enantiomeric enamine intermediates and by comparison of the 
obtained ratios of the with the enantiomeric ratios obtained in the forward reaction.  
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Scheme 8: Enamine versus enol mechanism.  
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1.3 Thesis Outline 
The aim of the research project described in chapter 2 of this thesis was to develop an efficient 
bifunctional phosphine catalyst that outperforms literature-known catalysts in the Morita-Baylis-
Hillman reaction of methyl acrylate with aldehydes. For the evaluation of the chiral organocatalysts 
a mass spectrometric back reaction screening protocol of quasi-enantiomeric substrates was 
applied. Based on this technique, a multi-catalyst screening was developed which allowed the 
simultaneous determination of the intrinsic enantioselectivities of phosphines in a crude catalyst 
mixture. Finally, based on the data from the back reaction screening in hand together with kinetic 
measurements, the rate- and enantioselectivity-determining step in the catalytic cycle were 
identified.  
 
In chapter 3, the synthesis of new morpholine- and piperidine-based triazolium salts and their use 
as NHC catalysts for the asymmetric cross-benzoin reaction is discussed. In particular, the cross-
benzoin reaction between benzaldehyde and hydrocinnamaldehyde was studied. The aim of this 
project was to design a catalyst that could produce the desired cross-benzoin product with high 
enantiomeric excess and chemoselectivity.  
 
Chapter 4 deals with the development of chiral NHC-phosphine ligands for the asymmetric iridium-
catalyzed hydrogenation of different model substrates. This project was inspired by the previous 
work of Nanchen, a former member of the Pfaltz group. He synthesized a small library of different 
NHC-phosphine ligands for the hydrogenation of various substrates, however only moderate 
results in terms of reactivity and enantioselectivity were achieved. The aim of this project was to 
investigate NHC-based catalysts with conformationally more rigid structures.   
 
  
          
Chapter 2 
 
 
 
 
Asymmetric Morita-Baylis-Hillman Reaction 
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2.1 Introduction 
2.1.1 Multifunctional Chiral Phosphine Organocatalysts 
Despite the discoveries of Price[24], Rauhut and Currier[25] and Morita[26] in the 1960s using 
nucleophilic phosphines as catalysts for Michael-type addition reactions, no further applications 
were published until the mid-1990s, when the great potential of phosphines was rediscovered by 
Lu[27] for [3 + 2] annulation reactions. Since then, the research field of phosphine-catalyzed 
reactions has massively grown and for many asymmetric reactions chiral phosphine-based 
catalysts were developed.[28] Compared to amine-based organocatalysts, the phosphorus center 
has several advantages for asymmetric catalysis. Phosphines are less basic and more 
nucleophilic compared to amines with similar substitution patterns at the heteroatom center.[29,30]  
The most commonly used lead structure of chiral phosphines for asymmetric catalysis is presented 
in Figure 1. Many bifunctional phosphines are derived from commercially available amino acids, 
which facilitate the synthesis of enantiopure organocatalysts. The modular nature of the lead 
structure is ideal for systematic structural optimization. This multifunctional system has a 
nucleophilic phosphorus center which can react with various electrophiles to form nucleophilic 
zwitterionic intermediates. Moreover, a hydrogen-bonding unit (typically a thiourea moiety) is 
attached to the chiral backbone and can interact with the substrate or the zwitterionic intermediate 
via hydrogen-bonding interactions and these non-covalent interactions can increase the reactivity 
or selectivity of the reaction. By changing the residue of the chiral backbone the effect of steric 
hindrance can be investigated.[28] 
chiral 
backbone
bulky
group
H-bond
donor P nucleophilic centre
steric hindrance
H
H
hydrogen-bonding
interactions  
Figure 1: General structure of a multifunctional chiral phosphine catalyst.  
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A potential application area of bifunctional phosphines is the enantioselective annulation reaction 
of allenes and Michael acceptors to form chiral cyclic molecules.[31] Another example is the 
formation of chiral bicyclic imides 5 via [3 + 2] annulation of MBH carbonates 2 and maleimides 3 
catalyzed by functionalized phosphine 4 (Scheme 9).[32] 
R1
OBoc
EWG + NR2
O
O
NR2
O
OR1
H
H
EWG
OTBDMS
NH
PPh2
O
NHBoc
4
2 3 5
R1
 = aryl, alkyl, vinylic        
CO2Et, H
R2
 = aryl, alkyl
cat-4 (5 mol%)
toluene, RT, 24 h
88-98% yield
95-99% ee
 
Scheme 9: [3 + 2] annulation of MBH carbonates. 
In the first step of the proposed mechanism of the [3 + 2] annulation of MBH carbonates (Figure 
2), the MBH adduct undergoes a nucleophilic attack by the phosphine catalyst to form a cationic 
intermediate after decarboxylation. At this point proton α to the phosphorus center is deprotonated 
to form a ylide adduct which attacks the γ-position of maleimide. In the last steps, cyclization of 
the enolate intermediate followed by β-elimination of the catalyst generates the final product.  
O
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O
O H
H
N
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Figure 2: Proposed mechanism of the [3 + 2] annulation of MBH carbonates by Lu.[32]   
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2.1.2 Morita-Baylis-Hillman Reaction 
The Morita-Baylis-Hillman (MBH) reaction is a powerful method for the atom-economical formation 
of a carbon-carbon bond between the α position of a Michael acceptor and an electrophile 
(Scheme 10). In 1968, the first phosphine-catalyzed addition of acrylates to aldehydes yielding 
functionalized allylic alcohols was published by Morita.[26] In their approach, they used 
tricyclohexylphosphine as a catalyst for the formation of MBH-adducts between methyl acrylate or 
acrylonitrile and different aldehydes. Four years later the tertiary amine-catalyzed version of this 
transformation was described in a patent by Baylis and Hillman.[33]  
R1
X
R2
EWG+ EWG
XH
R1
R2
cat. (tert. amine or phosphine)
X
R1 aryl, alkyl, hetereoaryl
O, NCO2R3, NSO2Ar
R2 H, CO2R, alkyl
EWG COR3, CHO, CN, CO2R3, 
PO(OEt)2, SO2Ph
=
=
=
=
 
Scheme 10: General scheme for the Morita-Baylis-Hillman reaction.  
In the last two decades, many variations of the MBH reaction were developed such as the aza-
MBH reaction,[34,35] using imines as electrophiles or the intramolecular MBH reaction.[36,37] This 
reaction has several advantages compared to metal-catalyzed transformations. The use of a 
nucleophilic organocatalyst instead of metal-based catalyst is advantageous for the synthesis of 
pharmaceutical compounds in industry by avoiding metal impurities in products. Furthermore, this 
organocatalytic transformation is performed under mild reaction conditions at room temperature 
and does not need any special experimental setup.[38] Moreover a huge variety of different starting 
materials are commercially available, allowing for broad substrate scope. Finally, resulting MBH 
products are densely functionalized building blocks, which can be easily modified in various ways 
to form complex molecules starting from simple educts.[37,39–41]  
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2.1.3 Asymmetric Morita-Baylis-Hillman Reaction 
In the last two decades many chiral tertiary-amine-based catalysts have been reported for the 
MBH reaction, however their scope is generally limited (representative examples in Scheme 11). 
In 1995, Hirama and coworkers introduced a chiral 2,3-disubstituted 1,4-diazabicyclo[2.2.2]octane 
catalyst 6 for the asymmetric Baylis-Hillman (BH) reaction between aromatic aldehydes and 
methyl vinyl ketones or methyl acrylates to form the resulting MBH adducts with low to moderate 
yield and very low enantioselectivity. Moreover, the desired product was only observed under 
high-pressure.[42] Nine years later, Hayashi developed the chiral diamine catalyst 7 which forms 
the corresponding BH products with moderate to excellent yield and moderate to good 
enantioselectivity.[43] The catalytic potential of β-isocupreidine 8 as BH catalyst was investigated 
by Hatakeyama in 2006. Good yield and excellent selectivities were achieved when 
hexafluoroisopropyl acrylate was used as a Michael acceptor. Unfortunately, for all other acrylates 
only poor yield and enantioselectivities were detected.[44] In 2011, the Tan group from Singapore 
published a new approach using chiral imidazolines as organocatalysts. In this work catalyst 9 
was used for the BH reaction between different aromatic aldehydes and vinyl ketones or acrylates. 
Using a high catalyst loading and after long reaction times, the resulting BH adducts were formed 
with moderate to good yield and moderate selectivity.[45]  
R1
O
H R
1
∗
OH O
R2
R2
O
+
N
N
OBn
OBn
N
O
N
HO
N
N
Ph
N
N
8[44]7[43] 9[45]6[42]
with 15 mol% cat-6, 
THF, 30 °C, 10 kBar, 17-23 h 
R1
 = aryl, R2
 = Me or OMe
yield 14-68%, 
ee 12-15%
with 50 mol% cat-9, 
 
toluene, RT, 3-11 d
R1
 = aryl, R2
 = alkyl or OMe
yield 59-84%, 
ee 47-69%
with 30 mol% cat-7,
EtOH, 0 °C, 2-6 d
R1
 = aryl, R2
 = Me
yield 40-96%, 
ee 44-75%
with 10 mol% cat-8, 
DMF, 
−
55 °C, 1-120 h
R1
 = aryl or alkyl, R2
 = OCH(CF3)2
yield 23-82%, 
ee 1-99%
Ncat
 
Scheme 11: Overview of literature-known chiral tertiary-amine-based organocatalyst. 
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In 2008, Wu and coworkers published the first asymmetric MBH reaction between aryl aldehydes 
and methyl vinyl ketone 10 using a chiral phosphine-based catalyst 11 (Scheme 12). Compared 
to the previous work using amine-based organocatalysts they were able to isolate the resulting 
products with higher yield (up to 91%) and excellent enantioselectivity (up to 94%) after a shorter 
reaction time (three hours).[46]  
Ar
O
H Ar
∗
OH O
O
+
P
NH
S NH
11
yield 15-91%, 
ee 82-94%
10 mol% cat-11
CHCl3, 13 °C, 15min-3h
10
 
Scheme 12: Asymmetric MBH reaction of aryl aldehydes and vinyl ketone catalyzed by bifunctional phosphine 11. 
Inspired by these results many groups began to develop new chiral phosphine-based 
organocatalysts for the more challenging MBH reaction between simple acrylic esters and various 
aldehydes (representative examples in Scheme 13). The valine-derived catalyst 12 was able to 
perform the MBH reaction between acrylates and electron-deficient aromatic aldehydes in good 
yield and selectivities.[47] With the cyclic catalyst 13 slightly better yield and similar 
enantioselectivities were observed for the MBH reaction.[48] In 2011, Lu introduced a threonine-
derived bifunctional organocatalyst 14 for the asymmetric MBH reaction between a wide range of 
aryl aldehydes and methyl acrylate to form the resulting adducts with moderate to high yield and 
good to very good enantioselectivity.[49] Excellent yield and enantioselectivities were observed 
when a ferrocene-derived catalyst 15 was tested for the MBH reaction but unfortunately only when 
hexafluoroisopropyl acrylate was used was Michael acceptor.[50] For all literature-known catalytic 
systems benzaldehyde, halogenated aromatic aldehydes or aliphatic aldehydes are very 
challenging substrates.  
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Ar
O
H Ar
∗
OH O
OR
OR
O
+
12[47]
with 10 mol% cat-12, 
THF, RT, 47-72 h
R = alkyl
yield 11-93%, 
ee 50-83%
N
H
OTBDMS
PPh2
N
H
S
F
PPh2
NH
S NH
C12H25
N
H PPh2
N
H
S
Fe
PPh2
N
H
N
H
S
CF3
CF3
13[48]
with 8 mol% cat-13, 
THF, RT, 7-24 h
R = alkyl
yield 24-96%, 
ee 7-77%
14[49]
with 10-20 mol% cat-14, 
THF, RT, 24-96 h
R = alkyl
yield 25-92%, 
ee 70-90%
15[50]
with 10 mol% cat-15, 5 mol% NaOH
THF, RT, 7-24 h
R = alkyl or CH(CF3)2
yield 41-84%, 
ee 26-99%
Pcat
 
Scheme 13: Overview of literature-known chiral phosphine-based organocatalysts. 
However, although many chiral catalysts have been reported, their scope is generally limited. 
Especially for MBH reactions of simple acrylic esters with aldehydes, more efficient catalysts with 
broader application range are needed. 
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2.1.4 Mechanistic Investigations 
In 1983, the first mechanistic proposal was reported by Hoffmann and coworkers,[51] which a few 
years later was supported by kinetic investigations of Hill and Isaacs (Figure 1).[52] In the catalytic 
cycle, the Michael acceptor undergoes first a reversible nucleophilic attack by the amine-catalyst 
and the resulting zwitterionic intermediate A is formed. Subsequently, the carbon-carbon bond 
between the α position of the DABCO-acrylonitrile adduct and the aldehyde is formed by an aldol 
type reaction. After an intramolecular 1,3 proton shift followed by catalyst elimination, the BH 
product is generated. In this complex catalytic cycle either the aldol step or the proton transfer can 
be the rate-determining step (RDS). As a model system Hill and Isaacs investigated the kinetics 
of the DABCO catalyzed BH reaction between acetaldehyde and acrylonitrile and the results 
showed third-order kinetics (rate = k[MeCHO][acrylonitrile][DABCO]). Based on the comparison 
of the experimental results between acrylonitrile and the α-deuterated acrylonitrile a low kinetic 
isotopic effect (KIE) was detected and therefore they suggested that the aldol step is the RDS.[52] 
Ncat
CN
Ar H Ar
O
Ncat
O
N
N
Ar
Ncat
OH
CN
Ar
OH
CN
N
H(D)
kH/kD
 = 1.03
N
A
RDS
 
Figure 3: Mechanism proposed by Hofmann.[51] 
Because of the complexity of the catalytic cycle various research groups became interested in 
clarifying the BH mechanism. Recent mechanistic studies by Singleton have demonstrated that at 
current computational methods are unable to cope with the complex multi-step catalytic cycle of 
MBH reactions and, therefore, fail to produce reliable results.[53]   
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In 2005, Aggarwal and Lloyd-Jones reevaluated the mechanism using kinetic studies. In their 
approach, competitions experiments between α-deuterated ethyl acrylate and ethyl acrylate were 
performed to determine KIEs. Based on these results they proposed that in the beginning of the 
reaction (< 20% conversion) the proton transfer is the rate-limiting step. Afterwards the aldol step 
becomes rate-limiting because the proton transfer step is accelerated by autocatalysis of the 
product (Figure 4). For the proton shift, a six-membered transition state was predicted in which 
the alkoxide is protonated by the alcohol intermediate and at the same time the α-methine is 
deprotonated. An intramolecular proton transfer is disfavored because the proton shift would 
proceed via a strained four membered transitions state.[54–56] 
OMe
O
OMe
O
Ncat
O
OMeAr H Ar
O
Ncat
O
O
OMeAr
Ncat
OH
O
OMeAr
OH
H O
HO R
Ncat
MeO2C
Ar
Ncat
RDS
(conv. < 20%)
RDS
(conv. > 20%)
transition state of the proton transfer step  
Figure 4: Mechanism proposed by Aggarwal.[54-56]  
A different mechanism was postulated by McQuade and coworkers (Figure 5). Under the 
investigated reaction conditions, they observed that the reaction is second order in aldehyde. Due 
to this result two aldehyde molecules must be present in the rate-limiting step and therefore the 
aldol step cannot be the RDS. In the proposed catalytic cycle, the alkoxide intermediate is reacting 
with a second equivalent of aldehyde to form a hemiacetal intermediate followed by a rate-limiting 
proton shift. This proton transfer is mediated by the alkoxide group via a six-membered transition 
state. In a further experiment using methyl α-2H acrylate, a primary KIE (KIE = 5.2 in DMSO) was 
observed. Thins findings supports their proposed mechanism, with the C-H cleavage being 
involved in the RDS.[57] 
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Figure 5: Mechanism proposed by McQuade.[57] 
For phosphine-based catalysts only one computational study was reported, which predicted the 
proton transfer step to be rate-determining. The total free energy profile of the trimethylphosphine 
catalyzed MBH reaction between ethanal and acrylonitrile in CH2Cl2 was calculated using DFT 
methods (Figure 6).[58] 
Pcat
CN
Ar H
O
Pcat
O
Pcat
OH
CN
OH
CN
NN
PMe3
RDS
 
Figure 6: Proposed catalytic cycle of the MBH calculated by DFT calculations.[58]  
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2.2 Catalyst Synthesis 
Based on the results obtained during my master thesis and various studies reported in the 
literature (see chapter 2.1.2), we became interested in the use of bifunctional phosphines as 
suitable catalysts for the asymmetric MBH reaction. Starting point was the lead structure shown 
in Figure 7 that was patterned after the catalysts developed by Wu[47] and Lu[49]. Due to the modular 
nature it seemed to be ideal to further catalyst optimization studies. The core structure can be 
varied at several positions to investigate the effect for each unit in terms of reactivity or 
enantioselectivity. For example, starting from different enantiopure amino acids, the influence of 
the chiral backbone can be investigated. Moreover, the effect of the phosphine residue can be 
studied by using various phosphine precursors in the catalyst synthesis. Also the hydrogen-
bonding subunit can be diversified to see how different functional groups such as thioureas or 
squaramides influence the stereoselectivity of the MBH reaction. Furthermore, the pKa value of 
the two acidic N-H bonds of the bifunctional subunit can be tuned and therefore the hydrogen-
bond interaction with the substrate can be optimized simply by changing the residue at the N-
position of the H-bonding moiety.  
N
P
N
H H
chiral backbone
phosphine residues
H-bonding
subunit
N-residue
 
Figure 7: Catalyst lead structure for the asymmetric MBH reaction. 
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2.2.1 Synthesis of 1st Generation Catalysts 
The first generation catalyst contains a thiourea group as an additional functional group. All amino 
phosphine precursors were derived from commercially available N-Boc-protected amino alcohols. 
For the investigation of the effect of the chiral backbone, different phenyl thiourea-based catalysts 
19a-f were synthesized according to a slightly modified literature-known three-step procedure 
developed by Wu (Table 1).[60] In the first step, thionyl chloride was allowed to react with the 
hydroxy group of substrates 16a-f to yield the alkyl chloride intermediate, which was subsequently 
cyclized by intramolecular nucleophilic attack of the amine group. The Boc group was deprotected 
to give the corresponding 2-oxazolidinones 17a-f in good to excellent yield. In the next step, the 
cyclic structure of the oxazolidione intermediate 17 was opened under acidic conditions by 
nucleophilic attack of diphenylphosphide. This gave amino phosphines 18a-f in moderate to good 
yield. In the last step of the synthetic sequence, the amine group in 18a-f was coupled with phenyl 
isothiocyanate to afford the N-phenyl thiourea-based organocatalysts 19a-f in high yield.  
Table 1: Synthesis of N-phenyl thiourea-based organocatalysts 19a-f derived from various Boc-amino alcohols 16a-f. 
R
NHBoc
OH
O NH
R
O
SOCl2
THF, 0 °C →
 
RT, 
16 h
HPPh2, TfOH
toluene, 120 °C, 
24 h
R
NH2
P
R
N
HP
PhNCS
CH2Cl2, RT, 
16 h
S
N
H
16a-f 17a-f 18a-f 19a-f  
entry R oxazolidinone 17  (yield in %) 
amino phosphine 18 
(yield in %) 
catalyst 19 
(yield in %) 
1 
 
17a (94) 18a (69) 19a (90) 
2 
 
17b (85) 18b (54) 19b (99) 
3 
 
17c (90) 18c (50) 19c (92) 
4 
 
17d (95) 18d (89) 19d (96) 
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5 
 
17e (85) 18e (62) 19e (71) 
6 
 
17f (90) 18f (70) 19f (70) 
To study the effect of the N-residue of the thiourea-group, different derivatives of the 
phenylalanine-derived amino phosphine 18d were synthesized. For the synthesis of the resulting 
bifunctional phosphines two different strategies were pursued. In strategy A, the amine group in 
18d was coupled with commercially available N-aryl isothiourea precursors. This procedure was 
applied to the synthesis of catalyst 20a-c and the resulting products were isolated in high yield 
(Table 2, entries 1-3). The thiourea products derived from non-commercially available isothiourea 
precursors were synthesized based on a different approach (strategy B). In this synthetic route, 
originally developed by Shi,[61] the amine group in 18d was converted to an isothiocyanate group. 
Subsequent attack of carbon disulfide by the amine group gives a dithiocarbamic acid intermediate 
which undergoes decomposition to the isothiocyanato 21 mediated by N,N'-dicyclohexyl-
carbodiimide (DCC). Afterwards, the intermediate 21 was treated with various amines to provide 
the resulting organocatalysts 20d-g in excellent yield (entries 4-7). This advantageous strategy 
allows the construction of diverse catalysts through the late stage reaction with structurally diverse 
and readily available primary amines. 
Table 2: Synthesis of thiourea-based organocatalysts 20a-g derived from amino phosphine 18d. 
NH2
P
DCC, CS2
THF, 
−
20 °C →
 
RT, 18 h
89%
N
P
S
N
HP
S
N
H
RRNH2
CH2Cl2, RT, 16 h
N
HP
S
N
H
RRNCS
CH2Cl2, RT, 16 h
strategy
 A
strategy
 B
20a-c
20d-g21
18d
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entry strategy R catalyst 20 (yield in %) entry strategy R 
catalyst 20 
(yield in %) 
1 A 
CF3
CF3  
20a (85) 4 B 
 
20d (92) 
2 A 
CF3
 
20b (92) 5 B 
OH  
20e (96) 
3 A 
OMe
 
20c (83) 6 B 
PPh2
 
20f (94) 
    7 B 
 
20g (99) 
 
 
  
ASYMMETRIC MORITA-BAYLIS-HILLMAN REACTION        CHAPTER 2 
26 
2.2.2 Synthesis of 2nd Generation Catalysts 
The key element in the lead structure of the second generation catalyst is a squaramide group. 
Compared to thioureas, squaramides are more acidic and form stronger hydrogen-bonding 
interactions.[62] Moreover, the corresponding catalysts are easily prepared starting from 
inexpensive dimethyl squarate 22. Different monosubstituted squaramide precursors 24a-m were 
formed by treating dimethyl squarate 22 with one equivalent of the corresponding primary amine 
23a-m. After filtration, the resulting precipitated squaramide intermediates 24a-m were isolated in 
good yield, except when electron-deficient aniline 23b was employed (Table 3, entry 1 vs entry 2). 
The low yield obtained for the 3,5-bis(trifluoromethyl)aniline-derived adduct 24b can be explained 
by the lower nucleophilicity of the amine group which disfavors the nucleophilic substitution of the 
methoxy group of the squarate 22 (entry 2). In the case of the cyclohexyl amine, the high 
nucleophilicity tended to promote competitive disubstitution of compound 22 and the desired 
monosubstituted product 24e (entry 5) was isolated in low yield. However, for squaramides-
derived from benzhydrylamine 23f (entry 6), 3,5-bis(trifluoromethyl)benzylamine 23g (entry 7), 
(1S,2R)-2-amino-1,2-diphenylethanol 23h (entry 8) or (R)-(+)-alpha-(1-napthyl)ethylamine 23i 
(entry 9) good yield were achieved. The amine precursors 23j, 23k and 23l were synthesized 
according to a modified procedure by Huang.[63] In this two-step process, a nitro diaryl intermediate 
was formed by a Suzuki coupling of the corresponding aryl bromide with the boronic acid. 
Reduction of the nitro group by Pd/C in hydrazine afforded the crude amine which was used 
without further purification in the next coupling reaction with dimethyl squarate 22 to give the 
desired monosubstituted squaramides in good yield (entries 10-12). Lastly, ammonia was coupled 
with squarate 22 to yield the precursor 24m (entry 13). 
Table 3: Synthesis of squaramide precursors 24a-m.  
MeO OMe
OO
MeO N
H
OO
R
+ H2N
R
MeOH, RT, 48 h
24a-m23a-m22  
entry R squaramide 24 (yield in %) entry R 
squaramide 24 
(yield in %) 
1 
 
24a (94) 8 
OH  
24h (50) 
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2 
CF3
CF3  
24b (17) 9 
 
24i (54) 
3 
OMe
 
24c (79) 10 
 
24j (87) 
4 
HO
OH  
24d (75) 11 OMe
 
24k (73) 
5 
 
24e (12) 12 OH
 
24l (59) 
6 
 
24f (63) 13 H 24m (56) 
7 
CF3
CF3  
24g (48)    
In the last step of the catalyst synthesis, the squaramide precursor 24a was coupled with amino 
phosphines 18a-f by stirring in methanol. Fortunately, the product precipitated from the solution 
and therefore the catalyst was simply purified by filtration. For all amino phosphines with different 
chiral backbones the resulting organocatalysts 25a-f were isolated in good yield (Table 4).  
Table 4: Synthesis of squaramide-based organocatalysts 25a-f derived from amino phosphines 18a-f.  
MeO N
H
OO
+
MeOH, RT, 48 h
R
NH2
P
R
N
HP
O
O
HN
25a-f18a-f 24a  
ASYMMETRIC MORITA-BAYLIS-HILLMAN REACTION        CHAPTER 2 
28 
entry R catalyst 25 (yield in %) entry R 
catalyst 25 
(yield in %) 
1 
 
25a (78) 4 
 
25d (85) 
2 
 
25b (84) 5 
 
25e (79) 
3 
 
25c (70) 6 
 
25f (66) 
For studies regarding the effect of the N-residue of the squaramide unit, different precursors 
24b-m were coupled with the phenylalanine-derived amino phosphine 18d. All bifunctional 
phosphines 26a-m were isolated in moderate to excellent yield (Table 5). For the dimeric catalyst 
26m (entry 13), the synthetic protocol was slightly modified. Dimethyl squarate 22 and two 
equivalents of the amino phosphine 18d were stirred to yield the dimeric phosphine catalyst 26m 
after filtration.  
Table 5: Synthesis of squaramide-based organocatalysts 26a-m derived from amino phosphine 18d. 
MeO N
H
OO
R
+
MeOH, RT, 48 hNH2
P
N
HP
O
O
HN R
26a-m18d 24b-m  
entry R catalyst 26 (yield in %) entry R 
catalyst 26 
(yield in %) 
1 
CF3
CF3  
26a (25) 8 
 
26h (91) 
2 
OMe
 
26b (99) 9 
 
26i (54) 
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3 
HO
OH  
26c (82) 10 OMe
 
26j (33) 
4 
 
26d (73) 11 OH
 
26k (77) 
5 
 
26e (71) 12 H 26l (92) 
6 
CF3
CF3  
26f (98) 13 
PPh2
 
26m (55) 
7 
OH  
26g (82)    
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2.2.3 Synthesis of 3rd Generation Catalysts 
Compared to the previous catalyst generations, the third generation of bifunctional phosphines 
shown in Figure 8 has a more modular core structure. Four different positions can be derivatized, 
which permits the synthesis of a broader variety of catalysts. 
This type of catalyst is derived from β-hydroxy amino acids such as threonine or phenylserine. 
Because of the additional hydroxy group, the synthesis of the resulting amino phosphine 
precursors has to been modified compared to the phosphine adducts from the first or second 
generation catalyst. In Figure 8 the retrosynthetic analysis of the lead structure is presented. This 
proposed seven-step synthesis starts from different inexpensive commercially available amino 
acids, which enables the formation of catalysts with various R2 substituents. The key-intermediate 
is the mesyl N-Boc 2,2-dimethyl oxazolidine, since this adduct is the precursor to the amino 
phosphine synthesis. The use of different diaryl or dialkyl phosphides for the nucleophilic 
substitution of the mesyl intermediate gave catalysts modified at the R4 positions. Interestingly, 
until today the effect of the residues on the phosphorus atom has not yet been investigated in 
terms of selectivity or reactivity for the MBH reaction. Further structural diversity of the catalyst 
can be achieved by modification of the secondary hydroxyl group with a wide variety of different 
silyl groups or by using different isothiourea precursors for the coupling with the amino group.   
N
H
N
H
S
R1
P
R4R4
R2 O
R3
N
H
N
H
S
R1
P
R4R4
R2 OH
H2N
P
R4R4
R2 OH
O NBoc
R2 OMs
O NBoc
R2 OH
O NBoc
R2 OMe
O
HO
R2 NH2
OH HO
R2 NHBoc
OMe
O O
3rd
 
generation
 
Figure 8: Retrosynthetic analysis of 3rd generation catalysts. 
The threonine-derived mesyl oxazolidine was synthesized according to a slightly modified four-
step procedure by Lu (Scheme 14).[49] N-Boc protected threonine methyl ester 28 was isolated in 
quantitative yield after treatment of the corresponding hydrochloride salt 27 with di-tert-butyl 
dicarbonate ((Boc)2O) and triethylamine. Next, the Boc adduct 28 was converted to the 
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corresponding 2,2-dimethyl oxazolidine intermediate 29 by a camphorsulfonic acid (CSA) 
catalyzed cyclization reaction with 2,2-dimethoxy propane (DMP). After reduction of the ester 
group with lithium aluminum hydride the resulting alcohol 30 was mesylated to give mesyl 
oxazolidine 31 in 94% yield.  
O
NH3Cl
OMe
O
NHBoc
OMe
O NBoc
O
OMe
CH2Cl2, 0 °C →
 
RT, 4 h
94%
DMP, CSA (cat.)
O NBoc
OH
O NBoc
OMs
LiAlH4
THF, 0 °C →
 
RT, 2 h
74%
OHOH
CH2Cl2, 0 °C →
 
RT, 16 h
94%
MsCl, NEt3
MeCN, RT, 6 h
quant.
(Boc)2O, NEt3
292827
3031  
Scheme 14: Synthesis of mesyl oxazolidine 31 derived from L-threonine methyl ester hydrochloride 27.  
For the preparation of the phenylserine-derived mesyl oxazolidine 34 a different synthetic 
approach was used (Scheme 15). In the first step, (1S,2S)-(+)-2-amino-1-phenyl-1,3-propanediol 
32 and acetone were refluxed in a flask equipped with a Dean-Stark apparatus to form the 
resulting 2,2-dimethyl oxazolidine intermediate. Directly after the work-up, the free amine was Boc 
protected to form compound 33 in moderate yield over two steps. In the last step, the O-mesyl 
intermediate 34 was isolated in very good yield after treating alcohol adduct 33 with mesyl chloride 
and triethylamine.  
OH
NH2
OH
acetone
toluene, 130 °C, 18 h
1)
(Boc)2O, NEt3
THF, RT, 16 h
56%
2) NBocO
OH
CH2Cl2, 0 
°C →
 
RT, 6 h
92%
MsCl, NEt3
NBocO
OMs
3432 33  
Scheme 15: Synthesis of mesyl oxazolidine 34 derived from amino alcohol 32.  
With the two mesyl intermediates 31 and 34 in hand, the nucleophilic substitution by potassium 
diphenylphosphide and the final steps for the catalyst synthesis were investigated. The threonine-
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derived oxazolidine 31 was used for initial studies. The corresponding amino phosphine 35 was 
obtained in a two-step one-pot process. The mesylate group was displaced by diphenylphosphide 
in a nucleophilic substitution reaction. Afterwards, the in situ formed oxazolidine phosphine 
intermediate was hydrolyzed and Boc deprotected using concentrated hydrochloric acid to form 
the resulting amino phosphine 35 in 70% yield (Scheme 16). Then, the free amine was coupled 
with N-phenyl isothiocyanate to form thiourea intermediate 36. After silylation of the secondary 
alcohol, the resulting bifunctional catalyst 37 was formed in good yield over two steps.  
NBocO
OMs KPPh2
THF, 0 °C → RT, 14 h
then: aq. 37% HCl
0 °C → RT, 4 h
70%
NH2P
OH
HNP
OH
S
HN
HNP
OTBDMS
S
HN
DIPEA, TBDMSOTf
CH2Cl2, 0 °C → RT, 4 h 
79%
PhNCS
CH2Cl2, RT, 16 h
89%
35
3637
31
 
Scheme 16: Synthesis of threonine-derived catalyst 37.  
For the synthesis of the phenylserine-derived amino phosphine 38, the same synthetic procedure 
as for phosphine 35 was applied. In the case of oxazolidine 34, the resulting phosphine product 
38 was isolated even in higher yield compared to the threonine-derived amino phosphine 35 
(Scheme 17).  
NBocO
OMs
KPPh2
THF, 0 °C →
 
RT, 14 h
then: aq. 37% HCl
0 °C →
 
RT, 4 h
86%
NH2P
OH
3834  
Scheme 17: Synthesis of amino phosphine 38.  
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Another aim of the project was the synthesis of amino phosphines with various substituents at the 
phosphorus atom to investigate the effect of the phosphine residues on the MBH reaction. For this 
synthetic goal a new approach had to be developed using a nucleophilic phosphine source for the 
substitution of the mesyl group. As a test system, the nucleophilic substitution of oxazolidine 34 
with chlorodi(ortho-tolyl)phosphine 39a as a pronucleophile was investigated. The electrophilic 
diarylchlorophosphine can be reduced to the resulting nucleophilic diarylphosphide by stirring the 
precursor with a strong reductant such as lithium, sodium or potassium, according to literature 
known-procedures.[64–66] This synthetic strategy enabled the synthesis of a wide variety of 
phosphines because the required diarylchlorophosphines were either commercially available or 
could be easily prepared from the corresponding aromatic bromides.  
Three different alkali di(ortho-tolyl)phosphides were freshly prepared by refluxing an excess of the 
corresponding alkali metal and 39a in THF (Scheme 18). The formation of the resulting metal 
phosphide intermediate was observed by 31P-NMR analysis of the crude reaction mixture and for 
all three metals the corresponding adduct was observed. Using lithium phosphide, the formation 
of the amino phosphine 40a was not detected by either 31P-NMR or ESI-MS analysis of the crude 
reaction mixture. When the metal was changed to sodium, conversion to the desired product 40a 
was observed, and it was then isolated in low yield. The yield drastically improved using the 
corresponding potassium di(ortho-tolyl)phosphide.  
NBocO
OMs
THF, 0 °C → RT, 16 h
then: aq. 37% HCl, 0 °C → RT, 4 h
NH2P
OH
P
Cl
+ metal
THF, reflux, 6 h
metal:
lithium
sodium
potassium
yield:
0%
17%
68%
40a
39a
34
 
Scheme 18: Screening of different alkali metals for the nucleophilic substitution of 34 by alkali phosphide.  
Various diarylchlorophosphines were synthesized by a slightly modified one-pot procedure of 
Wass.[67] N,N-Diethylphosphoramidous dichloride was treated with the Grignard reagent prepared 
from the corresponding aryl bromides 41a-d to form the resulting diaryl diethylphosphoramidous 
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intermediate. This intermediate was converted into the corresponding diarylchlorophosphines 
displacing the diethylamine group by a chloride with hydrogen chloride. After purification by 
Kugelrohr distillation, all chlorophosphines 39a-d were obtained in good to excellent yield (Table 
6).  
Table 6: Synthesis of diarylchlorophosphines 39a-d.  
R
Br
R
P
R
Cl
Mg
THF, RT →
 
65 °C, 4 h
Cl2PNEt2
THF, 0 °C →
 
RT, 4 h
HCl in dioxane
1)
2)
3)
39a-d41a-d  
entry R chlorophosphine 39 (yield in %) entry R 
chlorophosphine 39 
 (yield in %) 
1 
 
39a (84) 3 
F
 
39c (90) 
2 
 
39b (52) 4 
tBu
tBu  
39d (95) 
With the optimized conditions in hand, various diarylchlorophosphines 39a-d were utilized in the 
synthesis of the resulting amino phosphines 40a-k (Table 7). For all chlorophosphines with ortho 
alkyl substituted phenyl systems (entries 1-2), naphthyl groups (entry 3) or 3,5-dialkyl substituted 
phenyl systems (entries 4-5), the phosphide formation with potassium was detected by 31P-NMR 
analysis of the crude reaction mixture. Then, these in situ generated phosphides were directly 
used for the nucleophilic displacement of the mesylate group in intermediate 34. The resulting 
amino phosphines 40a-e were isolated in low to good yield after hydrolysis of the oxazolidine and 
cleavage of the Boc group (entries 1-5). In the case of bis(2,4,6-trimethylphenyl)phosphorus 
chloride (entry 6) the nucleophilic phosphide intermediate was formed by potassium reduction but 
no conversion to the amino phosphine 40f was detected by ESI-MS or 31P-NMR analysis of the 
crude reaction mixture before hydrochloric acid addition. It is possible that the nucleophilic 
substitution of the mesylate group by the potassium dimesitylphosphide is disfavored due to the 
steric bulkiness of the phosphorus residues. With chlorophosphines that contain methoxy, fluorine 
or trifluoromethyl groups on the phenyl ring (entries 7-10) or 2-furyl groups (entry 11), the formation 
of the resulting amino phosphines 40j-k was not detected. In these examples, the problematic 
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step was the formation of the potassium diarylphosphide adduct as crude 31P-NMR analysis of the 
reduction step showed decomposition under the reaction conditions (entries 7-11). 
Table 7: Synthesis of amino phosphines 40a-k. 
NBocO
OMs
THF, 0 °C →
 
RT, 16 h
then: aq. 37% HCl, 0 °C →
 
RT, 4 h NH2PR
OH
P
R
Cl
R +
THF, reflux, 6 h
K
39a-k
40a-k34
R
 
entry R amino phosphine 40 (yield in %) entry R 
amino phosphine 40 
(yield in %) 
1 
 
40a (68) 7 
OMe  
40g (0) 
2 
 
40b (38) 8 
OMe
 
40h (0) 
3 
 
40c (79) 9 
F
 
40i (0) 
4 
 
40d (32) 10 
CF3
CF3  
40j (0) 
5 
 
40e (29) 11 
O
 
40k (0) 
6 
 
40f (0)    
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The nucleophilic substitution with potassium dimesitylphosphide was further studied (Scheme 19) 
using different leaving groups or higher reaction temperatures. With mesyl oxazolidine 34 and an 
increased reaction temperature of 70 °C, formation of the resulting phosphine 40f was not 
detected. Thus, oxazolidines with different leaving groups were synthesized by refluxing 
oxazolidine 34 with the corresponding lithium halide salt to form the resulting bromo or iodo 
oxazolidine intermediate 41 or 42. Unfortunately, for both adducts conversion to the desired 
product 40f was not observed using standard conditions or higher reaction temperatures. These 
results indicate that because of the steric hindrance of the phosphine and due to the steric 
environment of the oxazolidine a nucleophilic substitution with KP(Mes)2 is impossible.  
NBocO
X
THF, 0 °C → 70 °C, 16 h
then: aq. 37% HCl, 0 °C → RT, 4 h
NH2P
OH
X = OMs
X = Br
X = I
KP(Mes)2
40f34
41
42  
Scheme 19: Investigations towards the synthesis of amino phosphine 40f.  
Because of the limited reproducibility of the amino phosphine synthesis (yield between 15 and 
79% for bisnapthylchlorophosphine-derived amino phosphine 40c), the high costs for the 
corresponding chlorophosphines and the potential hazards associated with molten potassium on 
a large scale synthesis, a new synthetic strategy was investigated. Instead of alkali metal mediated 
reduction of the chlorophosphine the nucleophilic potassium phosphide intermediate can also be 
formed by deprotonation of the corresponding phosphine adduct with potassium hydride. The 
advantages of this approach are that many phosphines are commercially available and the prices 
per gram are lower compared to the corresponding chlorophosphines. Moreover, the phosphide 
is formed under milder reaction conditions which could extend the scope to methoxy- or fluorine 
substituted aryl phosphines.  
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For the synthesis of phosphines that were not commercially available, a two-step synthetic 
procedure developed by Busacca[68] was applied (Table 8). In the first step secondary phosphine 
oxides 43a-f were synthesized by Grignard addition to diethyl phosphite. Almost all oxides 43a-f 
were isolated in moderate to excellent yield after trituration of the crude reaction mixture in 
hexane/ether (entries 1-5). Only in the case of 3,5-bis(trifluoromethyl)phenylmagnesium bromide 
was product formation not detected by 31P-NMR analysis of the crude mixture (entry 6). In the next 
step, the phosphine oxides were reduced with DIBAL to form the resulting phosphines 44a-f with 
yields between 65 and 93% (entries 1-5). All phosphines were directly used in the next step after 
filtration of the crude reaction mixture over a pad of silica gel under inert gas.   
Table 8: Synthesis of diarylphosphines 44a-f.  
Mg
THF, 70 °C, 4 h
1)
HOP(OEt)2, NaH
THF, 0 °C →
 
RT, 16 h
2)R
Br
R
P
H R
O
R
H
P
R
DIBAL in toluene
THF, 0 °C →
 
RT, 16 h
43a-f 44a-f41a-f  
entry R 
phosphine 
oxide 43  
(yield in %) 
phosphine 
44 
(yield in %) 
entry R 
phosphine 
oxide 43  
(yield in %) 
phosphine 
44 
(yield in %) 
1 
 
43a (87) 44a (93) 4 
 
43d (43) 44d (80) 
2 
 
43b (73) 44b (76) 5 
F
 
43e (56) 44e (65) 
3 
 
43c (96) 44c (87) 6 
CF3
CF3  
43f (0) 44f (-) 
With phosphines 44a-e in hand, the new synthetic approach that employed secondary phosphines 
for the synthesis of amino phosphines was investigated (Table 9). In all cases the resulting 
potassium diarylphosphide was formed by deprotonation of the corresponding phosphine with 
potassium hydride and the resulting red reaction solution was directly treated with oxazolidine 34 
followed by a hydrochloric acid induced oxazolidine opening and Boc deprotection. To our 
satisfaction, phosphines 44a-d/f (entries 1-4 and 6) gave the corresponding amino phosphines 
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40a-d/f in much higher yield compared to the previous methodology (Table 7, entry 3). Moreover, 
the yields were more reproducible between different batches and for amino phosphine 40c the 
scale could be increased from 0.4 mmol to 3.0 mmol without any problems. Unfortunately, for 
bis(2,4,6-trimethylphenyl)phosphine and for bis(4-flurophenyl)phosphine (Table 9, entries 5 and 
7) no product formation was detected.  
Table 9: Synthesis of amino phosphines 40a-g starting from phosphines 44a-g.  
KH
THF, 
 
0 °C →
 
RT, 5 h
then: aq. 37% HCl, 0 °C → RT, 16 hR
H
P
RNBocO
OMs
NH2P
R
R
OH+
40a-g44a-g34  
entry R amino phosphine 40 (yield in %) entry R 
amino phosphine 40 
(yield in %) 
1 
 
40a (78) 5 
F
 
40e (0) 
2 
 
40b (72) 6 
 
40f (79) 
3 
 
40c (89) 7 
 
40g (0) 
4 
 
40d (64)    
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With all of the desired amino phosphines in hand, the last two-steps of the catalyst synthesis were 
investigated using the same synthetic procedure as described for catalyst 37 in Scheme 16. In the 
first step the amino group in 38 was coupled with different commercially available isothiocyanate 
precursors to yield the thiourea intermediate 45a-f (Table 10, entries 1-5). Only in the case of 
cyclohexyl isothiocyanate a low yield was observed due to its lower reactivity (entry 6). Next, the 
secondary benzylic alcohol was silylated with tert-butyldimethylsilyl trifluoro-methanesulfonate 
(TBDMSOTf) and DIPEA as a base. All bifunctional catalysts 46a-f were isolated with yield 
between 65-90% for the silylation step (entries 1-6). 
Table 10: Synthesis of bifunctional organocatalyst 46a-f with differnet thiourea units. 
NH2P
OH
HNP
OH
S
HN R
HNP
OTBDMS
S
HN R
RNCS
CH2Cl2, RT, 16 h
TBDMSOTf, DIPEA
CH2Cl2, 0 
°C →
 
RT, 4 h
46a-f45a-f38  
entry R thiourea 45  (yield in %) 
catalyst 46 
(yield in %) entry R 
thiourea 45  
(yield in %) 
catalyst 46 
(yield in %) 
1 
 
45a (84) 46a (90) 4 
CF3
CF3  
45d (87) 46d (80) 
2 
F
 
45b (91) 46b (77) 5 
OMe
 
45e (91) 46e (65) 
3 
F
F
F
F
F
 
45c (58) 46c (72) 6 
 
45f (39) 46f (68) 
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In Table 11 the catalyst synthesis starting from differently substituted phosphines 40a-d/f is 
presented. All bifunctional phosphines 47a-g were synthesized using the standard two-step 
procedure and the desired organocatalysts 48a-g were isolated in moderate to good overall yield.  
Table 11: Synthesis of bifuntional organocatalysts 48a-g with different phosphine residues.  
ArNCS
CH2Cl2, RT, 16 h
TBDMSOTf, DIPEA
CH2Cl2, 0 °C → RT, 4 h
NH2P
R
R
OH
HNP
R
R
OH
HN
S
Ar
HNP
R
R
OTBDMS
HN
S
Ar
48a-h47a-h40a-d/f  
entry R Ar thiourea 47 (yield in %) 
catalyst 48 
(yield in %) 
1 
  
47a (55) 48a (53) 
2 
 
F
 
47b (73) 48b (72) 
3 
  
47c (75) 48c (91) 
4 
  
47d (83) 48d (69) 
5 
 
F
 
47e (98) 48e (76) 
6 
  
47f (95) 48f (88) 
7 
 
 
47g (36) 48g (71) 
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Next organocatalysts derived from phosphine thiourea precursor 45a with various silyl groups 
were synthesized using two different strategies (Scheme 20). For trimethyl (TMS)- and triisopropyl 
(TIPS) silyl protected alcohols, the method using the corresponding triflates was applied and the 
catalysts 49a and 49b were isolated in high yield. The dimethylthexylsilyl (TDS) catalyst 49c was 
formed using a different strategy. In this approach, the benzylic alcohol was deprotonated by 
sodium hydride followed by addition of chlorodimethylthexylsilane to form the desired catalyst 49c 
in 54% yield after purification by column chromatography. 
DIPEA, ROTf
CH2Cl2, 0 
°C →
 
RT, 4 h
HNP
OH
HN
S
HNP
OR
HN
S
or
RCl, NaH
THF, 0 °C →
 
RT, 16h
R = TMS (81%)
R = TIPS (90%)
R = TDS (54%)
45a 49a
49b
49c  
Scheme 20: Synthesis of bifunctional organocatalysts 49a-c with different siyl groups.  
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For the synthesis of dicyclohexyl phosphine-based organocatalyst 52 a different synthetic 
procedure was developed due to the sensitivity towards oxidation of the alkylphosphine moiety. 
In the first step, the borane-protected phosphine oxazolidine intermediate 50 was formed by 
nucleophilic substitution of the corresponding mesyl intermediate 34. Next, the oxazolidine ring 
was opened and the Boc group was cleaved using HCl, followed by phenyl isothiocyanate coupling 
in a biphasic solvent system with potassium carbonate. This sequence gave thiourea intermediate 
51 in a 3:1 ratio of deprotected to protected phosphine. The mixture of phosphine 51 was stirred 
overnight in diethylamine at 50 °C to deprotect the phosphine, and after silylation the resulting 
bifunctional catalyst 52 was isolated in moderate overall yield (Scheme 21).  
O NBoc
OMs
O NBoc
P
H3B
P HN
S
HN
OH
H3B
P HN
S
HN
OTBS
aq. 37% HCl
THF, RT, 4 h
1)
PhNCS, K2CO3
CH2Cl2/H2O, RT, 
12 h
87%
2)THF, 0 °C →
 
RT,
6 h
72%
BH3•HPCy2, KH
515034
52
1) HNEt2
50 °C, 16 h
2) TBSOTf, DIPEA
CH2Cl2, 
0 °C →
 
RT, 12 h
93%
 
Scheme 21: Synthesis of dicyclohexyl phosphine based organocatalyst 52.  
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To investigate the effect of the chiral backbone on the enantioselectivity of the MBH reaction, 
catalyst 56, which contained a cyclohexyl residue in the chiral backbone was synthesized. Mesyl 
intermediate 53 was synthesized by rhodium on activated alumina catalyzed reduction of the 
phenyl group in 34 under hydrogen atmosphere. Next, the amino phosphine 54 was formed using 
the standard synthetic procedure. After phenylthiourea coupling and silylation the desired 
organocatalyst 56 was isolated in a low overall yield (Scheme 22). The problematic step was the 
introduction of the TBDMS group due to the steric hindrance of the secondary alcohol.  
O NBoc
OMs Rh on alox, H2
 
(5 bar)
MeOH, RT, 16 h
quant.
O NBoc
OMs
KPPh2
THF, 0 °C → RT, 14 h
then: aq. 37% HCl
0 °C → RT, 4 h
76%
PhNCS
CH2Cl2, RT, 16 h
87%
NH2P
OH
HNP
OH
S
HN
HNP
OTBDMS
S
HN
DIPEA, TBDMSOTf
CH2Cl2, 0 
°C →
 
RT, 4 h
10%
545334
5556  
Scheme 22: Synthesis of bifunctional organocatalyst 56.  
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2.2.4 Synthesis of 4th Generation Catalysts 
In the 4th catalyst generation, the match-mismatch effect for each diastereomer of the catalyst in 
the asymmetric MBH reaction was investigated by inverting the stereogenic center at the 
secondary alcohol position to get the like-diastereomer of the bifunctional phosphine (Figure 9). 
N
H
N
H
S
R1
P
R4R4
R2 O
R3
N
H
N
H
S
R1
P
R4R4
R2 O
R3
unlike-diastereomer like-diastereomer  
Figure 9: Lead structure of the fourth catalyst generation. 
First, the threonine-based amino phosphine 62 was synthesized through a five-step process which 
began with commercially available (2S,3R)-threonine hydrochloride methyl ester 57. In the initial 
step, Boc-protection of threonine methyl ester 57 followed by camphoricsulfonic acid (CSA) 
catalyzed oxazolidine formation with 2,2-dimethoxypropane (DMP) gave the resulting 2,2-dimehtyl 
oxazolidine intermediate 59 in good yield. Next, the ester was reduced using lithium aluminium 
hydride and the resulting alcohol 60 was mesylated to obtain O-mesyl adduct 61. Installation of 
the phosphine followed by oxazolidine hydrolysis gave the resulting amino phosphine 62 in 
moderate yield (Scheme 23).  
O
NH3Cl
OMe
O
NHBoc
OMe
O NBoc
O
OMe
CH2Cl2, 0 °C →
 
RT, 4 h
84%
DMP, CSA (cat.)
O NBoc
OH
O NBoc
OMs
LiAlH4
THF, 0 °C →
 
RT, 2 h
87%
OHOH
CH2Cl2, 0 °C →
 
RT, 16 h
91%
MsCl, NEt3
THF, RT, 6 h
98%
(Boc)2O, NEt3
KPPh2
THF, 0 °C → RT, 14 h
then: aq. 37% HCl
0 °C → RT, 16 h
51%
NH2P
OH
59
62
5857
6061  
Scheme 23: Synthesis of (S,S)-amino phosphine 62.  
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Afterwards, (S,S)-catalyst 64 was synthesized through a two-step sequence in which the amino 
group was first coupled with phenyl isothiocyanate and then silylated to yield the bifunctional 
phosphine 64 in moderate overall yield (Scheme 24).  
CH2Cl2, 0 °C → RT, 
4 h
77%
DIPEA, TBDMSOTfPhNCS
CH2Cl2, RT,
16 h
79%
NH2P
OH
HNP
OH
S
HN
HNP
OTBDMS
S
HN
63 6462  
Scheme 24: Synthesis of (S,S)-catalyst 64.  
Unfortunately, for phenylserine-derived phosphines the (R,S)-diastereomer 65 of the precursor is 
not commercially available. In Figure 10 two possible retrosynthetic analyses are presented. In 
strategy A, the synthesis starts from the commercially available ethyl cinnamate 68. Enantio-
selective Sharpless dihydroxylation with AD-mix-β should form the chiral diol intermediate 67. 
Then, the hydroxy group next to the ethyl ester moiety has to been converted into a leaving group 
which afterwards can be displaced by an azide under inversion of configuration to form azide 
adduct 66. Reduction of the azide, then leads to amino alcohol 65. A shorter synthetic approach 
is based on strategy B. In this synthetic sequence the starting point is the commercially available 
(S,S)-diastereomer of amino alcohol 32. In the first steps, the primary alcohol and the amino group 
have to be protected to form intermediate 69. Inversion of the benzylic hydroxyl group through a 
Mitsunobu reaction should give the desired (R,S)-product 65.  
OH
NH2
OH
OEt
O
OEt
OOH
OH
OEt
OOH
N3
OH
NH2
OH
OH
NHBoc
OTBS
65
69
66 67
32
68strategy
 A
strategy
 B
 
Figure 10: Retrosynthetic analysis of (1R,2S)-2-amino-1-phenylpropane-1,3-diol 65. 
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Following strategy A, the unlike-diol 67 was synthesized from ethyl cinnamate 68 according to a 
procedure of Hormi (Scheme 25).[69] After Sharpless asymmetric dihydroxylation using AD-mix-
beta in combination with methansulfonamide as general acid catalyst, the product 67 was isolated 
in excellent yield and high enantioselectivity (>99% ee) as only one diastereomer (confirmed by 
1H-NMR analysis using a chiral shift reagent). Next, the hydroxy group adjacent to the ester 
functionality was selectively converted into a 4-nitrobenzenesulfonyl group by treatment of the diol 
67 with nosyl chloride and triethylamine.[70] This gave compound 70 in 65% yield. Then, the O-
nosyl group was substituted by an azide to form the resulting intermediate 66 with inversion of 
configuration. Reduction of the azide and ester group by lithium aluminum hydride gave the 
desired (1R,2S)-amino alcohol 65 in quantitative yield. The Boc 2,2-dimethyl oxazolidine 
intermediate 71 was synthesized from the crude alcohol 65 through a condensation reaction with 
acetone under reflux conditions. After subsequent Boc-protection of the oxazolidine adduct, 
intermediate 71 was isolated in very low yield compared to the synthesis starting from the (1S,2S)-
amino alcohol 32. Moreover, also for the mesylation step a lower yield was obtained in the 
synthesis of adduct 72 when compared to the preparation of diastereomer 34 (see Scheme 15).  
OEt
O
OEt
OOH
OH
OH
OH
NH2
OEt
OOH
ONs
OEt
OOH
N3O NBoc
OH
O NBoc
OMs
AD-mix-β, CH3SO2NH2
t-BuOH/H2O, RT, 16 h
93%
NsCl, NEt3
CH2Cl2, 0 °C →
 
RT, 16 h
65%
LiAlH4
THF, 0 °C →
 
70 °C, 5 h
98%
NaN3
DMF, 50 °C, 16 h
74%
acetone
toluene, 125 °C, 16 h
1)
Boc2O
THF, RT, 16 h
16%
2)
MsCl, NEt3
CH2Cl2, 0 °C →
 
RT, 16 h
55%
68 67 70
71 65 66
72  
Scheme 25: Synthesis (4S,5R)-mesyl oxazolidine 72.  
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Due to the low yield in the last two steps of strategy A (Scheme 25), strategy B was investigated 
for the synthesis of diastereomer 72. In this process, the primary alcohol and the amino group of 
(1S,2S)-2-amino-1-phenylpropane-1,3-diol were protected using a stepwise one-pot procedure to 
form intermediate 69 in very good yield. Afterwards, the secondary alcohol was inverted in a 
Mitsunobu reaction with diisopropyl azodicarboxylate (DIAD), triphenylphosphine and 4-
nitrobenzoic acid as a pronucleophile. This gave the corresponding ester adduct which was then 
hydrolyzed to the alcohol product 73 with potassium carbonate in methanol. Next, oxazolidine 71 
was synthesized according to a one-pot procedure of Yokomatsu and Shimeno.[71] In this 
sequence, compound 73 was cyclized to the resulting TBDMS-protected oxazolidine in a p-
toluenesulfonic acid (p-TsOH) catalyzed condensation with 2,2-dimethoxypropane (DMP) 
followed by desilylation with TBAF yielded the alcohol 71 in 50% yield over two steps. After 
mesylation, the intermediate 72 was subjected to the standard protocol for the synthesis of amino 
phosphines using potassium diphenylphosphide followed by hydrolysis with concentrated 
hydrochloride acid. The resulting amino phosphine product 74 was isolated in 45% yield (Scheme 
26).  
MsCl, NEt3
CH2Cl2, 0 °C →
 
RT, 16 h
91%
DIAD, PPh3, 
4-nitrobenzoic acid
THF, 0 °C →
 
RT, 12 h
1)
K2CO3
MeOH, RT, 80 min
93%
2)OH
OH
NH2
O NBoc
OH
O NBoc
OMs
OTBDMS
OH
NHBoc
OTBDMS
OH
NHBoc
1) DMP, 
p-TsOH (cat.)
benzene, 
100 °C, 12 h
2) TBAF
THF, 70 °C, 5 h
50%
(Boc)2O
MeOH, 0 °C, 1 h
1)
TBDMSCl, 
imidazole
DMF, RT, 16 h
88%
2)
KPPh2
THF, 0 °C → RT, 5 h
then: aq. 37% HCl
0 °C → RT, 16 h
45%
NH2P
OH
32
74
69
72 71
73
 
Scheme 26: Synthesis of (1R,2R)-amino phosphine 74.  
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With the mesyl oxazolidine 72 in hand, the nucleophilic substitution with diarylphosphides was 
investigated using di(ortho-tolyl)phosphine 44a as a test reagent. Using the previous reaction 
conditions (Scheme 17), conversion to the desired amino phosphine product 75a was not detected 
by ESI-MS analysis of the crude reaction mixture. Also after longer reaction times or at higher 
reaction temperatures the nucleophilic displacement of the mesylate group was not observed 
(Scheme 27). In the (4S,5R)-diastereomer the methylene position is blocked by the phenyl- and 
Boc groups, explaining the lack of reactivity of compound 72.  
KH
THF, 
 
0 °C →
 
T, t
then: aq. 37% HCl, 0 °C → RT, 16 h
H
P
NBocO
OMs
NH2P
OH
+
conditions (T, t):
25 °C, 5 h
25 °C, 16 h
75 °C, 16 h
conversion:
no
no
no
75a72 44a
 
Scheme 27: Investigations towards the synthesis of amino phosphine 75a.  
Due of the problem in the substitution step using oxazolidine 72, a new approach via the less rigid 
mesyl adduct 78 was investigated (Scheme 28). In the first step of the synthesis, the hydroxy 
group of the inverted protected product 73 was silylated using TBDMS chloride, DMAP and 
imidazole to give fully protected intermediate 76. In the following step, the primary alcohol was 
deprotected using a catalytic amount of camphoricsulfonic acid (CSA) in a CH2Cl2/MeOH mixture 
to form primary alcohol intermediate 77 in only 5% yield. Afterwards, the alcohol group in 77 was 
mesylated using mesyl chloride and triethylamine but, unfortunately, this step was not 
reproducible. This could be due to intramolecular aziridine formation as a possible undesired side 
reaction. In this case the nucleophilic substitution of the O-mesyl group by potassium di(ortho-
tolyl)phosphide was indeed observed but nevertheless the yield of N-Boc-protected amino 
phosphine product 79a fluctuated between different batches. In this step, aziridine formation might 
also be a possible side reaction. 
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NHBocP
OTBDMS
OTBDMS
OH
NHBoc
OTBDMS
OTBDMS
NHBoc
OH
OTBDMS
NHBoc
OMs
OTBDMS
NHBoc
TBDMSCl, DMAP, 
imidazole
DMF, RT, 16 h
90%
CSA (cat.)
CH2Cl2/MeOH, RT, 1 h
5%
KH, HP(oTol)2
THF, 0 °C →
 
RT, 4 h
2-43%
MsCl, NEt3
CH2Cl2, 0 
°C →
 
RT
9-72%
73
79a 78
7776
 
Scheme 28: Synthesis of N-Boc-protected amino phosphine 79a.  
Because of problems with the reproducibility in two last steps of the amino phosphine synthesis 
presented in Scheme 28, a different synthetic protocol was investigated in which an N-protected 
cyclic sulfamidates was utilized as an electrophile for the nucleophilic substitution step. Fully 
protected intermediate 76 was selectively deprotected at the primary alcohol position using HF-
pyridine complex as fluoride donor to yield the resulting alcohol intermediate 77 in good yield. 
Afterwards, sulfonamidate adduct 80 was formed in a two-step one pot procedure. First, N-Boc 
protected amino alcohol intermediate 77 was treated with thionyl chloride to form an 
oxathiazolidin-2-oxide intermediate which was subsequently oxidized with RuCl3 and sodium 
periodate. The final product 80 was isolated in 78% yield (Scheme 29).  
OTBDMS
OTBDMS
NHBoc
OH
OTBDMS
NHBoc
HF-pyridine, pyridine
THF, 0 °C →
 
RT, 
3.5 h
78%
OTBDMS
BocN
O
S
OO
SOCl2, pyridine
CH2Cl2/MeCN, 
−
78 °C →
 
RT, 
16 h
1)
NaIO4, RuCl3•H2O (cat.)
MeCN/H2O, 0 °C → RT, 60 min
78%
2)
807776  
Scheme 29: Synthesis of N-protected cyclic sulfonamidate 80. 
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Next, the nucleophilic ring-opening of 80 was investigated using potassium diarylphosphide 
followed by hydrolysis with diluted sulfuric acid. For all tested phosphine precursors (Table 12, 
entries 1-5) the resulting N-Boc protected amino phosphines 79a-d were isolated in moderate to 
good yield. Using this strategy, it was finally possible to synthesize an amino phosphine-derived 
from bis(2-methoxyphenyl)phosphine (entry 4). Afterwards the Boc group was removed using 
trifluoroacetic acid (TFA) in dichloromethane and after basic aqueous work-up the crude mixture 
was directly used in the next step. In the last synthetic step, the amino group was coupled with 
different N-aryl isothiocyanates and after column chromatography the resulting bifunctional 
organocatalysts 81a-e were isolated in very good yield (entries 1-5).  
Table 12: Synthesis of (R,R)-catalysts 81a-e. 
OTBDMS
BocN
O
S
OO
KPR2
THF, 
  −
78 °C →
 
RT, 16 h
NHBocP
R
R
OTBDMS
TFA
CH2Cl2, 0 °C →
 
RT, 12 h
1)
ArNCS
CH2Cl2, RT, 16 h
2)
HNP
R
R
OTBDMS
HN
S
Ar
80 79a-d 81a-e  
entry R Ar Boc-amino phosphine 79 (yield in %) 
catalyst 81 
(yield in %) 
1 
  
79a (58) 81a (88) 
2 
  
79b (80) 81b (80) 
3 
 
F
 
79b (80) 81c (86) 
4 
OMe   
79c (66) 81d (89) 
5 
  
79d (54) 81e (86) 
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Additionally, squaramide-catalyst 83 was synthesized to evaluate whether the enantioselectivity 
of the MBH reaction could be improved by replacing the hydrogen-bonding subunit. The 
bifunctional catalyst 83 was isolated in moderate yield after mixing squaramide precursor 24a with 
amino phosphine 82 in methanol for three days.  
MeO N
H
OO
+
MeOH, RT, 72 h
55%
24a
NH2P
OTBDMS
83
HNP
OTBDMS
HN
O
O
82  
Scheme 30: Synthesis of squaramide-based organocatalysts 83.  
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2.3 Catalyst Evaluation by ESI-MS Back Reaction Screening  
The principle behind our screening methodology for the MBH reaction is depicted in Scheme 31. 
Starting from a 1:1 mixture of mass-labelled quasi-enantiomeric MBH products 84a and 84b, a 
catalyst-mediated back reaction via intermediates 85a and 85b is induced, which then undergo 
cleavage to the aromatic aldehyde (in the present study 4-nitrobenzaldehyde) and the mass-
labelled catalyst-substrate adducts 87a and 87b. If we assume that a fast equilibrium is 
established between intermediates 84a and 84b and the corresponding catalyst adducts 85a and 
85b, followed by a slow rate-determining C–C bond cleavage (Curtin-Hammet conditions), the 
ratio 87a/87b will be identical to the enantiomeric ratio produced in the MBH reaction in the forward 
direction according to the principle of microscopic reversibility. The ratio 87a/87b can be reliably 
determined even at very low concentration by electrospray ionization mass spectrometry (ESI-
MS). Under the conditions of ESI-MS analysis, intermediates 87a and 87b are protonated and 
their ratio is determined from the signal ratio of the corresponding cationic species 89a and 89b.  
OCH3
O
Ar
OH
Ar
OH
OCD3
O
Pcat
O
OCH3
OH
Ar
OH
OCD3
O
Pcat
Ar
O
OCH3
O
Ar
O
OCD3
O
Pcat
Pcat
Ar
Pcat
O
OCH3
OCD3
O
Pcat
OCH3
O
Pcat
OCD3
O
Pcat
H
Pcat
OCH3
O
Pcat
OH
Ar
OCD3
O
Pcat
OH
Ar
H
H H
catalyst-mediated back MBH reaction ESI-MS analysis
+ ++
H
84a 85a 86a 87a 89a
88a
84b 85b 86b 87b 89b
88b
ArCHO
H
 
Scheme 31: Principle of the back reaction screening methodology for the MBH reaction. 
The results obtained during my master thesis showed that upon treatment of MBH adducts derived 
from acrylic esters and 4-nitrobenzaldehyde with triphenylphosphine, signals of catalyst adducts 
resulting from C–C bond cleavage could be detected by ESI-MS. During my master studies a 
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suitable pair of quasi-enantiomeric MBH products was developed. Alkyl esters which differed in 
the number of carbon atoms, which we evaluated first, gave unsatisfactory results as they slightly 
differed in reactivity. This reactivity difference resulted in unequal ratios of catalyst-substrate 
adducts with an achiral catalyst. We eventually found that the methyl and trideuteromethyl esters 
84a and 84b proved to be optimal as they possessed identical reactivity and gave rise to easily 
detectable signal pairs.  
Successful application of back reaction screening requires the C–C bond forming step to be rate- 
and enantioselectivity-determining. However, in several studies the proton transfer after the aldol 
step was found to be, at least in part, rate-determining.[53,58] We therefore conducted preliminary 
experiments with chiral bifunctional phosphine-based catalyst during my master studies. We were 
pleased to find that the ratios 89a/89b produced in the back reaction closely matched the 
enantiomeric ratios determined for the preparative forward reaction. This implied that our 
screening protocol should indeed be applicable (see Figure 11 for representative examples). 
Encouraged by these results, we started a systematic evaluation of chiral MBH catalysts based 
on the screening protocol shown in Scheme 31. 
N
H
N
H
S
P
N
H
N
H
S
P
N
HP
S
O
O
N
H
N
H
S
P
N
HP
O
O
HN
N
HP
O
O
HN
95
27:73
 
(28:72)
91
24:76
 
(26:74)
90
35:65
 
(33:67)
92
20:80
 
(21:79)
93
37:63
 
(39:61)
94
19:81
 
(20:80)  
Figure 11: Catalyst overview of my master thesis (enantiomeric ratio determined in the forward reaction is given in 
brackets).  
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2.3.1 Single Catalyst Screening of Bifunctional Phosphines 
First, purified first generation catalysts with different chiral backbones were subjected to the single 
back reaction screening protocol for the evaluation of the intrinsic enantioselectivities. For back 
reaction screening an equimolar mixture of quasi-enantiomers 84a and 84b was allowed to react 
with 10 mol% of catalyst in CH2Cl2 at room temperature. After 30 minutes, the reaction mixture 
was diluted ten-fold with CH2Cl2 and a sample was then immediately injected into the 
spectrometer. The signals of the positively charged retro-MBH products 89a and 89b as well as 
the cationic species 88a and 88b generated by protonation of intermediates 85a/86a and 85b/86b 
were all clearly visible with high intensity (see Figure 12 for a representative ESI-MS spectrum 
with triphenylphosphine as catalyst).  
 
Figure 12: ESI-MS spectrum with triphenylphosphine as catalyst for back reaction screening.  
To validate the screening results, the ratios 89a/89b measured by ESI-MS were compared to the 
enantiomeric ratios (e.r.) determined for the forward reaction by HPLC on a chiral stationary 
phase. To our satisfaction the results from the back reaction screening and from the corresponding 
preparative MBH reactions closely matched each other. In some cases, the e.r. of the preparative 
reaction was significantly lower than the selectivity of the back reaction. However, this divergence 
was caused by slow catalyst-induced racemization of the MBH products under the reaction 
conditions. After a short reaction time of 30 minutes the selectivities of the back and forward 
reaction matched again.  
0
100
re
l. 
In
t.
m/z
89a 89b 
88a 88b 
OCH3
O
Ph3P OCD3
O
Ph3P
OCD3
O
Ph3P
Ar
OH
OCD3
O
Ph3P
Ar
OH
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The effect of the chiral backbone of thiourea-based organocatalysts from different amino 
phosphines for the selectivity of the MBH reaction is summarized in Table 13. For catalyst 19a 
derived from phenyl glycine only a low ee of 22% was measured. The enantioselectivity was 
improved by increasing the steric hindrance at the α-position of the amino phosphine as in catalyst 
19b. Moreover, a slightly higher enantiomeric ratio was observed for the isoleucine based catalyst 
19f. Catalysts 19c with an iso-butyl group in the backbone gave an enantiomeric excess of 42% 
and the selectivity was increased to 54% ee by replacing the butyl group by a phenyl residue as 
in phosphine 19d. A further increase of the steric hindrance in catalyst 19e with the cyclohexyl 
moiety resulted in a decrease of selectivity from 23:77 to 26:74. To conclude, the best selectivities 
were observed for catalysts derived from phenylalanine (catalyst 19d) or isoleucine (catalyst 19f).  
Table 13: Screening results for the first catalyst generation – investigation of the effect of the chiral backbone on the 
enantioselectivity.  
O2N
OH O
OCH3
O2N
OH O
OCD3+
Pcatalyst
 
(10 mol%)
CH2Cl2, RT, 30 min
89a
OCH3
O
OCD3
O
Pcat Pcat
+
89b84b84a  
Pcatalyst ESI-MS screening 89a/89b (e.r. prep.[a]) Pcatalyst 
ESI-MS screening 
89a/89b (e.r. prep.[a]) 
N
HP
S
N
H
19a
 
39:61 (38:62[b]) N
HP
S
N
H
19d
 
23:77 (23:77) 
N
HP
S
N
H
19b
 
23:77 (22:78[b]) N
HP
S
N
H
19e
 
26:74 (25:75) 
N
HP
S
N
H
19c
 
29:71 (28:72) NHP
S
N
H
19f
 
21:79 (20:80[b]) 
[a]: Reaction conditions: 4-nitrobenzaldehyde (1.0 eq.), methyl acrylate (1.5 eq.), 10 mol% catalyst, CH2Cl2, RT, 
18 hours. Determined by HPLC on a chiral stationary phase. [b]: Ratio determined after 30 minutes. 
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Based on the results of the single catalyst screening in Table 13, (S)-1-(diphenylphosphanyl)-3-
phenylpropan-2-amine was chosen as a core structure to study the influence of the thiourea group 
on the enantioselectivity of the MBH reaction (Table 14). Introduction of electron-withdrawing 
(catalyst 20a or 20b) or electron-donating (catalyst 20c) substituents attached to the N-phenyl 
group had only a marginal effect on the enantioselectivity. The selectivity was slightly improved 
by installing a bulkier diphenylmethane unit at the thiourea moiety (catalyst 20d). Next, the 
influence of a chiral hydroxyl group attached to the thiourea unit was investigated to test if the 
proton transfer step could be accelerated. An additional hydrogen-bonding donor could help in the 
orientation of the substrate by non-covalent interactions. Indeed, compared to N-phenyl thiourea-
derived catalyst 19d (see Table 13) the enantiomeric excess increased to 68% which could be an 
indication for the positive effect of the chiral alcohol group in catalyst 20e (Table 14) on the 
selectivity. With an e.r. of 20:80 the selectivity obtained with catalyst 20g containing a N-benzyl 
residue was similar to phosphine 19d (see Table 13). For the dimeric catalyst 20f (Table 14) a 
marginally higher enantioselectivity was observed. For all catalysts with an N-alkyl group at the 
thiourea unit a catalyst induced product racemization was observed over time which reflected the 
high reactivity of these catalysts. Only after short reaction times, a match between the ratio 
89a/89b and the e.r. of the forward reaction was achieved.  
Table 14: Screening results for the first catalyst generation – investigation of the effect of the N-residue at the 
thiourea group on the enantioselectivity. 
O2N
OH O
OCH3
O2N
OH O
OCD3+
Pcatalyst
 
(10 mol%)
CH2Cl2, RT, 30 min
89a
OCH3
O
OCD3
O
Pcat Pcat
+
89b84b84a  
Pcatalyst ESI-MS screening 89a/89b (e.r. prep.[a]) Pcatalyst 
ESI-MS screening 
89a/89b (e.r. prep.[a]) 
N
HP
S
N
H
CF3
CF3
20a
 
23:77 (23:77) N
HP
S
N
H OH
20e
 
16:84 (14:86[b]) 
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N
HP
S
N
H
CF3
20b
 
23:77 (25:75) N
HP
S
N
H P
PhPh
20f  
16:84 (14:86[b]) 
N
HP
S
N
H
OMe
20c
 
22:78 (24:76) N
HP
S
N
H
20g
 
20:80 (21:79[b]) 
N
HP
S
N
H
20d
 
16:84 (17:83[b])   
[a]: Reaction conditions: 4-nitrobenzaldehyde (1.0 eq.), methyl acrylate (1.5 eq.), 10 mol% catalyst, CH2Cl2, RT, 
18 hours. Determined by HPLC on a chiral stationary phase. [b]: Ratio determined after 30 minutes. 
Next, the second catalyst generation was screened using the back reaction screening protocol. 
Replacement of the thiourea group by a squaramide unit led to improved e.r. values for all catalysts 
when compared to the corresponding thiourea derivatives (see Table 15 vs Table 13). The 
enantioselectivity was lowered by increasing steric hindrance in the chiral backbone with a 
cyclohexyl group (catalyst 25b or catalyst 25e) compared to phenyl substituted bifunctional 
phosphines 25a and 25d. For catalyst structures with an isobutyl group (catalyst 25c) or 
isoleucine-derived catalyst 25f no further improvement of the intrinsic selectivity was achieved. In 
conclusion, the best selectivities were observed for the phenylalanine and phenyl glycine-derived 
organocatalysts 25d and 25a, respectively.  
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Table 15: Screening results for the second catalyst generation – investigation of the effect of the chiral backbone on 
the enantioselectivity. 
O2N
OH O
OCH3
O2N
OH O
OCD3+
Pcatalyst
 
(10 mol%)
CH2Cl2, RT, 30 min
89a
OCH3
O
OCD3
O
Pcat Pcat
+
89b84b84a  
Pcatalyst ESI-MS screening 89a/89b (e.r. prep.[a]) Pcatalyst 
ESI-MS screening 
89a/89b (e.r. prep.[a]) 
N
HP
O
O
HN
25a  
14:86 (12:88) N
HP
O
O
HN
25d  
15:85 (15:85) 
N
HP
O
O
HN
25b  
18:82 (19:81) N
HP
O
O
HN
25e  
18:82 (19:81) 
N
HP
O
O
HN
25c  
18:82 (18:82) NHP
O
O
HN
25f  
17:83 (15:85) 
[a]: Reaction conditions: 4-nitrobenzaldehyde (1.0 eq.), methyl acrylate (1.5 eq.), 10 mol% catalyst, CH2Cl2, RT, 
18 hours. Determined by HPLC on a chiral stationary phase.  
In a next step the influence of the N-substituent on the squaramide unit on the selectivity was 
investigated. The results in Table 16 show the effect of various N-aryl groups. Trifluoromethyl 
(catalyst 26a) or methoxy (catalyst 26b) residues on the N-phenyl substituent did not have any 
effect on the stereoselectivity of the reaction. For catalyst 26c with two phenolic hydroxyl groups, 
only low conversion in the preparative reaction was detected by TLC. This could be due to the 
possible protonation of the enolate intermediate by the acidic phenol groups which reduced the 
reactivity of the bifunctional phosphine 26c. Next, squaramide catalyst 26j with a N-2-
methoxybiphenyl residue gave a lower enantiomeric ratio. Moreover, catalyst 26k with 2-
hydroxybiphenyl gave similar selectivity compared to the O-methylated catalyst 26j but was likely 
due to racemization as indicated by the detected higher selectivity by ESI-MS. The installation of 
an anthracene unit at the ortho position of the N-phenyl residue as a steric shield did not influence 
the e.r. of the catalyst 26i.  
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Table 16: Screening results for the second catalyst generation – investigation of the effect of the N-aryl substituent at 
the squaramide group on the enantioselectivity. 
O2N
OH O
OCH3
O2N
OH O
OCD3+
Pcatalyst
 
(10 mol%)
CH2Cl2, RT, 30 min
89a
OCH3
O
OCD3
O
Pcat Pcat
+
89b84b84a  
Pcatalyst ESI-MS screening 89a/89b (e.r. prep.[a]) Pcatalyst 
ESI-MS screening 
89a/89b (e.r. prep.[a]) 
N
HP
O
O
HN
CF3
CF3
26a
 
16:84 (17:83) 
N
HP
O
O
HN
OMe26j  
23:77 (25:75) 
N
HP
O
O
HN
OMe
26b  
14:86 (14:86) 
N
HP
O
O
HN
OH26k  
24:76 (25:75[b]) 
N
HP
O
O
HN
HO
HO
26c  
15:85 (11:89) 
N
HP
O
O
HN
26i
 
16:84 (16:84) 
[a]: Reaction conditions: 4-nitrobenzaldehyde (1.0 eq.), methyl acrylate (1.5 eq.), 10 mol% catalyst, CH2Cl2, RT, 
18 hours. Determined by HPLC on a chiral stationary phase. [b]: Ratio determined after 30 minutes. 
The effect of an N-alkyl substituent on enantioselectivities obtained with squaramide catalysts is 
presented in Table 17. The e.r. decreased from 15:85 to 20:80 when a cyclohexyl group was 
attached to the squaramide unit in catalyst 26d compared to catalyst 25d (see   
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Table 15). For catalysts with a diphenylmethane (catalyst 26e) or (S)-naphthylethyl (catalyst 26h) 
(Table 17) substituted squaramide moiety only a marginal influence of the steric hindrance was 
detected compared to the sterically less demanding catalysts 25d (Table 15). Moreover, catalyst 
26f (Table 17) derived from 3,5-bis(trifluoromethyl)-benzylamine substituted squaramide did not 
increase the enantioselectivity compared to catalyst 25d (Table 15). The dimeric catalyst 26m or 
organocatalysts 26g (Table 17) with an additional chiral hydroxyl group did not improve the e.r. 
Interestingly, the bifunctional phosphine 26l with an amino group attached to the squaramide gave 
slightly higher enantioselectivity but racemization occurred during the preparative reaction. 
Table 17: Screening results for the second catalyst generation – investigation of the effect of the N-alkyl substituent at 
the squaramide group on the enantioselectivity. 
O2N
OH O
OCH3
O2N
OH O
OCD3+
Pcatalyst
 
(10 mol%)
CH2Cl2, RT, 30 min
89a
OCH3
O
OCD3
O
Pcat Pcat
+
89b84b84a  
Pcatalyst ESI-MS screening 89a/89b (e.r. prep.[a]) Pcatalyst 
ESI-MS screening 
89a/89b (e.r. prep.[a]) 
N
HP
O
O
HN
26d  
20:80 (20:80) NHP
O
O
HN
Ph2P
26m  
18:82 (15:85) 
N
HP
O
O
HN
26e  
15:85 (15:85) NHP
O
O
HN
HO
26g  
16:84 (16:84b) 
N
HP
O
O
HN
CF3
F3C
26f
 
19:81 (18:82) NHP
O
O
NH2
26l  
12:88 (15:85b) 
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N
HP
O
O
HN
26h  
16:84 (16:84)   
[a]: Reaction conditions: 4-nitrobenzaldehyde (1.0 eq.), methyl acrylate (1.5 eq.), 10 mol% catalyst, CH2Cl2, RT, 
18 hours. Determined by HPLC on a chiral stationary phase. [b]: Ratio determined after 30 minutes. 
The effect of the chiral backbone of the third catalyst generation on the enantioselectivity is shown 
in Table 18. Threonine-derived catalyst 37 gave a moderate enantiomeric excess of 54%. A more 
pronounced increase of the e.r. resulted when the methyl group of catalyst 37 was replaced by a 
phenyl group (catalyst 46a). In contrast, a lower selectivity was detected for catalyst 56 with a 
cyclohexyl group in the backbone. Catalyst 45a which lacked a silyl protecting group gave racemic 
product. A smaller silyl group like TMS or bigger groups such as TIPS or TDS resulted in a 
decreased e.r. of the MBH product compared to TBDMS-protected phosphine 46a.  
Table 18: Screening resutls for third generation catalysts – investigation of the effect of the chiral backbone on the 
enantioselectivity. 
O2N
OH O
OCH3
O2N
OH O
OCD3+
Pcatalyst
 
(10 mol%)
CH2Cl2, RT, 30 min
89a
OCH3
O
OCD3
O
Pcat Pcat
+
89b84b84a  
Pcatalyst ESI-MS screening 89a/89b (e.r. prep.[a]) Pcatalyst 
ESI-MS screening 
89a/89b (e.r. prep.[a]) 
N
HP
S
N
H
OTBDMS
37
 
23:77 (24:76) N
HP
S
N
H
OTMS
49a
 
85:15 (83:17) 
N
HP
S
N
H
OTBDMS
46a
 
91:9 (90:10) N
HP
S
N
H
OTIPS
49b
 
82:18 (81:19) 
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N
HP
S
N
H
OTBDMS
56
 
70:30 (80:20) N
HP
S
N
H
OTDS
49c
 
83:17 (84:16) 
N
HP
S
N
H
OH
45a
 
52:48 (50:50)   
[a]: Reaction conditions: 4-nitrobenzaldehyde (1.0 eq.), methyl acrylate (1.5 eq.), 10 mol% catalyst, CH2Cl2, RT, 
18 hours. Determined by HPLC on a chiral stationary phase.  
The screening results in Table 18 show that the TBDMS and the phenyl group are crucial for the 
selectivity of the MBH reaction. The next task was to study the effect of the N-substituent of the 
thiourea unit for the best catalyst 46a on the stereoselectivity of the MBH reaction (Table 19). 
When different electron-donating (catalyst 46e) or electron-withdrawing substituents (catalyst 46d) 
were installed next to the thiourea group only a marginal effect on the selectivity was detected. In 
contrast, an N-cyclohexyl substituent (catalyst 46f) lowered the enantiomeric ratio from 90:10 to 
80:20. Furthermore, in the case of the N-pentafluorophenyl-based catalyst 46c a racemization 
process over time was observed. Ultimately, the N-phenyl group was found to be the best residue 
in terms of enantioselectivity. 
Table 19: Screening resutls for third generation catalysts – investigation of the effect of the thiourea group on the 
enantioselectivity. 
O2N
OH O
OCH3
O2N
OH O
OCD3+
Pcatalyst
 
(10 mol%)
CH2Cl2, RT, 30 min
89a
OCH3
O
OCD3
O
Pcat Pcat
+
89b84b84a  
Pcatalyst ESI-MS screening 89a/89b (e.r. prep.[a]) Pcatalyst 
ESI-MS screening 
89a/89b (e.r. prep.[a]) 
N
HP
S
N
H
OTBDMS F
46b
 
88:12 (87:13) N
HP
S
N
H
OTBDMS OMe
46e
 
87:13 (87:13) 
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N
HP
S
N
H
OTBDMS
F
F
FF
F
46c  
91:9 (90:10[b]) N
HP
S
N
H
OTBDMS
46f
 
83:17 (80:20) 
N
HP
S
N
H
OTBDMS
CF3
CF3
46d
 
89:11 (87:13)   
[a]: Reaction conditions: 4-nitrobenzaldehyde (1.0 eq.), methyl acrylate (1.5 eq.), 10 mol% catalyst, CH2Cl2, RT, 
18 hours. Determined by HPLC on a chiral stationary phase. [b]: Ratio determined after 30 minutes. 
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Next, the influence of the phosphine residue on the intrinsic selectivity were studied by 
investigating various phosphines in the back reaction screening. A significant increase in 
enantioselectivity was achieved by replacing the P-phenyl groups with bulkier ortho-tolyl (catalyst 
48a,b), ortho-iPr-phenyl (catalyst 48c), or 1-naphthyl (catalyst 48d,e) groups (Table 20). In 
contrast, the N-aryl residue did not affect the selectivity of the MBH reaction. These screening 
results demonstrated the importance that steric hindrance at the ortho position of the aromatic 
residue on the phosphorus center has for the stereoselectivity of the reaction. The reactivity drops 
with increasing steric hindrance from ortho-tolyl to 1-napthyl to ortho-iPr-phenyl substituted 
phosphines-based on analysis of the detected intensities of the catalyst-substrate adducts by ESI-
MS.  
Table 20: Screening resutls for third generation catalysts – investigation of the effect of aryl substituted phosphines 
on the enantioselectivity. 
O2N
OH O
OCH3
O2N
OH O
OCD3+
Pcatalyst
 
(10 mol%)
CH2Cl2, RT, 30 min
89a
OCH3
O
OCD3
O
Pcat Pcat
+
89b84b84a  
Pcatalyst ESI-MS screening 89a/89b (e.r. prep.[a]) Pcatalyst 
ESI-MS screening 
89a/89b (e.r. prep.[a]) 
N
HP
S
N
H
OTBDMS
48a
 
94:6 (94:6) NHP
S
N
H
OTBDMS
48d
 
96:4 (95:5) 
N
HP
S
N
H
OTBDMS F
48b
 
93:7 (94:6) NHP
S
N
H
OTBDMS F
48e
 
95:5 (95:5) 
N
HP
S
N
H
OTBDMS
48c
 
94:6 (93:7)   
[a]: Reaction conditions: 4-nitrobenzaldehyde (1.0 eq.), methyl acrylate (1.5 eq.), 10 mol% catalyst, CH2Cl2, RT, 
18 hours. Determined by HPLC on a chiral stationary phase.  
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Next, the electronic and the steric effects of 3,5-substituted aryl phosphines were investigated. 
Catalysts 48g and 48h with 3,5-dialkyl-substituted P-phenyl groups gave inferior results (Table 
21). A more drastic effect was observed for the dicylcohexyl phosphine-derived catalyst 52 which 
gave racemic product mixtures. Electron-rich phosphine-based organocatalysts were very 
reactive but unfortunately gave only low enantioselectivities. 
Table 21: Screening resutls for third generation catalysts – investigation of the effect of electron-rich phosphines on 
the enantioselectivity. 
O2N
OH O
OCH3
O2N
OH O
OCD3+
Pcatalyst
 
(10 mol%)
CH2Cl2, RT, 30 min
89a
OCH3
O
OCD3
O
Pcat Pcat
+
89b84b84a  
Pcatalyst ESI-MS screening 89a/89b (e.r. prep.[a]) Pcatalyst 
ESI-MS screening 
89a/89b (e.r. prep.[a]) 
N
HP
S
N
H
OTBDMS
48g
 
79:21 (79:21) N
HP
S
N
H
OTBDMS
52
 
50:50 (49:51) 
N
HP
S
N
H
OTBDMS
tBu
tBu tBu
tBu
48h
 
80:20 (81:19)   
[a]: Reaction conditions: 4-nitrobenzaldehyde (1.0 eq.), methyl acrylate (1.5 eq.), 10 mol% catalyst, CH2Cl2, RT, 
18 hours. Determined by HPLC on a chiral stationary phase.  
In the fourth catalyst generation the effect of the stereogenic center at the secondary alcohol 
position was studied (Table 22). In the case of the threonine-based organocatalysts 64, the e.r. 
was improved from 23:77 to 13:87 by switching from the (R,S)- to the (S,S)-diastereomer. 
Motivated by this result, various like-diastereomers of phenyl serine-derived organocatalysts were 
screened and we were pleased to see that for each catalyst a higher selectivity was observed 
(see Tables 18-21 for the (R,S)-analogs). Again, electron rich phosphines such as the 3,5-
dimethylphenyl (catalyst 81e) or the 2-methoxyphenyl (catalyst 81d) substituted phosphines gave 
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lower selectivities. Moreover, for catalyst 81e racemization was observed during the preparative 
MBH reaction. Unfortunately, no further improvement of the selectivity was detected by replacing 
the thiourea unit by a squaramide group (catalyst 83). These results show that the stereogenic 
center at the alcohol position can influence the selectivity of the catalyst and that the like-
diastereomer is the preferred diastereomer. 
Table 22: Screening resutls for forth generation catalysts – investigation of the effect of the chiral backbone and 
phosphine residue on the enantioselectivity. 
 
Pcatalyst ESI-MS screening 89a/89b (e.r. prep.[a]) Pcatalyst 
ESI-MS screening 
89a/89b (e.r. prep.[a]) 
N
HP
S
N
H
OTBDMS
64
 
13:87 (13:87) N
HP
S
N
H
OTBDMS F
81c
 
95:5 (95:5) 
N
HP
S
N
H
OTBDMS
81a
 
93:7 (94:6) N
HP
S
N
H
OTBDMS
OMe
MeO
81d
 
71:29 (71:29) 
N
HP
S
N
H
OTBDMS
81b
 
95:5 (95:5) NHP
S
N
H
OTBDMS
81e
 
89:11 (89:11[b]) 
N
HP HN
O
OO
TBDMS
83  
93:7 (92:8)   
[a]: Reaction conditions: 4-nitrobenzaldehyde (1.0 eq.), methyl acrylate (1.5 eq.), 10 mol% catalyst, CH2Cl2, RT, 
18 hours. Determined by HPLC on a chiral stationary phase. [b]: Ratio determined after 30 minutes. 
O2N
OH O
OCH3
O2N
OH O
OCD3+
Pcatalyst
 
(10 mol%)
CH2Cl2, RT, 30 min
89a
OCH3
O
OCD3
O
Pcat Pcat
+
89b84b84a
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2.3.2 Single Catalyst Screening of Tertiary Amine Catalysts 
Herein, tertiary amines were applied to the back reaction screening protocol. Unfortunately, back 
reaction was not detected by ESI-MS for DABCO 96, chiral diamine catalyst 97, chiral quinine 
catalyst 98 or chiral imidazole-based catalyst 99 using the standard screening conditions (Table 
23). For all catalyst the corresponding forward reaction was observed and for the chiral amine-
based organocatalysts some levels of enantioselectivity were determined by HPLC analysis on a 
chiral stationary phase.  
Table 23: Screening results for amine-based catalysts. 
O2N
OH O
OCH3
O2N
OH O
OCD3+
Ncatalyst
 
(10 mol%)
CH2Cl2, RT, 30 min
89a
OCH3
O
OCD3
O
Ncat Ncat
+
89b84b84a  
Ncatalyst ESI-MS screening 89a/89b (e.r. prep.[a]) Ncatalyst 
ESI-MS screening 
89a/89b (e.r. prep.[a]) 
N
N
96  
n.d.[b] (50:50) N
OH
N
MeO H
98  
n.d.[b] (70:30) 
N
N
97  
n.d.[b] (63:37) N
N
99
 
n.d.[b] (55:45) 
[a]: Reaction conditions: 4-nitrobenzaldehyde (1.0 eq.), methyl acrylate (1.5 eq.), 10 mol% catalyst, CH2Cl2, RT, 
18 hours. Determined by HPLC on a chiral stationary phase. [b]: No back reaction intermediates detected by ESI-MS 
analysis.  
For the diamine catalyst 97 the reaction parameters for the back reaction screening were 
investigated (Table 24). When dichloromethane was used as the solvent, the back reaction was 
not observed using longer reaction times (entries 1-2), higher temperature (entry 3) or higher 
catalyst loading (entry 4). One explanation might be that the proton transfer is too high in energy 
and therefore the back MBH reaction cannot take place. The proton transfer could be accelerated 
by the addition of protic additives which in principle might have a positive effect on the retro-
activity. Unfortunately, for all additives tested, formation of back reaction intermediates (entries 5-
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6) was not detected by ESI-MS analysis. Also when the solvent was changed to iso-propanol the 
formation of catalyst-substrate adducts 89a/89b was not observed under various screening 
conditions (entries 8-10). Moreover, even the intermediate which should be formed after 
nucleophilic attack of the catalyst to the MBH adduct was not detected by ESI-MS. Compared to 
phosphines, amines are less nucleophilic and therefore the nucleophilic attack to the substrate 
might be disfavored. 
Table 24: Screening of reaction parameters for back reaction screening.  
O2N
OH O
OCH3
O2N
OH O
OCD3+
97 (x mol%)
solvent, temperature,
time, additive
89a
OCH3
O
OCD3
O
Ncat Ncat
+
89b84b84a  
entry x mol% solvent temperature [°C] time [min] additive ESI-MS screening 89a/89b 
1 10 CH2Cl2 25 30 no n.d.[a] 
2 10 CH2Cl2 25 120 no n.d.[a] 
3 10 CH2Cl2 50 30 no n.d.[a] 
4 10 CH2Cl2 50 120 no n.d.[a] 
5 30 CH2Cl2 25 30 no n.d.[a] 
6 10 CH2Cl2 25 30 PNP (10 mol%) n.d.
[a] 
7 10 CH2Cl2 25 30 water (10 mol%) n.d.
[a] 
8 10 iPrOH 25 30 no n.d.[a] 
9 10 iPrOH 25 120 no n.d.[a] 
10 10 iPrOH 50 30 no n.d.[a] 
[a]: No back reaction intermediates detected by ESI-MS analysis.  
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2.3.3 Multi-Catalyst Screening 
Conventional determination of catalyst selectivities relies on product analysis by HPLC or GC on 
a chiral stationary phase. Using the back reaction screening methodology, evaluation of several 
catalysts with different molecular masses in a single experiment should be possible because each 
phosphine will form mass-labelled adducts, that appear at different positions in the mass 
spectrum. Moreover, in principle, crude mixtures of phosphines could be applied in the multi-
catalyst ESI-MS screening because potential catalytically active impurities should not influence 
the ratios of the detected phosphine intermediates. The only requirements for the multi-catalyst 
screening are that all catalysts in the crude mixture should have a similar activity in the back MBH 
reaction and that the signals of the mass-labelled substrate-catalyst intermediates should not 
overlap.  
First, a crude mixture of the first generation catalysts was synthesized to investigate the effect of 
the N-aryl residue at the thiourea moiety on the stereoselectivity of the reaction. For that purpose, 
amino phosphine 18d was reacted for 16 hours with an equimolar mixture of three different 
aromatic isothiocyanates. After evaporation of the solvent under high vacuum, a crude mixture 
which contained three catalysts was obtained (Scheme 32). 
NH2
P
N
HP
CH2Cl2, RT, 16 h
S
N
H
N
HP
S
N
H
CF3
N
HP
S
N
H
CF3
CF3
+
19d 20b
20a
18d
PhNCS/4-CF3-PhNCS/
3,5-(CF3)2
-PhNCS (1:1:1)
 
Scheme 32: Synthesis of the crude catalyst mixture for the first catalyst generation.  
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This mixture was subjected to the standard back reaction screening protocol and after 30 minutes 
all three catalyst-substrate adducts were detected with high intensity (Figure 13). Moreover, the 
ratios perfectly matched with the results from the single catalyst screening protocol (ratio in 
brackets).  
Ar
OH O
OCH3 Ar
OH O
OCD3
P +10 mol% cat. mix. H
N
H
N
S
R
OCH3
O
R = Ph (m/z
 = 541)
R = 4-CF3Ph (m/z
 = 609)
R = 3,5-(CF3)2Ph (m/z
 = 677)
P H
N
H
N
S
R
OCD3
O
R = Ph (m/z
 = 544)
R = 4-CF3Ph (m/z
 = 612)
R = 3,5-(CF3)2Ph (m/z
 = 680)
CH2Cl2, RT, 30 min
+
 
 
Figure 13: Results of the catalyst mixture screening of first generation catalyst.  
Next, the one-batch crude mixture screening was extended to the second catalyst generation. An 
equimolar mixture of three different amino phosphines was treated with squaramide precursor 24a 
and after two days the precipitated catalyst mixture was filtered off (Scheme 33). With this 
approach only one screening experiment is needed for the investigation of the effect of the chiral 
backbone on the enantioselectivity of the MBH reaction  
0
100
re
l. 
In
t.
m/z
23:77
(24:76)
23:77
(24:76) 24:76
(23:77)
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NH2
PPh2
N
HPPh2
MeOH, RT, 48 h
18c
NH2
PPh2
+
NH2
PPh2
OO
NHPhMeO
24a
NHPh
O
+
N
HPPh2 NHPh
O
O
N
HPPh2 NHPh
O
O
+
100 18d
92 25c
25d
O
 
Scheme 33: Synthesis of the crude catalyst mixture for the second catalyst generation. 
For all catalysts the corresponding key-intermediates were detected by ESI-MS analysis. 
However, compared to thiourea-based catalysts the intensity was lower due to the lower reactivity 
of the squaramide-based phosphines. Again the most selective catalyst could be directly identified 
from the crude mixture (Figure 14). 
10 mol% cat. mix.
CH2Cl2, RT, 30 minAr
OH O
OCH3 Ar
OH O
OCD3
P +H
N
R
OCH3
O
R = iPr (m/z
 = 528)
R = iBu (m/z
 = 542)
R = Bn (m/z
 = 577)
P H
N
R
OCD3
O
R = iPr (m/z
 = 531)
R = iBu (m/z
 = 545)
R = Bn (m/z
 = 580)
+ NHPh
O
O
NHPh
O
O
 
 
Figure 14: Results of the catalyst mixture screening of second generation catalyst.  
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100
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l. 
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The modular structure of third generation catalyst seemed to be ideal for the crude catalyst mixture 
screening protocol due to the two different positions that can be derivatized during the synthesis. 
In this case a library of six catalysts was synthesized following a two-step procedure. Three 
different amino phosphines were mixed with a one to one mixture of two aryl isothiocyanate 
precursors to form the resulting six thiourea intermediates in situ. Afterwards, the crude mixture 
was dried under high vacuum for four hours, the secondary alcohol was TBDMS protected and 
after aqueous workup the crude catalyst mixture was obtained (Scheme 34).  
1. PhNCS/4-F-PhNCS (1:1)
CH2Cl2, RT, 16 h
2. TBDMSOTf, NEt3
CH2Cl2, 0 °C →
 
RT, 6 h
OH
NH2P
+
OTBDMS
HNP
S
HN
OH
NH2P
OH
NH2P
+
OTBDMS
HNP
S
HN
OTBDMS
HNP
S
HN
+ +
OTBDMS
HNP
S
HN
OTBDMS
HNP
S
HN
OTBDMS
HNP
S
HN
+ +
FFF
46b
46a
38
48b 101
48g48a
40d40a
 
Scheme 34: Synthesis of crude catalyst mixture for the third catalyst generation. 
By using the catalyst mixture from above, the effect of the phosphine substituents and the 
influence of the N-aryl substituent was investigated in one experiment. Thus, the resulting crude 
mixture was directly subjected to back reaction screening. For all catalysts the corresponding 
ASYMMETRIC MORITA-BAYLIS-HILLMAN REACTION        CHAPTER 2 
73 
signals of intermediates 89a and 89b were detected. Although the selectivities obtained by multi-
catalyst screening were somewhat lower than the e.r. values from single catalyst screening, the 
selectivity order among the six catalysts was correctly displayed by the data. Thus, the most 
selective catalysts in a combinatorial library can be readily identified using this screening protocol 
(Figure 15). The deviation of the ratios 89a/89b from the actual e.r. values is likely caused by the 
high catalyst loading (30 mol%) that had to be used in order to obtain satisfactory signal to noise 
ratios. Under these conditions the assumption of a rapid pre-equilibrium between 85a and 86a, 
and 85b and 86b, is no longer valid. 
Ar
OH O
OCH3 Ar
OH O
OCD3
P +30 mol% cat. mix.
Ar
Ar H
N
OCH3
O
Ar = Ph, R = Ph (m/z
 = 671 and 674)
Ar = Ph, R = 4-F-Ph (m/z
 = 689 and 692)
Ar = oTol, R = Ph (m/z
 = 699 and 702)
Ar = oTol, R = 4-F-Ph (m/z
 = 717 and 720)
Ar = 3,5-(CH3)2-Ph, R = Ph (m/z
 = 727 and 730)
Ar = 3,5-(CH3)2-Ph, R = 4-F-Ph (m/z
 = 745 and 748)
P
Ar
Ar H
N
OCD3
O
CH2Cl2, RT, 30 min
+ H
N
S
R
H
N
S
R
OTBDMS OTBDMS
 
 
Figure 15: Results of the catalyst mixture screening of third generation catalyst.  
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For the fourth generation catalysts a crude catalyst synthesis was developed which began from 
the N-Boc protected cyclic sulfonamidate 80. The advantage of this method is, that no amino 
phosphine precursor has to be isolated in advance. In the first step, the amino phosphine 
intermediates were formed by nucleophilic attack of the sulfonamidate by an equimolar mixture of 
a phosphide solution prepared from phosphines 102, 44a and 44d. After hydrolysis and aqueous 
work up the crude mixture was directly used in the Boc deprotection step with TFA. Then, the 
crude reaction mixture from the deprotection step was washed with saturated aqueous sodium 
carbonate solution and the crude amine mixture was used without purification. A subsequent 
coupling reaction with two different isothiocyanate precursors gave six different bifunctional 
phosphines (Scheme 35).   
OTBDMS
HNP
S
HN
OTBDMS
HNP
S
HN
OTBDMS
HNP
S
HN
+ +
OTBDMS
HNP
S
HN
OTBDMS
HNP
S
HN
OTBDMS
HNP
S
HN
+ +
FFF
BocN
S
O
O O
OTBDMS
P
H
P
H
P
H
+ + +
1. KH
THF, 
−
78 °C →
 
RT, 16 h
3. PhNCS, 4-F-PhNCS (1:1)
CH2Cl2, 
 
RT, 16 h
2. TFA
CH2Cl2, 0 
°C →
 
RT, 16 h
81a
103
80
10481c
81f81b
44a 44d102
 
Scheme 35: Synthesis of crude catalyst mixture for the fourth catalyst generation. 
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The catalyst mixture was then directly subjected to back reaction screening and after 30 minutes 
all intermediate ratios could be determined by ESI-MS analysis. The most selective catalyst was 
clearly identified, but again a slight variation of the ratios between multiple and single catalyst 
screening was observed. These results demonstrate the potential of the screening protocol for 
combinatorial catalyst development. 
Ar
OH O
OCH3 Ar
OH O
OCD3
P +30 mol% cat. mix.
Ar
Ar H
N
OCH3
O
Ar = Ph, R = Ph (m/z
 = 671 and 674)
Ar = Ph, R = 4-F-Ph (m/z
 = 689 and 692)
Ar = oTol, R = Ph (m/z
 = 699 and 702)
Ar = oTol, R = 4-F-Ph (m/z
 = 717 and 720)
Ar = 3,5-(CH3)2-Ph, R = Ph (m/z
 = 727 and 730)
Ar = 3,5-(CH3)2-Ph, R = 4-F-Ph (m/z
 = 745 and 748)
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Ar
Ar H
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N
S
R
OTBDMS OTBDMS
 
 
Figure 16: Results of the catalyst mixture screening of fourth catalyst generation.  
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2.4 Mechanistic Investigations  
The results obtained from the back reaction screening also provided insights into the catalytic 
cycle. Mechanistic studies of amine-catalyzed MBH reactions have shown that C–C bond 
formation and the subsequent proton transfer have similar activation barriers and, depending on 
the reaction conditions, one or the other step may become primarily rate-limiting. For phosphine-
based catalysts only a computational study was reported, which predicted the proton transfer step 
to be rate-determining. However, Plata and Singleton have recently demonstrated that at present 
computational methods are unable to cope with the complex multi-step catalytic cycle of MBH 
reactions and, therefore, fail to produce reliable results.[53] 
104a, 104b
87a, 87b
84a,
 
84b
∆G
∆∆G1
 
(aldol)
∆∆G2
 
(proton transfer)
86a
86b
85a
85b
RO2C
RO2C
Pcat
RO2C
Pcat
Ar
O
RO2C
Pcat
Ar
OH
RO2C Ar
OH
RO2C
Pcat
H
RO2C
Pcat
Ar
OH
104a, 104b 87a, 87b 86a, 86b 85a, 85b 84a, 84b
89a, 89b 88a, 88b
ESI-MS
Ar = 4-NO2-Ph
a R = CH3
b R = CD3
 
Figure 17: Estimated qualitative energy profiles based on the results from the ESI-MS back reaction screening. 
The close match between the selectivities obtained from the back reaction screening and the 
preparative forward reaction indicates that C–C bond formation is the rate- and enantioselectivity-
determining step. A qualitative reaction coordinate consistent with the selectivity data is shown in 
Figure 17. The consensus between the product e.r. of the forward reaction and the ratio 87a/87b 
ASYMMETRIC MORITA-BAYLIS-HILLMAN REACTION        CHAPTER 2 
77 
determined from the ESI-MS signals of intermediates 89a and 89b in the back reaction implies 
that both ratios depend on the same transition state. This is the case if the aldol step is the step 
with the highest energy barrier. If the proton transfer were rate-determining (Figure 18), 
equilibration between intermediates 86a/86b and 87a/87b would occur, due to the now reversible 
aldol step. Thus, the ratio 89a/89b would depend on both ΔΔG⧧ of the proton transfer and the 
equilibrium constants K(86a/87a) and K(86b/87b), which differ because of the unequal relative energies 
of 86a and 86b, while the enantioselectivity of the forward reaction would be determined solely by 
ΔΔG⧧ of the proton transfer. Accordingly, the ratio 89a/89b would be expected to deviate from the 
e.r of the forward reaction, in contradiction to the observed match between the forward and back 
reaction.  
104a, 104b
87a, 87b
84a, 84b
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∆∆G2
 
(proton transfer)
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b R = CD3
 
Figure 18: Estimated qualitative energy profiles based on the results from the ESI-MS back reaction screening. 
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In addition, kinetic measurements were carried out to determine the reaction order in aldehyde by 
in situ 1H-NMR analysis of reaction process based on the signals of the methyl ester group of 
acrylate 104a (3.73 ppm) and MBH adduct 84a (3.71 ppm). Data were taken from four reactions, 
in which the aldehyde/acrylate ratio was varied from 0.5 to 3.0. The results clearly showed the 
reaction to be first order in aldehyde, providing further evidence that the aldol step is rate-limiting 
(Figure 19). 
O
H +
OMe
O
OH
OMe
O
CD2Cl2, RT
(1R,2R)-81b
 
(10 mol%)
105a 84a104a
O2N O2N
 
 
Figure 19: Kinetic analysis of the MBH reaction of methyl acrylate with 4-nitrobenzaldehyde. Double logarithmic plot of 
the dependence of the reaction rate on the initial aldehyde concentration. The data points correspond to aldehyde 
concentrations of 41.7, 83.3, 166.7, and 250.0 mmol/L and a constant acrylate concentration of 83.3 mmol/L. Linear fit 
for 105a: y = 0.9959x –12.175 (R2 = 0.99), consistent with first order in 105a. 
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2.5 Optimization of the Preparative Reaction 
From our screening experiments with 62 catalysts, three efficient catalysts (1R,2R)-81b, (1S,2R)-
48a, and (1S,2R)-48d, have emerged which all induce an e.r. of 95:5 in the reaction of methyl 
acrylate with 4-nitrobenzaldehyde. For further studies addressing the reaction parameters, 
(1R,2R)-81b was chosen because of its higher reactivity. First, the effect of different solvents was 
investigated. Using aprotic-polar solvents such as THF or Me-THF high yield and very good 
enantioselectivities were achieved (Table 25, entries 1-2). When the solvent system was changed 
to non-polar dichloromethane the enantiomeric excess was reduced by 4% (entry 3). On the other 
side, the same result like for THF was observed for toluene (entry 4). For protic solvents such as 
hexafluoro-2-propanol (HFIP) no conversion or for methanol low yield and enantioselectivity were 
detected (entries 5-6). Because of the acidity of HFIP, the enolate intermediate might be 
protonated which would quench the reactivity. In the case of MeOH, the hydrogen-bonding 
network of the catalyst-substrate intermediate could be disturbed which would influence the 
selectivity. Also the polar solvents acetonitrile and propylene carbonate gave only poor results 
(entries 7-8).  
Table 25: Screening of different solvents for the MBH reaction with 4-nitrobenzaldehyde 105a.[a]  
O
H +
OMe
O
OH
OMe
O
solvent [1M], RT, 6 h
(1R,2R)-81b
 
(10 mol%)
105a 84a104a
O2N O2N
OTBDMS
HNP
S
HN
(1R,2R)-81b
 
entry solvent yield [%][b] ee [%][c] entry solvent yield [%][b] ee [%][c] 
1 THF 92 94 (S) 5 HFIP n.d.[d] - 
2 Me-THF  90 93 (S) 6 MeOH 60 64 (S) 
3 CH2Cl2  91 90 (S) 7 MeCN 70 80 (S) 
4 Toluene 92 94 (S) 8 PC 74 80 (S) 
[a]: 0.1 mmol 105a, 0.2 mmol 104a in 0.1 mL solvent. [b]: After purification by preparative TLC. [c]: Determined by HPLC 
on a chiral stationary phase. [d]: No conversion to the product was observed by 1H-NMR analysis of the crude mixture.  
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Next, the influence of reaction time, ratio of the two starting materials, concentration, catalyst 
loading and addition of molecular sieves were investigated. Using a 5:1 acrylate to aldehyde ratio 
the MBH adduct was obtained with high yield and enantiomeric excess after both eight hours and 
six hours reaction time (Table 26, entries 1-2). When, the amount of methyl acrylate was lowered 
from five to two equivalents no loss of reactivity was observed (entry 4). Slightly higher 
enantioselectivity was obtained when the reaction solution was more diluted, however a lower 
yield was obtained (entry 5). With the use of activated molecular sieves the yield was further 
improved (entry 6). With a lower catalyst loading (5 mol%), lower yield and enantioselectivity were 
obtained using the standard conditions (entry 7).  
Table 26: Screening of different reaction parameters for the MBH reaction with 4-nitrobenzaldehyde.  
O
H +
OMe
O
OH
OMe
O
THF, RT, time
(1R,2R)-81b
 
(10 mol%)
105a 84a104a
O2N O2N
OTBDMS
HNP
S
HN
(1R,2R)-81b
 
entry 105 [mmol] 104a [mmol] time [h] THF [µL] yield [%][a] ee [%][b] 
1 0.1 0.5 8 50 98 93 (S) 
2 0.1 0.5 6 50 96 93 (S) 
3 0.1 0.5 4 50 93 93 (S) 
4 0.1 0.2 6 50 95 93 (S) 
5 0.1 0.2 6 100 92 94 (S) 
6[c] 0.1 0.2 6 100 98 94 (S) 
7[c,d] 0.1 0.2 6 100 84 92 (S) 
[a]: After purification by preparative TLC. [b]: Determined by HPLC on a chiral stationary phase. [c]: 50 mg Activated 
molecular sieves were used. [d]: 5 mol% Organocatalysts was used.  
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After the reaction conditions were optimized, the substrate scope was analyzed. Under the 
optimized conditions a wide range of aromatic and heteroaromatic aldehydes afforded the 
resulting chiral MBH products with high enantioselectivities and yield in the preparative reaction 
(Table 27, entries 1-12), with the exception of 4-methylbenzaldehyde 105k, which showed lower 
reactivity (entry 11) and cyclohexane carbaldehyde 105l, which gave only low enantiomeric 
excess and yield. Overall, catalyst (1R,2R)-81b clearly outperformed the best literature-known 
catalysts such as (2R,3S)-37 in terms of enantioselectivity and yield. 
Table 27: Substrate scope.[a] 
R
O
H
+
OMe
O R
OH
OMe
O
THF, rt
molecular sieves
(1R,2R)-81b
 
(x mol%)
105a-m 106a-m104a  
entry R product x t [h] yield [%][b] ee [%][c] 
1 4-NO2-C6H4 (105a) 106a 10 6 98 94 (S) 
2 2-NO2-C6H4 (105b) 106b 10 6 88 80 (S) 
3 4-CN-C6H4 (105c) 106c 10 18 93 92 (S) 
4 3,5-(CF3)-C6H3 (105d) 106d 10 18 98 92 (S) 
5 4-F-C6H4 (105e) 106e 20 48 69 90 (S) 
6 4-Cl-C6H4 (105f) 106f 20 48 89 90 (S) 
7 4-Br-C6H4 (105g) 106g 20 48 90 92 (S) 
8 C6H5 (105h) 106h 20 72 82 (73)[d] 90 (S) (90)[d] 
9 2-pyridine (105i) 106i 20 72 95 90 (S) 
10 2-furfural (105j) 106j 20 72 83 80 (S) 
11 4-Me-C6H4 (105k) 106k 20 96 42 85 (S) 
11 C6H11 (105l) 106l 20 96 36 30 (S) 
[a]: 0.1 mmol 105a-m, 0.2 mmol 104a in 0.1 mL THF. [b]: After purification by preparative TLC. [c]: Determined by HPLC 
on a chiral stationary phase. [d]: 1 mmol scale.   
ASYMMETRIC MORITA-BAYLIS-HILLMAN REACTION        CHAPTER 2 
82 
2.6 Conclusion 
In conclusion, the synthesis of four different catalyst generations starting from commercially 
available amino acids was described in this chapter (Figure 20). The effect of the chiral backbone, 
the H-bond donor moiety and the phosphine residue on the enantioselectivity of the MBH reaction 
was investigated by evaluating these catalysts.   
N
HP
S
N
H
1st Catalyst Generation
N
HP
O
O
HN
2nd Catalyst Generation
N
HP
3rd Catalyst Generation
N
H
S
O
N
HP
N
H
S
OTBDMS
4th Catalyst Generation  
Figure 20: Overview about synthesized catalyst generations.  
Moreover, the potential of mass spectrometric back reaction screening for the evaluation of 
catalysts for asymmetric MBH reactions was demonstrated. Screening of 62 bifunctional 
phosphines has led to an efficient catalyst for the reaction of methyl acrylate with aldehydes, 
showing improved enantioselectivity and scope compared to previously reported catalysts (Figure 
21). Finally, the back reaction screening protocol was successfully extended to multi-catalyst 
screening of crude catalyst mixtures containing up to six bifunctional phosphines.  
+
ESI-MS screening CatalystNO2
HO OCH3
O
NO2
HO OCD3
O H3CO
O
Pcat
OCD3
O
Pcat
+
TBDMSO
NH
P
NH
S
Pcat
 
Figure 21: Evaluation of chiral bifunctional phosphines by back reaction screening.  
In addition, the results from back reaction screening and additional kinetic studies have provided 
evidence that the enantioselectivity is determined in the C–C bond-forming step which is turnover-
limiting.  
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3.1 Introduction 
3.1.1 N-Heterocyclic Carbenes  
Carbenes are neutral carbon-based molecules that contain a divalent carbon atom with an 
electron sextet.[72] Their existence was first postulated by Dumas in 1835.[73] In the early stages of 
carbene research, it was assumed that carbenes were reactive intermediates that could not be 
isolated. For example, Wanzlick prepared an N-heterocyclic carbene upon vacuum pyrolysis of 
the corresponding trichloromethyl dihydroimidazole. However, they were only able to isolate the 
resulting dimeric carbene intermediate due to the high reactivity of the carbene. The equilibrium 
between the free and the dimeric carbene forms is now referred to as the Wanzlick equilibrium 
(Scheme 36).[74,75]  
N
N
Ph
Ph
CCl3
H 150 °C−
HCCl3
N
N
Ph
Ph
N
N
Ph
Ph
N
N
Ph
Ph
N
N
Ph
Ph
 
Scheme 36: N-heterocyclic carbene by Wanzlick.[74]  
Years later, after the pioneering reports by Bertrand in 1988[76] and Arduengo in 1991[77] 
(Figure 22) in which isolable heteroatom-stabilized carbenes were described, the research field 
which pertains to practical use of carbenes as catalysts for several organo- or metal-catalyzed 
transformations has grown tremendously.[78] For example, Enders and Teles developed the first 
triazolium-derived carbene which was the first commercially available N-heterocyclic carbene 
(NHC) catalyst.[79] 
P SiMe3
N
N
iPriPr
iPr
iPr
NNAd Ad
Bertrand in 1988[76] Ardunengo
 
in 1991[77]
N
NNPh Ph
Ph
Enders in 1995[79]  
Figure 22: Stable carbenes by Bertrand[76], Arduengo[77] and Enders[79].  
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The different NHC precursors can be divided into five key categories (Figure 23) depending on 
the number and nature of the heteroatoms in the ring structure. However, all categories contain 
at least one nitrogen atom in the ring system as a common element.[80] For organocatalysis, only 
triazolium-, imidazoline-, imidazole- and thiazole-derived precatalysts are used while cyclic alkyl 
amino carbenes (CAAC)[81] are predominantly utilized in metal-catalyzed transformations.  
N
N NR1
H
R3
R2
Triazolium-based NHC
N NR1
H
R4
R3R2
Imidazoline-based NHC
N NR1
H
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R3R2
Imidazole-based NHC
S N
H
R4
R3R2
Thiazole-based NHC
N
H
Ar
CAAC
R2
R1
 
Figure 23: Overview different structure types of NHC precatalysts.  
The most common lead structure used in asymmetric organocatalytic carbene-catalyzed reactions 
contains a triazolium ring system. The modular nature of this type of core structure permits the 
synthesis of a variety of chiral precatalysts. Furthermore, these type of azoles are easily 
accessible by many literature-described synthetic procedures.[80] Very often the active carbene is 
formed upon deprotonation of the azolium precursor by a base. The thermodynamic stability and 
the reactivity[82] of the resulting nucleophilic carbene is influenced by the different substituents on 
the triazolium unit (R1 to R3) and by heteroatoms in the ring structure. Compared to classical 
carbenes, NHC’s have a singlet ground-state configuration in which the carbene carbon has an 
sp2-hybridized lone pair (HOMO) and a p-orbital which is part of a π-system with a low lying 
unoccupied antibonding orbital. The two nitrogen heteroatoms stabilize the free carbene through 
a π-donating interaction of the N-lone pairs with the p-orbital. In addition, a σ-withdrawing effect of 
the C-N bonds exists (Figure 24).[83] The acidity of the different azole-based carbene precursor 
was investigated by Smith and O’Donoghue, who showed that the most acidic precursor contains 
a triazolium ring and the acidity can be further increased by installing electron-withdrawing N-aryl  
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substituents.[84] Mayr evaluated the effect of the azole ring and the N-substituents on the 
nucleophilicity experimentally and found that imidazoline-based carbenes are more nucleophilic 
compared to the triazolium-derived carbenes.[82] 
X
N NR
H Y
base
X
N
C
N
R
π−donating interactions
σ−withdrawing effect
- acidity of C-H
- nucleophilicity
- stability of carbene
- enantioselectivity
- rigidity
 
Figure 24: Lead structure for the triazolium-based organocatalysts. 
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3.1.2 Benzoin Reaction 
The most studied carbene-catalyzed reaction is the benzoin reaction in which two aldehydes are 
coupled to give the so-called homo-benzoin product.[78,80] The first example of a benzoin reaction 
was discovered by Wöhler and Liebig in 1832 which employed cyanide as catalyst.[85] Much years 
later the first carbene-based pathway was developed by Ukai using thiazolium salts in combination 
with a base.[86] After these seminal discoveries were reported many research groups around the 
world began to design chiral N-heterocyclic carbenes for the asymmetric benzoin-coupling (see 
Scheme 37 for representative reactions of benzaldehyde). The first chiral thiazolium-based 
catalyst 106 was developed by Sheenan in 1974, from which the chiral benzoin product was 
obtained in very low yield and moderate enantioselectivity.[87] Years later, Leeper introduced chiral 
triazolium salt-based precatalysts 107 for the asymmetric aldehyde coupling, and with this new 
carbene a higher enantiomeric excess and moderate yield was observed.[88] This lead structure 
was further optimized by the Enders group and from this work precatalyst 108 was developed.[89] 
This was the first time excellent selectivities and high yield were obtained with a chiral NHC 
catalyst. One year later, Connon and Zeitler introduced the bifunctional triazolium salt 109 as a  
powerful catalyst for the asymmetric benzoin reaction showing high reactivity and 
enantioselectivity.[90] In 2010, the Waser group developed a thiourea-based triazolium salt 110 
and they observed high enantioselectivity but low yield in the benzoin coupling.[91]  
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H Ph
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NEt3
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Scheme 37: Representative examples of carbene-catalyzed asymmetric benzoin reaction.  
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After more than half a century since the cyanide-catalyzed benzoin condensation mechanism was 
postulated by Lapworth,[92] the mechanism of thiazolium-catalyzed benzoin reactions was 
proposed by Breslow in 1958.[93] In this proposal, the thiazolium salt is first deprotonated by an 
external base to form the active nucleophilic carbene which can then react in the catalytic cycle 
presented in Figure 25. In the first step, the electrophilic carbonyl carbon is nucleophilically 
attacked by the carbene, thereby generating the resulting zwitterionic thiazolium-aldehyde 
intermediate. After a proton shift, the nucleophilic and neutral Breslow intermediate is formed 
which has an inverted reactivity compared to the aldehyde. Recently, the diamino enol species 
(Breslow intermediate) derived from imidazoline-based carbene and aromatic aldehydes was 
characterized by Berkessel using NMR studies.[94] Moreover, the investigations have shown that 
this intermediate can react as a nucleophilic acyl anion equivalent. In the next step of the catalytic 
cycle, a second aldehyde molecule is attacked by the Breslow intermediate to form a zwitterionic 
adduct. The final benzoin product is released after elimination of the carbene catalyst. Very recent  
computational studies have shown that the proton-transfer step for the formation of the Breslow 
intermediate is the rate-limiting step.[95,96] 
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Figure 25: Catalytic cycle of the benzoin reaction proposed by Breslow.[93]  
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In 2004, the Houk group investigated the stereoselectivity of the asymmetric benzoin reaction. 
Therein they used computational methods in order to determine the transition state for the 
enantioselectivity-determining C-C bond formation step.[97] As a model system they studied the 
benzoin condensation of benzaldehyde catalyzed by a triazolium-based catalyst developed by 
Enders.[98] The lowest-energy transition state is depicted in Figure 26. Because of steric 
interactions, the phenyl substituent of the aldehyde in the Breslow intermediate adopts an anti-
configuration to the tert-butyl group of the catalyst to generate an E-enolamine intermediate. The 
aromatic system of the second aldehyde molecule is situated anti to the phenyl group of the 
Breslow intermediate and anti to the N-phenyl substituent of the catalyst. From the structure of the 
transition state a distance between the iminium ion and the aromatic system of benzaldehyde of 
≈3.4 Å was calculated which is consistent with π-aryl-iminium ion interactions. Therefore, together 
with the steric shielding of one side by the tert-butyl group of the catalyst, the corresponding re 
transition state is favored. 
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Figure 26: Transition state of the C-C bond-forming step.  
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3.1.3 Cross-Benzoin Reaction 
The benzoin-type coupling reaction of two different electrophiles catalyzed by a NHC-catalyst is 
known as the cross-benzoin reaction (with two aldehydes a representative example is shown in 
Scheme 38). Because of the use of a different second aldehyde, four possible hydroxyl ketone 
products can be formed. Therefore, the challenging problem in this scenario is to obtain the 
desired cross-benzoin product chemoselectively in high yield and prevent the formation of to the 
undesired homo-benzoin products. One strategy which promotes formation of the cross-product 
is to tune the reactivity of one aldehyde such that the Breslow intermediate is preferably formed 
with the sterically less demanding or more electrophilic aldehyde. When both aldehydes have 
similar sterical and electronic chemical properties, a statistical or thermodynamic product mixture 
is observed. To further complicate this process, the reversibility of the cross-benzoin reaction 
hampers the chemoselective formation of the kinetic products.[80] 
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Scheme 38: Cross-benzoin reaction of two aldehydes.  
In 1976, the first intramolecular cross-benzoin reaction was developed by Cookson and 
coworkers. [99] In this approach, the two aldehyde functions of pentanedials were coupled to form 
a racemic cyclic α-ketol. This transformation was catalyzed by a thiazolium salt, but unfortunately 
the desired cross-product was not formed chemoselectively and a mixture of both hydroxyl 
ketones was isolated (Scheme 39).  
NHCcat, NEt3
O O MeCN, 80 °C
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O
O
OH
+
S
N Cl
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Scheme 39: First intramolecular cross-benzoin reaction by Cookson[99].  
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In the same year, Stetter introduced the first intermolecular cross-benzoin reaction between 
aromatic and aliphatic aldehydes catalyzed by a thiazolium derived carbene (Scheme 40). Good 
chemoselectivity towards the cross-benzoin products was achieved by using an excess (three 
equivalents) of the aliphatic aldehyde. Nevertheless, only with ortho substituted aromatic 
aldehydes was good selectivity to one cross-acyloin product observed, showing that this reaction 
was mainly controlled by the substrate.[100] 
S
N Cl
NHCcatAr
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EtOH, 80 °C Ar
O
OH
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Ar
OH
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Alk+
OHAr = Ph, 2-Cl-Ph Alk = iPr, CH3, nPr  
Scheme 40: First intermolecular cross-benzoin reaction by Stetter.[100]  
Inspired by the work of Stetter, in 2011 Zeitler and Connon developed a cross-acyloin 
condensation between aliphatic and ortho substituted aromatic aldehydes using a triazolium salt 
with an N-pentafluorophenyl substituent.[101] The resulting cross-benzoin product was isolated with 
high chemoselectivity and in good yield from a wide variety of substituted aromatic and aliphatic 
aldehydes (Scheme 41). In this case, high chemoselectivity was achieved because of the selective 
Breslow intermediate formation with the alkyl aldehyde due to steric hindrance of the ortho 
substituent of the aryl aldehyde. Moreover, retro-benzoin reactivity was prevented by steric 
shielding of the ortho residue in the cross-acyloin, which prevented the attack of the NHC catalyst 
on the product. Finally, an asymmetric cross-benzoin reaction between ortho trifluoromethyl 
benzaldehyde and propionaldehyde was achieved in high yield and 77% ee using a bifunctional 
chiral triazolium salt.  
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Scheme 41: Cross-benzoin reaction between aryl and alkyl aldehydes by Zeitler and Connon.[101]  
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The effect of the aldehyde ratio on the chemoselectivity of the cross-benzoin reaction was further 
investigated by Yang in 2011.[102] In this approach, a large excess (10 equivalents) of acetaldehyde 
was used in the cross-benzoin condensation with different para-substituted aryl aldehydes. The 
precatalyst used contained a core structure which was identical to that of Zeitler and Connon. This 
species gave the resulting products in high chemoselectivity and in high yield. In one example thy 
carried out a cross-benzoin condensation between 4-chlorobenzaldehyde and acetaldehyde 
catalyzed by a chiral bifunctional precatalyst. This reaction gave the chiral hydroxyl ketone product 
in excellent chemoselectivity, moderate yield and enantioselectivity. 
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Scheme 42: Cross-benzoin reaction between aryl and acetaldehyde by Yang.[102]  
In 2014, the Gravel group introduced a new concept for the synthesis of cross-acyloin products 
between aliphatic and aromatic aldehydes.[103] In their approach, the chemoselectivity of the 
reaction was achieved by catalyst design rather than substrate control. The chemoselectivities 
obtained after the screening of various triazolium salts indicated that the size of the fused ring 
system is crucial for the selective formation of the cross-benzoin product (Scheme 43). More 
specifically, they found that precatalysts with a six-membered fused ring system gave the best 
chemoselectivities. With the reaction conditions optimized, they investigated the substrate scope 
and a wide variety of different aldehydes were coupled. By using a chiral triazolium salt, moderate 
enantioselectivities were obtained. In all cases, the resulting cross-benzoin products were isolated 
in high yield and with excellent chemoselectivity.  
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Scheme 43: Catalyst screening for the cross-benzoin reaction by Gravel.[103]  
In a different approach to the cross-benzoin reaction, ketones were coupled with aldehydes to 
give aldehyde-ketone cross-benzoin products. One example of an intramolecular aldehyde-ketone 
cross-benzoin reaction was developed by Ema and Sakai[104,105] for the synthesis of chiral bicyclic 
tertiary alcohols from the corresponding cyclic diketone. High enantioselectivies and moderate to 
good yield were achieved on a wide variety of different six- or five-membered cyclic starting 
materials when the chiral triazolium salt was used (Scheme 44). 
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Scheme 44: Cross-aldehyde-ketone benzoin reaction by Ema and Sakai.[104]  
In 2009 the Enders group developed an intramolecular coupling of aromatic aldehydes with 
trifluoromethyl ketones to form racemic α-hydroxy-α-trifluoromethyl ketones catalyzed by an 
achiral triazolium salt.[106] One year later, the same research group extended the synthetic protocol 
towards an asymmetric version using a chiral precatalyst (Scheme 45). The resulting chiral 
hydroxyl ketones were isolated in good to excellent yield and with enantioselectivities of up to 83% 
ee.[107]  
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Scheme 45: Intermolecular cross-benzoin reaction of aldehydes with ketones by Enders.[106]  
One example of a synthetically useful extension of the cross-benzoin reaction is the coupling of 
Breslow intermediates with imines to obtain chiral amine products. In 2001, the first cross-aza-
benzoin reaction was introduced by Murry and Frantz. In their approach, α-amido ketones were 
synthesized via a thiazolium-catalyzed coupling of aldehydes with acylimines.[108] Recently, the 
Rovis group developed a more synthetically useful asymmetric aza-benzoin reaction between 
alkyl aldehydes and N-Boc protected aromatic imines which gave highly enantioenriched Boc-
protected amines. All amines were isolated in high yield and with excellent enantioselectivities 
(Scheme 46).[109]  
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Scheme 46: Asymmetric cross-aza-benzoin reaction by Rovis.[109]  
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3.1.4 Mechanistic Investigations 
Recently, Gravel and coworkers investigated the mechanism of the piperidone-based carbene 
catalyzed cross-benzoin reaction through experimental and computational studies.[110] In the 
proposed catalytic cycle (Figure 27), first the active carbene is formed by deprotonation followed 
by nucleophilic attack to generate a zwitterionic intermediate, which is in agreement with the 
mechanism of Breslow (Figure 25). A carbene-aldehyde adduct is formed after intermolecular 
protonation, followed by a second deprotonation to create a resonance-stabilized zwitterion, 
respectively Breslow intermediate. Then, the carbonyl center of a second aldehyde molecule is 
attacked by the nucleophilic acyl intermediate, and after catalyst regeneration the final cross-
benzoin product is released.  
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Figure 27: Mechanism of the cross-benzoin reaction proposed by Gravel.[110]  
In the mechanistic investigations by Gravel the reaction coordinate of the cross-benzoin reaction 
was calculated and compared for every possible aldehyde combination. According to these 
calculations, the Breslow intermediate was preferably formed with the aliphatic aldehyde 
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compared to the aromatic aldehyde, because the Breslow intermediate derived from aryl aldehyde 
was found to be 5.7 kcal/mol higher in energy. Because of stabilizing π-stacking and π-cation 
interactions of the phenyl ring with the triazolium ring, the nucleophilic attack from the Breslow 
intermediate to the aryl aldehyde was favored for the cross-benzoin condensation. Modulation of 
the transition state for the rate-limiting carbon-carbon bond-forming step showed that the Z-
Breslow adduct is generated which then attacks the aldehyde on the si face. Additionally, the 
reversibility of the cross-benzoin reaction was studied by 1H-NMR analysis of cross-over 
experiments in which either cross- or homo benzoin products were mixed with aldehyde and 
catalyst. In case of the cross-benzoin products, the results showed that this reaction was fully 
reversible. Only with the alkyl-alkyl benzoin product no crossed products were detected, which 
indicated that this benzoin reaction is irreversible. Based on the results of the DFT calculations 
and experimental studies, the chemoselectivity is governed by kinetic control. Last, the effect of 
the fused-ring system of the catalyst on the chemoselectivity was studied. For carbenes with a 
five, six or seven membered ring system the corresponding transition state for the carbon-carbon 
formation step was calculated. Based on the comparison of the energies of these three transition 
states the authors suggested that steric interactions of the fused-ring system might control the 
chemoselectivity of the reaction. If the ring system was too small, a thermodynamic mixture of the 
products was obtained because all steps were found to be reversible. According to computational 
studies, the energy barriers in the reaction profile were found to be lower compared to the six-
membered catalyst. Moreover, if the fused-ring system was too big, the energy of the C-C forming 
step would be increased by 2.7 kcal/mol which is reflected by the lower reactivity of this type of 
catalyst with a seven-membered ring.  
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3.2 Catalyst Synthesis 
The precatalyst lead structure for the asymmetric cross-benzoin reaction is presented in Figure 
28. Its modular structure seemed to be ideal for catalyst development because the effect of several 
structural units can be investigated. For example, by varying the N-aryl residue at the triazolium 
ring system the effect of the acidity of the carbene C-H proton or the nucleophilicity can be studied. 
Moreover, starting from different chiral building blocks the role of the chiral back bone can be 
investigated. In addition to steric hindrance, the effect of hydrogen-bonding units has to be 
considered. The influence of rotation of the chiral backbone on the chemo- and enantioselectivity 
of the reaction can be studied installing groups next to the stereogenic center. Studies by 
Gravel[103] have shown that six-membered fused ring systems are crucial for the chemoselectivity 
of the cross-benzoin reaction. Thus, morpholine- (X=O) or piperidine (X=CH2) -based catalysts 
can be prepared to investigate this phenomenon.  
X
∗ N
N
N
BF4 N-aryl residue
steric effects
chiral backbone  
Figure 28: Catalyst lead structure for the asymmetric cross-benzoin reaction.  
 
 
  
ASYMMETRIC CROSS-BENZOIN REACTION         CHAPTER 3 
99 
3.2.1 Synthesis of Morpholine-Based Triazolium Salts 
The retrosynthetic analysis of chiral morpholine-based precatalysts is shown in Figure 29. This 
catalyst generation is derived from commercially available enantiopure amino acids which are 
converted to the resulting N-protected methyl esters. Using different Grignard reagents for the 
synthesis of the tertiary alcohol intermediates, the steric effect of the residues next the stereogenic 
center can be investigated. The lactam adduct can be synthesized in a one-pot two step procedure 
of Glorius starting from the deprotected amino alcohol.[111] In the last step, the triazolium salt 
intermediate can be formed using the one-pot three-step procedure of Rovis.[112] In this one-pot 
synthetic strategy, different N-aryl hydrazines can be employed which allow the modification at 
the N-aryl position of the precatalyst.  
O
∗ N
N
N
R3
R2
R1
R1
BF4 O
∗ NH
R2
R1
R1
O OH
∗ NHPG
R2
R1
R1
O
∗ NHPG
R2
MeO
 
Figure 29: Retrosynthetic analysis of morpholine-based precatalysts. 
First, commercially available amino alcohols 111a-f were converted to the resulting lactams 112a-
f by treating the starting material with chloroacetyl chloride (CAC) to form the chloro acetamide 
intermediate. Afterwards, sodium hydride was added to the crude chloro acetamide and after 
cyclization the corresponding lactams 112a-f were isolated in low to moderate yield. In the last 
step, the triazolium salts 113a-f were synthesized using the one-pot three-step synthetic protocol 
developed by the Rovis group.[112] First an imidate intermediate was formed by treatment of the 
lactam with Meerwein’s salt followed by amidrazone adduct formation. In the last step, the 
precatalyst was formed by refluxing the crude amidrazone intermediate in trimethyl orthoformate. 
After purification of the crude product all triazolium salts 113a-f were isolated in low yield. In each 
case the crude reaction mixture after the cyclization step with orthoformate was analyzed by ESI-
MS analysis and indicated predominantly product formation. However, because of purification 
problems only low yield were achieved (Table 28).  
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Table 28: Synthesis of triazolium salts derived from commercially available amino alcohols 113a-f.  
O
N
N
N
BF4
R
NH2
OH
N
H
O
R O
R
C6F5
CAC, NEt3
CH2Cl2, 0 °C →
 
RT, 16 h
1)
NaH
THF, 0 °C →
 
RT, 4 h
2)
C6F5-NHNH2
CH2Cl2, RT, 4 h
2)
CH(OMe)3
MeCN, 80 °C, 18-24 h
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
113a-f112a-f111a-f  
entry R lactam 112 (yield in %) 
triazolium salt 113 
(yield in %) 
1 
 
112a (64) 113a (10) 
2 
 
112b (64) 113b (34) 
3 
 
112c (52) 113c (4) 
4 
 
112d (85) 113e (19) 
5 
 
112e (47) 113f (35) 
To study the effect of residues next to the stereogenic center, catalysts such as 117a or 117b 
were synthesized in a six-step synthesis. Tertiary alcohols 115a-b were formed by treating the 
corresponding amino acid hydrochloride salts 114a-b with an excess of methyl magnesium 
bromide reagent and after lactam formation intermediates 116a-b were isolated in good to 
moderate yield over two steps. Again, the challenging step was the isolation of the precatalyst. 
After the one-pot, three-step synthesis the triazolium salts 117a-b were only obtained in low to 
moderate yield (Scheme 47).  
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O
N
N
N
BF4
R
NH3Cl
OMe
N
H
O
R O
R
C6F5
CAC, NEt3
CH2Cl2, 0 °C →
 
RT, 16 h
1)
NaH
THF, 0 °C →
 
RT, 4 h
2)
C6F5-NHNH2
CH2Cl2, RT, 4 h
2)
CH(OMe)3
MeCN, 80 °C, 18-24 h
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
O
R
NH2
OH
MeMgBr
Et2O, 
 
0 °C →
 
50 °C, 16 h
R = Ph (83%)
R = Bn (99%)
115a
115b
R = Ph
R = Bn
114a
114b
R = Ph (27%)
R = Bn (66%)
116a
116b
R = Ph (10%)
R = Bn (64%)
117a
117b  
Scheme 47: Synthesis of triazolium salts 117a-b. 
To obtain a more modular lead structure, the amino acid was changed to threonine, thereby 
increasing the possible positions which could be optimized. For threonine-derived triazolium salts 
both diastereomers of the precatalyst were prepared following an eight-step synthetic procedure. 
In the first step, the secondary alcohol was protected with TBDMS chloride followed by addition of 
different Grignard reagents to afford the resulting tertiary alcohol intermediates 120a-d. After 
palladium catalyzed carboxybenzyl (Cbz) deprotection of the amino group under hydrogen 
atmosphere, the resulting crude amines were directly used for the one-pot lactam synthesis. 
Afterwards the crude reaction mixture was purified by column chromatography to give the lactams 
121a-d in low to good yield. Only in the case of the diethyl substituted lactam the yield was low. 
This could be explained by the steric hindrance of the ethyl substituents, which might disfavor the 
cyclization of the chloro acetamide intermediate. For lactam 121a and 121b the final precatalysts 
122a respectively 122b were isolated in low yield after using the one-pot standard procedure 
(Table 29, entries 1-2). Moreover, for diethyl substituted lactam 121c the desired precatalyst 122c 
was isolated in moderate yield (entry 3). No pure product was obtained in the synthesis of 
triazolium salt derived from the diphenyl substituted lactam 121d due to the low solubility of the 
lactam precursor in dichloromethane. Moreover, problems in the purification step which resulted  
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from low conversion to the desired product and byproduct formation further lowered the yield of 
triazolium salt formation (entry 4).  
Table 29: Synthesis of threonine-derived triazolium salts 122a-d. 
N
H
O
∗
O
CAC, NEt3
CH2Cl2, 0 °C →
 
RT, 16 h
2)
NaH
THF, 0 °C →
 
RT, 4 h
3)
Pd/C, H2 (1 atm)
MeOH, RT, 16 h
1)
R
R
TBDMSCl,
DMAP (cat.), imidazole
DMF, RT, 48 h
∗
OH
NHCbz
OMe
O
∗
TBDMSO
NHCbz
OMe
O
RMgBr
Et2O, 
 
0 °C →
 
RT, 16 h
∗
TBDMSO
NHCbz
OH
RR
TBDMSO
120a-d(96%)
(96%)
(2R,3S)-119a
(2S,3S)-119b
(2R,3S)-118a
(2S,3S)-118b
121a-d
O
N
N
N
BF4
C6F5
C6F5-NHNH2
CH2Cl2, RT, 4 h
2)
CH(OMe)3
80 °C, 18-24 h
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
∗
TBDMSO
R
R
122a-d  
entry start material R alcohol 120  (yield in %) 
lactam 121 
(yield in %) 
triazolium salt 122 
(yield in %) 
1 (2R,3S)-115a Me 120a (91) 121a (73) 122a (18) 
2 (2S,3S)-115b Me 120b (99) 121b (73) 122b (19) 
3 (2R,3S)-115a Et 120c (80) 121c (29) 122c (40) 
4 (2R,3S)-115a Ph 120d (84) 121d (84) 122d (-[a]) 
[a]: No pure product was isolated.  
To investigate the effect of the N-aryl residue on the triazolium ring on the asymmetric cross-
benzoin reaction, threonine-derived precatalysts with different N-substituents were synthesized 
(Table 30). The aromatic hydrazines used were either commercially available (phenyl hydrazine) 
or freshly prepared by basic aqueous extraction (saturated sodium carbonate solution in ether) of 
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the corresponding hydrochloride salt. 2,4,6-Trimethylphenylhydrazine hydrochloride was 
commercially available and the other hydrazine precursors were prepared by a of Bolm.[113] In this 
process, di-tert-butyl azodicarboxylate was treated with the corresponding Grignard reagent to 
form the resulting Boc protected hydrazine which was converted to the final hydrazine 
hydrochloride salt after Boc deprotection. Finally, all hydrazines were successfully applied for the 
synthesis of four different triazolium salts derived from lactam 121a and in all cases the resulting 
precatalysts 123a-d were isolated in moderate yield. 
Table 30: Synthesis of different N-aryl substituted precatalysts 123a-d derived from lactam 121a.  
N
H
O
O
TBDMSO
R-NHNH2
CH2Cl2, RT, 4 h
2)
CH(OMe)3
80 °C, 6-18 h
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
O
N
N
N
BF4
R
TBDMSO
121a 123a-d  
entry R triazolium salt 123  (yield in %) entry R 
triazolium salt 123 
(yield in %) 
1 
 
123a (58) 1 
iPr
iPr
iPr
 
123c (36) 
2 
 
123b (55) 2 
MeO
OMe  
123d (53) 
Precatalyst 128 was designed in order to investigate the steric effect of the silyl group on the 
stereo- and chemoselectivity of the cross-benzoin reaction. TMS protected threonine intermediate 
125 was prepared in very good yield by silylation of the hydroxyl group with TMS chloride. After 
methyl Grignard addition, the purified alcohol adduct 126 was subjected to palladium catalyzed 
Cbz deprotection under hydrogen atmosphere. The crude amine was then directly converted into 
the lactam adduct to give lactam 127 in only 9% yield. A possible explanation for the low yield 
might be the low stability of the TMS group towards hydrolysis so that under the applied reaction 
conditions the TMS group might have been cleaved. Unfortunately, ESI-MS analysis of the crude 
reaction mixture of the triazolium salt synthesis showed no conversion to the desired precatalyst 
128 (Scheme 48). Again, due to the low stability of the TMS-ether group only the product without  
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a TMS-ether group and various unknown byproducts were detected by ESI-MS analysis.  
N
H
O
O
CAC, NEt3
CH2Cl2, 0 
°C →
 
RT,
 
16 h
2)
NaH
THF, 0 °C →
 
RT, 4 h
9%
3)
Pd/C, H2 (1 atm)
EtOAc, RT, 16 h
1)
TMSCl, imidazole
DMF, RT, 48 h
95%
OH
NHCbz
OMe
O TMSO
NHCbz
OMe
O
MeMgBr
Et2O, 
 
0 °C →
 
RT, 16 h
88%
TMSO
NHCbz
OH
TMSO
126125124
127
O
N
N
N
BF4
C6F5
C6F5-NHNH2
CH2Cl2, RT, 4 h
2)
CH(OMe)3
80 °C, 18 h
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
TMSO
128  
Scheme 48: Synthesis of TMS-protected threonine-derived triazolium salt 128.  
Because of the problems encountered in the synthesis of the TMS protected threonine-derived 
precatalyst and the failed isolation of the triazolium salt 128, a different approach which began 
from the commercially available O-tert-butyl-L-threonine methyl ester hydrochloride 129 was 
investigated. Herein, a smaller group was installed at the hydroxyl position to study the effect of 
steric interaction on the chemoselectivity of the cross-benzoin reaction. Cbz protected amine 130 
was obtained in moderate yield and after Grignard addition the resulting tertiary alcohol adduct 
131 was isolated in good yield. In the next synthetic sequence, the alcohol intermediate was 
converted to the lactam 132 according to the three step procedure for the previous lactam 
synthesis. Following a standard protocol for the synthesis of a triazolium salt, the final precatalyst 
133 was not isolated after purification by column chromatography (Scheme 49). ESI-MS analysis 
of the crude reaction mixture after hydrazine addition showed clearly the formation of the 
amidrazone intermediate, but after refluxing in trimethyl orthoformate only one by-product without 
the tert-butyl group was detected which indicated that the alcohol was deprotected under 
condensation reaction conditions.  
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N
H
O
O
CAC, NEt3
CH2Cl2, 0 
°C →
 
RT, 
16 h
2)
NaH
THF, 0 °C →
 
RT, 4 h
66%
3)
Pd/C, H2 (1 atm)
MeOH, RT, 16 h
1)
CbzCl, NEt3
CH2Cl2, 0 °C →
 
RT, 16 h
49%
O
NH3Cl
OMe
O O
NHCbz
OMe
O
MeMgBr
Et2O, 
 
0 °C →
 
RT, 16 h
77%
O
NHCbz
OH
O
131130129
O
N
N
N
BF4
C6F5
O
133 132
C6F5-NHNH2
CH2Cl2, RT, 4 h
2)
CH(OMe)3
80 °C, 18 h
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
 
Scheme 49: Synthesis of O-tert-butyl threonine-derived triazolium salt 133.  
The synthetic approach to the phenyl serine-derived triazolium salt is presented in Scheme 50. 
Starting from L-phenyl serine 134, the N-Cbz protected methyl ester intermediate 135 was isolated 
in 95% yield after treatment of amino acid 134 with thionyl chloride in methanol followed by amino 
group protection with benzyl chloroformate. The O-TBDMS protected adduct 136 was isolated in 
moderate yield using the standard synthetic protocol with TBDMS chloride, catalytic amount of 
DMAP and imidazole. The reason for the lower yield obtained in this case compared to the 
threonine derivative could be due to the steric hindrance at the benzylic alcohol position which 
disfavors the TBDMS silylation of the hydroxyl group. This is reinforced by the observation, that 
after column chromatography 50% of the starting material 135 was recovered. After Grignard 
addition to the ester adduct 136, Cbz deprotection and one-pot lactam formation, intermediate 138 
was isolated in good yield over all steps. Lastly, the phenyl serine-derived triazolium salt 139 was 
formed in 18% yield using the previous standard methodology for the precatalyst synthesis.  
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N
H
O
O
TBDMSCl,
DMAP (cat.), imidazole
DMF, 
 
RT, 48 h
50%
OH
NHCbz
OMe
O TBDMSO
NHCbz
OMe
O
TBDMSO
NHCbz
OH
TBDMSO
137
136135
138
OH
NH2
OH
O
134
thionyl chloride
MeOH, 0 °C →
 
75 °C, 16 h
1)
CbzCl, DIPEA
THF, 0 °C →
 
RT, 16 h
95%
2)
MeMgBr
Et2O, 
 
0 °C →
 
RT, 
16 h
91%
CAC, NEt3
CH2Cl2, 0 °C →
 
RT, 16 h
2)
NaH
THF, 0 °C →
 
RT, 4 h
71%
3)
Pd/C, H2 (1 atm)
MeOH, RT, 16 h
1)
O
N
N
N
BF4
C6F5 C6F5-NHNH2
CH2Cl2, RT, 4 h
2)
CH(OMe)3
80 °C, 24 h
18%
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
TBDMSO
139  
Scheme 50: Synthesis of phenyl serine-derived triazolium salt 139.  
The last type of morpholine-based precatalyst contains a chiral diphenylmethane group. 
Triazolium salt 144 was synthesized following an eight step sequence which began from Boc-L-
serine methyl ester 140 (Scheme 51). First, dimethyl oxazolidine 141 was obtained by refluxing 
compound 140 with 2,2-dimethoxypropane and a catalytic amount of p-TsOH. Alcohol 
intermediate 141 was isolated in good yield after treating ester 142 with an excess of phenyl 
magnesium bromide. In the following step amino alcohol 143 was synthesized according to a 
procedure of Avenoza.[114] In this synthetic approach, catalytic dehydroxylation occurred via 
formation of a carbamate intermediate which was then cleaved by palladium hydroxide in 
hydrogen atmosphere. Subsequent hydrolysis in sodium hydroxide water/methanol solution gave 
amino alcohol 143 in good yield. The crude amino alcohol 139 was directly converted to the lactam 
144 and the final precatalyst 145 was isolated in 14% yield following the modified Rovis 
procedure.[112]  
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Pd(OH)2, 
H2
 
(1atm)
formic acid, 
65 °C, 48 h
NaOH
MeOH/H2O,
70 °C, 16 h
91%
O
NHBoc
HO OMe
O NBoc
O
OMe
O NBoc
OH
NH2
HO
N
H
O
O
C6F5-NHNH2
CH2Cl2, RT, 4 h
2)
CH(OMe)3
MeCN, 80 °C, 24 h
14%
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
O
N
N
N
BF4
C6F5 CAC, NEt3
CH2Cl2, 0 
°C →
 
RT, 16 h
1)
NaH
THF, 0 °C →
 
RT, 4 h
70%
2)
PhMgBr
THF, 0 °C →
 
RT, 16 h
87%
DMP, p-TsOH (cat.)
toluene, 125 °C, 6 h
57%
145 143144
142140 141
1)
 
2)
 
Scheme 51: Synthesis of triazolium salt 145 derived from diphenylmethane lactam 144.  
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3.2.2 Synthesis of Piperidine-Based Triazolium Salts 
For the synthesis of piperidine-based precatalysts two different synthetic approaches were 
developed (Figure 30). In strategy A, the ester lactam precursor was synthesized following a multi-
step sequence which began with the commercially available lysine methyl ester hydrochloride. 
The resulting lactam intermediate is a useful synthetic precursor because the ester group can be 
converted to different functional groups easily, which permits the preparation of structurally diverse 
precatalysts. In the last step, the triazolium salt can be formed using the standard cyclization 
protocol from the previously described syntheses. Because the cyclization of the fully protected 
lysine intermediate under harsh reaction conditions proved to be problematic and therefore an 
alternative approach was developed. For the strategy B, the synthetic precursor was the 
commercially available N-Boc protected pipecolic acid. After alpha oxidation and Boc deprotection 
the ester lactam adduct could be formed and then converted to different functionalized lactams. 
The synthesis of the triazolium salt synthesis proceeded in the same manner as in strategy A. 
∗ N
N
N
R2
R1
BF4
∗ N
OHO
Boc
O
NH2
∗H2N
∗ NH
O
OMeO
∗ NH
R1
O
strategy
 A
strategy
 B
OMe
• 2 HCl
 
Figure 30: Retrosynthetic analysis of piperidine-based triazolium salts.  
The first strategy was investigated by Mirjam Schreier during her Wahlpraktikum. In this approach, 
lysine methylester hydrochloride 146 was converted to the double Boc protected amino acids 147 
using Boc anhydride and sodium hydrogen carbonate as a base. Afterwards, the amide 148 was 
obtained in high yield by oxidation of the alpha position to the primary N-Boc amino group using 
ruthenium oxide and sodium periodate in an ethyl acetate/water mixture. Lactam ester 149 was 
isolated in 71% yield after trifluoroacetic acid induced cyclization of the amide intermediate 148. 
In the following steps, the ester group was converted to the tertiary alcohol adduct 150 by adding 
the Grignard reagent. After silylation with TBDMS triflate the final O-TBDMS-protected lactam 151 
was isolated in good yield over the last two steps (Scheme 52).  
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BocHN
OMe
O
EtOAc/H2O, RT, overnight
80%
RuO2, NaIO4
H2N OMe
O
Boc2O, NaHCO3
MeOH, RT, 3 days
69%
TFA
reflux, 
overnight
71%
• 2 HCl
THF, 0 °C →
 
RT, 4 h
70%
PhMgBr
NH2 NHBoc
BocHN
OMe
O
NHBoc
O
N
H
O
MeO
O
CH2Cl2, 0 °C →
 
RT, 15 h
70%
TBDMSOTf, NEt3N
H
O
TBDMSO
N
H
O
HO
146 147 148
151 150 149  
Scheme 52: Synthesis of TBDMS-protected diphenylmethane-derived lactam 141.  
In the last step of the precatalyst synthesis, lactam 151 was subjected to the one-pot three step 
protocol of Rovis[112] and after column chromatography the resulting triazolium salt 152 was 
isolated in low yield (Scheme 53).  
BF4
C6F5-NHNH2
CH2Cl2, RT, 4 h
2)
CH(OMe)3
80 °C, 18 h
8%
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
N
HTBDMSO
O
N
N
N
C6F5
OTBDMS
152151  
Scheme 53: Synthesis of triazolium salt 152 starting from O-TBDMS protected diphenylmethane lactam 151.  
For investigations of the effect of the benzylic substituent on the stereoselectivity and 
chemoselectivity of the cross benzoin reaction, fluoro substituted diphenyl lactam-derived 
triazolium salt 154 was synthesized in a two-step procedure (Scheme 54). Fluorine atoms exert a 
conformational effect (Gauche effect) which restricts the free rotation of the fluoro diphenyl group 
and favors the gauche conformation between the F- and N atoms.[115,116] Fluoro lactam 153 was 
isolated in excellent yield after deoxyfluorination of alcohol adduct 150 with diethylaminosulfur 
trifluoride (DAST). The corresponding triazolium salt 154 was obtained in 27% yield after using 
the previously established one-pot three-step synthetic protocol.  
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BF4
C6F5-NHNH2
CH2Cl2, RT, 4 h
2)
CH(OMe)3
80 °C, 18 h
27%
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
N
HF
O
N
N
N
C6F5
F
154153
N
HHO
O
150
DAST
CH2Cl2, 0 °C →
 
RT, 16 h
94%
 
Scheme 54: Synthesis of fluorodiphenyl substituted triazolium salt 154.  
For studies concerning the effect of hydrogen-bonding subunits on the chemo- and 
enantioselectivity of the cross-benzoin reaction, bifunctional precatalysts were synthesized by 
Mirjam Schreier during her Master practical course (Scheme 55). First, the azide lactam-derived 
triazolium salt 158 was synthesized following a modified procedure by Waser.[91] In this multi-step 
synthesis the ester group of lactam 149 was reduced to the resulting alcohol intermediate 155 
using sodium borohydride. After mesylation of the alcohol group followed by nucleophilic 
substitution with sodium azide, the azide lactam 157 was isolated in excellent yield over two steps. 
In the last part of the triazolium salt synthesis, the lactam was converted to the resulting precatalyst 
158 using Meerwein’s salt for imidate formation (step 1). Pentafluorophenylhydrazine was used 
for amidrazone formation (step 2) and finally the amidrazone adduct was cyclized to give the 
corresponding triazolium salt 158 by refluxing in triethyl orthoformate (step 3).  
NaBH4
EtOH, RT, overnight
84%
NaN3
,
DMF, 85 °C, 16 h
95%
O
HO
NH
O
MsO
NH
O
N3
NHN
N
N
C6F5
BF4
O
O
MeO
NH
N3
MsCl, Et3N
CH2Cl2, 0 °C →
 
RT, 16 h
96%
C6F5-NHNH2
CH2Cl2, RT, 4 h
2)
CH(OEt)3
MeOH, 100 °C, 18 h
56%
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
149 156155
157158  
Scheme 55: Synthesis of azide lactam-derived triazolium salt 158.  
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In the last step of the synthesis, the azide group was reduced by palladium catalyzed 
hydrogenation and the resulting crude amine was directly used for the coupling reaction with the 
corresponding aryl isothiocyanate to yield the resulting bifunctional triazolium salts 159a and 159b 
in moderate yield (Scheme 56).  
N
N
N
C6F5
BF4
N
N
N
C6F5
BF4
N3
NH
NHS
Ar
H2
 
(3 bar), Pd/C
MeOH, RT, overnight
1)
ArNCS
CH3CN, RT, overnight
2)
158 Ar = C6H5
 
(50%)
Ar = 3,5-(CF3)2-C6H3
 
(45%)
159a
159b  
Scheme 56: Synthesis of bifunctional triazolium salts 159a/b.  
For the synthesis of the chiral diaryl piperidine-2-one derivatives strategy 2 was applied. In this 
synthetic approach the lactam 165a-b was formed following a multi-step synthesis starting from 
commercially available (R)-1-Boc piperidine-2-carboxylic acid 160 (Scheme 57). Methyl ester 161 
was isolated after methylation of the carboxylic acid with methyl. In the following step, the α 
position of the N-Boc group was oxidized with ruthenium oxide and sodium periodate as a co-
oxidant to yield ester lactam intermediate 162 in good yield. After Boc deprotection with TFA and 
aryl Grignard addition to the ester moiety the resulting alcohol lactam intermediates 164a-b were 
isolated in 83 to 99% yield. In the last step, the hydroxyl group was removed by BF3 induced 
deoxygenation with triethylsilane. For phenyl systems the resulting deoxygenated product 165a 
was isolated in excellent yield. Unfortunately, starting from the difluoro phenyl substituted 
derivative 164b, no conversion to the desired product was observed by 1H-NMR analysis of the 
crude mixture and the starting material was fully recovered.   
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N O
TFA,
CH2Cl2, 0 °C → RT, 16 h
53%
MeI, K2CO3
DMF, RT, 42 h
72%
MeO
O
N
MeO
O BocBoc
N
HO
O Boc
N
H
O
MeO
O
N
H
O
Ar
OH
Ar
N
H
O
Ar
Ar
ArMgBr
THF, 0 °C →
 
RT, 16 h
Et3SiH, BF3
•Et2O
CH2Cl2, 
−
35 °C → RT, 
36 h
RuO2·H2O, NaIO4
EtOAc/H2O, RT, 16 h
72%
160
R = C6H5
 
(83%)
R = 3,5-(F)2-C6H3
 
(99%)
164a
164b
163
162161
R = C6H5
 
(83%)
R = 3,5-(F)2-C6H3
 
(0%)
165a
165b  
Scheme 57: Synthesis of chiral diaryl piperidin-2-ones 165a-b.  
To investigate the impact of steric hindrance on the asymmetric cross-benzoin reaction the phenyl 
rings of lactam 165a were reduced to give the resulting cyclohexyl residue by rhodium on alumina 
catalyzed hydrogenation, giving lactam 166 in quantitative yield (Scheme 58).  
N
H
O N
H
ORh on alox, H2
 
(5 bar)
MeOH, RT, 16 h
165a 166  
Scheme 58: Synthesis of chiral dicylcohexyl piperidin-2-one 166.  
Lastly, lactams 165a and 166 were subjected to the synthesis of the corresponding triazolium salts 
using the one-pot three-step synthetic procedure of Rovis. This procedure gave precatalysts 167 
and 168 in low yield (Scheme 59).  
C6F5-NHNH2
CH2Cl2, RT, 4 h
2)
CH(OMe)3
MeCN, 80 °C, 18 h
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
N
N
N
BF4
C6F5
R R
N
H
O
R
R
R = C6H5
 
R = C6H11
165a
166
R = C6H5
 
(30%)
R = C6H11
 
(19%)
167
168  
Scheme 59: Synthesis of triazolium salt 167/168 derived from chrial disubstituted piperdine-2-ones 155a/166.   
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3.3 Catalyst Screening for the Asymmetric Cross-Benzoin 
Reaction 
3.3.1 Screening of Morpholine-Based Triazolium Salts 
First, the effect of the chiral backbone of morpholine-based precatalysts on the chemo- and 
enantioselectivity of the cross-benzoin condensation between benzaldehyde 105a and 
hydrocinnamaldehyde 169 was investigated. Chiral catalyst 109a developed by the Gravel 
group[103] was used as a reference system (Table 31, entry 1). With this catalyst, the cross-benzoin 
product was obtained with excellent chemoselectivity, moderate enantioselectivity and good 
conversion. Similar conversion and slightly lower enantioselectivity was observed when the steric 
hindrance at the α-position was increased by replacing the iso-propyl group with a tert-butyl group, 
but the chemoselectivity was eroded from 20:1 to 2:1 (entry 2). The chemo- and stereoselectivity 
was further improved by using precatalyst 113c with a planar phenyl substituent in the chiral 
backbone (entry 3). Again, increasing steric hindrance in triazolium salt 113d with an cyclohexyl 
moiety resulted in inferior results (entry 4). Moreover, the cross-benzoin product 170 was obtained 
with low enantiomeric excess and poor chemoselectivity, using either benzyl- or diphenylmethane 
substituted carbenes (entries 5-6).  
Table 31: Screening of morpholine-based precatalysts with different chiral backbones.  
O
H +
CH2Cl2, RT, 16 h
NHCcat
 
(20 mol%)
DIPEA (100 mol%) *
OH
171
H
O
*
OH
O
+
O
105a 169 170  
entry NHCcat  conversion [%][a] ratio 170/171[a] ee [%][b] 170 
1 
O
N
N
N
BF4
C6F5
 
113a 94 20:1 40 (R) 
2 
O
N
N
N
BF4
C6F5
 
113b 95 2:1 36 (R) 
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3 
O
N
N
N
BF4
C6F5
 
113c 90 5:1 50 (R) 
4 
O
N
N
N
BF4
C6F5
 
113d 97 4:1 26 (R) 
5 
O
N
N
N
BF4
C6F5
 
113e 98 3:1 10 (S) 
6 
O
N
N
N
BF4
C6F5
 
145 76 4:1 4 (S) 
[a]: Determined by 1H-NMR analysis of the crude reaction mixture. [b]: Determined by HPLC on a chiral stationary 
phase.  
Next, the effect of the steric hindrance at the β-position on the chemo- and enantioselectivity was 
investigated. Better chemo- and slightly higher enantioselectivity was observed, however reactivity 
decreased when NHC catalyst 117a was used (Table 32, entry 1). Compared to catalyst 113c 
(Table 31, entry 3), carbene 117a (Table 32, entry 1) contains a dimethyl group at the β-position 
which may block the free rotation of the phenyl group. This higher rigidity of the catalyst structure 
could have a positive impact on the selectivity. A more drastic increase of chemo- and 
enantioselectivity was achieved when the β-position of the catalyst 117b was substituted with two 
methyl groups (entry 2). With identical reactivity, the ratio was increased towards the cross-
benzoin product 170 from 3:1 to 5:1 and the enantiomeric excess improved by 40%.  
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Table 32: Screening of β-dimethylated morpholine-based precatalysts.  
O
H +
CH2Cl2, RT, 16 h
NHCcat
 
(20 mol%)
DIPEA (100 mol%) *
OH
171
H
O
*
OH
O
+
O
105a 169 170  
entry NHCcat  conversion [%][a] ratio 170/171[a] ee [%][b] 170 
1 
O
N
N
N
BF4
C6F5
 
117a 68 7:1 52 (R) 
2 
O
N
N
N
BF4
C6F5
 
117b 97 5:1 50 (S) 
[a]: Determined by 1H-NMR analysis of the crude reaction mixture. [b]: Determined by HPLC on a chiral stationary 
phase.  
Next, threonine-derived NHCs were investigated. First, the (S,R)-diastereomer of the threonine-
derived precatalyst was tested in the asymmetric cross-benzoin reaction and the cross-benzoin 
product 170 was obtained with good chemo- and enantioselectivity (Table 33, entry 1). The other 
diastereomer of the catalyst gave lower selectivities but had similar reactivity (entry 2), indicating 
that the (S,R)-configuration of the catalyst is optimal. The stereoselectivity was further improved 
by installing sterically more demanding ethyl groups at the β-position but unfortunately the 
reactivity and the cross-selectivity was reduced (entry 3). With the phenyl serine-derived triazolium 
salt 139 the steric effect of the chiral backbone on the asymmetric cross-benzoin reaction was 
investigated. With this catalyst, lower reactivity and slightly lower selectivities were obtained 
(entry 4).  
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Table 33: Screening of threonine- and phenyl serine-derived precatalysts.  
O
H +
CH2Cl2, RT, 16 h
NHCcat
 
(20 mol%)
DIPEA (100 mol%) *
OH
171
H
O
*
OH
O
+
O
105a 169 170  
entry NHCcat  conversion [%][a] ratio 170/171[a] ee [%][b] 170 
1 
O
N
N
N
BF4
C6F5
OTBDMS  
122a 86 10:1 60 (S) 
2 
O
N
N
N
BF4
C6F5
OTBDMS  
122b 85 5:1 38 (S) 
3 
O
N
N
N
BF4
C6F5
OTBDMS  
122c 72 8:1 66 (S) 
4 
O
N
N
N
BF4
C6F5
OTBDMS
 
139 70 9:1 56 (S) 
[a]: Determined by 1H-NMR analysis of the crude reaction mixture. [b]: Determined by HPLC on a chiral stationary 
phase.  
Last, the effect of the N-residue on the chemo- and enantioselectivity was studied using different 
N-substituted threonine-derived precatalysts. NHC 123a with an N-phenyl substituent gave the 
desired cross-benzoin product 170 with moderate enantioselectivity but low chemoselectivity. 
Furthermore, the reactivity observed was quite low (Table 34, entry 1). An additional improvement 
of the enantioselectivity was achieved after installing an N-mesitylene group. However, only low 
conversion to the products was observed (entry 2). To investigate the effect of steric hindrance at 
the N-phenyl residue, triazolium salt 123c with an iso-propyl substituted N-phenyl ring was tested. 
Unfortunately, this catalyst showed essentially no chemo- and enantioselectivity (entry 3). The 
reactivity of the precatalyst was slightly increased compared to N-phenyl catalyst 123a by installing 
an N-(2,6-dimethoxy)phenyl residue on the triazolium moiety. Moreover, excellent chemo- and 
improved stereoselectivity was detected for NHC 123d (entry 4).  
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Table 34: Screening of threonine-derived precatalysts with different N-aryl residues.  
O
H +
CH2Cl2, RT, 16 h
NHCcat
 
(20 mol%)
DIPEA (100 mol%) *
OH
171
H
O
*
OH
O
+
O
105a 169 170  
entry NHCcat  conversion [%][a] ratio 170/171[a] ee [%][b] 170 
1 
O
N
N
N
BF4
OTBDMS  
123a 12 3:1 58 (S) 
2 
O
N
N
N
BF4
OTBDMS  
123b 7 20:1 85 (S) 
3 
O
N
N
N
BF4OTBDMS
iPr
iPr
iPr
 
123c 94 1:1 4 (R) 
4 
O
N
N
N
BF4
OTBDMS
O
O
 
123d 27 30:1 66 (S) 
[a]: Determined by 1H-NMR analysis of the crude reaction mixture. [b]: Determined by HPLC on a chiral stationary 
phase.  
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3.3.2 Screening of Piperidine-Based Triazolium Salts 
In further studies, piperidine-based triazolium salts were evaluated for the asymmetric cross-
benzoin reaction between benzaldehyde 105a and hydrocinnamaldehyde 169. First, precatalysts 
containing a diphenylmethylene group in the chiral backbone were investigated. NHC 152, 
synthesized and evaluated by Mirjam Schreier, gave the desired cross-benzoin product in good 
chemo- and moderate enantioselectivity.[117] However, the reactivity observed was low. It may be 
argued that this result could arise from the steric hindrance of the TBDMS-protected alcohol group 
which blocks the nucleophilic center (Table 35, entry 1). In the carbene structure 154, the silyl 
group was replaced by a fluoride atom, to see if the fluorine-gauche effect could influence the 
outcome of the cross-benzoin reaction. Compared to TBDMS-NHC 152, higher reactivity, but 
lower chemo- and enantioselectivities were observed (entry 2).   
Table 35: Screening of diphenyl substituted piperidine-based precatalysts. 
O
H +
CH2Cl2, RT, 16 h
NHCcat
 
(20 mol%)
DIPEA (100 mol%) *
OH
171
H
O
*
OH
O
+
O
105a 169 170  
entry NHCcat  conversion [%][a] ratio 170/171[a] ee [%][b] 170 
1 BF4
N
N
N
C6F5
OTBDMS
 
152 17 10:1 30 (S) 
2 BF4
N
N
N
C6F5
F
 
154 66 5:1 8 (S) 
[a]: Determined by 1H-NMR analysis of the crude reaction mixture. [b]: Determined by HPLC on a chiral stationary 
phase.   
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A different approach to the selective cross-product formation was investigated by Mirjam Schreier 
during her Master practicum using piperidine derived bifunctional NHCs.[117] Herein, the effect of 
possible H-bonding interactions with the substrates to achieve higher selectivities was studied. 
However, in both cases insufficient selectivities were observed (Table 36, entries 1-2). Moreover, 
using THF as reaction solvent and cesium carbonate as a base, the benzoin product 171 was 
formed preferably when NHC 159b was used as catalyst (entry 2).  
Table 36: Screening of bifunctional precatalysts.  
O
H +
CH2Cl2, RT, 16 h
NHCcat
 
(20 mol%)
DIPEA (100 mol%) *
OH
171
H
O
*
OH
O
+
O
105a 169 170  
entry NHCcat  conversion [%][a] ratio 170/171[a] ee [%][b] 170 
1 
BF4
N
N N
C6F5
N
H
N
H
S
 
159a 60 2:1 12 (S) 
2[c] 
BF4
N
N N
C6F5
N
H
N
H
S
F3C
CF3
 
159b 64 1:2 22 (S) 
[a]: Determined by 1H-NMR analysis of the crude reaction mixture. [b]: Determined by HPLC on a chiral stationary 
phase. [c]: THF was used as solvent and Cs2CO3 as a base.  
Finally, precatalysts derived from chrial disubstituted piperdine-2-ones were investigated. For 
NHC 167, with contained a diphenyl residue in the chiral backbone good reactivity was detected. 
However, only very low chemo- and enantioselecitivty towards the cross-product 170 were 
achieved (Table 37, entry 1). Moreover, installing more sterically demanding dicyclcohexyl 
residues such as in catalyst 168 in the chiral backbone resulted in lower reactivity and 
enantioselecitivty in the cross-benzoin reaction. Neverthless, the chemoselectivity was slightliy 
improved from 2:1 to 5:1 compared to NHC 167 (entry 1 vs. entry 2). 
  
ASYMMETRIC CROSS-BENZOIN REACTION         CHAPTER 3 
120 
Table 37: Screening of chiral precatalysts with an disubstituted group.  
O
H +
CH2Cl2, RT, 16 h
NHCcat
 
(20 mol%)
DIPEA (100 mol%) *
OH
171
H
O
*
OH
O
+
O
105a 169 170  
entry NHCcat  conversion [%][a] ratio 170/171[a] ee [%][b] 170 
1 BF4
N
N
N
C6F5
 
167 88 2:1 6 (S) 
2 BF4
N
N
N
C6F5
 
168 53 5:1 2 (R) 
[a]: Determined by 1H-NMR analysis of the crude reaction mixture. [b]: Determined by HPLC on a chiral stationary 
phase.  
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3.4 Conclusion and Outlook 
In conclusion, the synthesis of two different catalyst classes is described in chapter three (Figure 
31). For morpholine-based precatalysts, the effects of the chiral backbone, the N-residue on the 
triazolium ring and the substituents next to the stereogenic center on the chemo- and 
enantioselectivity of the cross-benzoin reaction were investigated. Moreover, for piperidine-based 
triazolium salts the effect of the chiral backbone and the impact of an additional hydrogen-bonding 
subunit on the outcome of the cross-coupling of aldehydes was studied.  
O
∗ N
N
N
BF4
morpholine-based NHCs
∗ N
N
N
BF4 F
F F
F
F
piperidine-based NHCs  
Figure 31: Catalyst classes for the asymmetric cross-benzoin reaction.  
Only threonine-derived morpholine-based precatalysts gave good results in terms of chemo- and 
enantioselectivity. For NHC-catalyst 122a (R = Me) and 122c (R = Et) good chemo selectivities 
and reactivities were obtained, indicating the importance of the N-pentafluoro phenyl residue on 
the triazolium unit. Moreover, for catalyst 122c higher enantioselectivity was achieved by installing 
a N-mesyl group such as in catalyst 123b.  
Future work on this project might be directed towards the optimization of the reaction conditions 
for catalyst 122a/c and 123b. A new catalyst is presented in Figure 32 which combines the 
important structural units of both NHCs. A new N-residue was designed containing ortho-
substituents for steric interactions to improve enantioselectivity. In addition, fluorine residues are 
present to promote π-stacking interaction which could potentially impact the chemoselectivity.  
O
N
N
N
BF4 F
F F
F
F
TBDMSO
R
R
O
N
N
N
BF4
TBDMSO
O
N
N
N
BF4
F
TBDMSO
R
R
F
F
123b122a/c
new NHC-catalyst
 
Figure 32: New possible NHC-precatalyst for the asymmetric cross-benzoin reaction. 
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4.1 Introduction 
4.1.1 Carbenes as Ligands for Metal-Complexes 
In 1964, the first isolated and characterized transition-metal carbene complex was reported by 
Fischer and Maasböl.[118] In their approach, a tungsten carbonyl carbene complex was isolated 
after nucleophilic addition of phenyllithium to a carbonyl of tungsten hexacarbonyl followed by 
acidic work-up and O-methylation with diazomethane (Figure 33). Since then, complexes with 
singlet carbene ligands which are electrophilic at the carbene carbon are referred to as Fischer 
carbenes.[119] 
PhLi
W
OC
OC CO
CO
CO
CO
W
OC
OC CO
CO
CO
Ph
O
CH2N2 W
OC
OC CO
CO
CO
OMe
Ph
Fischer Carbene  
Figure 33: Synthesis of the first transition-metal carbene complex by Fischer.[118] 
Four years later, the first imidazole-2-ylidene-based NHC-transition metal complexes were 
independently synthesized and characterized by Wanzlick[120] and Öfele.[121] In the approach of 
Wanzlick, the preligand was mixed with mercury(II) acetate and afterwards the resulting mercury 
carbene complex was isolated. In the example of Öfele, a chromium(0) NHC complex was 
generated by refluxing the ligand precursor which contained the chromium metal as anion 
(Figure 34). 
Hg(OAc)2
N N PhPh
ClO4
N N PhPh
2 ClO4
Hg2+
N N PhPh
N N MeMe
[HCr(CO)5]
N N MeMe
Cr(CO)5
NHC-metal complex by Wanzlick[120] NHC-metal complex by Öfele[121]  
Figure 34: Synthesis of first NHC-metal complexes by Wanzlick[120] and Öfele.[121] 
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Ten years after the seminal reports of Fischer carbenes, a different class of metal-carbene 
complexes was developed by Schrock.[122] The typical characteristics of the so-called Schrock 
carbenes are that the carbene carbon has a nucleophilic character. (Figure 35). 
2 LiCH2(CH3)3Ta
Cl
Cl
tBu
tBu
Ta
tBu
tBu
tBu tBu
tBu
tBu
H Ta
tBu
tBu
tBu
tBu
−
2 LiCl
−
C(CH3)4
Schrock Carbene  
Figure 35: Synthesis of the first Schrock carbene by Schrock.[122]  
In Figure 36, the three possible orbital interaction between a carbene and a metal center are 
presented. Because of the relatively weak π-acceptor properties of NHC-ligands, σ-donation is the 
most important interaction involved in ligand bonding. Moreover, NHC π-donation to the d-orbital 
of the metal only plays a role in electron poor complexes with empty d-orbitals.[123] 
a) NHC →
 M σ−donation b) M →
 NHC π∗
−
backdonation
c) NHC →
 M π−donation
N
N
N
N
N
N
d
d
d
 
Figure 36: Three orbital contributions to the metal-NHC bond.  
Because of the strong σ-donating and weak π-acceptor properties of NHCs, this ligand class is 
comparable with phosphine-type ligands.[124] However, NHCs are stronger electron-donating 
compared to phosphines and therefore the corresponding metal-carbene bond is stronger and 
shorter. This leads to thermally and oxidatively more stable metal-complexes compared to 
complexes with phosphine ligands.[125] Furthermore, carbene-type ligands are sterically more 
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demanding due to the concave structure of the carbene unit (Figure 37). Moreover, the phosphine 
center is sp3-hybridizied which results in a cone-shaped spatial arrangement of the ligand.[126]  
M
N N
M
P
NHC-metal complex phosphine-metal complex  
Figure 37: Comparison of steric hindrance in a metal-complex by a NHC- or phosphine-type ligand.  
Because of these unique features and the beneficial properties of the resulting metal-complexes 
many NHC-based catalyst systems were developed for a wide variety of transition-metal catalyzed 
transformations. For examples, NHC-ruthenium complexes are used for the olefin metathesis 
reaction. In the Grubbs first generation catalyst the metal center was coordinated with two 
phosphine ligands and the activity was further improved in cross- and ring-closing metathesis by 
replacing one phosphine-ligand by a NHC-ligand. The second generation Grubbs catalysts are 
thermally more stable, can be applied with lower catalyst loadings and have a broader substrate 
scope (Figure 38).[127] 
Ru
PhPCy3
Cl
Cl
NNMes Mes
Ru
Ph
PCy3
PCy3
Cl
Cl
Grubbs Catalyst 1st
 
Generation Grubbs Catalyst 2nd
 
Generation  
Figure 38: Grubbs catalysts for the olefin metathesis reaction.[125]  
A different application range of NHC-ligands are palladium-catalyzed cross-coupling reactions. 
Because of the electronic and steric properties of the carbene ligand, the Pd(0) intermediate in 
the catalytic cycle is stabilized and due to the electron-donating properties of the NHC the 
oxidative addition is facilitated. Moreover, due to the steric-hindrance of the carbene-ligand the 
reductive elimination step is promoted. In 2006, Organ and coworkers reported a Pd-PEPPSI-
NHC (Pyridine-Enhanced Precatalyst Preparation Stabilization and Initiation) precatalyst as a 
robust and reactive catalyst for the Suzuki–Miyaura Reaction (Figure 39).[128] Moreover, in the last 
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years this ligand class was successfully applied for a wide variety of different coupling reaction 
such as Negishi, Suzuki-Miyaura, Buchwald-Hartwig and Kumada reaction.[129,130] 
Pd ClCl
N
Cl
NN
R
R
R
R
 
Figure 39: General structure of PEPPSI-NHC precatalyst. 
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4.1.2 Asymmetric Hydrogenation 
Asymmetric hydrogenation is a powerful methodology for the transformation of an unsaturated 
and prochiral substrate to a chiral product. This type of reaction has several advantages such as 
perfect atom economy, mild reaction conditions, low catalyst loading, often high enantiomeric 
excess and high conversions.[131] In 2001, the importance of asymmetric hydrogenation was 
rewarded with the Nobel prize in chemistry towards Knowles and Noyori together with Sharpless 
for his contribution in the asymmetric oxidation of organic molecules. Knowles developed rhodium 
complexes with P-chiral diphosphine ligands for the hydrogenation of α,β-dehydroamino acids 
(Scheme 60),[132] which were successfully applied for the asymmetric synthesis of L-DOPA, a 
medicament for the treatment of Parkinson.[133] 
[Rh(DiPAMP)(COD)]BF4
 
(0.005 mol%)
10 bar H2, MeOH, RT
CO2H
NHAc
OMe
AcO
CO2H
NHAc
OMe
AcO P P
MeO
OMe
DiPAMP
 
Scheme 60: Rhodium-catalyzed asymmetric hydrogenation step towards the L-DOPA synthesis.[133]  
Noyori introduced Ru catalysts based on BINAP as chiral ligand for the asymmetric reduction of 
ketones or functionalized alkenes.[134] For example, the unsaturated carboxylic acid was reduced 
by the ruthenium-complex and the resulting product (S)-naproxen, an anti-inflammatory agent, 
was isolated in high yield and excellent enantioselectivity (Scheme 61).[135] 
[Ru(BINAP)(AcO)2] (0.5 mol%)
137 bar H2, MeOH, RT
BINAP
CO2H
MeO
CO2H
MeO
PPh2
PPh2
 
Scheme 61: Ruthenium-catalyzed asymmetric hydrogenation of unsaturated carboxylic acid.[135]  
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Since these seminal reports by Knowles and Noyori many catalyst systems were developed and 
applied to different substrates classes. However, high enantioselectivity was only achieved when 
a coordinating group was attached next the carbon-carbon double bond.[125,126]  
In 1979, Crabtree and coworkers reported an iridium complex (the so called Crabtree catalyst) 
with a monodentate phosphine and pyridine ligand for the hydrogenation of nonfunctionalized 
mono-, di-, tri-, and tetra-substituted alkenes.[138] Years later, our group developed a chiral 
derivative of Crabtree’s system, which in contrast to rhodium and ruthenium catalysts allowed the 
hydrogenation of alkenes lacking coordinating groups with high enantiomeric excess and 
conversions.[139] In this approach, a chiral bidentate P,N-based phosphinooxazoline (PHOX) ligand 
was used, which was originally developed for the asymmetric palladium-catalyzed allylic 
substitution by Helmchen, Williams and Pfaltz (Figure 40).[140]  
Cy3P
Ir
N
PF6
Crabtree catalyst
N
O
(oTol)2P
Ir
BArF
PHOX-based iridium complex  
Figure 40: Iridium complexes for the hydrogenation of unfunctionalized alkenes.  
Since the first discoveries, many variation of P,N ligands were developed by our laboratory and 
other research groups around the world for the iridium-catalyzed asymmetric hydrogenation of a 
wide variety of different functionalized and nonfunctionalized substrates (see Figure 41 for 
representative ligand examples).[141] 
ThrePHOX
O
(R1)2P N
∗
R2 R2
O
∗
R3
SimplePHOX (X = O)
NeoPHOX (X = CH2)
X
(R1)2P N ∗
O
R2
N
∗
R2
O
P(R1)2
n
pyiridine-phosphinite
SpinPHOX
(R1)2P N
∗
O
R2
phosphino methyl-oxazoline
(R1)2P
N ∗
O
R2
N
N
PR2
Ph
phosphine-imidazole
N
S
P(R1)2
R2
phosphine-thiazole phosphinite-oxazoles
N
O
O
PR2
Ph
 
Figure 41: Representative examples of P,N-type ligands for the asymmetric iridium-catalyzed hydrogenation.  
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Since the seminal report of Herrmann about the use of rhodium-NHC complexes for asymmetric 
catalysis,[142] many catalyst systems with either monodentate, bidentate or even tridentate NHC 
ligands in combination with different transition-metals were developed for the asymmetric 
hydrogenation of different substrate classes.[143] A powerful iridium-catalyst for the asymmetric 
hydrogenation of nonfunctionalized alkenes was introduced by Burgess in 2001 (Figure 42).[144] 
High selectivities and conversions were achieved by using a chiral imidazolylidene ligand. Five 
years later, the Pfaltz group developed an oxazoline-NHC ligand which formed six-membered 
iridacycles. These catalysts showed good reactivity but lower selectivities compared to the 
Burgess type catalyst.[145] More recently, our group reported iridium complexes with chiral 
NHC/pyridine ligands as hydrogenation catalysts, which gave enantioselectivities comparable to 
the best P,N-ligand complexes. In addition, also acid-sensitive substrates containing groups such 
as OTMS or Boc were reduced due to the lower acidity of the iridium hydride intermediates formed 
in the catalytic cycle.[146] 
N
O
R1
N
Ir
BArF
N
R2
Pfaltz in 2006[143]
N
Ir
BArF
O
N
N
AdAr
Burgess in 2001[142]
N
N
Ir BArF
N
Pfaltz in 2013[144]
∗
PhR
R1
R2
R4
R3
R1
∗
R2
∗
R4
R3
H
HN-NHC-iridium complex
H2
N-NHC-iridium complexes:
 
Figure 42: Overview of N-NHC-iridium complexes for the asymmetric hydrogenation of alkenes. 
Most ligands for transition-metal catalyzed asymmetric hydrogenation contain a chiral phosphine 
moiety as an important structural motif for selectivity and reactivity issues. Therefore, the design 
of chiral phosphine-NHC ligands would combine advantages of both phosphine and NHC-
systems. The first achiral phosphine-carbene ligand was reported by Herrmann in 1996 which was 
used for metal-complex formation with ruthenium.[147] However, for hydrogenation reactions only 
few bidentate P-NHC ligands have been studied until now. Inspired from the Josiphos ligand, the 
Chung group developed the first chiral bidentate phosphine-NHC ligand for rhodium-catalyzed 
hydrogenation of alkenes. Unfortunately, the product after reduction of the terminal double-bond 
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in dimethyl itaconate was obtained in low enantiomeric excess.[148] One year later, Bolm and 
coworkers introduced a planar chiral phosphinyl-imidazolylidene ligand for the iridium-catalyzed 
hydrogenation of different olefins, but only moderate selectivities were achieved and long reaction 
time was needed to get reasonable conversions.[149] In 2006, an iridium-catalyst with a phosphine-
NHC ligand was investigated for the asymmetric reduction of functionalized and unfunctionalized 
alkenes by our research group.[150] However, only moderate enantioselectivities were observed 
for the tested substrates. More recently, the Shi group reported a bidentate ligand with a chiral 
1,1’-binaphthyl framework for the reduction of alkenes but also herein only moderate selectivities 
were obtained.[151] 
PPh2
N
N
R
Nanchen & Pfaltz in 2006[150]Chung in 2003[148]
 
Bolm in 2004[149]
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Shi in 2013[151]  
Figure 43: Overview of phosphine-NHC ligands for the asymmetric hydrogenation of alkenes. 
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4.2 Synthesis of Iridium Complexes derived from Chiral 
Bidentate NHC-Phosphine Ligands 
In the synthesis of chiral bifunctional triazolium salts (see Chapter 3.2.2) a mesyl lactam 
intermediate was used as a synthetic precursor. Inspried by the work of Nannchen, who developed 
different NHC-phosphine ligands (see Figure 43), it was thought that this mesylate intermediate 
could be an ideal precursor for the synthesis of bidentate NHC-phosphine-based preligands with 
conformationally more rigid structures.  
The retrosynthetic analysis of the iridium complexes derived from chiral bidentate NHC-phosphine 
type ligands is presented in Figure 44. For the synthesis of the ligand two different synthetic 
approaches were investigated. In strategy A, the phosphine residue was introduced in a late-stage 
of the synthesis to avoid problems of phosphine alkylation during the triazolium salt synthesis. The 
mesyl group of the triazolium salt was displaced by the phosphine source in a substitution reaction. 
Alternatively, in strategy B the phosphine is introduced in an early-stage of the synthesis. In this 
synthetic design, the mesyl lactam is converted to the resulting phosphine lactam which could 
then be subjected to the triazolium salt synthesis. The key-intermediate for both strategies is the 
mesyl lactam precursor-derived from the corresponding five or six-membered hydroxyl lactam.  
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H
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Figure 44: Retrosynthetic analysis of iridium complexes derived from chiral bidentate phosphine-NHC ligand.  
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First, synthetic strategy A was investigated. The mesyl triazolium salt 174 was synthesized via a 
four-step sequence which began with commercially available (S)-pyroglutaminol 172. First, mesyl 
lactam 173 was isolated in good yield after treating hydroxy lactam 172 with mesyl chloride and 
triethylamine. In the last step, triazolium salt 174 was synthesized according a one-pot three-step 
procedure by Rovis[112] to yield the final mesyl intermediate 174 in 81% yield (Scheme 62).  
MsO
N
N
N
BF4
N
H
O
MsO
N
H
O
HO MsCl, NEt3
CH2Cl2, 0 °C →
 
RT, 16 h
78%
C6H5-NHNH2
CH2Cl2, RT, 4 h
2)
CH(OMe)3
MeOH, 80 °C, 16 h
81%
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
174172 173  
Scheme 62: Synthesis of mesyl triazolium salt 174. 
As an alternative precursor for the phosphine triazolium salt synthesis, bromo triazolium salt 176 
was formed in a four-step sequence. Mesyl lactam 173 was converted to bromo lactam 175 by 
refluxing in THF with lithium bromide. Next, precursor 176 was obtained in very good yield after 
using the standard synthetic procedure for the triazolium salt synthesis.  
Br
N
N
N
BF4
N
H
O
Br
N
H
O
MsO LiBr
THF, 70 °C, 16 h
96%
C6H5-NHNH2
DCM, RT, 4 h
2)
CH(OMe)3
MeOH, 80 °C, 16 h
87%
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
176173 175  
Scheme 63: Synthesis of bromo triazolium salt 176. 
In the next step, the late-stage introduction of the phosphine residue was investigated using either 
from the mesyl- or bromo-triazolium salt. In initial studies, mesyl precursor 174 was used for the 
nucleophilic displacement by potassium or lithium diphenylphosphide. Unfortunately, for both 
phosphine sources conversion to the substituted product 177 (Table 38, entries 1-2,) was not 
detected by ESI-MS analysis of the crude reaction mixture. These analyses showed, that the 
starting material was decomposed to unknown by-products. A likely problem is the acidity of the 
carbene C-H proton, which could be deprotonated by the metal diphenylphosphide. In an attempt 
to alleviate this potential problem an excess of potassium diphenylphosphide (two equivalents) 
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was tested, however, no phosphine product 177 was formed. To avoid problems related to 
deprotonation of the triazolium salt, a less basic but nucleophilic diphenylphosphine in 
combination with a higher reaction temperature was applied for the nucleophilic substitution. 
Unfortunately, in this case as well product formation was not observed by ESI-MS analysis (entry 
3). When the leaving group was changed from a mesylate to a bromide such as in triazolium salt 
176, the formation of the desired phosphine product 177 was also not detected (entries 4-5).  
Table 38: Studies for the synthesis of phosphine-triazolium salt 177.  
X
N
N
N
BF4
Ph2P
N
N
N
BF4
phosphine source
THF, T, t
177174/176  
entry X phosphine source T [°C] t [h] conversion[a] 
1 OMs (174) KPPh2  0 4 no 
2 OMs (174) LiPPh2 0 4 no 
3 OMs (174) HPPh2 75 16 no 
4 Br (177) KPPh2  0 4 no 
5 Br (177) HPPh2 75 16 no 
[a]: Determined by ESI-MS analysis of the crude reaction mixture.  
Because the late-stage phosphine introduction was not successful, synthetic strategy B was 
applied. In the first step, phosphine lactam 178 was obtained after nucleophilic substitution of the 
mesylate group of lactam 173 by potassium diphenylphosphide. Afterwards, the triazolium salt 
synthesis which began with phosphine lactam 178 was investigated. In the precatalyst synthesis 
the imidate formation might be the problematic step because of the possible alkylation of the 
phosphine residue by the alkylation reagent. Using standard reaction conditions with 
trimethyloxonium tetrafluoroborate (Meerwein’s salt) as an O-alkylation reagent, imidate 
intermediate 179 was not detected by ESI-MS analysis of the crude reaction mixture. Instead, the 
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P-methylated by-product was observed exclusively by 31P-NMR and ESI-MS analysis. Therefore, 
dimethyl sulfate was tested as an alternative alkylation reagent. Unfortunately, in this case the 
phosphorus atom was also alkylated. In a last attempt, phosphoryl chloride was used for the in 
situ formation of a Vilsmeier-type chloro iminiumion intermediate which then could be used for the 
nucleophilic displacement with phenyl hydrazine. Unfortunately, also herein no formation of the 
desired adduct was observed (Scheme 64).  
Ph2P
N
N
N
BF4
N
H
O
Ph2P
N
H
O
MsO KPPh2
THF, 0 °C →
 
RT, 16 h
58%
178 177
N O
Ph2P
conditions
179173
tested conditions for amidate formation:
1) OMe3BF4
 
in CH2Cl2
 
(no amidate formation)
2) C2H6O4S in MeCN (no amidate formation)
3) POCl3
 
in CH2Cl2 (no chloro iminiumion formation)  
Scheme 64: Synthesis of phosphine triazolium salt 177 by strategy B.  
To avoid alkylation of the phosphorus atom, strategy B was slightly modified. In the new approach, 
a borane-protected phosphine intermediate was used as the lactam precursor for the triazolium 
salt synthesis. The requisite phosphine-borane lactam 177 was isolated in excellent yield after 
treating mesyl lactam 173 with sodium diphenylphosphide borane adduct (Scheme 65). When the 
borane adduct 180 was subjected to the procedure for triazolium salt synthesis, no alkylation or 
borane-deprotection of the phosphine residue was observed using Meerwein’s salt for the imidate 
formation. Also treatment of the imidate intermediate with phenyl hydrazine did not deprotect the 
phosphorus atom. The synthetic procedure for the cyclization of the amidrazone intermediate was 
slightly optimized for the phosphine containing triazolium salt, in order to achieve borane-
deprotection in the same step. The desired deprotected product 177 was obtained in 9% yield 
after 16 hours in refluxing trimethyl orthoformate. ESI-MS analysis of the crude reaction mixture 
revealed that the main problem was the alkylation of the phosphine center after in situ borane 
deprotection. To prevent alkylation of the phosphorus atom, the condensation reagent was 
changed to the sterically bulkier triethyl orthoformate and the reaction time was reduced from 
16 hours to 90 minutes. With the optimized reaction conditions known, ligand precursor 177 was 
isolated in good yield after purification by column chromatography.  
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N
H
O
MsO Ph2PH BH3, NaH
THF, 0 °C →
 
RT, 4 h
98%
N
H
O
P
BH3
P
N
N
N
BF4
C6H5-NHNH2
CH2Cl2, RT, 4 h
2)
CH(OEt)3
115 °C, 90 min
78%
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
177173 180
Ph
Ph Ph
Ph
 
Scheme 65: Synthesis of phosphine triazolium salt 177 by a modified strategy B.  
Because the preferred anion of the hydrogenation-catalyst is BArF, an alternative ligand precursor 
with the BArF counterion was synthesized. Thus different N-substituted triazolium BArF salts were 
synthesized starting from the borane-protected diphenylphosphine lactam 180. After imidate 
formation, a range of hydrazines were used in the in situ formation of the resulting amidrazone 
intermediate. Compared to the synthesis of BF4 triazolium salts, an additional anion-exchange 
step was introduced by adding sodium BArF to the crude reaction mixture. An initial trial to 
exchange the counterion of the triazolium salt 177 failed, because of separation problems of the 
BF4 and BArF salts. After filtration of the crude amidrazone BArF salt followed by condensation 
with triethyl orthoformate all triazolium salts 181a-d were isolated in low to good yield (Table 39). 
Table 39: Synthesis of triazolium BArF salts with different N-residues.  
N
H
O
P
BH3
P
N
N
N
R
BArF
R-NHNH2
CH2Cl2, rt, 4 h
2)
NaBArF
CH2Cl2, rt, 16 h
3)
OMe3BF4
CH2Cl2, rt, 16 h
1)
Ph
Ph Ph Ph
CH(OEt)3
115 °C, 90 min
4)
181a-d180
 
entry R triazolium salt 181 (yield in %) entry R 
triazolium salt 181 
(yield in %) 
1 
 
181a (75) 3 
OMe
OMe  
181c (16) 
2 
 
181b (86) 4 
 
181d (67) 
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With the optimized conditions for the triazolium BArF salts synthesis in hand, three different 
phosphine substituted triazolium salts were synthesized. In the first step, phosphine lactam 
intermediates 182a-c were isolated in low to good yield after treating mesyl lactam 173 with the 
corresponding sodium phosphide borane adduct. All phosphine lactams were then subjected to 
the synthetic procedure for the triazolium salt synthesis and for all phosphine adducts the 
corresponding deprotected ligand precursors 183a-c were isolated in good to moderate yield 
(Table 40). Because of the stronger stability of the borane-dialkylphosphine adduct 182b and 
182c, the reaction time was increased from 90 to 120 minutes to get full deprotection of the 
phosphorus center.  
Table 40: Synthesis of triazolium BArF salts with different phosphine residues. 
N
H
O
MsO R2PH
•BH3, NaH
THF, 0 °C →
 
RT, 4 h
98%
N
H
O
P
BH3
P
N
N
N
Ph
BArF
C6H5-NHNH2
CH2Cl2, RT, 4 h
2)
NaBArF
CH2Cl2, RT, 16 h
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
R
R R R
CH(OEt)3
115 °C, time
4)
183a-c182a-c173
 
entry R phosphine lactam 182 (yield in %) 
time [min] 
(cyclisation step) 
triazolium salt 183 
(yield in %) 
1 
 
182a (84) 90 183a (75) 
2 
 
182b (18) 120 183b (66) 
3 
 
182c (59) 120 183c (27) 
In the next step, the complexation of ligand precursor 177 with iridium was investigated. First, a 
two-step sequence with the BF4 salt of the ligand precursor was studied. The precatalyst could be 
deprotonated by a base to form the bidentate ligand which then could coordinate with iridium to 
generate a complex with a BF4 counter ion. After counterion exchange with sodium BArF, the final 
iridium catalyst 184 should be obtained. Unfortunately, no conversion to the desired iridium 
complex 184 was detected by ESI-MS analysis of the crude reaction mixture when lithium tert-
butoxide was used as a base (Table 41, entry 1). Also, higher temperature or a change of the 
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base to potassium tert-butoxide did not result in product formation (entries 2-3). After the first test 
with the BArF precursor 181a and lithium tert-butoxide as base, no complex formation was 
detected by ESI-MS analysis. In the second trial, the carbene C-H proton was deprotonated by 
potassium tert-butoxide to form the free carbene and after addition of [Ir(cod)Cl]2 the desired 
iridium complex was observed by ESI-MS analysis. After purification of the crude mixture, the 
resulting iridium catalyst 184 was isolated in good yield as a red solid.  
Table 41: Studies for the complexdation with iridium.  
[Ir(COD)Cl]2, base
THF, temp., over night
1)
NaBArF
CH2Cl2, RT, over night
2)
P
N
N
N
X
P
Ir
N
N
N
BArF
184177/181a  
entry X base T [°C] conversion[a] yield [%][b] 
1 BF4 (177) LiOtBu  rt no - 
2 BF4 (177) LiOtBu 40 no - 
3 BF4 (177) KOtBu rt no - 
4[c] BArF (181a) LiOtBu  rt no - 
5[c] BArF (181a) KOtBu rt yes 78 
[a]: Determined by ESI-MS analysis of the crude reaction mixture. [b] Isolated yield. [c]: No BArF addition step.  
With the complexation conditions optimized, the formation of different iridium complexes derived 
from the corresponding ligand precursors 181/183a-c was investigated. The iridium complex 185a 
derived from the triazolium salt with a N-mesitylene group was obtained in lower yield compared 
to the N-phenyl substituted ligand such as in complex 184 (Table 42, entry 1) due to the steric 
hindrance. Moreover, also iridium catalyst 185b derived from a triazolium salt with a N-2,6-
dimethoxy phenyl residue gave only moderate yield (entry 2). Catalyst 185c derived from a N-tert 
butyl substituted precatalyst 181d was formed in 74% yield (entry 3). The introduction of sterically 
demanding ortho-tolyl, cyclohexyl or tert-butyl phosphine substituents lowered the yield of the 
desired iridium complex 185d, 185e and 185f (entry 4-6).  
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Table 42: Synthesis of iridium complexes 185a-f.  
[Ir(COD)Cl]2, KOtBu
THF, RT, 16 hP
N
N
N
R2BArF
P
Ir
N
N
N
R2
BArF
R1
R1
R1
R1
185a-f181a-c/183a-c  
entry R1 R2 iridium complex 185 (yield in %) 
1 
  
185a (46) 
2 
 OMe
OMe
 
185b (46) 
3 
  
185c (74) 
4c 
  
185d (32) 
5c 
  
185e (30) 
6 
  
185f (36) 
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For studies concerning the effect of the fused-ring system, a phosphine-NHC precursor with a six-
membered fused-ring was synthesized in a six-step synthetic sequence. In the first step, the 
borane protected phosphine intermediate 186 was isolated in 85% yield after nucleophilic 
displacement of the mesylate group in adduct 156 by sodium borane diphenylphosphide. Next, 
triazolium salt 187 was formed by using the four-step one-pot procedure to generate the ligand 
precursor 187 in good yield. Finally, the iridium complex 189 was formed in good yield after 
complexation with the deprotonated BArF salt 187 (Scheme 66).  
Ph2PH BH3, NaH
THF, 0 °C →
 
RT, 4 h
85%
N
N
N
BArF
C6H5-NHNH2
CH2Cl2, RT, 4 h
2)
NaBArF
CH2Cl2, RT, 16 h
3)
OMe3BF4
CH2Cl2, RT, 16 h
1)
CH(OEt)3
115 °C, 90 min
75%
4)
[Ir(COD)Cl]2, KOtBu
THF, RT, 16 h
59%
P
Ir
N
N
N
BArF
Ph
Ph
N
H
O
MsO
N
H
O
Ph2P
BH3
PPh2
188
187156 186
 
Scheme 66: Synthesis of iridium complex 182 derived from six-membered fused-ring phosphine-NHC precursor 181.  
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4.3 Hydrogenation Results of Model Substrates 
In an initial study the new ligand class was tested in the iridium-catalyzed asymmetric 
hydrogenation of unfunctionalized olefins, namely the model substrate 189 (Table 43). 
Unfortunately, the majority of the iridium-catalysts showed almost no reactivity (entries 1-3, 5-6 
and 8). Interestingly, when the N-residue on the triazolium ring was changed from an aromatic to 
an aliphatic group a drastic increase in reactivity was observed (entry 4 vs. entry 1). For example, 
by using catalyst 185c the chiral product 190 was obtained with complete conversion and 
moderate enantiomeric excess (entry 4). A further improvement of the enantioselectivity was 
observed with complex 185f (entry 7), however, low conversion to the desired product was 
observed.  
Table 43: Iridium-catalyzed asymmetric hydrogenation of (E)-1,2-diphenyl-1-propene 189. 
1.0 mol% [Ir-cat.]
50 bar H2
CH2Cl2
 
(0.2 M), RT, 2 h
∗
189 190  
entry Ir-catalyst  R conv. [%][a] ee [%][b] 
1 
2 
3 
4 
P
Ir
N
N
N
R
BArF
Ph
Ph
 
184 
185a 
185b 
185c 
Ph 
Mes 
1,3-(OMe2)-Ph 
tBu 
3 
1 
1 
99 
n.d. 
n.d. 
n.d. 
50 (R) 
5 
6 
7 
P
Ir
N
N
N
Ph
BArF
R
R
 
185d 
185e 
185f 
oTol 
Cy 
tBu 
1 
2 
14 
n.d. 
n.d. 
58 (R) 
8 P
Ir
N
N
N
Ph
BArF
Ph
Ph
 
188  7 n.d. 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst. [b]: Determined by HPLC analysis 
on a chiral stationary phase.   
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The results of the iridium-catalyzed hydrogenation of the (E)-double bond in substrate 191 using 
NHC-phosphine ligands are presented in Table 44. Moderate conversions and low ee’s (20%) of 
product 185 were obtained for ligands with a diphenylphosphine unit and an N-aryl residue 
(entries 1-3). Replacing the N-aryl unit to an N-alkyl unit resulted again in a drastic increase in 
reactivity and selectivity to give the reduced substrate 192 (entry 4). The steric hindrance at the 
phosphorus center was increased, but this gave only inferior results (entries 5-7). The ligand with 
a six-membered fused ring system showed a slightly higher reactivity compared to the five-
membered derivative (entry 8 vs. entry 1). However, the enantiomeric excess was reduced from 
20% to 7%.  
Table 44: Iridium-catalyzed asymmetric hydrogenation of (E)-2-(4-methoxyphenyl)-2-butene 191. 
1.0 mol% [Ir-cat.]
50 bar H2
CH2Cl2
 
(0.2 M), RT, 2 hMeO
∗
MeO
191 192  
entry Ir-catalyst  R conv. [%][a] ee [%][b] 
1 
2 
3 
4 
P
Ir
N
N
N
R
BArF
Ph
Ph
 
184 
185a 
185b 
185c 
Ph 
Mes 
1,3-(OMe2)-Ph 
tBu 
48 
37 
46 
>99 
20 (R) 
20 (R) 
20 (R) 
38 (R) 
5 
6 
7 
P
Ir
N
N
N
Ph
BArF
R
R
 
185d 
185e 
185f 
oTol 
Cy 
tBu 
20 
33 
27 
6 (S) 
8 (R) 
6 (R) 
8 P
Ir
N
N
N
Ph
BArF
Ph
Ph
 
188  58 7 (R) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst. [b]: Determined by HPLC analysis 
on a chiral stationary phase.  
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Next, the reduction of the terminal double bond in substrate 193 was investigated. In general, all 
iridium catalysts showed higher reactivity towards the hydrogenation of the terminal double bond 
compared to an internal one, as in substrate 191 (Table 45 vs. Table 44). Nevertheless, only poor 
enantioselectivities were achieved.  
Table 45: Iridium-catalyzed asymmetric hydrogenation of 1-(but-1-en-2-yl)-4-methoxybenzene 193. 
1.0 mol% [Ir-cat.]
50 bar H2
CH2Cl2
 
(0.2 M), RT, 2 hMeO
∗
MeO
193 194  
entry Ir-catalyst  R conv. [%][a] ee [%][a] 
1 
2 
3 
4 
P
Ir
N
N
N
R
BArF
Ph
Ph
 
184 
185a 
185b 
185c 
Ph 
Mes 
1,3-(OMe2)-Ph 
tBu 
73 
80 
98 
>99 
6 (S) 
4 (S) 
8 (S) 
4 (S) 
5 
6 
7 
P
Ir
N
N
N
Ph
BArF
R
R
 
185d 
185e 
185f 
oTol 
Cy 
tBu 
81 
75 
>99 
2 (S) 
5 (R) 
6 (R) 
8 P
Ir
N
N
N
Ph
BArF
Ph
Ph
 
188  >99 2 (S) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst. [b]: Determined by HPLC analysis 
on a chiral stationary phase.  
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Next, the asymmetric hydrogenation of the cyclic unfunctionalized olefin 195 was studied 
(Table 46). For all catalysts containing an N-aryl group at the triazolium ring conversion to the 
desired chiral product 196 was observed. However, only low enantioselectivities were achieved 
(entries 1-3 and 6). The reactivity of the catalyst was further increased when iridium complexes 
were used that contained either an N-alkyl residue (entry 4), P-alkyl substituents (entries 6-7) or 
a six-membered fused ring system on the ligand (entry 8). For this substrate class the best lead 
was identified to be complex 185c which gave the desired product 196 with high conversion but 
low enantiomeric excess (entry 4).   
Table 46: Iridium-catalyzed asymmetric hydrogenation of 6-methoxy-1-methyl-3,4-dihydronaphthalene 195. 
1.0 mol% [Ir-cat.]
50 bar H2
CH2Cl2
 
(0.2 M), RT, 2 hMeO
∗
MeO
195 196  
entry Ir-catalyst  R conv. [%][a] ee [%][b] 
1 
2 
3 
4 
P
Ir
N
N
N
R
BArF
Ph
Ph
 
184 
185a 
185b 
185c 
Ph 
Mes 
1,3-(OMe2)-Ph 
tBu 
47 
65 
53 
>99 
4 (S) 
8 (S) 
rac. 
24 (S) 
5 
6 
7 
P
Ir
N
N
N
Ph
BArF
R
R
 
185d 
185e 
185f 
oTol 
Cy 
tBu 
21 
47 
90 
14 (R) 
14 (R) 
16 (R) 
8 P
Ir
N
N
N
Ph
BArF
Ph
Ph
 
188  80 rac. 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst. [b]: Determined by HPLC analysis 
on a chiral stationary phase.  
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The trisubstituted α,β-unsaturated ester 197 proved to be more reactive than unfunctionalized 
alkenes (Table 44 or 46), and the reduced product 198 was obtained in almost every case with 
complete conversion (Table 47). Only in the case of catalyst 185a, which contained a sterically 
demanding N-mesitylene group, only moderate reactivity was detected (entry 3). However, for 
each of the iridium complexes only low to moderate enantioselectivities were observed. The best 
catalyst was iridium complex 185e which gave the chiral ester 198 with an enantiomeric excess 
of 32% (entry 6). 
Table 47: Iridium-catalyzed asymmetric hydrogenation of (E)-ethyl 3-phenylbut-2-enoate 197. 
1.0 mol% [Ir-cat.]
50 bar H2
CH2Cl2
 
(0.2 M), RT, 2 h
CO2Et
* CO2Et
197 198  
entry Ir-catalyst  R conv. [%][a] ee [%][b] 
1 
2 
3 
4 
P
Ir
N
N
N
R
BArF
Ph
Ph
 
184 
185a 
185b 
185c 
Ph 
Mes 
1,3-(OMe2)-Ph 
tBu 
>99 
56 
>99 
>99 
10 (S) 
22 (R) 
24 (R) 
8 (S) 
5 
6 
7 
P
Ir
N
N
N
Ph
BArF
R
R
 
185d 
185e 
185f 
oTol 
Cy 
tBu 
>99 
>99 
>99 
10 (R) 
32 (R) 
30 (R) 
8 P
Ir
N
N
N
Ph
BArF
Ph
Ph
 
188  >99 12 (S) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst. [b]: Determined by HPLC analysis 
on a chiral stationary phase.  
In the hydrogenation of allylic alcohol 199 the iridium complexes showed, in general, high 
reactivities (Table 48). For ligands with a diphenylphosphine moiety only low enantioselectivities 
were achieved (entries 1-4 and 8). The selectivity could not be improved by installing ortho-tolyl 
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or di-tert-butyl substituents at the phosphorus center (entry 5 and 7). The catalyst with a 
dicyclohexylphosphine unit in the ligand system showed high reactivity and moderate 
enantioselectivity (entry 6).  
Table 48: Iridium-catalyzed asymmetric hydrogenation of (E)-2-methyl-3-phenylprop-2-en-1-ol 199. 
1.0 mol% [Ir-cat.]
50 bar H2
CH2Cl2
 
(0.2 M), RT, 4 h
OH
*
OH
199 200  
entry Ir-catalyst  R conv. [%][a] ee [%][b] 
1 
2 
3 
4 
P
Ir
N
N
N
R
BArF
Ph
Ph
 
184 
185a 
185b 
185c 
Ph 
Mes 
1,3-(OMe2)-Ph 
tBu 
>99 
74 
84 
>99 
34 (S) 
18 (S) 
24 (S) 
26 (S) 
5 
6 
7 
P
Ir
N
N
N
Ph
BArF
R
R
 
185d 
185e 
185f 
oTol 
Cy 
tBu 
>99 
>99 
>99 
24 (S) 
50 (S) 
32 (S) 
8 P
Ir
N
N
N
Ph
BArF
Ph
Ph
 
188  >99 32 (S) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst. [b]: Determined by HPLC analysis 
on a chiral stationary phase.  
As a final test substrate, N-phenyl ketimine 201 was investigated (Table 49). First, the effect of 
the N-residue on the selectivity and reactivity was studied. Only catalyst 184 which contained an 
N-phenyl residue, gave full conversion to the chiral amine 202, albeit with low enantiomeric excess 
(entry 1). Although the selectivity was improved by installing more sterically hindered N-residues 
such as in N-mesitylene (entry 2) or N-di-ortho-methoxyphenyl (entry 3) groups, the reactivity 
observed was low. Moreover, for iridium catalyst 185c with a N-tert-butyl residue only inferior 
results were obtained (entry 4). Next the effect of different P-residues was investigated. Increasing 
the steric hindrance at the phosphorus center such as in catalyst 185d resulted in high reactivity 
BIDENTATE NHC-PHOSPHINE LIGANDS          CHAPTER 4 
148 
but almost no selectivity was observed (entry 5). Alkyl substituted phosphine ligands gave as well 
high conversions. In addition, higher enantioselectivities were achieved when compared to the 
diphenylphosphine-based ligands (entries 6-7 vs entries 1-5). Promising results were observed 
especially for dicyclohexylphosphine-NHC iridium complex 185e. Finally, for iridium complex 188, 
which contained a six-membered fused-ring system better enantioselectivity was obtained when 
compared to the five-membered system (entry 8 vs entry 1). 
Table 49: Iridium-catalyzed asymmetric hydrogenation of N-(1-phenylethylidene)-aniline 201. 
1.0 mol% [Ir-cat.]
50 bar H2
CH2Cl2
 
(0.2 M), RT, 4 h
N
*
N
H
201 202  
entry Ir-catalyst  R conv. [%][a] ee [%][b] 
1 
2 
3 
4 
P
Ir
N
N
N
R
BArF
Ph
Ph
 
184 
185a 
185b 
185c 
Ph 
Mes 
1,3-(OMe2)-Ph 
tBu 
>99 
68 
76 
17 
28 (R) 
44 (R) 
44 (R) 
8 (S) 
5 
6 
7 
P
Ir
N
N
N
Ph
BArF
R
R
 
185d 
185e 
185f 
oTol 
Cy 
tBu 
>99 
>99 
>99 
4 (S) 
64 (R) 
48 (R) 
8 P
Ir
N
N
N
Ph
BArF
Ph
Ph
 
188  95 58 (R) 
[a]: Determined by GC analysis of the reaction mixture after removal of the catalyst. [b]: Determined by HPLC analysis 
on a chiral stationary phase.   
BIDENTATE NHC-PHOSPHINE LIGANDS          CHAPTER 4 
149 
4.4 Conclusion and Outlook 
In conclusion, the synthesis of eight new chiral bidentate NHC-phosphine ligands and the 
formation of the corresponding iridium complexes is described in chapter four (Figure 45). The 
influence of each structural unit (N-residue on the triazolium ring, P-residues, size of fused-ring 
system) on the asymmetric hydrogenation of model substrates was investigated. Unfortunately, 
with unfunctionalized olefins only low conversions and low enantioselectivities were achieved for 
most ligands. Only catalyst 185c, with an N-alkyl group at the triazolium unit showed high reactivity 
towards unfunctionalized alkenes. On the other hand, alkenes with functional groups such as a 
hydroxy or ester group and an imine were suitable substrates for the hydrogenation reaction but 
only low to moderate enantioselectivities were observed. The best rests were obtained with 
catalyst 185e, which gave high conversion and moderate enantioselectivities in the reduction of 
allylic alcohol 199 (>99% conversion, 50% ee) and of imine 201 (>99% conversion, 64% ee). 
P
Ir
N
N
N
R
BArF
Ph
Ph
P
Ir
N
N
N
Ph
BArF
R
R
P
Ir
N
N
N
Ph
BArF
Ph
Ph
P
Ir
N
N
N
Ph
BArF
best catalyst
185e
 
Figure 45: Iridium complexes derived from chiral bidentate NHC-phosphine ligands.  
Future work on this project should be dedicated to the optimization of the catalyst lead structure 
to design a selective catalyst for the asymmetric hydrogenation of imines. Based on the screening 
results, a possible new iridium complex is oposed in Figure 46.  
P
Ir
N
N
N
BArF
R
R R = OMe, Me, iPr  
Figure 46: New possible iridium-complex for the asymmetric hydrogenation of imines.  
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5.1 General Informations 
5.1.1 Working Techniques 
Commercially available reagents were purchased from Acros, Aldrich, Alfa or Fluka and used as 
received. All preparative reactions, involving a phosphine compound were carried out in heat-gun 
dried glassware under inert atmosphere using Schlenk techniques. All reactions were carried out 
in dry solvents. The solvents were purchased from Aldrich in sure/sealedTM bottles. Column 
chromatographic purifications were performed on Fluka silica gel 60 (Buchs, particle size 40-
63 nm). The eluents for column chromatography were prepared from technical solvents. 
5.1.2 Analytical Methods 
Melting Points (M.P.): Melting points were determined on a Büchi 535 apparatus and are 
uncorrected. 
Thin Layer Chromatography (TLC): TLC plates were obtained from Machrey-Nagel (Polygram 
SIL/UV254, 0.2 mm silica with fluorescence indicator). UV light (254 nm), CER or basic 
permanganate solution were used to visualize the respective compounds. 
NMR-Spectroscopy (NMR): NMR spectra were measured either on a Bruker Avance 400 
(400 MHz) or a Bruker Avance 500 (500 MHz) spectrometer. The chemical shifts (δ) are given in 
ppm. The chemical shift δ values were corrected to the signal of the deuterated solvents: 7.26 ppm 
(1H NMR) and 77.16 ppm (13C NMR) for CDCl3; 5.32 ppm (1H NMR) and 54.00 ppm (13C NMR) 
for CD2Cl2 and 39.52 ppm (13C NMR) for (CD3)2SO. The assignment of 1H and 13C signals was 
accomplished, when needed by two-dimensional correlation experiments (HSQC (heteronuclear 
single quantum coherence) and HMBC (heteronuclear multiple quantum coherence)). Multiplets 
are assigned as: s (singlet), d (doublet), t (triplet), q (quartet), sept (septet) and m (multiplet). Broad 
signals are assigned with: br (broad). 
Infrared Spectroscopy (IR): Infrared spectra were collected on a Shimadzu FTIR-8400S 
spectrometer. The compounds were measured as pure substance via Specac ATR attachment. 
Absorption bands are given in wave numbers ([cm−1]). The peak intensity is describedby: 
s (strong), m (medium), w (weak). 
High Resolution Mass Spectrometry (HRMS-ESI): Mass spectra were measured by Dr. H. 
Nadig (Department of Chemistry, University of Basel) on a bruker maXis 4G. 
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Electrospray Ionization Mass Spectrometry (ESI-MS): ESI-MS spectra were measured on a 
Varian 1200L Quadrupol MS/MS spectrometer using mild desolvation conditions (39 psi 
nebulising gas, 4.9 kV spray voltage, 19 psi drying gas at 125 °C, 100 eV capillary voltage, 1300 
V detector voltage). The samples were diluted immediately prior to their analysis and measured 
using direct injection. The signals are given in mass-to-charge ratios (m/z) with the relative 
intensity in brackets. 
Optical Rotations: Optical rotations were measured on a Perkin Elmer Polarimeter 341 (in a 
cuvette (l = 1 dm)) at 20 °C at 589 nm. The concentration (c) is given in g/100 mL. 
Elemental Analysis (EA): Elemental analyses were measured by Sylvie Mittelheisser 
(Department of Chemistry, University of Basel) on a Leco CHN-900 (C-, H-, N-detection). The data 
are indicated in mass percent. 
Gas Chromatography (GC): Gas chromatographs were collected on Shimadzu GC 2010-Plus 
instrument. Achiral separations were performed on a Restek Rtx®-1701 column (30 m x 0.25 mm 
x 0.25 µm) or on a Optima 5-Amine (30 m x 0.25 mm x 0.25 µm) using He as carrier gas. 
High Performance Liquid Chromatography (HPLC): HPLC analyses were performed on 
Shimadzu systems with SLC-10A system controller, CTO-10AC column oven, LC10-AD pump 
system, DGU-14A degasser and SPD-M10A diode array- or UV/VIS detector. Chiral columns 
Chiracel OD-H or IC (4.6 x 250 mm) from Daicel Chemical Industries were used. 
Semipreparative High Performance Liquid Chromatography (Semipreparative HPLC): 
Separations by semipreparative HPLC were performed on Shimadzu systems with SIL 10 Advp 
autosampler, CTO 10 ASVP column oven, LC 10 Atvp pump system, FCV 10 Alvp degasser and 
SPD M10 Acp diode array detector. As column with chiral stationary phase Chiracel IC (2 x 25 cm) 
from Daicel Chemical Industries was used. 
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5.2 Asymmetric Morita-Baylis-Hillman Reaction 
5.2.1 Synthesis of 1st Generation Catalysts 
(S)-4-(Cyclohexylmethyl)oxazolidin-2-one (17e) 
O
NH
O  
Under argon atmosphere a heat-gun dried round-bottomed flask was charged with N-Boc-(1-
cyclohexyl-3-hydroxypropan-2-yl) (16e) (160 mg, 620 µmol) and THF (4 mL). At 0 °C, thionyl 
chloride (592 mg, 0.36 mL, 4.97 mmol) was added dropwise over 5 min. After complete addition 
the reaction mixture was stirred for additional three hours at 0 °C and for further 16 hours at room 
temperature. Afterwards the reaction mixture was concentrated under vacuum and the crude was 
purified by column chromatography (SiO2, CH2Cl2:ethyl acetate (5:2), d x h: 2.5 x 15 cm) to afford 
the product 17e (69.0 mg, 380 µmol, 61%) as a white solid.  
 
C10H17NO2 (183.25 g/mol): 
MP: 84-85 °C.  
TLC: Rf = 0.44 (SiO2, CH2Cl2:ethyl acetate (10:4)). 
1H NMR (400 MHz, CDCl3) δ/ppm: 5.88 (br s, 1H, NH), 4.52-4.44 (m, 1H, NCH), 4.01-3.92 (m, 2H, 
OCH2), 1.74-1.62 (m, 6H, cy-CH2, NCHCH2), 1.58-1.51 (m, 1H, cy-CH), 1.44-1.38 (m, 1H, cy-CH2), 
1.34-1.09 (m, 3H, cy-CH2), 1.00-0.86 (m, 2H, cy-CH2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm: 159.9, 70.9, 50.6, 43.3, 34.7, 33.7, 33.1, 26.4, 26.2, 26.1. 
IR (ATR) 𝑣𝑣�/cm-1 = 3251 (m), 2910 (s), 2844 (s), 1742 (s), 1709 (s), 1397 (m), 1243 (s), 1200 (w), 
1126 (w), 1079 (w), 1057 (s), 999 (m), 962 (w), 927 (s), 681 (m), 527 (w). 
EA (C10H17NO2) calc.: C 65.54, H 9.35, N 7.64; found: C 65.51, H 9.01, N 7.86. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −28.6 (c = 1.07, MeOH).  
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(S)-2-(Diphenylphosphanyl)-1-phenylethan-1-amine (18a) 
P NH2
 
Under argon atmosphere a heat-gun dried two-necked flask was charged with (S)-4-
phenyloxazolidin-2-one (17a) (702 mg, 4. 30 mmol) and toluene (15 mL). Then the reaction 
mixture was degassed three-times by freeze-pump-thaw method. Afterwards diphenylphosphine 
(1.69 g, 1.58 mL, 8.60 mmol) and trifluoromethanesulfonic acid (1.94 g, 1.15 mL, 12.9 mmol) were 
added to the reaction mixture. After complete addition, the mixture was refluxed for 24 hours. At 
room temperature, the reaction mixture was adjusted to an alkaline pH (>10) by addition of 
degassed aqueous saturated K2CO3 and then the mixture was extracted with Et2O (3 x 50 mL). 
The combined organic layers were dried over Na2SO4, filtered, concentrated under vacuum and 
the crude was purified by column chromatography (SiO2, cyclohexane:ethyl acetate (3:7) + 1% 
NEt3, d x h: 3.5 x 16 cm) to afford the product 18a (900 mg, 2.95 mmol, 69%) as a pale yellow oil. 
 
C20H20NP (305.36 g/mol): 
TLC: Rf = 0.30 (SiO2, cyclohexane:ethyl acetate (3:7) + 1% NEt3). 
1H NMR (400 MHz, CDCl3) δ/ppm: 7.53-7.42 (m, 4H, ar-H), 7.40-7.31 (m, 10H, ar-H), 7.30-
7.21 (m, 1H, ar-H), 4.03 (ddd, 3JHP = 9.3 Hz, 3JHH = 7.4 Hz, 3JHH = 4.8 Hz, 1H, CH), 2.57 (ddd, 
2JHP = 13.7 Hz, 3JHH = 4.8 Hz, 3JHH = 2.4 Hz, 1H, CH2), 2.45 (ddd, 2JHP = 13.6 Hz, 3JHH = 9.2 Hz, 
3JHH = 2.3 Hz, 1H, CH2), 1.78 (s, 2H, NH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm: 146.7 (d, JCP = 6.3 Hz), 138.9 (d, JCP = 12.1 Hz), 138.2 (d, 
JCP = 12.8 Hz), 133.2 (d, JCP = 19.4 Hz), 132.7 (d, JCP = 18.4 Hz), 129.0, 128.7, 128.6, 128.6, 
128.5, 127.3, 126.3, 53.8 (d, JCP = 16.0 Hz), 40.2 (d, JCP = 14.1 Hz). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm: −21.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 2913 (w), 2844 (w), 1652 (m), 1429 (w), 1308 (w), 880 (w), 767 (s), 739 (m), 
690 (s), 529 (m), 497 (s), 477 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C20H20NP+: 306.1406 [M+H]+; found: 
306.1408. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +0.9 (c = 1.11, MeOH).  
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(S)-1-Cyclohexyl-2-(diphenylphosphanyl)ethan-1-amine (18b) 
P NH2
 
Under argon atmosphere a heat-gun dried two-necked flask was charged with (S)-4-
cyclohexyloxazolidin-2-one (17b) (500 mg, 2.95 mmol) and toluene (9 mL). Then the reaction 
mixture was degassed three-times by freeze-pump-thaw method. Afterwards diphenylphosphine 
(1.16 g, 1.10 mL, 5.91 mmol) and trifluoromethanesulfonic acid (1.33 g, 0.78 mL, 8.86 mmol) were 
added to the reaction mixture. After complete addition, the mixture was refluxed for 24 hours. At 
room temperature, the reaction mixture was adjusted to an alkaline pH (>10) by addition of 
degassed aqueous saturated K2CO3 and then the mixture was extracted with Et2O (3 x 50 mL). 
The combined organic layers were dried over Na2SO4, filtered, concentrated under vacuum and 
the crude was purified by column chromatography (SiO2, cyclohexane:ethyl acetate (10:1 to 2:5) 
+ 5% NEt3, d x h: 4.5 x 15 cm) to afford the product 18b (496 mg, 1.59 mmol, 54%) as a colorless 
oil. 
 
C20H26NP (311.41 g/mol): 
TLC: Rf = 0.55 (SiO2, cyclohexane:ethyl acetate (2:5) + 5% NEt3). 
1H NMR (400 MHz, CDCl3) δ/ppm: 7.50-7.27 (m, 10H, ar-H), 2.69-2.57 (m, 1H, CH), 2.38 (dt, 
2JHP = 13.7 Hz, 3JHH = 3.6 Hz, 1H, CH2), 1.95 (ddd, 2JHP = 13.4 Hz, 3JHH = 10.0 Hz, 3JHH = 3.0 Hz, 
1H, CH2), 1.78-1.61 (m, 5H, NH2, cy-CH2, cy-CH), 1.39-0.94 (m, 8H, cy-CH2).  
13C{1H} NMR (101 MHz, CDCl3): δ/ppm: 139.6 (d, JCP = 12.1 Hz), 138.2 (d, JCP = 13.0 Hz), 
133.3 (d, JCP = 19.4 Hz), 132.5 (d, JCP = 18.3 Hz), 128.9, 128.6, 128.5, 128.5, 128.4, 128.4, 53.7 (d, 
JCP = 13.2 Hz), 45.0 (d, JCP = 7.1 Hz), 35.2 (d, JCP = 11.7 Hz), 29.5, 27.9, 26.7, 26.5, 26.4. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm: −21.6. 
IR (ATR): 𝑣𝑣�/cm-1: 3069 (w), 2919 (s), 2848 (m), 1571 (w), 1479 (w), 1432 (m), 1093 (w), 831 (w), 
735 (s), 693 (s), 504 (m), 479 (m), 420 (w).   
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C20H26NP+: 312.1876 [M+H]+; found: 
312.1878. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +40.1 (c = 1.02, MeOH).  
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(S)-1-(Diphenylphosphanyl)-4-methylpentan-2-amine (18c) 
P NH2
 
Under argon atmosphere a heat-gun dried two-necked flask was charged with (S)-4-
isobutyloxazolidin-2-one (17c) (450 mg, 3.14 mmol) and toluene (12 mL). Then the reaction 
mixture was degassed three-times by freeze-pump-thaw method. Afterwards diphenylphosphine 
(1.24 g, 1.15 mL, 6.29 mmol) and trifluoromethanesulfonic acid (1.42 g, 0.84 mL, 9.43 mmol) were 
added to the reaction mixture. After complete addition, the mixture was refluxed for 24 hours. At 
room temperature, the reaction mixture was adjusted to an alkaline pH (>10) by addition of 
degassed aqueous saturated K2CO3 and then the mixture was extracted with Et2O (3 x 50 mL). 
The combined organic layers were dried over Na2SO4, filtered, concentrated under vacuum and 
the crude was purified by column chromatography (SiO2, cyclohexane:ethyl acetate (2:5) + 1% 
NEt3, d x h: 3 x 16 cm) to afford the product 18c (451 mg, 1.58 mmol, 50%) as a pale yellow oil. 
 
C18H24NP (285.37 g/mol): 
TLC: Rf = 0.22 (SiO2, cyclohexane:ethyl acetate (2:5) + 1% NEt3). 
1H NMR (400 MHz, CDCl3) δ/ppm: 7.40-7.32 (m, 4H, ar-H), 7.29-7.18 (m, 6H, ar-H), 2.85-2.75 (m, 
1H, NCH), 2.21 (ddd, 2JHP = 13.6 Hz, 3JHH = 4.5 Hz, 3JHH = 2.5 Hz, 1H, PCH2), 1.94 (ddd, 
2JHP = 13.6 Hz, 3JHH = 8.6 Hz, 3JHH = 1.5 Hz, 1H, PCH2), 1.67-1.55 (m, 1H, CHCH2(CH3)2), 1.36 (br 
s, 2H, NH2), 1.36-1.16 (m, 2H, CH(CH3)2), 0.75 (d, 3JHH = 3.2 Hz, 3H, CHCH3), 0.74 (d, 
3JHH = 3.1 Hz, 3H, CHCH3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm: 139.2 (d, JCP = 11.9 Hz), 138.5 (d, JCP = 12.3 Hz), 133.1 (d, 
JCP = 19.0 Hz), 132.7 (d, JCP = 18.5 Hz), 128.8, 128.6, 128.6, 128.5, 49.1 (d, JCP = 7.7 Hz), 47.0 (d, 
JCP = 14.3 Hz), 38.9 (d, JCP = 12.4 Hz), 25.0, 23.3, 22.2. 
31P{1H} NMR (162 MHz, CDCl3) δ/ppm: −22.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 3069 (w), 3052 (w), 2952 (m), 2907 (w), 1756 (w), 1466 (w), 1432 (m), 1365 (w), 
1094 (w), 1026 (w), 836 (w), 816 (w), 737 (s), 693 (s), 503 (m), 478 (m).  
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C18H24NP+: 286.1719 [M+H]+; found: 
286.1721. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +21.7 (c = 1.00, MeOH).   
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(S)-1-Cyclohexyl-3-(diphenylphosphanyl)propan-2-amine (18e) 
P NH2
 
Under argon atmosphere a heat-gun dried two-necked flask was charged with (S)-4-
(cyclohexylmethyl)oxazolidin-2-one (17e) (800 mg, 4.37 mmol) and toluene (20 mL). Then the 
reaction mixture was degassed three-times by freeze-pump-thaw method. Afterwards 
diphenylphosphine (1.71 g, 1.60 mL, 8.74 mmol) and trifluoromethanesulfonic acid (1.97 g, 
1.16 mL, 13.1 mmol) were added to the reaction mixture. After complete addition, the mixture was 
refluxed for 24 hours. At room temperature, the reaction mixture was adjusted to an alkaline pH 
(>10) by addition of degassed aqueous saturated K2CO3 and then the mixture was extracted with 
Et2O (3 x 50 mL). The combined organic layers were dried over Na2SO4, filtered, concentrated 
under vacuum and the crude was purified by column chromatography (SiO2, cyclohexane:ethyl 
acetate (2:3) + 2% NEt3, d x h: 3.5 x 22 cm) to afford the product 18e (874 mg, 2.69 mmol, 62%) 
as a pale yellow oil. 
 
C21H28NP (325.44 g/mol): 
TLC: Rf = 0.32 (SiO2, cyclohexane:ethyl acetate (2:3) + 2% NEt3). 
1H NMR (400 MHz, CDCl3) δ/ppm: δ 7.50-7.37 (m, 4H, ar-H), 7.36-7.28 (m, 6H, ar-H), 2.98-
2.84 (m, 1H, NCH), 2.28 (ddd, 2JHP = 13.6 Hz, 3JHH = 4.5 Hz, 2JHH = 2.5 Hz, 1H, PCH2), 2.01 (ddd, 
2JHP = 13.7 Hz, 3JHH = 8.5 Hz, 2JHH = 1.6 Hz, 1H, PCH2), 1.71-1.58 (m, 4H, cy-CH2), 1.58-1.48 (m, 
1H, cy-CH), 1.45-1.05 (m, 8H, cy-CH2*, CHCH2*), 0.93-0.74 (m, 2H, cy-CH2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm: 139.3 (d, JCP = 12.1 Hz), 138.6 (d, JCP = 12.3 Hz), 133.1 (d, 
JCP = 19.1 Hz), 132.7 (d, JCP = 18.5 Hz), 128.8, 128.6 (d, JCP = 4.7 Hz), 128.5, 128.5, 47.7 (d, JCP = 
7.7 Hz), 46.3 (d, JCP = 14.3 Hz), 39.0 (d, JCP = 12.4 Hz), 34.6, 34.1, 33.0, 26.7, 26.4, 26.3. 
31P{1H} NMR (162 MHz, CDCl3) δ/ppm: −22.7. 
IR (ATR): 𝑣𝑣�/cm-1 = 3069 (w), 3051 (w), 2918 (m), 2847 (w), 1756 (w), 1584 (w), 1480 (w), 1432 (m), 
1094 (w), 968 (w), 841 (w), 737 (s), 693 (s), 504 (m), 478 (m), 422 (w).  
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C21H28NP+: 326.2032 [M+H]+; found: 
326.2034. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +10.2 (c = 0.94, MeOH).   
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General Procedure (GP1): Amino phosphine coupling with isothiocyanate precursor 
Under argon atmosphere, a heat-gun dried round-bottomed flask was charged with the amino 
phosphine (1.0 eq.), the isothiocyanate precursor (1.1 eq.) and CH2Cl2 (3 mL per mmol). Then the 
reaction mixture was stirred for 16 hours at room temperature. Afterwards the mixture was 
concentrated under vacuum and the crude product was purified by column chromatography.  
 
(S)-1-(1-Cyclohexyl-2-(diphenylphosphanyl)ethyl)-3-phenylthiourea (19b) 
P HN
HN
S
 
According to general procedure GP1, (S)-1-cyclohexyl-2-(diphenylphosphanyl)ethan-1-amine 
(18b) (105 mg, 337 µmol), phenyl isothiocyanate (51.2 mg, 45.2 µL, 371 µmol) and CH2Cl2 
(1.1 mL) were stirred for 16 hours and the crude product was purified by column chromatography 
(SiO2, cyclohexane:ethyl acetate (5:1), d x h: 3.5 x 20 cm) to afford the product 19b (150 mg, 336 
µmol, 99%) as a white solid. 
 
C27H31N2PS (446.60 g/mol): 
TLC: Rf = 0.30 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.66 (br s, 1H, NH), 7.43-7.35 (m, 4H, ar-H), 7.34-7.14 (m, 
9H, ar-H), 7.00 (d, 3JHH = 7.8 Hz, 2H, ar-H), 6.01 (br s, 1H, NH), 4.57 (br s, 1H, NCH), 2.41 (ddd, 
2JHP = 14.3 Hz, 3JHH = 5.5 Hz, 2JHH = 2.4 Hz, 1H, PCH2), 2.23 (dd, 2JHP = 14.3 Hz, 3JHH = 7.6 Hz, 
1H, PCH2), 1.67-1.50 (m, 6H, cy-CH2), 1.13-0.88 (m, 4H, cy-CH2), 0.85-0.71 (m, 1H, cy-CH). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 180.2, 136.1, 133.1 (d, JCP = 4.3 Hz), 133.0 (d, 
JCP = 4.4 Hz), 130.2, 129.0, 128.7 (d, JCP = 2.9 Hz), 128.6 (d, JCP = 3.1 Hz), 127.2, 125.3, 58.2 (d, 
JCP = 14.1 Hz), 41.8 (d, JCP = 8.1 Hz), 31.4 (d, JCP = 13.3 Hz), 29.7, 28.7, 26.5, 26.1, 26.1. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −24.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 3219 (w), 2919 (w), 2848 (w), 1522 (s), 1495 (s), 1305 (m), 1235 (m), 1166 (w), 
1094 (w), 1026 (w), 736 (s), 693 (s), 502 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C27H31N2PS+: 447.2018 [M+H]+; found: 
447.2018. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +16.1 (c = 0.65, MeOH). 
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(S)-1-(1-(Diphenylphosphanyl)-4-methylpentan-2-yl)-3-phenylthiourea (19c) 
P HN
HN
S
 
According to general procedure GP1, (S)-1-(diphenylphosphanyl)-4-methylpentan-2-amine (18c) 
(40 mg, 140 µmol), phenyl isothiocyanate (22.7 mg, 20.0 µL, 168 µmol) and CH2Cl2 (0.8 mL) were 
stirred for 16 hours and the crude product was purified by column chromatography (SiO2, 
cyclohexane:ethyl acetate (6:1), d x h: 1.5 x 14 cm) to afford the product 19c (54 mg, 128 µmol, 
92%) as a colorless gum. 
 
C25H29N2PS (420.55 g/mol): 
TLC: Rf = 0.25 (SiO2, cyclohexane:ethyl acetate (6:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.77 (br s, 1H, NH), 7.53-7.41 (m, 3H, ar-H), 7.39-7.23 (m, 
7H, ar-H), 7.05 (d, 3JHH = 7.7 Hz, 2H, ar-H), 6.05 (s, 1H, NH), 4.81 (s, 1H, CH), 2.56 (dd, 2JHP = 14.5 
Hz, 3JHH = 6.3 Hz, 1H), 2.45-2.37 (m, 1H, CH2), 1.59-1.42 (m, 3H, CH2CH(CH3)2*, CH2CH(CH3)2*), 
0.85 (d, 3JHH = 2.5 Hz, 3H, CH(CH3)2), 0.83 (d, 3JHH = 2.6 Hz, 3H, CH(CH3)2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 179.8, 133.3, 133.1, 132.9, 132.7, 130.2, 129.2, 129.0, 
128.7 (d, JCP = 3.3 Hz), 128.7 (d, JCP = 3.4 Hz), 127.2, 125.2, 52.3, 44.7 (d, JCP = 9.4 Hz), 34.4, 
25.3, 22.9, 22.6. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −25.3. 
IR (ATR): 𝑣𝑣�/cm-1 = 3370 (w), 3187 (w), 1595 (m), 1525 (s), 1496 (s), 1496 (m), 1433 (w), 1303 
(w), 1237 (m), 999 (w), 754 (s), 696 (s), 504 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C25H29N2PS+: 421.1862 [M+H]+; found: 
421.1866. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +25.8 (c = 0.85, CHCl3). 
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(S)-1-(1-Cyclohexyl-3-(diphenylphosphanyl)propan-2-yl)-3-phenylthiourea (19e) 
P HN
HN
S
 
According to general procedure GP1, (S)-1-cyclohexyl-3-(diphenylphosphanyl)propan-2-amine 
(18e) (60.0 mg, 184 µmol), phenyl isothiocyanate (27.9 mg, 24.7 µL, 202 µmol) and CH2Cl2 
(0.6 mL) were stirred for 16 hours and the crude product was purified by column chromatography 
(SiO2, cyclohexane:ethyl acetate (5:1), d x h: 2.5 x 15 cm) to afford the product 19e (84.2 mg, 155 
µmol, 71%) as a white solid. 
 
C28H33N2PS (460.62 g/mol): 
MP: 60-61 °C. 
TLC: Rf = 0.38 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = (br s, 1H, NH), 7.54-7.26 (m, 13H, ar-H), 7.06 (d, 
3JHH = 7.5 Hz, 2H, ar-H), 5.97 (d, 3JHH = 8.6 Hz, 1H, NH), 4.82 (br s, 1H, NCH), 2.55 (dd, 
2JHP = 14.1 Hz, 3JHH = 6.4 Hz, 1H, PCH2), 2.42 (ddd, 2JHP = 14.1 Hz, 3JHH = 5.4 Hz, 4JHH =1.7 Hz, 
1H, PCH2), 1.73-1.42 (m, 7H, cy-CH2*, cy-CH, NCHCH2), 1.24-1.06 (m, 4H, cy-CH2), 0.96-0.75 (m, 
2H, cy-CH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 179.6, 138.1 (d, JCP = 11.7 Hz), 135.9, 133.1 (d, 
JCP = 19.5 Hz), 132.7 (d, JCP = 19.1 Hz), 130.1, 128.8, 128.7, 128.5 (d, JCP = 3.7 Hz), 128.5 (d, 
JCP = 3.5 Hz), 127.1, 125.2, 51.7 (d, JCP = 15.5 Hz), 43.0 (d, JCP = 9.6 Hz), 34.5, 34.4, 33.3, 33.0, 
26.4, 26.2, 26.1. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −25.6. 
IR (ATR): 𝑣𝑣�/cm-1 = 3176 (w), 2914 (m), 2846 (m), 1650 (s), 1441 (m), 1403 (m), 1310 (w), 1089 (w), 
959 (w), 834 (m), 675 (w), 518 (w), 458 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. C28H33N2PS+: 983.3495 [2M+Cu]+; found: 
983.3473. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −12.3 (c = 0.62, MeOH). 
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(S)-(2-Isothiocyanato-3-phenylpropyl)diphenylphosphane (21) 
P N S
 
Under argon atmosphere, a heat-gun dried round two-necked flask was charged with (S)-1-
(diphenylphosphanyl)-3-phenylpropan-2-amine (18d) (520 mg, 1.63 mmol), N,N′-dicyclohexyl-
carbodiimide (336 mg, 1.63 mmol) and THF (15 mL). Then, the reaction mixture was cooled in an 
ice-bath and at 0 °C carbon disulfide (1.64 g, 1.30 mL, 21.5 mmol) was added dropwise over 
10 minutes to the reaction solution. After addition, the reaction mixture was stirred for 16 hours at 
room temperature and then the crude product was concentrated under vacuum and was purified 
by column chromatography (SiO2, cyclohexane:ethyl acetate (10:1), d x h: 3.5 x 15 cm) to afford 
the product 21 (489 mg, 1.35 mmol, 83%) as a pale yellow oil. 
 
C22H20NPS (361.44 g/mol): 
TLC: Rf = 0.30 (SiO2, cyclohexane:ethyl acetate (10:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.50-7.30 (m, 13H, ar-H), 7.25-7.19 (m, 2H, ar-H), 3.15 (dd, 
2JHP = 13.7 Hz, 3JHH = 5.1 Hz, 1H, PCH2), 3.09-3.01 (m, 1H, PCH2), 2.54-2.41 (m, 2H, Ph- CH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 136.4, 133.1, 132.9, 132.7, 129.6, 129.2, 129.2, 128.9, 
128.8, 128.8, 127.3, 57.7 (d, JCP = 18.9 Hz), 43.2 (d, JCP = 7.7 Hz), 35.1 (d, JCP = 16.8 Hz). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −22.3. 
IR (ATR): 𝑣𝑣�/cm-1 = 3052 (w), 3026 (w), 2919 (w), 2048 (s), 1480 (w), 1432 (m), 1339 (m), 1069 (w), 
1026 (w), 927 (w), 736 (s), 693 (s), 500 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C22H20NPS+: 362.1127 [M+H]+; found: 
362.1124. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +52.6 (c = 0.64, MeOH). 
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1-((S)-1-(Diphenylphosphanyl)-3-phenylpropan-2-yl)-3-((1R,2S)-2-hydroxy-1,2-diphenyl-
ethyl)thiourea (20e) 
P HN
HN
S
HO  
Under argon atmosphere, a heat-gun dried round-bottomed flask was charged with (S)-(2-
isothiocyanato-3-phenylpropyl)diphenylphosphane (21) (40 mg, 111 µmol) and CH2Cl2 (0.4 mL). 
Then, (1S,2R)-2-amino-1,2-diphenylethanol (30.7 mg, 144 µmol) was added in one portion to the 
corresponding reaction mixture and was stirred for 16 hours at room temperature. Afterwards the 
crude product was concentrated under vacuum and was purified by column chromatography 
(SiO2, cyclohexane:ethyl acetate (3:1), d x h: 2 x 20 cm) to afford the product 20e (61 mg, 
106 µmol, 96%) as a white solid. 
 
C36H35N2OPS (574.73 g/mol): 
MP: 79-80 °C. 
TLC: Rf = 0.38 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 8.02 (br s, 1H, NH), 7.44 (d, 3JHH = 8.3 Hz, 2H, ar-H), 7.41-
7.32 (m, 2H, ar-H), 7.32-7.12 (m, 11H, ar-H), 7.08-7.04 (m, 2H, ar-H), 6.92 (d, 3JHH = 8.3 Hz, 2H, 
ar-H), 6.03 (br s, 1H, NH), 4.83 (br s, 1H, CH), 3.04 (dd, 2JHP = 13.9 Hz, 3JHH = 6.3 Hz, 1H, PCH2), 
2.96 (dd, 2JHP = 13.9 Hz, 3JHH = 7.0 Hz, 1H, PCH2), 2.44-2.29 (m, 2H, Ph-CH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 181.1, 139.3, 137.9 (d, JCP = 11.5 Hz), 137.6, 136.0, 
133.1 (d, JCP = 19.4 Hz), 132.9 (d, JCP = 19.0 Hz), 129.8, 129.0, 128.8, 128.7, 128.7, 128.6, 128.3 
(d, JCP = 11.8 Hz), 128.1, 126.8, 126.7, 76.6, 63.8, 53.9 (d, JCP = 15.6 Hz), 40.8, 33.4. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −24.7. 
IR (ATR): 𝑣𝑣�/cm-1 = 3247 (w), 3027 (w), 1525 (m), 1492 (m), 1289 (w), 1212 (w), 1190 (w), 
1083 (m), 1050 (m), 1026 (w), 927 (w), 737 (m), 695 (s), 581 (w), 499 (m), 418 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C36H35N2OPS+: 575.2280 [M+H]+; found: 
575.2277. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +60.5 (c = 0.52, MeOH). 
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1,3-bis((S)-1-(Diphenylphosphanyl)-3-phenylpropan-2-yl)thiourea (20f) 
P
N
H
N
H
S
P
 
Under argon atmosphere, a heat-gun dried round-bottomeded flask was charged with (S)-(2-
isothiocyanato-3-phenylpropyl)diphenylphosphane (21) (27.0 mg, 74.7 µmol) and CH2Cl2 
(0.5 mL). Then, (S)-1-(diphenylphosphanyl)-3-phenylpropan-2-amine (28.6 mg, 89.6 µmol) was 
added to the corresponding reaction mixture in one portion and was stirred for 16 hours at room 
temperature. Afterwards the crude product was concentrated under vacuum and was purified by 
column chromatography (SiO2, cyclohexane:ethyl acetate (10:1), d x h: 2.5 x 14 cm) to afford the 
product 20f (48.0 mg, 71.0 µmol, 94%) as a white solid. 
 
C43H42N2P2S (680.83 g/mol): 
MP: 157-158 °C. 
TLC: Rf = 0.38 (SiO2, cyclohexane:ethyl acetate (10:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.35-7.11 (m, 26H, ar-H), 6.99 (d, 3JHH = 7.0 Hz, 4H, ar-H), 
5.28 (br s, 2H, NH), 4.21 (br s, 2H, NCH), 2.79 (br s, 4H, Ph-CH2), 2.22-2.07 (m, 4H, PCH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 180.2, 138.0, 137.9, 137.8, 137.4, 133.1 (d, 
JCP = 19.6 Hz), 132.9 (d, JCP = 19.3 Hz), 129.6, 129.1, 129.0, 128.8, 128.8, 128.7, 126.8, 53.4 (d, 
JCP = 15.5 Hz), 41.0 (d, JCP = 8.1 Hz), 33.4 (d, JCP = 15.4 Hz). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −24.6. 
IR (ATR): 𝑣𝑣�/cm-1 = 2839 (w), 2890 (w), 2856 (w), 1529 (m), 1355 (w), 1318 (w), 1234 (w), 1079 (m), 
814 (m), 736 (s), 692 (s), 534 (m), 493 (m), 469 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C43H42N2P2S+: 681.2617 [M+H]+; found: 
681.2615. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +23.5 (c = 0.77, MeOH). 
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(S)-1-Benzyl-3-(1-(diphenylphosphanyl)-3-phenylpropan-2-yl)thiourea (20g) 
P HN
HN
S
 
Under argon atmosphere, a heat-gun dried round-bottomed flask was charged with (S)-(2-
isothiocyanato-3-phenylpropyl)diphenylphosphane (21) (50.0 mg, 138 µmol) and CH2Cl2 (0.8 mL). 
Then, benzylamine (19.4 mg, 19.8 µL, 179 µmol) was added in one portion to the reaction mixture 
and was stirred for 16 hours at room temperature. Afterwards the crude product was concentrated 
under vacuum and was purified by column chromatography (SiO2, cyclohexane:ethyl acetate 
(5:1), d x h: 2.5 x 13 cm) to afford the product 20g (60.0 mg, 128 µmol, 93%) as a white solid. 
 
C29H29N2PS (468.60 g/mol): 
MP: 54-55 °C. 
TLC: Rf = 0.46 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = δ 7.36-7.03 (m, 20H, ar-H), 5.86-5.42 (br m, 2H, NH), 4.53 (s, 
1H, CH), 4.14 (s, 2H, benz-CH2), 2.97 (dd, 2JHP = 13.7 Hz, 3JHH = 5.8 Hz, 1H, PCH2), 2.88 (dd, 2JHP 
= 13.9, 3JHH = 6.8 Hz, 1H, PCH2), 2.30 (dd, 4JHP = 14.1, 3JHH = 6.2 Hz, 1H, Ph-CH2), 2.19 (dd, 
4JHP = 14.1, 3JHH = 6.8 Hz, 1H, Ph-CH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 181.2, 137.4, 133.1 (d, JCP = 16.5 Hz), 132.9 (d, 
JCP = 16.2 Hz), 129.6, 129.1, 129.0, 128.8 (d, JCP = 5.1 Hz), 128.8, 128.7, 128.1, 127.7, 126.8, 
54.1 (d, JCP = 14.3 Hz), 47.9, 41.1, 33.2. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −24.6. 
IR (ATR): 𝑣𝑣�/cm-1 = 3238 (m), 3051 (w), 3025 (w), 1532 (s), 1432 (m), 1342 (w), 1269 (w), 1226 (w), 
1025 (w), 732 (s), 691 (s), 500 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C29H29N2PS+: 469.1862 [M+H]+; found: 
469.1858. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +18.8 (c = 0.90, MeOH). 
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5.2.2 Synthesis of 2nd Generation Catalysts 
General Procedure (GP2): Amine coupling with dimethylsquarate 
Under argon atmosphere, a heat-gun dried round-bottomed flask was charged with 3,4-
dimethoxy-3-cyclobutene-1,2-dione (1.1 eq.) and methanol (3 mL per mmol dimethylsquarate). 
Then the primary amine (1.0 eq.) was added dropwise to the reaction mixture. The corresponding 
mixture was stirred for 48 hours at room temperature. The precipitated product was filtered off and 
the corresponding crystals were washed with ice-cold methanol to yield the desired squaramide 
precursor after high-vacuum drying.  
 
3-((2,6-Dihydroxyphenyl)amino)-4-methoxycyclobut-3-ene-1,2-dione (24d) 
OO
MeO HN
HO
HO  
According to general procedure GP2, 3,4-dimethoxy-3-cyclobutene-1,2-dione (22) (100 mg, 
704 µmol), methanol (2.2 mL) and 2-aminobenzene-1,3-diol (23d) (80.0 mg, 604 µmol) were 
stirred for 48 hours to give the product 24d (113 mg, 480 µmol, 75%) as a white solid. 
 
C11H9NO5 (235.20 g/mol): 
MP: 216-217 °C.  
1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.65 (br s, 3H, NH*, OH*), 6.87 (t, 3JHH = 8.1 Hz, 1H, ar-
H), 6.33 (d, 3JHH = 8.1 Hz, 2H, ar-H), 4.19 (s, 3H, OCH3). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 183.9, 173.1, 153.8, 127.6, 112.4, 106.5, 59.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 3435 (w), 3273 (m), 1807 (w), 1689 (m), 1606 (s), 1525 (m), 1503 (s), 1478 (s), 
1450 (m), 1370 (s), 1329 (m), 1260 (w), 1161 (s), 1064 (w), 1016 (s), 935 (m), 784 (w), 732 (m), 
631 (m), 588 (m).  
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C11H9NO5+: 258.0373 [M+Na]+; found: 
258.0375. 
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3-(Benzhydrylamino)-4-methoxycyclobut-3-ene-1,2-dione (24f) 
OO
MeO HN
 
According to general procedure GP2, 3,4-dimethoxy-3-cyclobutene-1,2-dione (22) (110 mg, 
774 µmol), methanol (2.3 mL) and benzhydrylamine (23f) (133 mg, 125 µL, 704 µmol) were stirred 
for 48 hours to give the product 24f (130 mg, 440 µmol, 63%) as a white solid. 
 
C18H15NO3 (293.32 g/mol): 
MP: 175-176 °C.  
1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.83/9.62* (d, 3JHH = 9.5 Hz, 1H, NH), 7.40-7.26 (m, 10H, 
ar-H), 6.47/5.94* (d, 3JHH = 9.3 Hz, 1H, CHPh2), 4.30 (s, 3H, OCH3). [* refers to signal of rotamers] 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 189.3/188.8*, 182.8/182.5*, 178.0/177.4*, 
171.7/171.0*, 141.3/140.9*, 128.6, 127.5, 127.2, 61.8/60.6*, 60.4/60.0*. 
IR (ATR): 𝑣𝑣�/cm-1 = 3239 (m), 1805 (m), 1699 (s), 1605 (s), 1468 (s), 1389 (s), 1120 (w), 1046 (w), 
918 (w), 805 (w), 742 (m), 696 (s), 603 (s), 514 (m), 473 (m).  
EA (C18H15NO3) calc.: C 73.71, H 5.15, N 4.78; found: C 73.61, H 5.24, N 4.94. 
 
3-(((1R,2S)-2-Hydroxy-1,2-diphenylethyl)amino)-4-methoxycyclobut-3-ene-1,2-dione (24h) 
OO
MeO HN
HO  
According to general procedure GP2, 3,4-dimethoxy-3-cyclobutene-1,2-dione (22) (183 mg, 
1.29 mmol), methanol (3.9 mL) and (1S,2R)-2-amino-1,2-diphenylethanol (23h) (250 mg, 
1.17 mmol) were stirred for 48 hours to give the product 24h (188 mg, 581 µmol, 50%) as a white 
solid.  
 
C19H17NO4 (293.32 g/mol): 
MP: 208-209 °C.  
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1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.18/9.01* (d, 3JHH = 9.9 Hz, 1H, NH), 7.48-7.21 (m, 10H, 
ar-H), 5.61 (br s, 1H, OH), 5.24/4.63* (t, 3JHH = 9.2 Hz, 1H, NCH), 4.86 (t, 3JHH = 9.7 Hz, 1H, OCH), 
4.21/4.19* (s, 3H, OCH3). [* refers to signal of rotamers] 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 189.1/188.8*, 182.2/182.1*, 177.3/176.8, 
171.4/171.0*, 142.6, 139.8/139.4*, 128.0, 128.0, 127.8, 127.7, 127.4, 127.4, 127.3, 127.1, 127.0, 
74.9, 64.7, 63.2, 60.2/59.9*. 
IR (ATR): 𝑣𝑣�/cm-1 = 3251 (w), 1680 (m), 1578 (s), 1492 (s), 1390 (s), 1114 (m), 1052 (w), 923 (w), 
828 (m), 761 (m), 698 (s), 608 (m), 553 (m), 527 (m), 411 (w). 
EA (C19H17NO4) calc.: C 70.58, H 5.30, N 4.33; found: C 70.64, H 5.36, N 4.52. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +98.3 (c = 0.95, DMSO). 
 
(S)-3-Methoxy-4-((1-(naphthalen-1-yl)ethyl)amino)cyclobut-3-ene-1,2-dione (24i) 
OO
MeO HN
 
According to general procedure GP2, 3,4-dimethoxy-3-cyclobutene-1,2-dione (22) (110 mg, 
774 µmol), methanol (2.3 mL) and (R)-(+)-alpha-(1-napthyl)ethylamine (23i) (121 mg, 704 µmol) 
were stirred for 48 hours to give product 24i (117 mg, 380 µmol, 54%) as a white solid.  
 
C17H15NO3 (281.31 g/mol): 
MP: 168-169 °C.  
1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.42/9.19* (d, 3JHH = 8.2 Hz, 1H, NH), 7.96-7.87 (m, 3H, 
ar-H), 7.84-7.80 (m, 1H, ar-H), 7.59-7.47 (m, 3H, ar-H), 5.45 and 4.98 (t, 3JHH = 7.4 Hz, 1H, NCH), 
4.30/4.28* (s, 3H, OCH3), 1.61 (d, 3JHH = 5.8 Hz, 3H, CHCH3). [* refers to signal of rotamers] 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 189.2, 182.5/182.2*, 177.7/177.2*, 171.4/171.2*, 
140.9/140.6*, 132.8, 132.2, 128.3, 127.8, 127.5, 126.3, 126.0, 124.4, 124.4, 124.2, 60.2/59.9*, 
54.0/53.1*, 22.3. 
IR (ATR): 𝑣𝑣�/cm-1 = 3214 (w), 3176 (w), 1797 (m), 1696 (s), 1586 (s), 1494 (s), 1466 (m), 1435 (m), 
1394 (m), 1326 (w), 1295 (w), 1178 (w), 1142 (w), 1080 (w), 1035 (w), 867 (s), 821 (m), 764 (m), 
718 (w), 612 (w), 482 (s).  
EA (C17H15NO3) calc.: C 72.58, H 5.37, N 4.98; found: C 72.80, H 5.46, N 5.22. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +216.5 (c = 0.95, DMSO). 
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3-((2-(Anthracen-9-yl)phenyl)amino)-4-methoxycyclobut-3-ene-1,2-dione (24j) 
OO
MeO HN
 
According to general procedure GP2, 3,4-dimethoxy-3-cyclobutene-1,2-dione (22) (85.4 mg, 
601 µmol), methanol (1.8 mL) and 2-(anthracen-9-yl)aniline (23j) (147 mg, 546 µmol) were stirred 
for 48 hours to give the product 24j (180 mg, 474 µmol, 87%) as a yellow solid.  
C17H15NO3 (281.31 g/mol): 
 
MP: 155-156 °C.  
1H NMR (400 MHz, DMSO-d6): δ/ppm = 10.05 (br s, 1H, NH), 8.70 (s, 1H, ar-H), 8.15 (d, 
3JHH = 8.8 Hz, 2H, ar-H), 7.65-7.60 (m, 1H, ar-H), 7.54-7.47 (m, 5H, ar-H), 7.46-7.46 (m, 1H, ar-H), 
7.42-7.32 (m, 3H, ar-H), 4.28/4.23* (s, 3H, OCH3). [* refers to signal of rotamers] 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 189.1, 184.1/183.9*, 178.3, 170.7, 136.6, 132.3, 
132.3, 132.2, 131.0, 129.7, 128.8, 128.5, 127.2, 126.7, 126.0, 125.9, 125.8, 125.3, 61.0/60.2*. 
IR (ATR): 𝑣𝑣�/cm-1 = 3170 (w), 3049 (w), 1799 (m), 1713 (m), 1577 (s), 1509 (m), 1473 (m), 
1444 (m), 1350 (s), 1012 (w), 934 (w), 737 (s), 636 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C17H15NO3+: 402.1101 [M+Na]+; found: 
402.1105. 
 
3-Methoxy-4-((2'-methoxy-[1,1'-biphenyl]-2-yl)amino)cyclobut-3-ene-1,2-dione (24k) 
OO
MeO HN
OMe
 
According to general procedure GP2, 3,4-dimethoxy-3-cyclobutene-1,2-dione (22) (78.5 mg, 
552 µmol), methanol (1.7 mL) and 2'-methoxy-[1,1'-biphenyl]-2-amine (23k) (110 mg, 552 µmol) 
were stirred for 48 hours to give the product 24k (125 mg, 404 µmol, 73%) as a white solid.  
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C18H15NO4 (309.32 g/mol): 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.96 (br s, 1H, NH), 7.49-7.27 (m, 6H, ar-H), 7.18-7.06 (m, 
2H, ar-H), 4.45 (s, 3H, OCH3), 3.91 (s, 3H, OCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 184.8, 155.5, 134.7, 132.2, 131.7, 130.2, 128.6, 126.7, 
125.8, 122.0, 121.3, 111.7, 60.8, 56.1. 
 
3-((2'-Hydroxy-[1,1'-biphenyl]-2-yl)amino)-4-methoxycyclobut-3-ene-1,2-dione (24l) 
OO
MeO HN
OH
 
According to general procedure GP2, 3,4-dimethoxy-3-cyclobutene-1,2-dione (22) (75.2 mg, 
529 µmol), methanol (1.6 mL) and 2'-amino-[1,1'-biphenyl]-2-ol (23l) (98 mg, 529 µmol) were 
stirred for 48 hours to give the product 24l (92.0 mg, 312 µmol, 59%) as a white solid.  
 
C17H13NO4 (295.29 g/mol): 
MP: 204-205 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.98 (br s, 1H, NH), 9.83 (br s, 1H, OH), 7.41-7.13 (m, 
6H, ar-H), 6.98-6.86 (m, 2H, ar-H), 4.24 (s, 3H, OCH3). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 183.9, 178.0, 170.2, 153.9, 135.1, 133.2, 131.7, 
131.1, 129.2, 127.6, 126.1, 125.1, 124.3, 119.4, 115.6, 60.1. 
IR (ATR): 𝑣𝑣�/cm-1 = 3298 (w), 3252 (m), 1808 (m), 1712 (m), 1570 (s), 1507 (s), 1478 (m), 1439 (m), 
1395 (m), 1287 (w), 1201 (w), 1162 (w), 1081 (w), 928 (w), 761 (s), 678 (m), 619 (m), 603 (m), 
559 (m), 506 (w), 426 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C17H13NO4+: 318.0737 [M+Na]+; found: 
318.0735. 
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General Procedure (GP3): Amino phosphine coupling with squaramide precursor 
Under argon atmosphere, a round-bottomed flask was charged with the amino phosphine (1.0 eq.) 
and MeOH (20 mL per mmol). After addition of the squaramide precursor (1.0 eq.) the reaction 
mixture was stirred for two days at room temperature. The resulting precipitate was filtered off and 
washed with MeOH (2 x 10 mL per mmol) to afford the pure product after drying under vacuum. 
 
(S)-3-((2-(Diphenylphosphanyl)-1-phenylethyl)amino)-4-(phenylamino)cyclobut-3-ene-1,2-
dione (25a) 
NH
P
N
H
O
O
 
According to general procedure GP3, (S)-2-(diphenylphosphanyl)-1-phenylethan-1-amine (18a) 
(30.0 mg, 98.2 µmol) in MeOH (2 mL) and 3-(methoxy)-4-(phenylamino)-3-cyclobutene-1,2-dione 
(24a) (18.1 mg, 89.3 µmol) were stirred for two days to give the product 25a (33.0 mg, 69.0 µmol, 
78%) as a white solid.  
 
C30H25N2O2P (476.51 g/mol):  
MP: >250 °C. 
1H{1H} NMR (400 MHz, DMSO-d6): δ/ppm = 9.49 (s, 1H, NH), 8.14 (d, 3JHH = 9.0 Hz, 1H, ar-H), 
7.51-7.26 (m, 19H, ar-H), 7.04 (t, 3JHH = 7.2 Hz, 1H, NH), 5.30-5.23 (m, 1H, CH), 2.95 (dd, 
2JHP = 14.0 Hz, 3JHH = 9.2 Hz, 1H, CH2), 2.82 (dd, 2JHP = 14.0, 3JHH = 6.0 Hz, 1H, CH2). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 183.3, 180.3, 168.0, 163.5, 142.2 (d, JCP = 5.9 Hz), 
138.8, 137.7 (d, JCP = 13.5 Hz), 137.5 (d, JCP = 13.0 Hz), 132.7 (d, JCP = 17.0 Hz), 132.5 (d, 
JCP = 16.7 Hz), 129.3, 128.8 (d, JCP = 3.5 Hz), 128.7, 128.6 (d, JCP = 2.3 Hz), 128.5 (d, 
JCP = 2.3 Hz), 127.7, 126.4, 122.7, 118.0, 55.8 (d, JCP = 18.4 Hz), 35.7 (d, JCP = 15.1 Hz). 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −22.6. 
IR (ATR): v/cm-1 = 3181 (w), 3119 (w), 3065 (w), 3036 (w), 1796 (w), 1652 (m), 1604 (m), 1563 (s), 
1542 (s), 1476 (s), 1431 (s), 1251 (w), 1028 (w), 837 (w), 731 (m), 689 (s), 512 (m). 
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HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C30H25N2O2P+: 477.1726 [M+H]+; found: 
477.1727. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +14.3 (c = 0.56, DMSO). 
 
(S)-3-((1-Cyclohexyl-2-(diphenylphosphanyl)ethyl)amino)-4-(phenylamino)cyclobut-3-ene-
1,2-dione (25b) 
NH
P
N
H
O
O
 
According to general procedure GP3, (S)-1-cyclohexyl-2-(diphenylphosphanyl)ethan-1-amine 
(18b) (58.0 mg, 186 µmol) in MeOH (4 mL) and 3-(methoxy)-4-(phenylamino)-3-cyclobutene-1,2-
dione (24a) (41.6 mg, 205 µmol) were stirred for two days to give the product 25b (75.0 mg, 155 
µmol, 84%) as a white solid.  
 
C30H25N2O2P (476.51 g/mol):  
MP: 98-99 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.35 (s, 1H, NH), 7.56 (d, 3JHH = 9.7 Hz, 1H, ar-H), 7.47-
7.22 (m, 14H, ar-H), 7.02 (t, 3JHH = 7.3 Hz, 1H, NH), 4.12 – 3.96 (m, 1H, NCH), 2.54 (d, 
2JHP = 15.2 Hz, 1H, PCH2), 2.36 (dd, 2JHP = 14.2 Hz, 3JHH = 10.1 Hz, 1H, PCH2), 1.77-1.53 (m, 6H, 
cy-CH2), 1.23-0.92 (m, 5H, cy-CH2, cy-CH). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 183.4, 180.0, 168.9, 162.9, 139.0, 138.1 (d, 
JCP = 12.6 Hz), 137.9 (d, JCP = 13.5 Hz), 132.7 (d, JCP = 2.1 Hz), 132.5 (d, JCP = 2.3 Hz), 129.3, 
128.8, 128.6, 128.5, 128.4, 122.5, 117.8, 57.1 (d, JCP = 15.6 Hz), 43.3 (d, JCP = 7.4 Hz), 32.0 (d, 
JCP = 12.8 Hz), 29.2, 27.0, 25.8, 25.5 (d, JCP = 3.7 Hz). 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −22.3. 
IR (ATR): v/cm-1 = 3172 (w), 3055 (w), 2923 (w), 2850 (w), 1793 (w), 1655 (m), 1603 (m), 1562 (s), 
1544 (s), 1446 (s), 1432 (s), 1250 (w), 1097 (w), 1029 (w), 831 (w), 748 (s), 730 (s), 685 (s), 505 
(m), 463 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C30H25N2O2P+: 483.2196 [M+H]+; found: 
483.2200. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +28.9 (c = 0.48, DMSO). 
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(S)-3-((1-(Diphenylphosphanyl)-4-methylpentan-2-yl)amino)-4-(phenylamino)cyclobut-3-
ene-1,2-dione (25c) 
NH
P
N
H
O
O
 
According to general procedure GP3, (S)-1-(diphenylphosphanyl)-4-methylpentan-2-amine (18c) 
(60.0 mg, 0.21 mmol) in MeOH (4 mL) and 3-(methoxy)-4-(phenylamino)-3-cyclobutene-1,2-dione 
(24a) (42.7 mg, 0.21 mmol) were stirred for two days to give of the product 25c (67.0 mg, 
150 µmol, 70%) as a pale yellow solid. 
 
C28H29N2O2P (456.20 g/mol):  
MP: >250 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.34 (s, 1H, NH), 7.62 (d, 3JHH = 8.9 Hz, 1H, NH), 7.49-
7.25 (m, 14H, ar-H), 7.03 (t, 3JHH = 7.2 Hz, 1H, NH), 4.33-4.20 (m, 1H, CH), 2.57-2.42 (m, 2H, 
CH2), 1.72-1.49 (m, 3H, CH2, CH(CH3)2), 0.85 (d, 3JHH = 6.2 Hz, 3H, CH(CH3)2), 0.81 (d, 
3JHH = 6.2 Hz, 3H, CH(CH3)2). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 183.3, 179.9, 168.6, 163.2, 139.0, 138.3 (d, 
JCP = 13.0 Hz), 137.8 (d, JCP = 12.6 Hz), 132.7 (d, JCP = 19.7 Hz), 132.4 (d, JCP = 19.1 Hz), 129.3, 
128.6 (d, JCP = 5.9 Hz), 128.5 (d, JCP = 6.9 Hz), 122.5, 117.8, 51.1 (d, JCP = 16.4 Hz), 45.8 (d, JCP 
= 8.2 Hz), 35.7 (d, JCP = 14.3 Hz), 24.4, 23.0, 21.3. 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −23.5. 
IR (ATR): v/cm-1 = 3170 (w), 2955 (m), 1793 (m), 1651 (s), 1601 (s), 1563 (s), 1539 (s), 1430 (s), 
1261 (m), 1025 (w), 728 (s), 684 (s), 496 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C28H29N2O2P+: 457.2039 [M+H]+; found: 
457.2042- [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +46.7 (c = 0.82, DMSO). 
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(S)-3-((1-(Diphenylphosphino)-3-phenylpropan-2-yl)amino)-4-(phenylamino)cyclobut-3-
ene-1,2-dione (25d) 
NH
P
N
H
O
O
 
According to general procedure GP3, (S)-1-(diphenylphosphino)-3-phenylpropan-2-amine (18d) 
(110.0 mg, 340 µmol) in MeOH (7 mL) and 3-(methoxy)-4-(phenylamino)-3-cyclobutene-1,2-dione 
(24a) (69.9 mg, 340 µmol) were stirred for two days to give the product 25d (142 mg, 290 µmol, 
85%) as a white solid. 
 
C31H27N2O2P (490.54 g/mol):  
MP: >250 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.35 (s, 1H, NH), 7.65 (d, 3JHH = 8.8 Hz, 1H, NH), 7.42-
7.25 (m, 16H, ar-H), 7.23-7.15 (m, 3H, ar-H), 7.07-6.97 (m, 1H, ar-H), 4.41-4.29 (m, 1H, CH), 
3.08 (dd, 2JHP = 13.7 Hz, 3JHH = 5.8 Hz, 1H, PCH2), 2.97 (dd, 2JHP = 13.7 Hz, 3JHH = 8.1 Hz, 1H, 
Ph-CH2), 2.63-2.56 (m, 1H, Ph-CH2), 2.45 (dd, 4JHP = 14.3 Hz, 3JHH = 9.4 Hz, 1H, PCH2). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 183.3, 180.1, 168.6, 163.2, 138.9, 138.0, 137.9, 
137.7, 137.6, 132.6, 132.4, 132.3, 129.3, 129.3, 128.7 (d, JCP = 6.1 Hz), 128.6 (d, JCP = 4.1 Hz), 
128.5 (d, JCP = 4.3 Hz), 128.3, 126.4, 122.5, 117.9, 54.2 (d, JCP = 16.5 Hz), 43.0 (d, JCP = 8.5 Hz), 
34.1 (d, JCP = 13.8 Hz). 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −23.2. 
IR (ATR): v/cm-1 = 3181 (w), 3031 (w), 1797 (m), 1653 (s), 1604 (s), 1539 (s), 1476 (s), 1431 (s), 
1295 (w), 1172 (w), 1071 (w), 836 (w), 731 (s), 688 (s). 
EA (C31H27N2O2P) calc.: C 75.90, H 5.55, N 5.71; found: C 75.90, H 5.59, N 5.73. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +50.9 (c = 0.92, DMSO). 
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(S)-3-((1-cyclohexyl-3-(diphenylphosphanyl)propan-2-yl)amino)-4-(phenylamino)cyclobut-
3-ene-1,2-dione (25e) 
NH
P
N
H
O
O
 
According to general procedure GP3, (S)-1-cyclohexyl-3-(diphenylphosphanyl)propan-2-amine 
(18e) (100 mg, 307 µmol) in MeOH (6 mL) and 3-(methoxy)-4-(phenylamino)-3-cyclobutene-1,2-
dione (24a) (56.7 mg, 279 µmol) were stirred for two days to give the product 25e (110 mg, 
222 µmol, 79%) as a white solid. 
 
C31H33N2O2P (496.59 g/mol):  
MP: >250 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.34 (br s, 1H, NH), 7.63 (d, 3JHH = 8.6 Hz, 1H, NH), 7.49-
7.39 (m, 6H, ar-H), 7.39-7.24 (m, 8H, ar-H), 7.03 (t, 3JHH = 7.2 Hz, 1H, ar-H), 4.35-4.20 (m, 1H, 
NCH), 2.56-2.42 (m, 2H, PCH2), 1.69 (d, 3JHH = 13.0 Hz, 1H, cy-CH), 1.64-1.49 (m, 6H, cy-CH2), 
1.38-1.26 (m, 1H, CH2), 1.22-1.03 (m, 3H, cy-CH2*, CH2*), 0.95-0.72 (m, 2H, cy-CH2). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 183.3, 179.9, 168.6, 163.2, 139.0, 138.3 (d, 
JCP = 12.9 Hz), 137.8 (d, JCP = 12.6 Hz), 132.7 (d, JCP = 19.5 Hz), 132.4 (d, JCP = 19.1 Hz), 129.3, 
128.7 (d, JCP = 2.9 Hz), 128.5 (d, JCP = 6.9 Hz), 122.5, 117.8, 50.4 (d, JCP = 16.2 Hz), 44.3 (d, JCP 
= 8.5 Hz), 35.7 (d, JCP = 13.9 Hz), 33.7, 33.2, 31.7, 26.0, 25.6, 25.4. 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −23.6. 
IR (ATR): v/cm-1 = 3180 (w), 3064 (w), 3038 (w), 2920 (m), 2849 (w), 1793 (w), 1656 (m), 
1605 (w), 1541 (s), 1480 (w), 1433 (s), 729 (s), 685 (s), 602 (w), 501 (m). 
EA (C31H33N2O2P) calc.: C 74.98, H 6.70, N 5.64; found: C 74.68, H 6.69, N 5.86. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −3.3 (c = 0.80, DMSO). 
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3-(((2S,3S)-1-(Diphenylphosphanyl)-3-methylpentan-2-yl)amino)-4-(phenylamino)cyclobut-
3-ene-1,2-dione (25f) 
NH
P
N
H
O
O
 
According to general procedure GP3, (2S,3S)-1-(diphenylphosphanyl)-3-methylpentan-2-amine 
(18f) (100 mg, 351 µmol) in MeOH (7 mL) and 3-(methoxy)-4-(phenylamino)-3-cyclobutene-1,2-
dione (24a) (64.8 mg, 319 µmol) were stirred for two days to give the product 25f (96.0 mg, 
210 µmol, 66%) as a white solid. 
 
C28H29N2O2P (456.53 g/mol):  
MP: 227-228 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.34 (s, 1H, NH), 7.59 (d, 3JHH = 9.6 Hz, 1H, NH), 7.48-
7.38 (m, 6H, ar-H), 7.38-7.22 (m, 8H, ar-H), 7.02 (t, 3JHH = 7.3 Hz, 1H, ar-H), 4.18-4.07 (m, 1H, 
NCH), 2.50-2.46 (m, 1H, PCH2), 2.35-2.27 (m, 1H, PCH2), 1.71-1.61 (m, 1H, CHCH3), 1.54-
1.40 (m, 1H, CH2CH3), 1.17-1.04 (m, 1H, CH2CH3), 0.89 (d, 3JHH = 6.7 Hz, 3H, CHCH3), 0.80 (t, 
3JHH = 7.3 Hz, 3H, CH2CH3). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 183.4, 180.0, 168.8, 163.0, 139.0, 138.1 (d, 
JCP = 12.6 Hz), 137.9 (d, JCP = 13.7 Hz), 132.7 (d, JCP = 14.8 Hz), 132.5 (d, JCP = 14.7 Hz), 129.3, 
128.9, 128.6, 128.5, 128.4, 122.5, 117.8, 56.6 (d, JCP = 15.8 Hz), 40.4 (d, JCP = 7.5 Hz), 31.1 (d, 
JCP = 13.3 Hz), 23.9, 14.9, 11.3. 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −21.9. 
IR (ATR): v/cm-1 = 3200 (w), 3137 (w), 3094 (w), 3066 (w), 2962 (w), 1794 (m), 1655 (m), 1561 (s), 
1544 (s), 1480 (m), 1433 (m), 730 (s), 686 (s), 501 (m), 464 (m). 
EA (C28H29N2O2P) calc.: C 73.67, H 6.40, N 6.14; found: C 73.54, H 6.36, N 6.48. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +40.4 (c = 0.76, DMSO). 
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(S)-3-((3,5-bis(Trifluoromethyl)phenyl)amino)-4-((1-(diphenylphosphanyl)-3-phenylpropan-
2-yl)amino)cyclobut-3-ene-1,2-dione (26a) 
NH
P
N
H
O
O
CF3
CF3
 
According to general procedure GP3, (S)-1-(diphenylphosphanyl)-3-phenylpropan-2-amine (18d) 
(40.0 mg, 125 µmol) in MeOH (2.5 mL) and 3-((3,5-bis(trifluoromethyl)phenyl)amino)-4-
methoxycyclobut-3-ene-1,2-dione (24b) (38.6 mg, 113 µmol) were stirred for two days to give the 
product 26a (17.5 mg, 28.0 µmol, 25%) as a pale yellow solid.  
 
C33H25F6N2O2P (626.54 g/mol):  
MP: 238-239 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.89 (s, 1H, NH), 7.97 (s, 2H, ar-H), 7.79 (d, 3JHH = 8.9 Hz, 
1H, NH), 7.67 (s, 1H, ar-H), 7.43-7.16 (m, 15H, ar-H), 4.53-4.34 (m, 1H, CH), 3.15-3.09 (m, 1H, 
PCH2), 3.03-2.95 (m, 1H, PCH2), 2.65-2.51 (m, 2H, Ph-CH2). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 184.0, 180.2, 169.3, 162.0, 140.9, 140.8, 137.8, 
137.6, 132.7, 132.6 (d, JCP = 2.8 Hz), 132.5 (d, JCP = 6.1 Hz), 132.4 (d, JCP = 2.6 Hz), 132.3, 131.5, 
129.3, 128.7, 128.7, 128.6 (d, JCP = 2.8 Hz), 128.5 (d, JCP = 2.9 Hz), 128.4, 128.3, 126.5, 124.5, 
121.8, 117.9, 114.7, 54.5 (d, JCP = 16.1 Hz), 43.0 (d, JCP = 7.9 Hz), 34.1 (d, JCP = 14.5 Hz). 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −23.3. 
19F{1H} NMR (376 MHz, DMSO-d6): δ/ppm = −61.8. 
IR (ATR): v/cm-1 = 3139 (w), 3070 (w), 3027 (w), 2930 (w), 1659 (m), 1567 (s), 1495 (m), 1463 (m), 
1375 (s), 1275 (s), 1180 (m), 1121 (s), 943 (w), 879 (w), 744 (m), 694 (s), 499 (m). 
EA (C33H25F6N2O2P) calc.: C 63.26, H 4.02, N 4.47; found: C 62.95, H 4.25, N 4.39. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −45.6 (c = 0.94, DMSO). 
  
EXPERIMENTAL PART            CHAPTER 5 
179 
(S)-3-((1-(Diphenylphosphanyl)-3-phenylpropan-2-yl)amino)-4-((4-methoxyphenyl)amino)-
cyclobut-3-ene-1,2-dione (26b) 
NH
P
N
H
O
O OMe
 
According to general procedure GP3, (S)-1-(diphenylphosphanyl)-3-phenylpropan-2-amine (18d) 
(75.3 mg, 236 µmol) in MeOH (4.5 mL) and 3-methoxy-4-((4-methoxyphenyl)amino)cyclobut-3-
ene-1,2-dione (24c) (50.0 mg, 214 µmol) were stirred for two days to give the product 26b 
(110 mg, 211 µmol, 99%) as a white solid. 
 
C32H29N2O3P (520.57 g/mol):  
MP: >250 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.26 (s, 1H, NH), 7.54 (d, 3JHH = 8.7 Hz, 1H, NH), 7.42-
7.15 (m, 17H, ar-H), 6.91 (d, 3JHH = 9.0 Hz, 2H, ar-H), 4.34 (s, 1H, CH), 3.73 (s, 3H, OCH3), 
3.07 (dd, 2JHP = 13.7 Hz, 3JHH = 5.8 Hz, 1H, PCH2), 2.97 (dd, 2JHP = 13.7 Hz, 3JHH = 8.0 Hz, 1H, 
PCH2), 2.63-2.53 (m, 1H, Ph-CH2), 2.44 (dd, 4JHP = 14.3 Hz, 3JHH =9.4 Hz, 1H, Ph-CH2). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 180.3, 168.1, 163.3, 155.1, 137.8, 132.5 (d, 
JCP = 18.0 Hz), 132.3 (d, JCP = 16.9 Hz), 132.0, 129.2, 128.7 (d, JCP = 6.3 Hz), 128.6 (d, 
JCP = 4.2 Hz), 128.5 (d, JCP = 4.4 Hz), 128.3, 126.4, 119.5, 114.5, 55.2, 54.1 (d, JCP = 16.9 Hz), 
43.0 (d, JCP = 7.0 Hz), 34.1 (d, JCP = 14.4 Hz). 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −23.3. 
IR (ATR): v/cm-1 = 3173 (w), 2999 (w), 1649 (m), 1610 (w), 1544 (s), 1515 (m), 1482 (m), 
1445 (m), 1250 (s), 1184 (m), 1033 (m), 827 (s), 747 (s), 731 (s), 693 (s), 508 (s). 
EA (C32H29N2O3P) calc.: C 73.83, H 5.62, N 5.38; found: C 73.47, H 5.71, N 5.57. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −42.7 (c = 0.56, DMSO). 
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(S)-3-((2,6-Dihydroxyphenyl)amino)-4-((1-(diphenylphosphanyl)-3-phenylpropan-2-
yl)amino)cyclobut-3-ene-1,2-dione (26c) 
NH
P
N
H
O
O HO
HO
 
According to general procedure GP3, (S)-1-(diphenylphosphanyl)-3-phenylpropan-2-amine (18d) 
(54.3 mg, 170 µmol) in MeOH (3.4 mL) and 3-((2,6-dihydroxyphenyl)amino)-4-methoxycyclobut-
3-ene-1,2-dione (24d) (40.0 mg, 170 µmol) were stirred for two days to give the product 26c (73.0 
mg, 140 µmol, 82%) as a white solid. 
 
C31H27N2O4P (522.54 g/mol):  
MP: >250 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.62 (br s, 2H, OH), 8.56 (br s, 1H, NH), 7.58-7.47 (m, 
1H, ar-H), 7.41-7.14 (m, 15H, ar-H, NH), 6.82 (t, 3JHH = 8.2 Hz, 1H, ar-H), 6.35 (d, 3JHH = 8.1 Hz, 
2H, ar-H), 4.25-4.13 (m, 1H, CH), 2.98 (d, 3JHH = 6.7 Hz, 2H, PCH2), 2.59-2.50 (m, 1H, Ph-CH2), 
2.34-2.27 (m, 1H, Ph-CH2). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 183.9, 181.8, 168.1, 167.1, 152.7, 138.4 (d, 
JCP = 12.5 Hz), 137.8, 137.4 (d, JCP = 13.9 Hz), 132.5 (d, JCP = 19.3 Hz), 132.3 (d, JCP = 19.0 Hz), 
129.3, 128.9, 128.7, 128.6, 128.3, 126.4, 126.2, 113.4, 106.6, 53.4 (d, JCP = 16.3 Hz), 43.3, 
33.9 (d, JCP = 13.2 Hz). 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −24.3. 
IR (ATR): v/cm-1 = 3158 (m), 3024 (m), 1793 (w), 1675 (m), 1588 (s), 1533 (m), 1450 (s), 1359 (m), 
1287 (w), 991 (s), 780 (m), 740 (m), 696 (s), 502 (w).31 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C31H27N2O4P+: 523.1781 [M+H]+; found: 
523.1784. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −0.4 (c = 0.68, DMSO). 
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(S)-3-((3,5-bis(Trifluoromethyl)benzyl)amino)-4-((1-(diphenylphosphanyl)-3-phenylpropan-
2-yl)amino)cyclobut-3-ene-1,2-dione (26f) 
NH
P
N
H
O
O
CF3
CF3
 
According to general procedure GP3, (S)-1-(diphenylphosphanyl)-3-phenylpropan-2-amine (18d) 
(49.7 mg, 125 µmol) in MeOH (3.2 mL) and 3-((3,5-bis(trifluoromethyl)benzyl)amino)-4-
methoxycyclobut-3-ene-1,2-dione (24g) (50.0 mg, 142 µmol) were stirred for two days to give the 
product 26f (89.0 mg, 139 µmol, 98%) as a white solid. 
 
C34H27F6N2O2P (520.57 g/mol):  
MP: 240-241 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 8.08 (br s, 1H, NH), 8.03 (s, 2H, ar-H), 7.54 (br s, 1H, 
NH), 7.37-7.09 (m, 16H, ar-H), 4.82 (s, 2H, ar-CH2), 4.24 (s, 1H, CH), 3.01 (dd, 2JHP = 13.6 Hz, 
3JHH = 5.6 Hz, 1H, PCH2), 2.90 (dd, 2JHP = 13.7 Hz, 3JHH = 8.3 Hz, 1H, PCH2), 2.57-2.52 (m, 1H, 
Ph-CH2), 2.43-2.35 (m, 1H, Ph-CH2). 
13C{1H} NMR (101 MHz, DMSO-d6) δ/ppm: 182.3, 167.6, 166.9, 142.6, 138.2 (d, JCP = 12.8 Hz), 
137.8, 132.5 (d, JCP = 7.6 Hz), 132.3 (d, JCP = 7.3 Hz), 130.9, 130.4 (d, JCP = 32.7 Hz), 130.0, 
129.3, 128.7, 128.5, 128.5, 128.4, 128.1, 127.4, 126.3, 124.7, 122.0, 53.9, 45.7, 43.1 (d, 
JCP = 7.8 Hz), 34.2. 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −23.2. 
19F{1H} NMR (376 MHz, DMSO-d6): δ/ppm = −61.3. 
IR (ATR): v/cm-1 = 3169 (w), 3072 (w), 1642 (m), 1560 (s), 1475 (m), 1434 (m), 1380 (w), 1355 (w), 
1278 (s), 1235 (w), 1182 (m), 1128 (s), 904 (w), 736 (m), 694 (s), 502 (m). 
EA (C34H27F6N2O2P) calc.: C 63.75, H 4.25, N 4.37; found: C 63.81, H 4.53, N 4.42. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −4.7 (c = 0.64, DMSO). 
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3-(((S)-1-(Diphenylphosphanyl)-3-phenylpropan-2-yl)amino)-4-(((1R,2S)-2-hydroxy-1,2-
diphenylethyl)amino)cyclobut-3-ene-1,2-dione (26g) 
NH
P
N
H
O
O
OH
 
According to general procedure GP3, (S)-1-(diphenylphosphanyl)-3-phenylpropan-2-amine (18d) 
(86.9 mg, 272 µmol) in MeOH (5.5 mL) and 3-(((1R,2S)-2-hydroxy-1,2-diphenylethyl)amino)-4-
methoxycyclobut-3-ene-1,2-dione (24h) (80.0 mg, 247 µmol) were stirred for two days to give the 
product 26g (123 mg, 201 µmol, 82%) as a white solid. 
 
C39H35N2O3P (610.70 g/mol):  
MP: >250 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 7.91 (d, 3JHH = 9.7 Hz, 1H, NH), 7.67 (d, 3JHH = 8.5 Hz, 
1H, NH), 7.39-7.06 (m, 25H, ar-H), 5.86 (s, 1H, OH), 5.30 (s, 1H, NCH), 5.09 (s, 1H, OCH), 4.11 (s, 
1H, CH), 3.00-2.85 (m, 2H, PCH2), 2.54 (br s, 1H, Ph-CH2), 2.33 (dd, 4JHP = 14.2 Hz, 3JHH = 9.4 Hz, 
1H, Ph-CH2). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 182.3, 182.1, 167.3, 166.9, 142.0, 138.6, 138.2 (d, 
JCP = 14.9 Hz), 137.8, 137.5 (d, JCP = 13.3 Hz), 132.5 (d, JCP = 5.9 Hz), 132.3 (d, JCP = 5.9 Hz), 
129.3, 128.8, 128.7, 128.6 (d, JCP = 5.0 Hz), 128.5, 128.2, 128.0, 127.6, 127.1, 127.1, 126.5, 
126.3, 75.1, 62.4, 53.6 (d, JCP = 16.2 Hz), 43.2 (d, JCP = 8.3 Hz), 33.9 (d, JCP = 13.1 Hz). 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −23.7. 
IR (ATR): v/cm-1 = 3136 (w), 3092 (w), 2971 (w), 2939 (w), 1638 (m), 1553 (s), 1477 (m), 1017 (w), 
734 (m), 695 (s), 615 (w), 499 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C39H35N2O3P+: 611.2458 [M+H]+; found: 
611.2454 [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +2.0 (c = 0.28, DMSO). 
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3-(((S)-1-(Diphenylphosphanyl)-3-phenylpropan-2-yl)amino)-4-(((S)-1-(naphthalen-1-
yl)ethyl)amino)cyclobut-3-ene-1,2-dione (26h) 
NH
P
N
H
O
O
 
According to general procedure GP3, (S)-1-(diphenylphosphanyl)-3-phenylpropan-2-amine (18d) 
(60.0 mg, 188 µmol) in MeOH (3.8 mL) and (S)-3-methoxy-4-((1-(naphthalen-1-yl)ethyl)amino-
)cyclobut-3-ene-1,2-dione (24i) (48.0 mg, 171 µmol) were stirred for two days to give the product 
26h (88.0 mg, 155 µmol, 91%) as a white solid. Because of the limited solubility in deuterated 
solvent, no carbon NMR was obtained.  
 
C37H33N2O2P (520.57 g/mol):  
MP: >250 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 8.00-7.04 (m, 22H, ar-H), 5.28 (br s, 1H, CH), 4.22 (br s, 
1H, CH), 3.04-2.95 (m, 1H, PCH2), 2.93-2.87 (m, 1H, PCH2), 2.46-2.32 (m, 2H, CH2), 1.59 (d, 
3JHH = 6.9 Hz, 3H, CH3). 
31P NMR (162 MHz, DMSO-d6): δ/ppm = −23.4. 
IR (ATR): v/cm-1 = 3155 (w), 3054 (w), 1637 (m), 1551 (s), 1465 (m), 1185 (w), 1073 (w), 819 (m), 
753 (s), 738 (s), 695 (s), 607 (w), 500 (m), 480 (m). 
EA (C37H33N2O2P) calc.: C 78.15, H 5.85, N 4.93; found: C 77.86, H 5.77, N 5.02. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +28.5 (c = 0.14, DMSO). 
 
(S)-3-((2-(Anthracen-9-yl)phenyl)amino)-4-((1-(diphenylphosphanyl)-3-phenylpropan-2-
yl)amino)cyclobut-3-ene-1,2-dione (26i) 
NH
P
N
H
O
O
 
EXPERIMENTAL PART            CHAPTER 5 
184 
According to general procedure GP3, (S)-1-(diphenylphosphanyl)-3-phenylpropan-2-amine (18d) 
(50.9 mg, 159 µmol) in MeOH (3.2 mL) and 3-((2-(anthracen-9-yl)phenyl)amino)-4-methoxy-
cyclobut-3-ene-1,2-dione (24j) (55.0 mg, 145 µmol) were stirred for two days to give the product 
26i (52.0 mg, 78.0 µmol, 54%) as a yellow solid. 
 
C45H35N2O2P (666.77 g/mol):  
MP: 243-244 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.70 (s, 1H, NH), 8.44 (s, 1H, ar-H), 8.01 (d, 3JHH = 8.9 Hz, 
2H, ar-H), 7.98 (d, 3JHH = 7.2 Hz, 1H, ar-H), 7.94 (d, 3JHH = 8.1 Hz, 1H, ar-H), 7.84 (d, 3JHH = 8.6 Hz, 
1H, ar-H), 7.60 (d, 3JHH = 8.9 Hz, 1H, ar-H), 7.45-7.39 (m, 2H, ar-H), 7.35-7.25 (m, 12H, ar-H), 
7.22-7.17 (m, 1H, ar-H), 7.15-7.07 (m, 3H, ar-H), 6.98 (d, 3JHH = 8.5 Hz, 1H, NH), 6.92-6.88 (m, 
3H, ar-H), 4.17-4.03 (m, 1H, CH), 2.87 (dd, 2JHP = 13.5 Hz, 3JHH = 5.7 Hz, 1H, PCH2), 2.79 (dd, 
2JHP = 13.5, 3JHH = 7.5 Hz, 1H, PCH2), 2.49-2.43 (m, 1H, Ph-CH2), 2.26-2.19 (m, 1H, Ph-CH2). 
13C{1H} NMR (101 MHz DMSO-d6): δ/ppm = 183.9, 180.5, 168.6, 164.2, 153.5, 138.0, 137.4, 
134.8, 133.6, 132.5 (d, JCP = 7.3 Hz), 132.3 (d, JCP = 7.4 Hz), 130.7, 130.0, 129.3, 128.8, 128.7, 
128.6 (d, JCP = 4.0 Hz), 128.5 (d, JCP = 3.9 Hz), 128.2 (d, JCP = 5.5 Hz), 128.2, 128.0, 126.5, 126.4, 
126.3, 125.2, 124.7, 123.7, 122.8, 122.7, 122.6, 118.7, 113.6, 53.6, 43.0, 33.7. 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −23.5. 
IR (ATR): v/cm-1 = 3211 (w), 3053 (w), 1781 (w), 1665 (w), 1567 (s), 1519 (s), 1486 (m), 1427 (s), 
1357 (w), 1305 (m), 1098 (w), 891 (w), 846 (w), 735 (s), 697 (s), 611 (w), 505 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C45H35N2O2P+: 667.2509 [M+H]+; found: 
667.2502. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +78.5 (c = 0.48, DMSO). 
 
(S)-3-((1-(Diphenylphosphanyl)-3-phenylpropan-2-yl)amino)-4-((2'-methoxy-[1,1'-biphenyl]-
2-yl)amino)cyclobut-3-ene-1,2-dione (26j) 
NH
P
N
H
O
O
OMe
 
According to general procedure GP3, (S)-1-(diphenylphosphanyl)-3-phenylpropan-2-amine (18d) 
(45.4 mg, 142 µmol) in MeOH (2.8 mL) and 3-methoxy-4-((2'-methoxy-[1,1'-biphenyl]-2-
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yl)amino)cyclobut-3-ene-1,2-dione (24k) (40.0 mg, 129 µmol) were stirred for two days to give the 
product 26j (25.0 mg, 42.0 µmol, 33%) as a white solid. 
 
C38H33N2O3P (596.67 g/mol):  
MP: 84-85 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 8.44 (s, 1H, NH), 7.82 (d, 3JHH = 8.6 Hz, 1H, NH), 7.47-
7.06 (m, 23H, ar-H), 4.26 and 4.11 (s, 1H, CH, rotamers), 3.56 (s, 3H, OCH3), 3.08-2.84 (m, 1H, 
PCH2), 2.58-2.52 (m, 1H, PCH2), 2.41-2.26 (m, 2H, Ph-CH2). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 183.8, 180.2, 164.1, 156.4, 137.8, 135.8, 132.5 (d, 
JCP = 7.5 Hz), 132.3 (d, JCP = 7.4 Hz), 131.3, 131.0, 129.9, 129.6, 129.3, 128.7 (d, JCP = 8.9 Hz), 
128.6, 128.6, 128.5, 128.3, 127.7, 126.5, 126.4, 124.0, 122.6, 120.9, 111.8, 99.5, 55.2, 53.6, 43.1, 
34.2 (d, JCP = 12.8 Hz). 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −23.7. 
IR (ATR): v/cm-1 = 3142 (w), 3053 (w), 3028 (w), 2946 (w), 1680 (w), 1583 (m), 1515 (s), 1429 (m), 
1235 (w), 1055 (s), 1024 (s), 999 (s), 842 (w), 748 (m), 731 (m), 697 (s), 501 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C38H33N2O3P+: 597.2302 [M+H]+; found: 
597.2307. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +24.0 (c = 0.21, DMSO). 
 
(S)-3-((1-(Diphenylphosphanyl)-3-phenylpropan-2-yl)amino)-4-((2'-hydroxy-[1,1'-biphenyl]-
2-yl)amino)cyclobut-3-ene-1,2-dione (26k) 
NH
P
N
H
O
O
OH
 
According to general procedure GP3, (S)-1-(diphenylphosphanyl)-3-phenylpropan-2-amine (18d) 
(59.5 mg, 186 µmol) in MeOH (3.7 mL) and 3-((2'-hydroxy-[1,1'-biphenyl]-2-yl)amino)-4-
methoxycyclobut-3-ene-1,2-dione (24l) (50.0 mg, 169 µmol) were stirred for two days to give the 
product 26k (76.0 mg, 130 µmol, 77%) as a white solid. 
C37H31N2O3P (582.64 g/mol):  
MP: >250 °C. 
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1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.61 (s, 1H, OH), 8.51 (s, 1H, NH), 7.85 (d, 3JHH = 8.6 Hz, 
1H, NH), 7.36-7.10 (m, 21H, ar-H), 7.00 (d, 3JHH = 8.1 Hz, 1H, ar-H), 6.92 (t, 3JHH = 7.4 Hz, 1H, ar-
H), 4.24 (br s, 1H, CH), 3.00 (dd, 2JHP = 13.5 Hz, 3JHH = 5.6 Hz, 1H, PCH2), 2.90 (dd, 2JHP = 13.5 Hz, 
3JHH = 7.7 Hz, 1H, PCH2), 2.56-2.51 (m, 1H, Ph-CH2), 2.38-2.27 (m, 1H, Ph-CH2). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 183.9, 180.5, 168.6, 164.1, 154.7, 138.1 (d, 
JCP = 12.8 Hz), 137.7, 135.7, 132.5 (d, JCP = 8.3 Hz), 132.3 (d, JCP = 8.0 Hz), 131.3, 131.2, 130.2, 
129.4, 129.2, 128.8, 128.7, 128.6 (d, JCP = 4.8 Hz), 128.5 (d, JCP = 5.0 Hz), 128.3, 127.6, 126.4, 
124.8, 123.8, 122.3, 119.3, 116.0, 53.8 (d, JCP = 16.3 Hz), 43.1 (d, JCP = 8.6 Hz), 33.9 (d, 
JCP = 14.0 Hz). 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −23.3. 
IR (ATR): v/cm-1 = 3163 (w), 3027 (w), 2942 (w), 1789 (w), 1679 (m), 1579 (s), 1522 (s), 1478 (m) 
,1431 (s), 1357 (m), 1283 (m), 1046 (s), 1021 (s), 996 (s), 820 (w), 751 (m), 696 (s), 502 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C37H31N2O3P+: 583.2145 [M+H]+; found: 
583.2143. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −4.7 (c = 0.41, DMSO). 
 
(S)-3-Amino-4-((1-(diphenylphosphanyl)-3-phenylpropan-2-yl)amino)cyclobut-3-ene-1,2-
dione (26l) 
NH
P
NH2
O
O
 
According to general procedure GP3, (S)-1-(diphenylphosphanyl)-3-phenylpropan-2-amine (18d) 
(69.1 mg, 186 µmol) in MeOH (4.3 mL) and 3-amino-4-methoxycyclobut-3-ene-1,2-dione 
(25.0 mg, 197 µmol) (24m) were stirred for two days to give the product 26l (75.0 mg, 181 µmol, 
92%) as a white solid  
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C25H23N2O2P (520.57 g/mol):  
MP: >250 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 7.49 (d, 3JHH = 8.1 Hz, 1H, NH), 7.40-7.12 (m, 16H, ar-H, 
NH), 4.14 (br s, 1H, CH), 3.04-2.88 (m, 2H, PCH2), 2.43-2.32 (m, 2H, Ph-CH2). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 182.8, 168.1, 138.3 (d, JCP = 16.1 Hz), 137.9, 137.6 
(d, JCP = 10.6 Hz), 132.5 (d, JCP = 7.8 Hz), 132.3 (d, JCP = 7.9 Hz), 129.3, 128.8, 128.6, 128.6, 
128.5, 128.2, 126.3, 53.5 (d, JCP = 15.1 Hz), 43.2 (d, JCP = 8.0 Hz), 34.2 (d, JCP = 13.4 Hz). 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −23.6. 
IR (ATR): v/cm-1 = 3300 (w), 3130 (m), 2932 (w), 1631 (m), 1564 (s), 1529 (s), 1475 (m), 1359 (w), 
1081 (w), 729 (m), 693 (s), 499 (m). 
EA (C25H23N2O2P) calc.: C 72.45, H 5.59, N 6.76; found: C 72.20, H 5.66, N 6.95. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −14.0 (c = 0.21, DMSO). 
 
3,4-bis(((S)-1-(Diphenylphosphanyl)-3-phenylpropan-2-yl)amino)cyclobut-3-ene-1,2-dione 
(26m) 
NH
P
N
H
O
O
P
 
Under argon atmosphere, a heat-gun dried round-bottomed flask was charged with 3,4-
dimethoxy-3-cyclobutene-1,2-dione (22) (20.0 mg, 131 µmol) and methanol (2.6 mL). Then, a 
solution of (S)-1-(diphenylphosphanyl)-3-phenylpropan-2-amine (18d) (112 mg, 352 µmol) in 
methanol (0.5 mL) was added in one portion. The corresponding mixture was stirred for two days 
at room temperature. The precipitate was filtered and washed with ice-cold methanol to yield the 
desired product 26m (56.0 mg, 78.0 µmol, 55%) as a white solid. Because of the limited solubility 
in deuterated solvent, no carbon NMR was obtained. 
 
C46H42N2O2P2 (716.80 g/mol):  
MP: >250 °C. 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 7.47-7.03 (m, 30H, ar-H), 4.11 (br s, 2H, CH), 3.01-
2.86 (m, 4H, PCH2), 2.47-2.28 (m, 4H, Ph-CH2). 
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31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −23.7. 
IR (ATR): v/cm-1 = 3155 (w), 3056 (w), 3024 (w), 2929 (w), 1636 (m), 1562 (s), 1471 (m), 1433 (m), 
1183 (w), 840 (w), 733 (s), 694 (s), 501 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C46H42N2O2P2+: 717.2794 [M+H]+; found: 
717.2796 [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −123.0 (c = 0.06, DMSO). 
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5.2.3 Synthesis of 3rd Generation Catalysts 
tert-Butyl (4S,5S)-4-(hydroxymethyl)-2,2-dimethyl-5-phenyloxazolidine-3-carboxylate (33) 
O NBoc
OH
 
Under argon atmosphere, a heat-gun dried round-bottomed flask was charged with (1S,2S)-(+)-
2-amino-1-phenyl-1,3-propanediol (32) (5.00 g, 29.9 mmol), acetone (6 mL) and toluene (20 mL). 
Then, a Dean-Stark apparatus was attached and the solution was refluxed for 24 hours. 
Afterwards the reaction mixture was concentrated under vacuum and the residue was dissolved 
in THF (20 mL). To the reaction solution di-tert-butyldicarbonat (7.18 g, 7.04 mL, 32.9 mmol) was 
added dropwise over five minutes and the resulting mixture was stirred for 16 hours at room 
temperature. Then, the mixture was concentrated under vacuum and the crude product was 
purified by column chromatography (SiO2, cyclohexane:ethyl acetate (3:1), d x h: 8 x 14 cm) to 
afford the product 33 (5.16 g, 29.9 mmol, 56%) as a pale yellow solid.  
 
C17H25NO4 (307.39 g/mol): 
MP: 73-74 °C. 
TLC: Rf = 0.38 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (500 MHz, DMSO-d6): δ/ppm = 7.42 (d, 3JHH = 7.6 Hz, 2H, ar-H), 7.38 (t, 3JHH = 7.5 Hz, 
2H, ar-H), 7.31 (t, 3JHH = 7.0 Hz, 1H, ar-H), 5.12-4.97 (br m, 2H, Ph-CH, OH), 3.81-3.70 (br m, 1 H, 
CH2), 3.69-3.58 (br m, 1 H, NCH), 3.56-3.47 (br m, 1H, CH2), 1.57 (s, 3H, CH3), 1.50 (s, 3H, CH3), 
1.41 (s, 9H, C(CH3)3). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 151.0, 140.3, 128.3, 127.9, 126.6, 93.7, 79.0, 65.3, 
58.9, 58.0, 28.0, 26.4, 25.7. 
IR (ATR): 𝑣𝑣�/cm-1 = 3456 (m), 2978 (w), 2934 (w), 2897 (w), 1666 (s), 1455 (s), 1404 (s), 1376 (m), 
1256 (s), 1204 (m), 1166 (s); 1147 (s), 1103 (s), 1069 (m), 1049 (m); 1027 (m), 974 (m), 912 (m), 
877 (m), 814 (m), 764 (s), 702 (m), 649 (m), 607 (w), 556 (w), 522 (w), 506 (m), 461 (w). 
EA (C17H25NO4) calc.: C 66.43, H 8.20, N 4.56; found: C 66.36, H 8.04, N 4.40. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +34.5 (c = 1.01, CH2Cl2). 
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tert-Butyl (4S,5S)-2,2-dimethyl-4-(((methylsulfonyl)oxy)methyl)-5-phenyloxazolidine-3-
carboxylate (34) 
O NBoc
OMs
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with tert-butyl (4S,5S)-
4-(hydroxymethyl)-2,2-dimethyl-5-phenyloxazolidine-3-carboxylate (33) (5.10 g, 16.6 mmol), 
CH2Cl2 (53 mL) and this mixture was cooled in an ice-bath to 0 °C. Then, triethylamine (4.36 g, 
5.83 mL, 41.5 mmol) was added, followed by dropwise addition of methanesulfonyl chloride (2.47 
g, 1.67 mL, 21.6 mmol) over 10 minutes at 0 °C. After addition the mixture was stirred for four 
hours at 0 °C and 16 hours at room temperature. Water (20 mL) was added and the biphasic 
mixture was extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were dried over 
Na2SO4, filtered, concentrated under vacuum and the crude product was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (4:1), d x h: 5 x 20 cm) to afford the product 34 
(5.46 g, 14.14 mmol, 85%) as a white solid.  
 
C18H27NO6S (385.48 g/mol):  
MP: 107-108 °C. 
TLC: Rf = 0.35 (SiO2, cyclohexane:ethyl acetate (4:1)). 
1H NMR (500 MHz, DMSO-d6): δ/ppm = 7.50-7.33 (m, 5H, ar-H), 5.04 (d, 3JHH = 7.1 Hz, 1H, Ph-
CH), 4.74-4.49 (br m, 1H, CH2), 4.24 (d, 3JHH = 9.8 Hz, 1H, NCH), 3.90 (br s, 1H, CH2), 3.22 (s, 
3H, SCH3), 1.61 (s, 3H, CH3), 1.52 (s, 3H, CH3), 1.44 (s, 9H, C(CH3)3). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 151.0, 138.4, 128.5, 128.4, 126.9, 94.2, 80.0. 77.7, 
65.6, 62.1, 36.7, 27.9, 26.4, 25.5. 
IR (ATR): 𝑣𝑣�/cm-1 = 2989 (w), 2933 (w), 1691 (s), 1454 (w), 1391 (m), 1380 (s), 1356 (s), 1330 (m), 
1281 (w), 1264 (m), 1238 (w), 1212 (w), 1175 (s), 1153 (s), 1101 (s), 1090 (m), 1075 (m), 1055 (m), 
1021 (m), 976 (s), 950 (w), 917 (s), 888 (s), 848 (m), 813 (s), 770 (w), 757 (m), 704 (s), 694 (m), 
528 (s), 517 (s), 456 (m). 
EA (C18H27NO6) calc.: C 56.09, H 7.06, N 3.63; found: C 56.08, H 6.83, N 3.47. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +5.2 (c = 1.45, CH2Cl2). 
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1-((2S,3R)-1-(Diphenylphosphanyl)-3-hydroxybutan-2-yl)-3-phenylthiourea (36) 
OH
HN
P
HN
S
 
According to general procedure GP1, (2R,3S)-3-amino-4-(diphenylphosphanyl)butan-2-ol (35) 
(140 mg, 512 µmol), phenyl isothiocyanate (77.7 mg, 68.7 µL, 563 µmol), CH2Cl2 (2.0 mL) were 
stirred for 16 hours and the crude product was purified by column chromatography (SiO2, 
cyclohexane:ethyl acetate (2:1), d x h: 2 x 10 cm) to afford the product 36 (187 mg, 511 µmol, 
90%) as a white solid. 
 
C23H25N2OPS (408.50 g/mol): 
MP: 66-67 °C. 
TLC: Rf = 0.20 (SiO2, cyclohexane:ethyl acetate (1:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.80 (br s, 1H, NH), 7.49-7.35 (m, 4H, ar-H), 7.35-7.13 (m, 
9H, ar-H), 7.03 (d, 3JHH = 8.1 Hz, 2H, ar-H), 6.54 (br s, 1H, NH), 4.64-4.49 (m, 1H, Ph-CH), 4.18-
4.08 (m, 1H, NCH), 2.52-2.36 (m, 2H, PCH2), 2.13 (br s, 1H, OH), 1.10 (d, 3JHH = 6.3 Hz, 3H, 
CHCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 180.4, 136.2, 133.0 (d, JCP = 9.3 Hz), 132.9 (d, 
JCP = 8.9 Hz), 130.2, 129.2, 128.8 (d, JCP = 2.2 Hz), 128.7 (d, JCP = 2.4 Hz), 127.1, 124.9, 69.0 (d, 
JCP = 8.8 Hz), 58.3 (d, JCP = 14.9 Hz), 31.7 (d, JCP = 12.5 Hz), 20.9. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −24.4. 
IR (ATR): 𝑣𝑣�/cm-1 = 3359 (w), 3226 (w), 1594 (w), 1519 (s), 1494 (s), 1450 (m), 1432 (m), 1314 
(w), 1296 (w), 1237 (m), 1160 (w), 1095 (w), 1015 (w), 871 (m), 736 (s), 692 (s), 555 (w), 504 (m), 
471 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C23H25N2OPS +: 409.1498 [M+H]+; found: 
409.1501. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +59.2 (c = 0.96, CHCl3). 
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General Procedure (GP4): Silylation of secondary alcohol 
Under argon atmosphere, a heat-gun dried round bottomed flask was charged with the thiourea 
precursor (1.0 eq.), DIPEA (2.0 eq.) or triethylamine (2.0 eq.) and CH2Cl2 (11 mL per mmol). At 
0 °C, silyl triflate (1.05 eq) was added dropwise to the reaction mixture over 5 minutes. After stirring 
for two hours at 0 °C and additional four hours at room temperature, the mixture was concentrated 
under vacuum and the crude product was purified by column chromatography.  
 
1-((2S,3R)-3-((tert-Butyldimethylsilyl)oxy)-1-(diphenylphosphanyl)butan-2-yl)-3-phenyl 
thiourea (37) 
OTBDMS
HN
P
HN
S
 
According to general procedure GP4, 1-((2S,3R)-1-(diphenylphosphanyl)-3-hydroxybutan-2-yl)-3-
phenylthiourea (36) (118 mg, 289 µmol), DIPEA (114 mg, 146 µL, 880 µmol), TBDMS triflate 
(83.7 mg, 72.8 µL, 317 µmol), CH2Cl2 (3.1 mL) were stirred for six hours and the crude product 
was purified by column chromatography (SiO2, cyclohexane:ethyl acetate (10:1), d x h: 2 x 13 cm) 
to afford the product 37 (120 mg, 230 µmol, 79%) as a white solid. 
 
C29H39N2OPSSi (522.76 g/mol): 
MP: 60-61 °C. 
TLC: Rf = 0.43 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.93 (br s, 1H, NH), 7.70-7.58 (m, 2H, ar-H), 7.45-7.23 (m, 
11H, ar-H), 7.19-7.14 (m, 2H, ar-H), 6.58 (d, 3JHH = 8.8 Hz, 1H, NH), 4.53-4.41 (m, 1H, Ph-CH), 
4.36-4.30 (m, 1H, NCH), 2.62 (ddd, 2JHP = 13.7 Hz, 3JHH = 6.3 Hz, 4JHH = 3.1 Hz, 1H, PCH2), 
2.12 (ddd, 2JHP = 13.8 Hz, 3JHH = 8.9 Hz, 4JHH = 2.1 Hz, 1H, PCH2), 1.12 (d, 3JHH = 6.2 Hz, 3H, 
CHCH3), 0.72 (s, 9H, SiC(CH3)3), 0.04 (s, 6H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.7, 136.8, 133.7 (d, JCP = 19.4 Hz), 133.3 (d, 
JCP = 19.1 Hz), 130.7, 129.4, 129.1, 129.0 (d, JCP = 5.1 Hz), 128.9 (d, JCP = 5.4 Hz), 127.5, 125.6, 
69.5 (d, JCP = 11.0 Hz), 59.1 (d, JCP = 17.7 Hz), 32.3 (d, JCP = 14.8 Hz), 26.07, 21.78, 18.20, −3.95, 
−4.31. 
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31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −24.7. 
IR (ATR): 𝑣𝑣�/cm-1 = 3366 (w), 3170 (w), 3052 (w), 2952 (m), 2926 (m), 1594 (w), 1510 (s), 1495 (s), 
1470 (m), 1432 (m); 1316 (w), 1248 (m), 1125 (m), 1067 (m), 960 (m), 914 (m), 827 (s), 775 (s), 
734 (s), 692 (s), 489 (w). 
EA (C29H39N2OPSSi) calc.: C 66.63, H 7.52, N 5.36; found: C 66.59, H 7.31, N 5.38. [𝛼𝛼]𝐷𝐷20 = +26.7 (c = 0.98, CH2Cl2). 
 
(1S,2R)-2-Amino-3-(diphenylphosphanyl)-1-phenylpropan-1-ol (38) 
OH
NH2
P
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with tert-butyl (4S,5S)-
2,2-dimethyl-4-(((methylsulfonyl)oxy)methyl)-5-phenyloxazolidine-3-carboxylate (34) (2.00 g, 
5.19 mmol) and THF (17 mL). Then, the reaction mixture was degassed by three freeze-pump-
thaw cycles. At 0 °C, potassium diphenylphosphide solution (0.5 M in THF, 1.48 g, 13.2 mL, 
6.60 mmol) was added dropwise over five minutes and afterwards the mixture was stirred two 
hours at 0 °C and two hours at room temperature. At ambient temperature, aqueous HCl (37%, 
3.82 g, 9.00 mL, 106 mmol) was added and then the mixture was stirred at room temperature for 
16 hours. The reaction mixture was adjusted to an alkaline pH (>10) by addition of degassed 
aqueous NaOH (2 M) and then the mixture was extracted with EtOAc (3 x 20 mL). The combined 
organic layers were dried over Na2SO4, filtered, concentrated under vacuum and the crude product 
was purified by column chromatography (SiO2, cyclohexane:ethyl acetate (1:5) + 5% NEt3, d x h: 
3.5 x 14 cm) to afford the product 38 (1.49 g, 4.44 mmol, 86%) as a pale yellow gum. 
 
C21H22NOP (335,39 g/mol): 
TLC: Rf = 0.29 (SiO2, cyclohexane:ethyl acetate (1:5) + 5% NEt3). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.28-7.16 (m, 15H, ar-H), 4.40 (d, 3JHH = 6.0 Hz, 1H, Ph-CH), 
2.90-2.83 (m, 1H, NCH), 2.27 (dt, 2JHP = 13.9 Hz, 3JHH = 3.4 Hz, 1H, PCH2), 2.20 (br s, 2H, NH2), 
1.95-1.88 (m, 1H, PCH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 142.1, 138.9 (d, JCP = 11.6 Hz), 137.1 (d, JCP = 12.1 Hz), 
133.2 (d, JCP = 19.4 Hz), 132.5 (d, JCP = 18.3 Hz), 129.1, 128.7, 128.7, 128.6, 128.5, 127.8, 126.8, 
77.5, 55.2 (d, JCP = 14.1 Hz), 34.0 (d, JCP = 12.0 Hz). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −22.6. 
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IR  (ATR): 𝑣𝑣�/cm-1 = 3354 (w), 3052 (w), 3026 (w), 2897 (w), 1734 (w), 1583 (m), 1480 (m), 
1450 (w), 1432 (s), 1240 (m), 1182 (w), 1125 (w), 1093 (w), 1046 (m), 1026 (m), 999 (w), 945 (w), 
914 (w), 839 (w), 737 (s), 696 (s), 507 (m), 478 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C21H22NOP+: 336.1512 [M+H]+; found: 
336.1517. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −86.1 (c = 0.89, CHCl3). 
 
General Procedure (GP5): Synthesis of chlorophosphine 
Under argon atmosphere, a heat-gun dried two-neck flasked with a reflux condenser was charged 
with magnesium turnings (5.0 eq.) and THF (2 mL per mmol bromide). Then, the bromide (2.7 eq.) 
was added dropwise and the Grignard reagent formation was started by heating with a heat gun. 
After the reaction had started, the reaction mixture was refluxed for four hours at 68 °C. 
Under argon atmosphere, a second heat-gun dried two-necked flask was charged with 
diethylphosphoramidous dichloride (1.0 eq.) and THF (1.1 mL per mmol phosphoramidous 
chloride). Then, this mixture was cooled in an ice-bath and at 0 °C the freshly prepared Grignard 
reagent was added dropwise. After complete addition, the mixture was stirred for six hours at room 
temperature. At 0 °C, the reaction mixture was treated with hydrogen chloride (4 M in dioxane, 
10.0 eq.). Afterwards, the crude product was conctentrated under vacuum and the resulting 
residue was either purified by Kugelrohr distillation or directly used for the amino phoshine 
synthesis.  
 
Chlorobis(2-isopropylphenyl)phosphane (39b) 
P
Cl
 
According to general procedure GP5, magnesium (209 mg, 8.59 mmol), 2-isopropylphenyl 
bromide (41b) (910 g, 700 µL, 4.57 mmol) and THF (9 mL) were stirred for four hours at 68 °C. In 
a second two-necked flask, diethylphosphoramidous dichloride (299 mg, 250 µL, 1.72 mmol), and 
THF (2 mL) were treated with the Grignard reagent and stirred for six hours. After addition of 
hydrogen chloride (4 M in dioxane, 4.98 g, 4.30 mL, 17.2 mmol) the crude product 39b (274 mg, 
899 µmol, 52%) was yielded as a white gum and directly used for the amiono phosphine synthesis.  
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C18H22ClP (304.11 g/mol): 
1H NMR (500 MHz, C6D6): δ/ppm = 7.56-7.42 (m, 2H, ar-H), 6.92-6.86 (m, 4H, ar-H), 6.77-6.72 (m, 
2H, ar-H), 3.57 (sept, 3JHH = 6.8 Hz, 2H, CH(CH3)2), 0.99 (d, 3JHH = 6.7 Hz, 6H, CH(CH3)2), 0.75 
(d, 3JHH = 6.8 Hz, 6H, CH(CH3)2). 
13C{1H} NMR (101 MHz, C6D6): δ/ppm = 152.3 (d, JCP = 27.5 Hz), 135.6 (d, JCP = 34.5 Hz), 
132.4 (d, JCP = 3.2 Hz), 130.9, 126.7, 125.7 (d, JCP = 3.7 Hz), 31.6, 31.4, 24.1, 23.6. 
31P{1H} NMR (162 MHz, C6D6): δ/ppm = 72.4. 
 
General Procedure: Synthesis of aminophosphines using chloro phosphines 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with the 
chlorophosphine (1.7 eq.) and THF (2 mL per mmol chlorophosphine). Then, the reaction mixture 
was degassed by three freeze-pump-thaw cycles. At 0 °C, potassium (4.0 eq.) was added in small 
portions over 20 minutes and afterwards the mixture was stirred for three hours at 75 °C. The red 
colored crude potassium phosphide solution was directly used for the next step without any 
purification. 
Under argon atmosphere, a second heat-gun dried two-necked flask was charged with tert-butyl 
(4S,5S)-2,2-dimethyl-4-(((methylsulfonyl)oxy)methyl)-5-phenyloxazolidine-3-carboxylate (1.0 eq.) 
and THF (1 mL per mmol oxazolidine). Then, the reaction mixture was degassed by three freeze-
pump-thaw cycles. At 0 °C, the freshly prepared potassium phosphide solution was added 
dropwise over five minutes and afterwards the mixture was stirred for two hours at 0 °C and two 
hours at room temperature. At ambient temperature, aqueous HCl (37%, 40.0 eq.) was added and 
then the mixture was stirred at room temperature for 16 hours. The reaction mixture was adjusted 
to an alkaline pH (>10) by addition of degassed aqueous NaOH (2 M) and then the mixture was 
extracted with EtOAc (3 x 5 mL per mmol oxazolidine). The combined organic layers were dried 
over Na2SO4, filtered, concentrated under vacuum and the crude product was purified by column 
chromatography. 
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tert-Butyl (4R,5S)-4-(bromomethyl)-2,2-dimethyl-5-phenyloxazolidine-3-carboxylate (41) 
O NBoc
Br
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with tert-butyl (4S,5S)-
2,2-dimethyl-4-(((methylsulfonyl)oxy)methyl)-5-phenyloxazolidine-3-carboxylate (34) (190 mg, 
493 µmol), lithium bromide (173 mg, 1.97mmol), and THF (2 mL). Then, this mixture was refluxed 
for 16 hours and afterwards water (5 mL) was added and the biphasic mixture was extracted with 
EtOAc (3 x 15 mL). The combined organic layers were washed with brine (15 ml), dried over 
Na2SO4, filtered, concentrated under vacuum and the crude mixture was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (10:1), d x h: 3.5 x 10 cm) to afford the product 
41 (117 mg, 315 µmol, 64%) as a colorless oil.  
 
C17H24BrNO3 (370.28 g/mol):  
TLC: Rf = 0.72 (SiO2, cyclohexane:ethyl acetate (10:1)). 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 7.49-7.33 (m, 5H, ar-H), 4.92 (d, 3JHH = 7.2 Hz, 1H, Ph-
CH), 4.11/3.95* (s, 1H, NCH), 3.84 (s, 1H, BrCH2), 3.50 (d, 3JHH = 10.6 Hz, 1H, BrCH2), 1.60 (s, 
3H, CH3), 1.57 (s, 3H, CH3), 1.44 (s, 9H, C(CH3)3). [* refers to signal of rotamers] 
 
tert-Butyl (4R,5S)-4-(iodomethyl)-2,2-dimethyl-5-phenyloxazolidine-3-carboxylate (42) 
O NBoc
I
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with tert-butyl (4S,5S)-
2,2-dimethyl-4-(((methylsulfonyl)oxy)methyl)-5-phenyloxazolidine-3-carboxylate (34) (385 mg, 
1.00 mmol), lithium iodide (1.34 g, 10 mmol), and THF (6 mL). Then, this mixture was refluxed for 
16 hours and afterwards water (20 mL) was added and the biphasic mixture was extracted with 
EtOAc (3 x 25 mL). The combined organic layers were washed with brine (25 ml), dried over 
Na2SO4, filtered, concentrated under vacuum and the crude mixture was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (20:1), d x h: 3.5 x 15 cm) to afford the product 
42 (358 mg, 858 µmol, 86%) as a white solid.  
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C17H24INO3 (417.29 g/mol):  
MP: 47-48 °C. 
TLC: Rf = 0.36 (SiO2, cyclohexane:ethyl acetate (20:1)). 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 7.46-7.33 (m, 5H, ar-H), 4.74 (d, 3JHH = 7.4 Hz, 1H, Ph-
CH), 3.88/3.69* (s, 1H, NCH), 3.35 (br s, 1H, CH2), 3.25 (d, 3JHH = 8.9 Hz, 1H, CH2), 1.62 (s, 3H, 
CH3), 1.59 (s, 3H, CH3), 1.44 (s, 9H, C(CH3)3). [* refers to signal of rotamers] 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 151.2/150.6*, 137.7/128.7*, 128.6/127.2*, 
94.5/94.0*, 80.9/80.6*, 79.9, 62.3/63.0*, 28.0, 26.8/26.4*, 9.6/8.6*.  
IR (ATR): 𝑣𝑣�/cm-1 = 2972 (w), 1678 (s), 1454 (w), 1396 (s), 1377 (s), 1364 (s), 1309 (m), 1270 (m), 
1156 (s), 1108 (m), 1080 (m), 1058 (s), 939 (w), 892 (m), 761 (s), 704 (m), 641 (w), 604 (w), 
504 (m). 
EA (C17H24INO3) calc.: C 48.93, H 5.80, N 3.36; found: C 49.02, H 5.82, N 3.66. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −2.1 (c = 1.35, MeOH). 
 
General Procedure (GP6): Synthesis of phosphine oxides 
Under argon atmosphere, a heat-gun dried two-necked flask with a reflux condenser was charged 
with magnesium tunings (5.0 eq.) and THF (2 mL per mmol bromide). Then, the bromide (2.5 eq.) 
was added dropwise and the Grignard reagent formation was initiated by heating with a heat gun. 
After the reaction had started, the reaction mixture was refluxed for four hours at 68 °C. 
Under argon atmosphere, a second heat-gun dried two-necked flask was charged with NaH (60% 
in mineral oil, 1.2 eq.) and THF (0.5 mL per mmol phosphite). Then this mixture was cooled in an 
ice-bath and at 0 °C diethyl phosphite (1.0 eq.) was added dropwise over 15 minutes. Afterwards 
the reaction mixture was stirred for 30 minutes at 0 °C and then the freshly prepared Grignard 
reagent was added dropwise. After complete addition, the mixture was stirred for 16 hours at room 
temperature and was then quenched with saturated aqueous NH4Cl solution (5 mL per mmol 
phosphite). The aqueous layer was extracted with CH2Cl2 (3 x 5 mL per mmol phosphite) and the 
combined organic layers were dried over NaSO4. After concentration under vacuum the resulting 
crude product was purified by trituration with hexane/MTBE (3:1, 1 mL per mmol phosphite) to 
yield the phosphine oxide after filtration and drying under vacuum.   
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Bis(2-isopropylphenyl)phosphine oxide (43b) 
P
H
O
 
According to general procedure GP6, magnesium (1.21 g, 49.9 mmol), 2-isopropylphenyl bromide 
(41b) (5.02 g, 3.86 mL, 25.0 mmol) and THF (50 mL) were stirred for four hours at 68 °C. In a 
second flask sodium hydride (60% in mineral oil, 479 mg, 12.1 mmol), diethyl phosphite (1.47 g, 
1.37 mL, 9.98 mmol) and THF (5 mL) were stirred for 30 minutes at 0 °C and treated with the 
Grignard reagent. The crude product was purified by trituration with MTBE/hexane (3:1, 10 mL) to 
afford the product 43 (2.10 g, 7.33 mmol, 73%) as a white solid. 
 
C18H23OP (286.35 g/mol): 
MP: 129-130 °C. 
 1H NMR (500 MHz, CDCl3): δ/ppm = 8.32 (d, 1JHP = 478.2 Hz, 1H, PH), 7.72 (ddd, 3JHP = 15.4 Hz, 
3JHH = 7.7 Hz, 4JHH = 1.5 Hz, 2H, ar-H), 7.52 (tt, 3JHH = 7.6 Hz, 4JHH = 1.5 Hz, 2H, ar-H), 7.39 (dd, 
3JHH = 8.0 Hz, 4JHH = 4.9 Hz, 2H, ar-H), 7.33-7.29 (m, 2H, ar-H), 3.25 (hept, 3JHH = 6.8 Hz, 2H, 
CH(CH3)2), 1.08 (d, 3JHH = 6.8 Hz, 6H, CH(CH3)2), 1.03 (d, 3JHH = 6.7 Hz, 6H, CH(CH3)2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 152.5 (d, JCP = 9.9 Hz), 132.9 (d, JCP = 2.6 Hz), 132.4 
(d, JCP = 12.4 Hz), 129.21 (d, JCP = 100.9 Hz), 126.6 (d, JCP = 10.3 Hz), 126.3 (d, JCP = 13.0 Hz), 
31.1 (d, JCP = 7.2 Hz), 23.9, 23.7. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = 20.7-14.5 (m). 
IR  (ATR): 𝑣𝑣�/cm-1 = 3313 (w), 3237 (w), 3170 (w), 3079 (w), 1517 (m), 1379 (m), 1275 (s), 
1174 (m), 1128 (s), 744 (m), 698 (m), 680 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH, NaOAc): (m/z) calc. for C18H23OP +: 309.1379 [M+Na]+; 
found: 309.1382. 
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General Procedure (GP7): Synthesis of amino phosphines using phosphines 
Non-commercial diarylphosphines were synthesized by reduction of the corresponding phosphine 
oxide following the procedure of C. A. Busacca.[68] 
Under argon atmosphere, a heat gun dried two-necked flask was charged with the phosphine 
(1.5 eq), potassium hydride (95%, 1.5 eq.) and degassed THF (2 mL per mmol phosphine). The 
corresponding mixture was stirred for 30 minutes at 0 °C and afterwards tert-butyl (4S,5S)-2,2-
dimethyl-4-(((methylsulfonyl)oxy)methyl)-5-phenyloxazolidine-3-carboxylate (1.0 eq.) was added 
in one portion at 0 °C. The reaction mixture was stirred for 30 minutes at 0 °C and for additional 
four hours at room temperature. Then, aqueous HCl (37%, 20 eq.) was added dropwise to the 
solution and the pale yellow solution was stirred at room temperature over night. The reaction 
mixture was adjusted to an alkaline pH (>10) by addition of degassed aqueous NaOH (2 M) and 
then the mixture was extracted with EtOAc (3 x 10 mL per mmol oxazolidine). The combined 
organic layers were dried over Na2SO4, filtered, concentrated under vacuum and the crude product 
was purified by column chromatography. 
 
(1S,2R)-2-Amino-3-(di-o-tolylphosphanyl)-1-phenylpropan-1-ol (40a) 
OH
NH2
P
 
According to general procedure GP7, di(o-tolyl)phosphine (44a) (390 mg, 1.82 mmol), potassium 
hydride (76.8 mg, 1.82 mmol) and THF (3.6 mL) were stirred for 30 minutes at 0 °C, followed by 
tert-butyl (4S,5S)-2,2-dimethyl-4-(((methylsulfonyl)oxy)methyl)-5-phenyloxazolidine-3-carbo-
xylate (34) (389 mg, 1.01 mmol) addition and after four hours aqueous HCl addition (37%, 1.99 g, 
1.78 mL, 20.2 mmol). The crude product was purified by column chromatography (SiO2, 
cyclohexane:ethyl acetate (1:5) + 5% NEt3, d x h: 3.5 x 11 cm) to afford the product 40a (286 mg, 
787 µmol, 78%) as a pale yellow oil. 
 
C23H26NOP (363.44 g/mol): 
TLC: Rf = 0.30 (SiO2, cyclohexane:ethyl acetate (1:5) + 5% NEt3). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.36-7.27 (m, 5H, ar-H), 7.23-7.13 (m, 4H, ar-H), 7.10-
6.99 (m, 3H, ar-H), 6.86-6.82 (m, 1H, ar-H), 4.44 (d, 3JHH = 5.9 Hz, 1H, Ph-CH), 3.00-2.93 (m, 1H, 
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NCH), 2.47 (s, 3H, ar-CH3), 2.36 (s, 3H, ar-CH3), 2.27 (ddd, 2JHP = 14.1 Hz, 3JHH = 3.2 Hz, 
4JHH = 2.4 Hz, 1H, PCH2), 1.86 (ddd, 2JHP = 14.1 Hz, 3JHH = 10.0 Hz, 4JHH = 4.1 Hz, 1H, PCH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 142.9, 142.6, 142.3, 142.1, 141.8, 136.7 (d, 
JCP = 11.7 Hz), 135.4 (d, JCP = 12.4 Hz), 131.5, 131.1, 130.3 (t, JCP = 5.2 Hz), 128.7 (d, 
JCP = 4.1 Hz), 128.5, 127.8, 126.9, 126.3 (d, J = 4.0 Hz), 77.8 (d, JCP = 8.8 Hz), 55.2 (d, 
JCP = 14.9 Hz), 32.9 (d, JCP = 12.0 Hz), 21.5 (d, JCP = 9.2 Hz), 21.2 (d, JCP = 9.1 Hz). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −44.1. 
IR (ATR): 𝑣𝑣�/cm-1 = 3354 (w), 3054 (w), 3003 (w), 2912 (w), 1587 (m), 1450 (s), 1377 (m), 1270 (m), 
1129 (w), 1042 (w), 835 (w), 744 (s), 699 (s), 546 (m), 451 (s). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C23H26NOP+: 364.1825 [M+H]+; found: 
364.1828. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −99.7 (c = 0.79, CHCl3). 
 
(1S,2R)-2-Amino-3-(bis(2-isopropylphenyl)phosphanyl)-1-phenylpropan-1-ol (40b) 
OH
NH2
P
 
According to general procedure GP7, di(o-isopropyl)phosphine (44b) (243 mg, 0.898 mmol), 
potassium hydride (37.9 mg, 0.898 mmol) and THF (2.0 mL) were stirred for 30 minutes at 0 °C, 
followed by tert-butyl (4S,5S)-2,2-dimethyl-4-(((methylsulfonyl)oxy)methyl)-5-phenyloxazolidine-
3-carbo-xylate (34) (192 mg, 0.50 mmol) addition and after four hours aqueous HCl addition (37%, 
983 mg, 900 µL, 10.0 mmol). The crude product was purified by column chromatography (SiO2, 
cyclohexane:ethyl acetate (1:2) + 5% NEt3, d x h: 3.5 x 14 cm) to afford the product 40b (150 mg, 
357 µmol, 72%) as a pale yellow oil. 
 
C27H34NOP (419.55 g/mol): 
TLC: Rf = 0.52 (SiO2, cyclohexane:ethyl acetate (1:4) + 5% NEt3). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.27-7.16 (m, 9H, ar-H), 7.04-6.95 (m, 2H, ar-H), 6.95-
6.87 (m, 1H, ar-H), 6.77-6.73 (m, 1H, ar-H), 4.36 (d, 3JHH = 6.0 Hz, 1H, Ph-CH), 3.76-3.57 (m, 2H, 
ar-CH(CH3)2), 2.95-2.83 (m, 1H, NCH), 2.37 (br s, 2H, NH), 2.17 (ddd, 2JHP = 14.1 Hz, 
3JHH = 3.0 Hz, 4JHH = 1.8 Hz, 1H, PCH2), 1.81-1.73 (m, 1H, PCH2), 1.19 (d, 3JHH = 6.8 Hz, 3H, 
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CH(CH3)2), 1.14 (d, 3JHH = 6.8 Hz, 3H, CH(CH3)2), 0.93 (d, 3JHH = 6.8 Hz, 3H, CH(CH3)2), 0.83 (d, 
3JHH = 6.8 Hz, 3H, CH(CH3)2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 153.4 (d, JCP = 23.6 Hz), 152.7 (d, JCP = 23.6 Hz), 142.2, 
136.2 (d, JCP = 10.3 Hz), 135.0 (d, JCP = 11.6 Hz), 132.0, 131.4, 129.2, 128.5, 127.8, 126.9, 
126.1 (d, JCP = 7.0 Hz), 125.7 (d, JCP = 4.7 Hz), 125.7 (d, JCP = 4.8 Hz), 77.8 (d, JCP = 8.7 Hz), 
55.1 (d, JCP = 15.1 Hz), 34.4 (d, JCP = 13.1 Hz), 31.3 (d, JCP = 10.5 Hz), 31.1 (d, JCP = 10.9 Hz), 
24.5, 24.3, 23.8, 23.7. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −49.4. 
IR (ATR): 𝑣𝑣�/cm-1 = 3361 (w), 3054 (w), 2957 (m), 2924 (w), 2855 (w), 1471 (m), 1452 (w), 1436 (w), 
1383 (w), 1361 (w), 1114 (m), 1051 (m), 1028 (w), 960 (s), 942 (s), 908 (s), 868 (w), 835 (w), 
732 (m), 700 (m), 506 (s), 484 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C27H34NOP+: 420.2451 [M+H]+; found: 
420.2457. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −76.9 (c = 0.72, CHCl3). 
 
(1S,2R)-2-Amino-3-(di(naphthalen-1-yl)phosphanyl)-1-phenylpropan-1-ol (40c) 
OH
NH2
P
 
According to general procedure GP7, di(naphthalene-1-yl)phosphine (44c) (496 mg, 1.73 mmol), 
potassium hydride (73.2 mg, 1.73 mmol) and THF (3.5 mL) were stirred for 30 minutes at 0 °C, 
followed by tert-butyl (4S,5S)-2,2-dimethyl-4-(((methylsulfonyl)oxy)methyl)-5-phenyloxazolidine-
3-carboxylate (34) (393 mg, 1.02 mmol) addition and after four hours aqueous HCl addition (37%, 
2.01 g, 1.79 mL, 20.4 mmol). The crude product was purified by column chromatography (SiO2, 
cyclohexane:ethyl acetate (1:5) + 5% NEt3, d x h: 3.5 x 12 cm) to afford the product 40c (346 mg, 
795 µmol, 78%) as a white solid.  
 
C29H26NOP (435.51 g/mol): 
MP: 78-79 °C. 
TLC: Rf = 0.35 (SiO2, cyclohexane:ethyl acetate (1:5) + 5% NEt3). 
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1H NMR (400 MHz, CDCl3): δ/ppm = 8.67-8.56 (m, 1H, ar-H), 8.46-8.37 (m, 1H, ar-H), 7.83-
7.67 (m, 4H, ar-H), 7.49-7.28 (m, 4H, ar-H), 7.30-7.13 (m, 7H, ar-H), 7.16-7.07 (m, 1H, ar-H), 7.05-
6.96 (m, 1H, ar-H), 4.38 (d, 3JHH = 6.3 Hz, 1H, Ph-CH), 3.01-2.89 (m, 1H, PCH2), 2.45-2.35 (m, 
1H, NCH), 2.25 (br s, 2H, NH2), 2.07-1.95 (m, 1H, PCH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 142.1, 136.0, 135.8, 135.4, 135.3, 135.1, 133.7 (t, 
JCP = 4.2 Hz), 133.5, 133.4, 130.9, 130.3, 129.7, 129.5, 129.0, 128.9, 128.5, 127.9, 127.0, 
126.6 – 126.5 (m), 126.2, 126.0, 125.8, 125.8, 125.7, 125.5, 77.72 (d, JCP = 9.2 Hz), 55.47 (d, 
JCP = 14.7 Hz), 33.33 (d, JCP = 11.6 Hz). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −46.7. 
IR (ATR): 𝑣𝑣�/cm-1 = 3345 (w), 3049 (w), 2866 (w), 1732 (w), 1501 (s), 1450 (m), 1382 (m), 1328 (m), 
1254 (w), 1045 (m), 1022 (m), 910 (w), 794 (s), 771 (s), 733 (s), 700 (s), 659 (w), 632 (w), 527 (w), 
439 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C29H26NOP+: 436.1825 [M+H]+; found: 
436.1830. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −121.0 (c = 0.78, CHCl3). 
 
(1S,2R)-2-Amino-3-(bis(3,5-dimethylphenyl)phosphanyl)-1-phenylpropan-1-ol (40d) 
OH
NH2
P
 
According to general procedure GP7, bis(3,5-dimethylphenyl)phosphine (44g) (300 mg, 
1.11 mmol), potassium hydride (45.6 mg, 1.11 mmol) and THF (4 mL) were stirred for 30 minutes 
at 0 °C, followed by tert-butyl (4S,5S)-2,2-dimethyl-4-(((methylsulfonyl)oxy)methyl)-5-
phenyloxazolidine-3-carboxylate (34) (286 mg, 740 µmol) addition and after four hours aqueous 
HCl addition (37%, 3.10 g, 2.67 mL, 20.4 mmol). The crude product was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (1:5) + 5% NEt3, d x h: 2.5 x 12 cm) to afford 
the product 40d (220 mg, 562 µmol, 76%) as a white solid.  
 
C25H30NOP (391.49 g/mol): 
MP: 55-56 °C. 
TLC: Rf = 0.21 (SiO2, cyclohexane:ethyl acetate (1:5) + 5% NEt3). 
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1H NMR (400 MHz, CDCl3): δ/ppm = 7.26-7.16 (m, 5H, ar-H), 6.88-6.80 (m, 6H, ar-H), 4.37 (d, 
3JHH = 6.3 Hz, 1H, Ph-CH), 2.87-2.80 (m, 1H, PCH2), 2.27-2.22 (m, 1H, NCH), 2.17 (s, 3H, ar-
CH3), 2.26 (s, 3H, ar-CH3), 1.81 (ddd, 2JHP = 14.0 Hz, 3JHH = 10.2 Hz, 4JHH = 3.8 Hz, 1H, PCH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 142.2, 138.7 (d, JCP = 11.0 Hz), 138.0 (t, JCP = 7.0 Hz), 
136.4 (d, JCP = 11.2 Hz), 131.0 (d, JCP = 1.8 Hz), 130.8, 130.4, 130.1, 123.0, 128.5, 127.8, 126.9, 
77.7 (d, JCP = 8.7 Hz), 55.3 (d, JCP = 13.8 Hz), 34.0 (d, JCP = 11.8 Hz), 21.4, 21.3. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −23.2. 
IR (ATR): 𝑣𝑣�/cm-1 = 3362 (w), 3027 (w), 2947 (w), 2912 (w), 2856 (w), 1597 (m), 1580 (m), 
1450 (m), 1412 (m), 1264 (w), 1125 (m), 1039 (m), 909 (s), 841 (m), 762 (m), 690 (s), 635 (w), 
544 (w), 420 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C25H30NOP+: 392.2138 [M+H]+; found: 
392.2144. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −100.0 (c = 0.49, CHCl3). 
 
(1S,2R)-2-Amino-3-(bis(3,5-di-tert-butylphenyl)phosphanyl)-1-phenylpropan-1-ol (40e) 
OH
NH2
P
 
According to general procedure GP7, bis(3,5-di-tert-butylphenyl)phosphine (44d) (490 mg, 
1.19 mmol), potassium hydride (50.4 mg, 1.19 mmol) and THF (2.4 mL) were stirred for 
30 minutes at 0 °C, followed by tert-butyl (4S,5S)-2,2-dimethyl-4-(((methylsulfonyl)oxy)methyl)-5-
phenyloxazolidine-3-carboxylate (34) (200 mg, 520 µmol) addition and after four hours aqueous 
HCl addition (37%, 1.02 g, 0.92 mL, 10.4 mmol). The crude product was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (10:1) + 5% NEt3, d x h: 2.5 x 10 cm) to afford 
the product 40e (185 mg, 331 µmol, 64%) as a white solid.  
 
C37H54NOP (559.82 g/mol): 
MP: 121-122 °C. 
TLC: Rf = 0.21 (SiO2, cyclohexane:ethyl acetate (10:1) + 5% NEt3). 
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1H NMR (400 MHz, CDCl3): δ/ppm = 7.33-7.30 (m, 1H, ar-H), 7.28-7.26 (m, 1H, ar-H), 7.24-
7.13 (m, 7H, ar-H), 7.11-7.09 (m, 2H, ar-H), 4.40 (d, 3JHH = 5.7 Hz, 1H, Ph-CH), 2.96-2.90 (m, 1H, 
PCH2), 2.36-2.34 (m, 1H, NCH), 1.92 (ddd, 2JHP = 13.8 Hz, 3JHH = 10.2 Hz, 4JHH = 3.3 Hz, 1H, 
PCH2), 1.25 (s, 4H, ar-C(CH3)3), 1.18 (s, 32H, ar-C(CH3)3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 150.9 (d, JCP = 7.0 Hz), 150.8 (d, JCP = 6.6 Hz), 142.4, 
137.6 (d, JCP = 10.2 Hz), 135.4 (d, JCP = 10.2 Hz), 128.5, 127.7, 127.4, 127.2, 126.9, 126.7, 126.7, 
123.3, 122.8, 77.7 (d, JCP = 8.3 Hz), 55.5 (d, JCP = 13.3 Hz), 35.1, 34.8 (d, JCP = 12.1 Hz), 31.6, 
31.5. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −20.7. 
IR (ATR): 𝑣𝑣�/cm-1 = 3136 (w), 2959 (s), 2903 (m), 2867 (m), 1577 (m), 1476 (m), 1418 (m), 1361 (s), 
1248 (m), 1135 (m), 1049 (m), 974 (m), 872 (m), 764 (m), 702 (s), 554 (w), 470 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C37H54NOP +: 560.4016 [M+H]+; found: 
560.4019. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −52.1 (c = 0.69, CHCl3). 
 
1-((1S,2R)-3-(Diphenylphosphanyl)-1-hydroxy-1-phenylpropan-2-yl)-3-phenylthiourea (45a) 
OH
HN
P
HN
S
 
According to general procedure GP1, (1S,2R)-2-amino-3-(diphenylphosphanyl)-1-phenylpropan-
1-ol (38) (530 mg, 1.58 mmol), phenyl isothiocyanate (240 mg, 210 µL, 1.74 mmol), CH2Cl2 
(4.7 mL) were stirred for 16 hours and the crude product was purified by column chromatography 
(SiO2, cyclohexane:ethyl acetate (5:1), d x h: 3.5 x 17 cm) to afford the product 45a (635 mg, 1.35 
mmol, 85%) as a white solid. 
 
C28H27N2OPS (470.57 g/mol): 
MP: 78-79 °C. 
TLC: Rf = 0.35 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (500 MHz, CDCl3): δ/ppm = 7.86 (s, 1H, NH), 7.54-7.50 (m, 2H, ar-H), 7.44-7.25 (m, 14H, 
ar-H), 7.20-7.18 (m, 2H, ar-H), 7.03-6.99 (m, 2H, ar-H), 6.48 (d, 3JHH = 8.2 Hz, 1H, NH), 5.12-
5.06 (m, 1H, Ph-CH), 4.88 (br s, 1H, NCH), 3.06 (br s, 1H, OH), 3.06-2.47 (m, 2H, PCH2). 
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13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 180.4, 141.1, 137.8, 137.4, 135.9, 133.1 (d, 
JCP = 3.5 Hz), 132.9 (d, JCP = 3.8 Hz), 130.1, 129.1 (d, JCP = 2.2 Hz), 128.7 (d, 3JCP = 7.0 Hz), 
128.5, 127.9, 127.3, 126.2, 125.3, 74.8 (d, JCP = 9.3 Hz), 58.9 (d, JCP = 15.5 Hz), 30.7 (d, 
JCP = 14.5 Hz). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −23.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 3362 (w), 3190 (w), 3052 (w), 1594 (w), 1519 (s), 1494 (s), 1448 (m), 1432 (m), 
1315 (w), 1296 (w), 1235 (m), 1182 (m), 1025 (w), 734 (s), 693 (s), 490 (m). 
EA (C28H27N2OPS) calc.: C 71.47, H 5.78, N 5.95; found: C 71.26, H 5.88, N 6.01. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −2.8 (c = 1.04, CHCl3). 
 
1-((1S,2R)-1-((tert-Butyldimethylsilyl)oxy)-3-(diphenylphosphanyl)-1-phenylpropan-2-yl)-3-
phenylthiourea (46a) 
OTBDMS
HN
P
HN
S
 
According to general procedure GP4, 1-((1S,2R)-3-(diphenylphosphanyl)-1-hydroxy-1-phenyl-
propan-2-yl)-3-phenylthiourea (45a) (71.5 mg, 152 µmol), DIPEA (39.3 mg, 50.2 µL, 304 µmol), 
TBDMS triflate (42.3 mg, 36.7 µL, 160 µmol), CH2Cl2 (1.7 mL) were stirred for six hours and the 
crude product was purified by column chromatography (SiO2, cyclohexane:ethyl acetate (10:1), d 
x h: 2 x 16 cm) to afford the product 46a (77.0 mg, 132 µmol, 87%) as a white solid. 
 
C34H41N2OPSSi (584.83 g/mol): 
MP: 67-68 °C. 
TLC: Rf = 0.22 (SiO2, cyclohexane:ethyl acetate (10:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.72-7.60 (m, 4H, ar-H), 7.49-7.20 (m, 12H, ar-H), 7.14-
7.10 (m, 2H, ar-H), 7.09-7.04 (m, 2H, ar-H), 6.43 (d, 3JHH = 8.6 Hz, 1H, NH), 5.29 (s, 1H, Ph-CH), 
4.63-4.50 (m, 1H, NCH), 2.51 (ddd, 2JHP = 13.8 Hz, 3JHH = 7.0 Hz, 4JHH = 1.9 Hz, 1H, PCH2), 
2.36 (ddd, 2JHP = 13.7 Hz, 3JHH = 8.2 Hz, 4JHH = 2.1 Hz, 1H, PCH2), 0.70 (s, 9H, SiC(CH3)3), 
0.06 (s, 3H, SiCH3), −0.02 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.6, 142.2, 139.4, 138.0, 136.6, 133.9 (d, 
JCP = 19.7 Hz), 133.3 (d, JCP = 18.8 Hz), 130.7, 129.6, 129.2, 129.1 (d, JCP = 2.6 Hz), 129.0 (d, 
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JCP = 2.3 Hz), 128.4, 128.0, 127.9, 126.7, 126.3, 74.3 (d, JCP = 7.5 Hz), 60.1 (d, JCP = 16.5 Hz), 
31.1 (d, JCP = 14.6 Hz), 26.2, 18.4, −4.3. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −24.4. 
IR (ATR): 𝑣𝑣�/cm-1 = 3366 (w), 3180 (w), 3029 (w); 2952 (w), 2926 (w), 1588 (w), 1510 (s), 1495 (s), 
1470 (w), 1449 (w), 1432 (w), 1313 (w), 1248 (m), 1090 (m), 1066 (s), 957 (m), 832 (s), 776 (s), 
733 (s), 693 (s), 504 (w). 
EA (C34H41N2OPSSi) calc.: C 69.83, H 7.07, N 4.79; found: C 69.64, H 7.24, N 4.88. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +48.8 (c = 0.65, CH2Cl2). 
 
1-((1S,2R)-3-(Diphenylphosphanyl)-1-hydroxy-1-phenylpropan-2-yl)-3-(4-fluorophenyl) 
thiourea (45b) 
OH
HN
P
HN
S
F  
According to general procedure GP1, (1S,2R)-2-amino-3-(diphenylphosphanyl)-1-phenylpropan-
1-ol (38) (100 mg, 298 µmol), 4-fluorophenyl isothiocyanate (48.8 mg, 318 µmol), CH2Cl2 (0.9 mL) 
were stirred for 16 hours and the crude product was purified by column chromatography (SiO2, 
cyclohexane:ethyl acetate (3:1), d x h: 2.5 x 17 cm) to afford the product 45b (132 mg, 270 µmol, 
91%) as a white solid. 
 
C28H26FN2OPS (488.56 g/mol): 
MP: 81-82 °C. 
TLC: Rf = 0.29 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.77-7.59 (br m, 1H, NH), 7.43-7.39 (m, 2H, ar-H), 7.33-
7.28 (m, 2H, ar-H), 7.26-7.14 (m, 11H, ar-H), 7.10-7.06 (m, 2H, ar-H), 6.92-6.86 (m, 2H, ar-H), 
6.37 (d, 3JHH = 8.3 Hz, 1H, NH), 4.98 (d, 3JHH = 4.2 Hz, 1H, Ph-CH), 4.78 (br s, 1H, NCH), 2.91 (br 
s, 1H, OH), 2.47-2.37 (m, 2H, PCH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 180.8, 162.7, 160.2, 141.1, 137.4, 133.0 (d, 
JCP = 18.8 Hz), 131.9, 129.2 (d, JCP = 4.6 Hz), 128.8 (d, JCP = 6.8 Hz), 128.6, 128.0, 127.8 (d, 
JCP = 8.5 Hz), 126.1, 74.9 (d, JCP = 9.2 Hz), 58.9 (d, JCP = 14.8 Hz), 30.6 (d, JCP = 13.6 Hz). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −23.4. 
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19F{1H} NMR (376 MHz, CDCl3): δ/ppm = −113.5. 
IR (ATR): 𝑣𝑣�/cm-1 = 3364 (w), 3205 (w), 3050 (w), 1504 (s), 1432 (w), 1214 (s), 1090 (m), 910 (m), 
831 (m), 733 (s), 693 (s), 502 (s), 476 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C28H26FN2OPS+: 489.1560 [M+H]+; found: 
489.1561. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −0.7 (c = 0.75, CHCl3). 
 
1-((1S,2R)-1-((tert-Butyldimethylsilyl)oxy)-3-(diphenylphosphanyl)-1-phenylpropan-2-yl)-3-
(4-fluorophenyl)thiourea (46b) 
OTBDMS
HN
P
HN
S
F  
According to general procedure GP4, 1-((1S,2R)-3-(diphenylphosphanyl)-1-hydroxy-1-phenyl-
propan-2-yl)-3-(4-fluorophenyl)thiourea (45b) (92.0 mg, 188 µmol), DIPEA (48.6 mg, 62.1 µL, 
376 µmol), TBDMS triflate (52.2 mg, 45.4 µL, 197 µmol), CH2Cl2 (2.1 mL) were stirred for six hours 
and the crude product was purified by column chromatography (SiO2, cyclohexane:ethyl acetate 
(8:1), d x h: 3 x 18 cm) to afford the product 46b (77.0 mg, 145 µmol, 77%) as a white solid. 
 
C34H40FN2OPSSi (602.82 g/mol): 
MP: 68-69 °C. 
TLC: Rf = 0.25 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.75-7.69 (br m, 1H, NH), 7.67-7.60 (m, 2H, ar-H), 7.47-
7.42 (m, 2H, ar-H), 6.23 (d, 3JHH = 8.5 Hz, 1H, NH), 5.29 (s, 1H, Ph-CH), 4.61-4.48 (m, 1H, NCH), 
2.52 (ddd, 2JHP = 13.8 Hz, 3JHH = 7.0 Hz, 4JHH = 1.9 Hz, 1H, PCH2), 2.34 (ddd, 2JHP = 13.8 Hz, 
3JHH = 8.2 Hz, 4JHH = 2.3 Hz, 1H, PCH2), 0.78 (s, 9H, SiC(CH3)3), 0.07 (s, 3H, SiCH3), −0.20 (s, 3H, 
SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.9, 163.4, 161.0, 142.2, 139.4, 138.0 (d, 
JCP = 12.8 Hz), 133.9 (d, JCP = 19.8 Hz), 133.2 (d, JCP = 19.0 Hz), 132.5, 129.6, 129.2, 129.1 (d, 
JCP = 3.5 Hz), 129.0 (d, JCP = 3.5 Hz), 128.5, 128.0, 126.6, 117.5 (d, JCP = 22.7 Hz), 74.3 (d, 
JCP = 7.2 Hz), 60.1 (d, JCP = 17.0 Hz), 31.2 (d, JCP = 15.0 Hz), 26.1, 18.4, −4.4. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −22.7. 
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19F{1H} NMR (376 MHz, CD2Cl2): δ/ppm = −112.3. 
IR (ATR): 𝑣𝑣�/cm-1 = 3367 (w), 3206 (w), 3053 (w), 2951 (w), 2927 (w), 2855 (w), 1504 (s), 1470 (m), 
1433 (w), 1251 (m), 1214 (s), 1089 (s), 1065 (m), 957 (w), 833 (s), 777 (s), 734 (s), 694 (s), 
554 (w), 503 (m), 476 (w). 
EA (C34H40FN2OPSSi) calc.: C 67.74, H 6.69, N 4.65; found: C 67.60, H 6.69, N 4.56. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +38.9 (c = 0.86, CH2Cl2) 
 
1-((1S,2R)-3-(diphenylphosphanyl)-1-hydroxy-1-phenylpropan-2-yl)-3-(perfluorophenyl)-
thiourea (45c) 
OH
HN
P
HN
S
F
F
F
F
F
 
According to general procedure GP1, (1S,2R)-2-amino-3-(diphenylphosphanyl)-1-phenylpropan-
1-ol (38) (100 mg, 298 µmol), pentafluorophenyl isothiocyanate (78.0 mg, 48 µL, 328 µmol), 
CH2Cl2 (0.9 mL) were stirred for 16 hours and the crude product was purified by flash column 
chromatography (SiO2, cyclohexane:ethyl acetate (5:1), 2.5 x 19 cm) to afford the product 45c 
(55.0 mg, 172 µmol, 58%) as a white solid. 
 
C28H22F5N2OPS (560.52 g/mol): 
MP: 84-85 °C. 
TLC: Rf = 0.25 (SiO2, cyclohexane:ethyl acetate (4:1)). 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.11 (br s, 1H, OH), 8.18 (d, 3JHH = 8.3 Hz, 1H, NH), 7.52-
7.43 (m, 4H, ar-H), 7.40-7.33 (m, 6H, ar-H), 7.31-7.20 (m, 5H, ar-H), 6.01 (d, 3JHH = 4.1 Hz, 1H, 
NH), 6.16-5.11 (br m, 1H, Ph-CH), 4.54-4.46 (m, 1H, NCH), 2.63 (dd, 2JHP = 13.7 Hz, 3JHH = 7.3 Hz, 
1H, PCH2), 2.26 (dd, 2JHP = 13.7 Hz, 3JHH = 7.5 Hz, 1H, PCH2). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 182.4, 145.1, 142.8, 142.5, 138.6 (d, JCP = 14.1 Hz), 
138.2, 138.0 (d, JCP = 13.4 Hz), 135.8, 132.2, 128.8, 128.5 (d, JCP = 3.3 Hz), 128.5 (d, 
JCP = 3.6 Hz), 127.7, 126.9, 126.3, 115.4, 71.5 (d, JCP = 9.9 Hz), 58.0 (d, JCP = 17.1 Hz), 29.5 (d, 
JCP = 14.1 Hz). 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = − 24.1. 
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19F{1H} NMR (376 MHz, DMSO-d6): δ/ppm = −144.6 (d, 3JFF = 24.4 Hz), −157.7 (t, 3JFF = 24.0 Hz), 
−164.5 (t, 3JFF = 23.4 Hz). 
IR (ATR): 𝑣𝑣�/cm-1 = 3032 (w), 2944 (w), 2905 (w), 2856 (w), 1515 (s), 1462 (s), 1359 (m), 1241 (m), 
1136 (m), 989 (s), 948 (w), 871 (m), 777 (s), 718 (m), 676 (m), 576 (w), 477 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C28H22F5N2OPS +: 561.1183 [M+H]+; found: 
561.1190. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −1.7 (c = 0.67, CHCl3). 
 
1-((1S,2R)-1-((tert-butyldimethylsilyl)oxy)-3-(diphenylphosphanyl)-1-phenylpropan-2-yl)-3-
(perfluorophenyl)thiourea (46c) 
OTBDMS
HN
P
HN
S
F
F
F
F
F
 
According to general procedure GP4, 1-((1S,2R)-3-(diphenylphosphanyl)-1-hydroxy-1-phenyl-
propan-2-yl)-3-(perfluorophenyl)thiourea (45c) (84.1 mg, 150 µmol), DIPEA (58.0 mg, 74.0 µL, 
450 µmol), TBDMS triflate (43.6 mg, 38.0 µL, 165 µmol), CH2Cl2 (1.2 mL) were stirred for six hours 
and the crude product was purified by flash column chromatography (SiO2, cyclohexane:ethyl 
acetate (8:1), 2 x 14 cm) to afford the product 46c (72.5 mg, 107 µmol, 73%) as a white solid. 
 
C34H36F5N2OPSSi (674.79 g/mol): 
MP: 77-78 °C. 
TLC: Rf = 0.50 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (500 MHz, DMSO-d6): δ/ppm = 9.06 (s, 1H, NH), 7.99 (d, 3JHH = 8.1 Hz, 1H, NH), 7.46 – 
7.18 (m, 15H, ar-H), 5.29 (d, 3JHH = 4.0 Hz, 1H, Ph-CH), 4.49-4.39 (m, 1H, NCH), 2.63 (dt, 
2JHP = 13.7 Hz, 3JHH = 3.5 Hz, 1H, PCH2), 1.79 (ddd, 2JHP = 14.1, 3JHH = 10.8 Hz, 4JHH = 3.6 Hz, 
1H, PCH2), 0.83 (s, 9H, SiC(CH3)3), −0.02 (s, 3H, SiCH3), −0.16 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 182.6, 140.5, 138.5 (d, JCP = 12.9 Hz), 137.8 (d, JCP 
= 15.1 Hz), 132.6 (d, JCP = 19.2 Hz), 132.1 (d, JCP = 18.8 Hz), 128.8, 128.6, 128.5, 127.8, 127.3, 
126.7, 73.1, 57.5 (d, JCP = 15.4 Hz), 27.8 (d, JCP = 13.7 Hz), 25.6, 17.7, −4.8, −5.0. 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −25.1. 
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19F{1H} NMR (376 MHz, DMSO-d6): δ/ppm = −144.55 (d, JFF = 23.8 Hz), −157.41 (t, JFF = 22.9 Hz), 
−164.35 (t, JFF = 23.1 Hz). 
IR (ATR): 𝑣𝑣�/cm-1 = 3032 (w), 2944 (w), 2905 (w), 2856 (w), 1515 (s), 1462 (s), 1359 (m), 1241 (m), 
1136 (m), 989 (s), 948 (w), 871 (m), 777 (s), 718 (m), 676 (m), 576 (w), 477 (w). 
EA (C34H36F5N2OPSSi) calc.: C 60.52, H 5.38, N 4.15; found: C 60.46, H 5.75, N 4.46. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +4.0 (c = 0.23, MeOH). 
 
1-(3,5-bis(Trifluoromethyl)phenyl)-3-((1S,2R)-3-(diphenylphosphanyl)-1-hydroxy-1-phenyl 
propan-2-yl)thiourea (45d) 
OH
HN
P
HN
S
CF3
CF3
 
According to general procedure GP1, (1S,2R)-2-amino-3-(diphenylphosphanyl)-1-phenylpropan-
1-ol (38) (100 mg, 298 µmol), 3,5-bis(trifluoromethyl)phenyl isothiocyanate (91.0 mg, 61.0 µL, 
328 µmol), CH2Cl2 (0.9 mL) were stirred for 16 hours and the crude product was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (5:1), d x h: 2.5 x 19 cm) to afford the product 
45d (158 mg, 260 µmol, 87%) as a white solid. 
 
C30H25F6N2OPS (606.57 g/mol): 
MP: 78-79 °C. 
TLC: Rf = 0.43 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 10.2 (s, 1H, OH), 8.25 (s, 2H, ar-H), 8.05 (d, 3JHH = 8.4 Hz, 
1H, NH), 7.69 (s, 1H, ar-H), 7.56-7.52 (m, 2H, ar-H), 7.45-7.42 (m, 2H, ar-H), 7.40-7.25 (m, 10H, 
ar-H), 7.23-7.18 (m, 1H, ar-H), 6.10 (br s, 1H, NH), 5.17-5.11 (m, 1H, Ph-CH), 4.65-4.57 (m, 1H, 
NCH), 2.58 (dd, 2JHP = 13.6 Hz, 3JHH = 7.8 Hz, 1H, PCH2), 2.45 (dd, 2JHP = 13.6 Hz, 3JHH = 6.9 Hz, 
1H, PCH2). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 179.6, 142.8, 141.8, 138.8 (d, JCP = 13.6 Hz), 
137.7 (d, JCP = 13.3 Hz), 132.9 (d, JCP = 19.6 Hz), 132.2 (d, JCP = 18.5 Hz), 130.2, 129.9, 128.8, 
128.5 (d, JCP = 4.1 Hz), 128.4 (d, JCP = 3.6 Hz), 127.8, 126.9, 126.1, 124.6, 121.9, 121.1, 115.8, 
71.8 (d, JCP = 10.3 Hz), 57.1 (d, JCP = 16.6 Hz), 30.1 (d, JCP = 14.8 Hz). 
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31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −24.1. 
19F{1H} NMR (376 MHz, DMSO-d6): δ/ppm = −61.6. 
IR (ATR): 𝑣𝑣�/cm-1 = 3246 (br s), 3070 (w), 3033 (w), 1521 (m), 1470 (w), 1380 (w), 1274 (s), 1171 
(s), 1126 (s), 885 (w), 846 (w), 736 (s), 646 (m), 503 (m), 475 (w). 
EA (C30H25 F6N2OPS) calc.: C 59.40, H 4.50, N 4.62; found: C 59.28, H 4.62, N 4.88. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +9.3 (c = 1.0, CHCl3). 
 
1-(3,5-bis(Trifluoromethyl)phenyl)-3-((1S,2R)-1-((tert-butyldimethylsilyl)oxy)-3-(diphenyl 
phosphanyl)-1-phenylpropan-2-yl)thiourea (46d) 
OTBDMS
HN
P
HN
S
CF3
CF3
 
According to general procedure GP4, 1-(3,5-bis(trifluoromethyl)phenyl)-3-((1S,2R)-3-(diphenyl-
phosphanyl)-1-hydroxy-1-phenylpropan-2-yl)thiourea (45d) (101 mg, 167 µmol), DIPEA (43.2 mg, 
55.2 µL, 334 µmol), TBDMS triflate (46.4 mg, 40.3 µL, 175 µmol), CH2Cl2 (1.8 mL) were stirred for 
six hours and the crude product was purified by column chromatography (SiO2, cyclohexane:ethyl 
acetate (8:1), d x h: 3.5 x 19 cm) to afford the product 46d (97.0 mg, 134 µmol, 80%) as a white 
solid. 
 
C36H39F6N2OPSSi (720.83 g/mol): 
MP: 67-68 °C. 
TLC: Rf = 0.43 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 10.08 (s, 1H, NH), 8.28 (s, 2H, ar-H), 7.84 (d, 
3JHH = 8.5 Hz, 1H, ar-H), 7.74 (s, 1H, ar-H), 7.46-7.22 (m, 15H, ar-H), 5.22 (d, 3JHH = 3.8 Hz, 1H, 
Ph-CH), 4.70-4.57 (m, 1H, NCH), 2.58 (ddd, 2JHP = 13.9 Hz, 3JHH = 4.3 Hz, 4JHH = 1.9 Hz, 1H, 
PCH2), 1.89 (ddd, 2JHP = 13.6 Hz, 3JHH = 10.3 Hz, 4JHH = 2.7 Hz, 1H, PCH2), 0.84 (s, 9H, SiC(CH3)3), 
0.01 (s, 3H, SiCH3), −0.15 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 180.2, 141.7, 140.7, 138.3 (d, JCP = 13.1 Hz), 
137.9 (d, JCP = 14.6 Hz), 132.6, 132.4 (d, JCP = 3.7 Hz), 132.2, 130.6, 130.3, 129.9, 129.6, 128.8, 
128.6, 128.5 (d, JCP = 3.7 Hz), 128.5 (d, JCP = 3.6 Hz), 127.8, 127.3, 126.7, 124.6, 122.0 (d, 
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JCP = 4.3 Hz), 121.9, 119.2, 116.2, 73.9 (d, JCP = 8.9 Hz), 56.7 (d, JCP = 15.5 Hz), 28.5 (d, 
JCP = 13.3 Hz), 25.7, 17.8, −4.9, −4.8. 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −25.0. 
19F{1H} NMR (376 MHz, DMSO-d6): δ/ppm = −61.5. 
IR (ATR): 𝑣𝑣�/cm-1 = 3376 (w), 3055 (w), 2952 (w), 2929 (w), 2856 (w), 1510 (m), 1470 (m), 1380 (s), 
1173 (s), 1131 (s), 1092 (s), 1066 (m), 961 (w), 943 (w), 883 (m), 778 (m), 734 (m), 695 (s), 
680 (s), 503 (m), 475 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C36H39F6N2OPSSi+: 721.2267 [M+H]+; 
found: 721.2273. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +18.2 (c = 0.76, CH2Cl2). 
 
1-((1S,2R)-3-(Diphenylphosphanyl)-1-hydroxy-1-phenylpropan-2-yl)-3-(4-methoxyphenyl) 
thiourea (45e) 
OH
HN
P
HN
S
OMe  
According to general procedure GP1, (1S,2R)-2-amino-3-(diphenylphosphanyl)-1-phenylpropan-
1-ol (38) (100 mg, 298 µmol), 4-methoxyphenyl isothiocyanate (54.0 mg, 45.0 µL, 328 µmol), 
CH2Cl2 (0.9 mL) were stirred for 16 hours and the crude product was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (5:1), d x h: 2.5 x 17 cm) to afford the product 
45e (136 mg, 272 µmol, 91%) as a white solid. 
 
C29H29N2O2PS (500.60 g/mol): 
MP: 86-87 °C. 
TLC: Rf = 0.21 (SiO2, cyclohexane:ethyl acetate (10:3)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.45-7.39 (m, 2H, ar-H), 7.39-7.36 (m, 12H, ar-H*, NH*), 7.09-
7.07 (m, 2H, ar-H), 6.84-6.78 (m, 4H, ar-H), 6.14 (br s, 1H, NH), 4.97 (d, 3JHH = 4.2 Hz,1H, Ph-
CH), 4.81-4.71 (br m, 1H, NCH), 3.75 (s, 3H, OCH3), 2.81 (br s, 1H, OH), 2.43 (d, 3JHH = 7.0 Hz, 
2H, PCH2). 
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13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 181.0, 159.0, 141.2, 133.1 (d, JCP = 3.3 Hz), 132.9 (d, 
JCP = 2.9 Hz), 129.2 (d, JCP = 6.3 Hz), 128.8 (d, JCP = 7.0 Hz), 128.5, 128.2, 127.9, 127.8, 126.2, 
115.2, 75.0 (d, JCP = 8.8 Hz), 58.8 (d, JCP = 15.0 Hz), 55.6, 30.6 (d, JCP = 13.3 Hz). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −23.6. 
IR (ATR): 𝑣𝑣�/cm-1 = 3360 (w), 3235 (w), 3049 (w), 1506 (s), 1432 (w), 1297 (w), 1163 (w); 1091 (m), 
1025 (m), 828 (m), 734 (s), 633 (w), 568 (w), 473 (m). 
EA (C29H29N2O2PS) calc.: C 69.58, H 5.84, N 5.60; found: C 69.34, H 5.88, N 5.69. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −4.6 (c = 0.76, CHCl3). 
 
1-((1S,2R)-1-((tert-Butyldimethylsilyl)oxy)-3-(diphenylphosphanyl)-1-phenylpropan-2-yl)-3-
(4-methoxyphenyl)thiourea (46e) 
OTBDMS
HN
P
HN
S
OMe  
According to general procedure GP4, 1-((1S,2R)-3-(diphenylphosphanyl)-1-hydroxy-1-phenyl-
propan-2-yl)-3-(4-methoxyphenylthiourea (45e) (130 mg, 260 µmol), DIPEA (67.2 mg, 85.9 µL, 
520 µmol), TBDMS triflate (75.6 mg, 65.7 µL, 290 µmol), CH2Cl2 (1.4 mL) were stirred for six hours 
and the crude product was purified by column chromatography (SiO2, cyclohexane:ethyl acetate 
(5:1), d x h: 2 x 14 cm) to afford the product 46e (103 mg, 0.17 mmol, 64%) as a white solid. 
 
C35H43N2O2PSSi (614.86 g/mol): 
MP: 67-68 °C. 
TLC: Rf = 0.47 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.68-7.63 (m, 2H, ar-H), 7.47-7.42 (m, 2H, ar-H), 7.38-
7.32 (m, 6H, ar-H), 7.29-7.21 (m, 3H, ar-H), 7.06-7.04 (m, 4H, ar-H), 6.95-6.91 (m, 2H, ar-H), 
6.26 (br s, 1H, NH), 5.27 (s, 1H, Ph-CH), 4.56-4.48 (m, 1H, NCH), 3.82 (s, 3H, OCH3), 2.53 (ddd, 
2JHP = 13.7 Hz, 3JHH = 6.8 Hz, 4JHH = 2.3 Hz, 1H, PCH2), 2.30 (ddd, 2JHP = 13.8 Hz, 3JHH = 8.6 Hz, 
4JHH = 2.4 Hz, 1H, PCH2), 0.75 (s, 9H, SiC(CH3)3), 0.05 (s, 3H, SiCH3), −0.23 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 181.2, 159.8, 142.3, 139.4, 137.8, 133.9 (d, 
JCP = 19.8 Hz), 133.3 (d, JCP = 18.8 Hz), 129.6, 129.2, 129.1 (d, JCP = 3.0 Hz), 129.0 (d, 
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JCP = 2.6 Hz), 128.9, 128.4, 127.9, 126.7, 115.7, 74.2 (d, JCP = 10.0 Hz), 60.0 (d, JCP = 16.5 Hz), 
56.0, 31.2 (d, JCP = 14.6 Hz), 26.1, 18.4, −4.4. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −24.6. 
IR (ATR): 𝑣𝑣�/cm-1 = 3365 (w), 3182 (w), 3051 (w), 2927 (w), 1507 (s), 2397 (w), 1239 (s), 1164 (w), 
1090 (m), 1066 (m), 1027 (m), 957 (w), 831 (s), 776 (s), 734 (s), 694 (s), 562 (w), 504 (w). 
EA (C35H43N2O2PSSi) calc.: C 68.37, H 7.05, N 4.56; found: C 68.46, H 7.12, N 4.68. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −25.4 (c = 0.87, CH2Cl2). 
 
1-Cyclohexyl-3-((1S,2R)-3-(diphenylphosphanyl)-1-hydroxy-1-phenylpropan-2-yl)thiourea 
(45f) 
OH
HN
P
HN
S
 
According to general procedure GP1, (1S,2R)-2-amino-3-(diphenylphosphanyl)-1-phenylpropan-
1-ol (38) (100 mg, 298 µmol), cyclohexyl isothiocyanate (46.0 mg, 46.5 µL, 328 µmol), CH2Cl2 
(0.9 mL) were stirred for 16 hours and the crude product was purified by column chromatography 
(SiO2, cyclohexane:ethyl acetate (5:1), d x h: 2.5 x 10 cm) to afford the product 45f (55.0 mg, 115 
µmol, 39%) as a white solid. 
 
C28H33N2OPS (476.62 g/mol): 
MP: 186-187 °C. 
TLC: Rf = 0.36 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 7.56-7.31 (m, 11H, ar-H, NH), 7.27-7.24 (m, 2H, ar-H), 
7.20-7.15 (m, 3H, ar-H), 5.84 (d, 3JHH = 4.1 Hz, NH), 5.07 (s, 1H, Ph-CH), 4.50 (s, 1H, NCH), 3.89 
(br s, 1H, CH), 2.53-2.45 (br m, 1H, PCH2), 2.18 (dd, 2JHP = 13.7 Hz, 3JHH = 7.3 Hz, 1H, PCH2), 
1.81-1.73 (m, 2H, cy-CH2), 1.67-1.55 (m, 2H, cy-CH2), 1.52-1.49 (m, 1H, cy-CH), 1.29-1.02 (m, 
5H, cy-CH2). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 181.0, 142.9, 138.9 (d, JCP = 14.6 Hz), 138.2 (d, 
JCP = 13.3 Hz), 132.7 (d, JCP = 19.2 Hz), 132.2 (d, JCP = 18.5 Hz), 128.6, 128.5, 128.4 (d, 
JCP = 2.4 Hz), 128.4, 127.6, 126.7, 126.3, 71.8, 56.5 (d, JCP = 16.9 Hz), 51.4, 32.2, 32.2, 29.9 (d, 
JCP = 9.2 Hz), 25.2, 24.2, 24.2. 
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31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −23.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 3410 (w), 3308 (m), 1531 (s), 1361 (m), 1256 (m), 1176 (w), 1056 (w), 973 (w), 
846 (w), 732 (s), 693 (s), 650 (m), 592 (w), 509 (m), 463 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C28H33N2OPS+: 477.2124 [M+H]+; found: 
477.2130. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −4.7 (c = 0.62, DMSO). 
 
1-((1S,2R)-1-((tert-Butyldimethylsilyl)oxy)-3-(diphenylphosphanyl)-1-phenylpropan-2-yl)-3-
cyclohexylthiourea (46f) 
OTBDMS
HN
P
HN
S
 
According to general procedure GP4, 1-cyclohexyl-3-((1S,2R)-3-(diphenylphosphanyl)-1-hydroxy-
1-phenylpropan-2-yl)-thiourea (45f) (45 mg, 94.4 µmol), DIPEA (24.4 mg, 31.2 µL, 189 µmol), 
TBDMS triflate (27.5 mg, 23.9 µL, 104 µmol), CH2Cl2 (1.0 mL) were stirred for six hours and the 
crude product was purified by column chromatography (SiO2, cyclohexane:ethyl acetate (8:1), d x 
h: 2 x 16 cm) to afford the product 46f (38 mg, 64 µmol, 68%) as a white solid. 
 
C34H47N2OPSSi (590.88 g/mol): 
MP: 66-67 °C. 
TLC: Rf = 0.30 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.59-7.50 (m, 2H, ar-H), 7.47-7.40 (m, 2H, ar-H), 7.37-
7.19 (m, 11H, ar-H), 5.75 (s, 1H, Ph-CH), 5.26 (s, 1H, NCH), 4.44 (br s, 1H, NH), 3.31 (s, 1H, NH), 
2.47 (dd, 2JHP = 13.7 Hz, 3JHH = 6.8 Hz, 1H, PCH2), 2.39-2.30 (m, 1H, PCH2), 1.90-1.83 (m, 2H, 
cy-CH2), 1.72-1.64 (m, 2H, cy-CH2), 1.63-1.55 (m, 1H, cy-CH), 1.33-1.05 (m, 6H, cy-CH2), 0.93 (s, 
9H, SiC(CH3)3), 0.11 (s, 3H, SiCH3), −0.10 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.7, 142.0, 138.9, 138.4, 133.6 (d, JCP = 19.6 Hz), 
133.4 (d, JCP = 19.1 Hz), 129.5, 129.3, 129.2, 129.1, 129.1, 129.1, 128.6, 128.1, 127.0, 75.0, 
59.1 (d, JCP = 15.2 Hz), 53.0, 33.4, 33.3, 30.9, 26.3, 25.9, 25.3, 25.2, 18.6, −4.3. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −23.9. 
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IR (ATR): 𝑣𝑣�/cm-1 = 3255 (w), 3051 (w), 2926 (m), 2853 (m), 1525 (s), 1433 (w), 1360 (w), 1251 (m), 
1090 (s), 1065 (s), 834 (m), 777 (s), 735 (s), 694 (s), 504 (m). 
EA (C34H47N2OPSSi) calc.: C 69.11, H 8.02, N 4.74; found: C 68.97, H 8.17, N 4.82. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −10.8 (c = 0.77, CH2Cl2) 
 
1-((1S,2R)-3-(di-o-Tolylphosphanyl)-1-hydroxy-1-phenylpropan-2-yl)-3-phenylthiourea 
(47a) 
OH
HN
P
HN
S
 
According to general procedure GP1, (1S,2R)-2-amino-3-(di-o-tolylphosphanyl)-1-phenylpropan-
1-ol (40a) (180 mg, 495 µmol), phenyl isothiocyanate (75.1 mg, 66.4 µL, 545 µmol), CH2Cl2 
(1.4 mL) were stirred for 16 hours and the crude product was purified by column chromatography 
(SiO2, cyclohexane:ethyl acetate (4:1), d x h: 3.5 x 15 cm) to afford the product 47a (222 mg, 445 
µmol, 90%) as a white solid. 
 
C30H31N2OPS (498.62 g/mol): 
MP: 84-85 °C. 
TLC: Rf = 0.36 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.88 (br s, 1H, NH), 7.44-7.09 (m, 16H, ar-H), 7.03 (d, 
3JHH = 7.6 Hz, 2H, ar-H), 6.48 (d, 3JHH = 8.2 Hz, 1H, NH), 5.11-5.05 (br m, 1H, Ph-CH), 4.98-4.83 
(br m, 1H, NCH), 3.15 (br s, 1H, OH), 2.47 (s, 3H, ar-CH3), 2.43 (s, 3H, ar-CH3), 2.42-2.34 (m, 2H, 
PCH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 180.4, 142.6, 142.3 (d, JCP = 4.5 Hz), 142.0, 141.2, 
135.9, 131.8, 131.6, 130.3 (t, JCP = 4.7 Hz), 130.1, 128.9 (d, JCP = 4.2 Hz), 128.5, 127.9, 127.3, 
126.4 (d, JCP = 4.9 Hz), 126.3, 125.3, 75.3 (d, JCP = 8.2 Hz), 58.8 (d, JCP = 16.9 Hz), 29.1 (d, 
JCP = 14.4 Hz), 21.5, 21.3. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −45.4. 
IR (ATR): 𝑣𝑣�/cm-1 = 3356 (w), 3256 (w), 3193 (w), 3054 (w), 1589 (w), 1518 (s), 1448 (m), 1235 
(m), 1184 (m), 1050 (w), 1027 (w), 938 (w), 858 (w), 739 (s), 695 (s), 602 (w), 491 (m), 451 (s). 
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HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C30H31N2OPS+: 499.1967 [M+H]+; found: 
499.1974. [𝛼𝛼]𝐷𝐷20 = +0.4 (c = 0.61, CHCl3). 
 
1-((1S,2R)-1-((tert-Butyldimethylsilyl)oxy)-3-(di-o-tolylphosphanyl)-1-phenylpropan-2-yl)-3-
phenylthiourea (48a) 
OTBDMS
HN
P
HN
S
 
According to general procedure GP4, 1-((1S,2R)-3-(di-o-tolylphosphanyl)-1-hydroxy-1-phenyl-
propan-2-yl)-3-phenylthiourea (47a) (50.0 mg, 100 µmol), triethylamine (20.2 mg, 28.0 µL, 
200 µmol), TBDMS triflate (27.8 mg, 24.0 µL, 105 µmol), CH2Cl2 (1.4 mL) were stirred for six hours 
and the crude product was purified by column chromatography (SiO2, cyclohexane:ethyl acetate 
(8:1), d x h: 2 x 14 cm) to afford the product 48a (42.0 mg, 69.0 µmol, 69%) as a white solid. 
 
C36H45N2OPSSi (612.89 g/mol): 
MP: 73-74 °C. 
TLC: Rf = 0.23 (SiO2, cyclohexane:ethyl acetate (8:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.70 (s, 1H, NH), 7.39-7.06 (m, 17H, ar-H), 6.17 (d, 
3JHH = 8.4 Hz, 1H, NH), 5.26 (s, 1H, Ph-CH), 4.54 (s, 1H, NCH), 2.46-2.41 (m, 1H, PCH2), 2.40 (s, 
6H, ar-CH3), 2.06 (ddd, 2JHP = 13.9 Hz, 3JHH = 8.5 Hz, 4JHH = 1.6 Hz, 1H, PCH2), 0.77 (s, 9H, 
SiC(CH3)3), 0.00 (s, 3H, SiCH3), −0.22 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.7, 143.2 (d, JCP = 16.5 Hz), 143.0 (d, 
JCP = 16.7 Hz), 141.7, 137.2, 137.0, 136.9, 136.6, 132.6, 131.9, 130.7, 130.6 (d, JCP = 5.0 Hz), 
129.2 (d, JCP = 4.8 Hz), 128.4, 128.0, 127.8, 127.0, 126.7 (d, JCP = 4.8 Hz), 126.1, 74.3, 59.4 (d, 
JCP = 16.8 Hz), 29.2 (d, JCP = 14.5 Hz), 26.2, 21.8 (d, JCP = 4.3 Hz), 21.6 (d, JCP = 4.7 Hz), 18.5, 
−4.4, −4.5. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −47.3. 
IR (ATR): 𝑣𝑣�/cm-1 = 3374 (w), 3158 (w), 2927 (w), 1516 (m), 1494 (m), 1449 (m), 1376 (w), 1247 
(m), 1186 (w), 1091 (m), 1065 (m), 958 (w), 883 (w), 834 (s), 774 (m), 740 (s), 696 (s), 498 (m), 
449 (m). 
EA (C36H45N2OPSSi) calc.: C 70.55, H 7.40, N 4.57; found: C 70.62, H 7.42, N 4.62. 
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[𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +6.6 (c = 0.61, CH2Cl2) 
 
1-((1S,2R)-3-(di-o-Tolylphosphanyl)-1-hydroxy-1-phenylpropan-2-yl)-3-phenylthiourea 
(47b) 
OH
HN
P
HN
S
F  
According to general procedure GP1, (1S,2R)-2-amino-3-(di-o-tolylphosphanyl)-1-phenylpropan-
1-ol (40a) (50.2 mg, 138 µmol), 4-fluorophenyl isothiocyanate (22.2 mg, 10.2 µL, 152 µmol), 
CH2Cl2 (0.5 mL) were stirred for 16 hours and the crude product was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (4:1), d x h: 3.5 x 13 cm) to afford the product 
47b (69.0 mg, 134 µmol, 97%) as a white solid. 
 
C30H30FN2OPS (516,62 g/mol): 
MP: 81-82 °C. 
TLC: Rf = 0.33 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.52 (s, 1H, NH), 7.40-7.38 (m, 1H, ar-H), 7.33-7.27 (m, 3H, 
ar-H), 7.24-7.08 (m, 9H, ar-H), 7.06 (m, 2H, ar-H), 6.96-6.91 (m, 2H, ar-H), 6.23 (d, 3JHH = 8.2 Hz, 
1H, NH), 6.10-6.03 (br m, 1H, Ph-CH), 4.87 (br s, 1H, NCH), 2.95 (br s, 1H, OH), 2.44 (s, 3H, ar-
CH3), 2.43-2.33 (m, 5H, ar-CH3*, PCH2*). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 180.9, 160.3, 142.6, 142.3, 142.1, 141.1, 135.6 (d, 
JCP = 6.0 Hz), 135.5 (d, JCP = 6.1 Hz), 131.8, 131.6, 130.4 (d, JCP = 2.5 Hz), 130.3 (d, JCP = 2.0 Hz), 
129.0 (d, JCP = 4.9 Hz), 128.6, 128.0, 127.9, 126.4 (d, JCP = 5.8 Hz), 126.2, 117.0 (d, 
JCP = 22.7 Hz), 75.1, 58.9 (d, JCP = 16.6 Hz), 29.2 (d, JCP = 14.8 Hz), 21.6 (d, JCP = 2.0 Hz), 
21.3 (d, JCP = 1.1 Hz). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −45.7. 
19F{1H} NMR (376 MHz, CDCl3): δ/ppm = −113.1. 
IR (ATR): 𝑣𝑣�/cm-1 = 3356 (w), 3222 (w), 3055 (w), 1504 (s), 1449 (w), 1334 (w), 1215 (s), 1152 (m), 
1089 (w), 1052 (w), 1028 (w), 832 (m), 744 (s), 699 (s), 634 (m), 504 (m), 454 (s). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C30H30FN2OPS+: 517.1873 [M+H]+; found: 
517.1880. 
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[𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −0.9 (c = 0.34, CHCl3). 
 
1-((1S,2R)-1-((tert-Butyldimethylsilyl)oxy)-3-(di-o-tolylphosphanyl)-1-phenylpropan-2-yl)-3-
(4-fluorophenyl)thiourea (48b) 
OTBDMS
HN
P
HN
S
F  
According to general procedure GP4, 1-((1S,2R)-3-(di-o-tolylphosphanyl)-1-hydroxy-1-phenyl-
propan-2-yl)-3-phenylthiourea (47b) (70.0 mg, 135 µmol), DIPEA (52.5 mg, 67.0 µL, 406 µmol), 
TBDMS triflate (43.0 mg, 37.0 µL, 163 µmol), CH2Cl2 (1.4 mL) were stirred for six hours and the 
crude product was purified by column chromatography (SiO2, cyclohexane:ethyl acetate (5:1), d x 
h: 3.5 x 17 cm) to afford the product 48b (61.3 mg, 97 µmol, 72%) as a white solid. 
 
C36H44FN2OPSSi (630.88 g/mol): 
MP: 84-85 °C. 
TLC: Rf = 0.36 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.67 (s, 1H, NH), 7.40-7.04 (m, 17H, ar-H), 6.02 (s, 1H, NH), 
5.28 (s, 1H, Ph-CH), 4.56 (s, 1H, NCH), 2.49-2.38 (m, 7H, ar-CH3, PCH2), 2.17-2.08 (m, 1H, 
PCH2), 0.80 (s, 9H, SiC(CH3)3), 0.04 (s, 3H, SiCH3), −0.19 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): 181.0, 163.4, 160.9, 143.2 (d, JCP = 9.4 Hz), 143.0 (d, 
JCP = 9.8 Hz), 141.7, 137.2, 136.9 (d, JCP = 13.4 Hz), 132.6, 131.9, 130.8 (d, JCP = 5.0 Hz), 
130.6 (d, JCP = 5.2 Hz), 129.2 (d, JCP = 5.1 Hz), 128.9 (d, JCP = 8.5 Hz), 128.4, 128.0, 127.0, 
126.7 (d, JCP = 3.4 Hz), 117.4 (d, JCP = 22.9 Hz), 74.3, 59.4 (d, JCP = 17.0 Hz), 29.3 (d, 
JCP = 14.7 Hz), 26.1, 21.8 (d, JCP = 4.5 Hz), 21.6 (d, JCP = 5.0 Hz), 18.4, −4.4, −4.5. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −47.4. 
19F{1H} NMR (376 MHz, CD2Cl2): δ/ppm = −14.3. 
IR (ATR): 𝑣𝑣�/cm-1 = 3691 (m), 1506 (s), 1433 (m), 1335 (m), 1243 (m), 987 (s), 737 (m), 693 (s), 
503 (w), 475 (w). 
EA (C36H44FN2OPSSi) calc.: C 68.54, H 7.03, N 4.44; found: C 68.46, H 7.32, N 4.37. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +13.1 (c = 0.49, CH2Cl2). 
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1-((1S,2R)-3-(bis(2-Isopropylphenyl)phosphanyl)-1-hydroxy-1-phenylpropan-2-yl)-3-
phenylthiourea (47c) 
OH
NH
P
NH
S
 
According to general procedure GP1, (1S,2R)-2-amino-3-(bis(2-isopropylphenyl)phosphanyl)-1-
phenylpropan-1-ol (40b) (80.0 mg, 191 µmol), phenyl isothiocyanate (28.9 mg, 25.6 µL, 
210 µmol), CH2Cl2 (0.6 mL) were stirred for 16 hours and the crude product was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (4:1), d x h: 2.5 x 11 cm) to afford the product 
47c (138 mg, 195 µmol, 85%) as a white solid. 
 
C34H39N2OPS (554,73): 
MP: 87-88 °C. 
TLC: Rf = 0.43 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.49-7.39 (m, 2H, ar-H*, NH*), 7.30-7.13 (m, 13H, ar-H), 7.12-
7.08 (m, 1H, ar-H), 7.05-7.01 (m, 1H, ar-H), 6.85 (d, 3JHH = 7.5 Hz, 2H, ar-H), 6.36 (br s, 1H, NH), 
5.07 (s, 1H, Ph-CH), 4.92-4.79 (br m, 1H, NCH), 3.79-3.57 (m, 2H, ar-CH(CH3)2), 2.83 (br s, 1H, 
OH), 2.44-2.29 (m, 2H, PCH2), 1.16 (d, 3JHH = 6.8 Hz, 6H, CH(CH3)2), 0.93 (d, 3JHH = 6.8 Hz, 3H, 
CH(CH3)2)), 0.90 (d, 3JHH = 6.8 Hz, 3H, CH(CH3)2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 180.4, 153.1, 152.9, 152.9, 152.7, 141.2, 135.9, 134.8, 
132.4, 132.2, 130.1, 129.5, 128.5, 127.9, 127.3, 126.3 (d, JCP = 13.6 Hz), 126.2 (d, JCP = 2.6 Hz), 
125.8, 125.4, 74.8 (d, JCP = 9.0 Hz), 58.9 (d, JCP = 16.2 Hz), 31.5 (d, JCP = 6.6 Hz), 31.2 (d, 
JCP = 7.3 Hz), 30.5, 24.5, 24.4, 23.9, 23.8. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −50.7. 
IR (ATR): 𝑣𝑣�/cm-1 = 3370 (w), 3274 (w), 3048 (w), 1589 (m), 1519 (s), 1495 (s), 1470 (m), 1380 (w), 
1316 (s), 1295 (w), 1232 (m), 1054 (w), 1026 (w), 939 (w), 870 (w), 832 (w), 735 (s), 695 (s), 
604 (w), 507 (m). 
EA (C34H39N2OPS) calc.: C 73.62, H 7.09, N 5.05; found: C 73.68, H 6.93, N 5.29. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +17.1 (c = 0.72, CHCl3). 
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1-((1S,2R)-3-(bis(2-Isopropylphenyl)phosphanyl)-1-((tert-butyldimethylsilyl)oxy)-1-
phenylpropan-2-yl)-3-phenylthiourea (48c) 
OTBDMS
NH
P
NH
S
 
According to general procedure GP4, 1-((1S,2R)-3-(bis(2-isopropylphenyl)phosphanyl)-1-
hydroxy-1-phenylpropan-2-yl)-3-phenylthiourea (47c) (73.6 mg, 133 µmol), DIPEA (52.3 mg, 66.8 
µL, 404 µmol), TBDMS triflate (38.4 mg, 33.0 µL, 145 µmol), CH2Cl2 (1.5 mL) were stirred for six 
hours and the crude product was purified by column chromatography (SiO2, cyclohexane:ethyl 
acetate (10:1), d x h: 2 x 13 cm) to afford the product 48c (81 mg, 121 µmol, 91%) as a white 
solid. 
 
C40H53N2OPSSi (668.99 g/mol): 
MP: 78-79 °C. 
TLC: Rf = 0.57 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.71 (s, 1H, NH), 7.46-7.05 (m, 16H, ar-H), 6.28 (d, 
3JHH = 8.4 Hz, 1H, NH), 5.34 (s, 1H, Ph-CH), 4.60 (s, 1H, NCH), 3.87-3.71 (m, 2H, ar-CH(CH3)2), 
2.46 (ddd, 2JHP = 14.0 Hz, 3JHH = 7.0 Hz, 4JHH = 2.3 Hz, 1H, PCH2), 2.05 (ddd, 2JHP = 14.0 Hz, 
3JHH = 8.1 Hz, 4JHH = 1.8 Hz, 1H, PCH2), 1.28 (d, 3JHH = 6.8 Hz, 3H, CH(CH3)2), 1.18 (d, 
3JHH = 6.9 Hz, 3H, CH(CH3)2), 1.06 (d, 3JHH = 6.9 Hz, 3H, CH(CH3)2), 0.95 (d, 3JHH = 6.8 Hz, 3H, 
CH(CH3)2), 0.80 (s, 9H, SiC(CH3)3), 0.04 (s, 3H, SiCH3), −0.19 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): 180.5, 153.6 (d, JCP = 6.9 Hz), 153.4 (d, JCP = 7.5 Hz), 141.7, 
136.4, 135.8 (d, JCP = 12.5 Hz), 133.1, 132.0, 130.5, 129.4 (d, JCP = 9.2 Hz), 128.2, 127.8, 127.7, 
126.8, 126.4 (d, JCP = 5.6 Hz), 126.0, 126.0, 125.8 (d, JCP = 5.0 Hz), 74.1, 59.2 (d, JCP = 17.0 Hz), 
31.5 (d, JCP = 6.7 Hz), 31.3 (d, 3JCP = 7.8 Hz), 30.5 (d, JCP = 16.3 Hz), 26.0, 24.5, 24.4, 24.1, 23.9, 
18.3, −4.5, −4.7. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −52.2. 
IR (ATR): 𝑣𝑣�/cm-1 = 3372 (w), 3163 (w), 3052 (w), 2955 (m), 2856 (w), 1589 (w), 1496 (s), 1470 (s), 
1249 (m), 1091 (s), 1065 (s), 833 (s), 734 (s), 696 (s), 506 (m), 485 (m). 
EA (C40H53N2OPSSi) calc.: C 71.82, H 7.99, N 4.19; found: C 71.62, H 8.05, N 4.21. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +1.4 (c = 0.85, CH2Cl2). 
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1-((1S,2R)-3-(di(naphthalen-1-yl)phosphanyl)-1-hydroxy-1-phenylpropan-2-yl)-3-phenyl-
thiourea (47d) 
OH
HN
P
NH
S
 
According to general procedure GP1, (1S,2R)-2-amino-3-( di(naphthalen-1-yl phosphanyl)-1-
phenylpropan-1-ol (40c) (210 mg, 482 µmol), phenyl isothiocyanate (69.8 mg, 61.8 µL, 506 µmol), 
CH2Cl2 (1.5 mL) were stirred for 16 hours and the crude product was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (3:1), d x h: 2.5 x 12 cm) to afford the product 
47d (215 mg, 377 µmol, 78%) as a white solid. 
 
C36H31N2OPS (570.69 g/mol): 
MP: 197-198 °C. 
TLC: Rf = 0.40 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 9.70 (br s, 1H, OH), 8.65-8.58 (m, 1H, ar-H), 8.57-8.52 (m, 
1H, ar-H), 8.02-7.90 (m, 4H, ar-H), 7.85-7.78 (m, 1H, NH), 7.65-7.44 (m, 8H, ar-H), 7.42-7.35 (m, 
2H, ar-H), 7.33-7.15 (m, 7H, ar-H), 7.03 (t, 3JHH = 7.3 Hz, 1H, ar-H), 6.16 (d, 3JHH = 3.7 Hz, 1H, 
NH), 5.28 (s, 1H, Ph-CH), 4.78-4.71 (m, 1H, NCH), 2.72-2.67 (m, 1H, PCH2), 2.57-2.53 (m, 1H, 
PCH2). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 179.7, 143.0, 139.1, 135.1, 135.0 (d, JCP = 3.8 Hz), 
134.8, 134.6, 134.4, 134.2, 133.2 (t, JCP = 4.1 Hz), 131.2, 130.2, 129.4, 129.1, 128.8 (d, 
JCP = 6.0 Hz), 128.5, 127.8, 126.9, 126.5-126.2 (m), 126.0 (d, JCP = 6.4 Hz), 125.8, 125.4 (d, 
JCP = 3.7 Hz), 125.2 (d, JCP = 4.9 Hz), 124.1, 122.6, 71.6 (d, JCP = 10.7 Hz), 57.0 (d, JCP = 17.6 Hz), 
29.5 (d, JCP = 14.6 Hz). 
31P{1H} NMR (162 MHz, DMSO-d6): δ/ppm = −47.0. 
IR (ATR): 𝑣𝑣�/cm-1 = 3405 (m), 3351 (m), 3257 (w), 1519 (s), 1495 (s), 1452 (m), 1377 (m), 1232 (m), 
1094 (m), 1022 (m), 925 (w), 797 (s), 772 (s), 741 (s), 691 (m), 642 (m), 609 (w), 507 (m), 437 (s). 
EA (C36H31N2OPS) calc.: C 75.77, H 5.48, N 4.91; found: C 75.57, H 5.67, N 5.01. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +37.3 (c = 0.91, DMSO). 
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1-((1S,2R)-1-((tert-Butyldimethylsilyl)oxy)-3-(di(naphthalen-1-yl)phosphanyl)-1-phenyl 
propan-2-yl)-3-phenylthiourea (48d) 
OTBDMS
HN
P
NH
S
 
According to general procedure GP4, 1-((1S,2R)-3-(di(naphthalen-1-yl)phosphanyl)-1-hydroxy-1-
phenylpropan-2-yl)-3-phenylthiourea (47d) (184 mg, 322 µmol), DIPEA (125 mg, 160 µL, 
966 µmol), TBDMS triflate (93.6 mg, 81.5 µL, 354 µmol), CH2Cl2 (3.3 mL) were stirred for six hours 
and the crude product was purified by flash column chromatography (SiO2, cyclohexane:ethyl 
acetate (5:1), d x h: 3.5 x 12 cm) to afford the product 48d (102 mg, 148 µmol, 46%) as a white 
solid. 
 
C42H45N2OPSSi (684.95 g/mol): 
MP: 94-95 °C. 
TLC: Rf = 0.55 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (500 MHz, CD2Cl2): δ/ppm = 8.79-8.69 (m, 1H, ar-H), 8.65-8.58 (m, 1H, ar-H), 7.93-
7.76 (m, 5H, ar-H*, NH*), 7.69-7.60 (m, 2H, ar-H), 7.55-7.36 (m, 8H, ar-H), 7.31 (t, 3JHH = 7.5 Hz, 
1H, ar-H), 7.23-7.17 (m, 3H, ar-H), 7.14-7.10 (m, 2H, ar-H), 7.03-6.96 (m, 2H, ar-H), 6.42 (d, 
3JHH = 8.4 Hz, 1H, NH), 5.35 (s, 1H, Ph-CH), 4.66 (s, 1H, NCH), 2.64-2.51 (m, 2H, PCH2), 0.76 (s, 
9H, SiC(CH3)3), 0.05 (s, 3H, SiCH3), −0.20 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.7, 142.0, 136.5, 136.3, 136.1, 135.9, 135.8, 135.7, 
135.1 (d, JCP = 14.5 Hz), 134.3 (d, JCP = 1.7 Hz), 134.2 (d, JCP = 2.0 Hz), 132.3, 131.0, 130.7, 
123.0 (d, J = 11.7 Hz), 129.3 (d, JCP = 9.2 Hz), 128.4, 128.0, 126.9 (d, JCP = 2.5 Hz), 126.8 (d, JCP 
= 1.9 Hz), 126.6, 126.5 (d, JCP = 1.4 Hz), 126.5 (d, JCP = 1.5 Hz), 126.4, 126.3, 126.2 (d, 
JCP = 1.5 Hz), 126.0, 74.5, 59.9 (d, JCP = 17.0 Hz), 30.4 (d, JCP = 15.5 Hz), 26.2, 18.5, −4.3, −4.4. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −50.1. 
IR (ATR): 𝑣𝑣�/cm-1 = 3369 (w), 3169 (w), 3052 (w), 2950 (w), 2925 (w), 2853 (w), 1590 (s), 1495 (m), 
1379 (w), 1316 (w), 1249 (m), 1185 (w), 1090 (m), 1065 (m), 833 (m), 771 (s), 695 (m), 498 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C42H45N2OPSSi+: 685.2832 [M+H]+; found: 
685.2832. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +12.6 (c = 0.62, CH2Cl2). 
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1-((1S,2R)-3-(Di(naphthalen-1-yl)phosphanyl)-1-hydroxy-1-phenylpropan-2-yl)-3-(4-
fluorophenyl)thiourea (47e) 
OH
HN
P
NH
S
F  
According to general procedure GP1, (1S,2R)-2-amino-3-( di(naphthalen-1-yl phosphanyl)-1-
phenylpropan-1-ol (40c) (145 mg, 333 µmol), 4-fluorophenyl isothiocyanate (54.7 mg, 350 µmol), 
CH2Cl2 (1 mL) were stirred for 16 hours and the crude product was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (4:1), d x h: 3.5 x 13 cm) to afford the product 
47e (153 mg, 260 µmol, 78%) as a white solid. 
 
C36H30FN2OPS (588,68): 
MP: 141-142 °C. 
TLC: Rf = 0.35 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (500 MHz, CDCl3): δ/ppm = 8.55-8.50 (m, 1H, ar-H), 8.41 (dd, 3JHH = 8.4 Hz, 4JHH = 4.4 Hz, 
1H, ar-H), 7.77-7.74 (m, 3H, ar-H), 7.72-7.65 (m, 3H, ar-H), 7.40-7.31 (m, 5H, ar-H), 7.27-7.20 (m, 
2H, ar-H), 7.17-7.12 (m, 3H, ar-H), 7.06-7.03 (m, 2H, ar-H), 6.84-6.80 (m, 2H, ar-H), 6.76-6.72 (m, 
2H, ar-H), 6.29 (br s, 1H, NH), 5.14 (br s, 1H, Ph-CH), 4.88 (br s, 1H, NCH), 3.12 (br s, 1H, OH), 
2.61-2.51 (m, 2H, PCH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 180.8, 162.6, 160.2, 141.2, 135.4 (d, JCP = 4.3 Hz), 
135.2 (d, JCP = 4.5 Hz), 133.7 (d, JCP = 4.9 Hz), 131.7, 131.5, 131.1, 129.9 (d, JCP = 9.0 Hz), 129.0, 
128.5, 128.00, 127.8 (d, JCP = 8.5 Hz), 126.6 (d, JCP = 5.4 Hz), 126.2, 126.1, 126.0 (d, 
JCP = 1.9 Hz), 125.9, 125.8, 125.6 (d, JCP = 5.0 Hz), 116.8 (d, JCP = 22.9 Hz), 74.7 (d, 
JCP = 10.1 Hz), 58.9 (d, JCP = 16.0 Hz), 29.4 (d, JCP = 13.4 Hz). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −46.9. 
19F{1H} NMR (376 MHz, CDCl3): δ/ppm = −113.3. 
IR (ATR): 𝑣𝑣�/cm-1 = 3398 (w), 3355 (m), 3261 (w), 3043 (w), 1508 (s), 1478 (s), 1373 (w), 1218 (m), 
1089 (w), 1020 (m), 826 (w), 796 (s), 771 (s), 739 (s), 698 (m), 640 (w), 537 (w), 486 (w), 439 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C30H30FNOPS+: 589.1873 [M+H]+; found: 
589.1883. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +12.4 (c = 0.92, CHCl3). 
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1-((1S,2R)-1-((tert-Butyldimethylsilyl)oxy)-3-(di(naphthalen-1-yl)phosphanyl)-1-phenyl 
propan-2-yl)-3-(4-fluorophenyl)thiourea (48e) 
OTBDMS
HN
P
NH
S
F  
According to general procedure GP4, 1-((1S,2R)-3-(di(naphthalen-1-yl)phosphanyl)-1-hydroxy-1-
phenylpropan-2-yl)-3-(4-fluorophenyl)thiourea (47e) (108 mg, 183 µmol), triethylamine (37.0 mg, 
51.0 µL, 366 µmol), TBDMS triflate (50.8 mg, 44.0 µL, 192 µmol), CH2Cl2 (1.8 mL) were stirred for 
six hours and the crude product was purified by column chromatography (SiO2, cyclohexane:ethyl 
acetate (10:1), d x h: 2 x 12 cm) to afford the product 48e (98 mg, 139 µmol, 76%) as a white 
solid. 
 
C42H44FN2OPSSi (702.94 g/mol): 
MP: 108-109 °C. 
TLC: Rf = 0.51 (SiO2, cyclohexane:ethyl acetate (4:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 8.76-8.68 (m, 1H, ar-H), 8.64-8.57 (m, 1H, ar-H), 7.92-
7.84 (m, 4H, ar-H, NH), 7.68-7.60 (m, 1H, ar-H), 7.55-7.37 (m, 7H, ar-H), 7.25-7.20 (m, 3H, ar-H), 
7.08 (d, 3JHH = 6.6 Hz, 4H, ar-H), 7.03-6.99 (m, 2H, ar-H), 6.28 (s, 1H, NH), 5.45 (s, 1H, Ph-CH), 
4.65 (s, 1H, NCH), 2.59 (d, 3JHH = 7.5 Hz, 2H, PCH2), 0.78 (s, 9H, SiC(CH3)3), 0.07 (s, 3H, SiCH3), 
−0.19 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 181.1, 163.4, 160.9, 141.9, 136.2 (d, JCP = 23.5 Hz), 
135.7 (d, JCP = 22.4 Hz), 134.2 (d, JCP = 4.7 Hz), 132.5, 132.3, 131.1, 130.2, 130.1, 129.4 (d, 
JCP = 9.2 Hz), 129.0 (d, JCP = 8.4 Hz), 128.4, 128.0, 126.9 (d, JCP = 4.7 Hz), 126.8, 126.6, 126.3, 
126.2, 126.0, 117.4 (d, JCP = 22.8 Hz), 74.4, 59.8 (d, JCP = 16.8 Hz), 30.3, 26.1, 18.4, −4.3, −4.4. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −50.1. 
19F{1H} NMR (376 MHz, CD2Cl2): δ/ppm = −114.1. 
IR (ATR): 𝑣𝑣�/cm-1 = 3366 (w), 3055 (w), 2950 (w), 2927 (w), 2854 (w), 1503 (s), 1251 (w), 1214 (m), 
1098 (m), 1065 (m), 958 (w), 833 (m), 795 (m), 771 (s), 700 (w), 508 (w), 422 (w). 
EA (C42H44FN2OPSSi) calc.: C 71.76, H 6.31, N 3.99; found: C 71.58, H 6.59, N 4.02. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +12.4 (c = 0.92, CHCl3). 
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1-((1S,2R)-3-(bis(3,5-Dimethylphenyl)phosphanyl)-1-hydroxy-1-phenylpropan-2-yl)-3-
phenylthiourea (47g) 
OH
HN
P
NH
S
 
According to general procedure GP1, (1S,2R)-2-amino-3-(bis(3,5-dimethylphenyl)phosphanyl)-1-
phenylpropan-1-ol (40f) (152 mg, 388 µmol), phenyl isothiocyanate (58.9 mg, 52.0 µL, 427 µmol), 
CH2Cl2 (1.5 mL) were stirred for 16 hours and the crude product was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (5:1), d x h: 2.5 x 16 cm) to afford the product 
47g (195 mg, 370 µmol, 95%) as a white solid. 
 
C32H35N2OPS (526,68 g/mol): 
MP: 86-87 °C. 
TLC: Rf = 0.43 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.86-7.51 (br m, 1H, NH), 7.31-7.15 (m, 6H, ar-H), 7.11-
7.04 (m, 4H, ar-H), 6.95 (d, 3JHH = 8.3 Hz, 2H, ar-H), 6.88 (d, 3JHH = 8.6 Hz, 4H, ar-H), 6.41 (br s, 
1H, NH), 5.03-4.97 (m, 1H, Ph-CH), 4.84-4.69 (m, 1H, NCH), 3.13-2.84 (br m, 1H, OH), 2.48-
2.34 (m, 2H, PCH2), 2.21 (s, 6H, ar-CH3), 2.19 (s, 6H, ar-CH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 180.4, 141.3, 138.2 (d, JCP = 3.4 Hz), 138.1 (d, 
JCP = 3.4 Hz), 136.0, 131.0 (d, JCP = 6.1 Hz), 130.7, 130.7, 130.6, 130.5, 130.0, 128.5, 127.8, 
127.2, 126.2, 125.2, 74.9 (d, 3JCP = 8.7 Hz), 59.1 (d, 2JCP = 14.4 Hz), 30.5 (d, 1JCP = 13.7 Hz), 21.5, 
21.4. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −24.6. 
IR (ATR): 𝑣𝑣�/cm-1 = 3360 (w), 3022 (w), 1596 (m), 1517 (s), 1494 (s), 1448 (m), 1375 (w), 1296 (w), 
1235 (w), 1184 (m), 1028 (w), 935 (w), 842 (s), 737 (s), 692 (s), 603 (w), 493 (w). 
EA (C32H35N2OPS) calc.: C 72.98, H 6.70, N 5.32; found: C 72.70, H 6.72, N 5.36. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −0.3 (c = 0.78, CHCl3). 
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1-((1S,2R)-3-(bis(3,5-Dimethylphenyl)phosphanyl)-1-((tert-butyldimethylsilyl)oxy)-1-
phenylpropan-2-yl)-3-phenylthiourea (48g) 
OTBDMS
HN
P
NH
S
 
According to general procedure GP4, 1-((1S,2R)-3-(bis(3,5-dimethylphenyl)phosphanyl)-1-
hydroxy-1-phenylpropan-2-yl)-3-phenylthiourea (47g) (100 mg, 190 µmol), DIPEA (74.8 mg, 
95.5 µL, 579 µmol), TBDMS triflate (55.0 mg, 47.5 µL, 208 µmol), CH2Cl2 (2.0 mL) were stirred for 
six hours and the crude product was purified by column chromatography (SiO2, cyclohexane:ethyl 
acetate (10:1), d x h: 2 x 13 cm) to afford the product 48g (107 mg, 167 µmol, 88%) as a white 
solid. 
 
C38H49N2OPSSi (640.94 g/mol): 
MP: 66-67 °C. 
TLC: Rf = 0.38 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 8.03 (br s, 1H, NH), 7.42 (t, 3JHH = 7.7 Hz, 2H, ar-H), 7.35-
7.19 (m, 6H, ar-H), 7.17-6.95 (m, 8H, ar-H), 6.56 (br s, 1H, NH); 5.31 (s, 1H, Ph-CH), 4.52 (s, 1H, 
NCH), 2.66-2.57 (m, 1H, PCH2), 2.40-2.20 (m, 13H, CH2, ar-CH3), 0.79 (s, 9H, SiC(CH3)3), 0.08 
(s, 3H, SiCH3), −0.20 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.1, 142.2, 138.5, 138.4, 138.3, 136.6, 131.5, 131.3, 
130.7, 130.5, 130.4, 128.2, 127.7, 127.6, 126.5, 126.0, 74.1 (d, JCP = 12.0 Hz), 60.0 (d, 
JCP = 18.0 Hz), 30.7, 26.0, 21.4, 18.3, −4.5. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −25.4. 
IR (ATR): 𝑣𝑣�/cm-1 = 3370 (w), 3167 (w), 2927 (m), 2855 (m), 1597 (m), 1513 (s), 1469 (m), 1377 (w), 
1314 (w), 1250 (s), 1187 (w), 1093 (s), 1037 (w), 961 (m), 837 (s), 778 (s), 739 (s), 694 (s). 
EA (C38H49N2OPSSi) calc.: C 71.21, H 7.71, N 4.37; found: C 70.86, H 7.66, N 4.43. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +63.3 (c = 1.00, CH2Cl2). 
 
  
EXPERIMENTAL PART            CHAPTER 5 
228 
1-((1S,2R)-3-(bis(3,5-di-tert-Butylphenyl)phosphanyl)-1-hydroxy-1-phenylpropan-2-yl)-3-
phenylthiourea (47h) 
OH
HN
P
NH
S
 
According to general procedure GP1, (1S,2R)-2-amino-3-(bis(3,5-di-tert-butylphenyl)-
phosphanyl)-1-phenylpropan-1-ol (40d) (100 mg, 179 µmol), phenyl isothiocyanate (24.7 mg, 
22.0 µL, 179 µmol), CH2Cl2 (0.6 mL) were stirred for 16 hours and the crude was purified by 
column chromatography (SiO2, cyclohexane:ethyl acetate (5:1), d x h: 2.5 x 13 cm) to afford the 
product 47h (81.0 mg, 117 µmol, 65%) as a white solid. 
 
C44H59N2OPS (695.00 g/mol): 
MP: 95-96 °C. 
TLC: Rf = 0.33 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.70-7-65 (br m, 1H, NH), 7.46-7.40 (m, 2H, ar-H), 7.39-
7.22 (m, 12H, ar-H), 7.19-7.11 (m, 2H, ar-H), 6.97 (d, 3JHH = 7.7 Hz, 1H, ar-H), 6.51 (d, 
3JHH = 8.1 Hz, 1H, NH), 5.16-5.12 (br m, 1H, Ph-CH), 4.94-4.83 (br m, 1H, NCH), 2.93 (br s, 1H, 
OH), 2.62 (dd, 2JHP = 14.1 Hz, 3JHH = 6.5 Hz, 1H, PCH2), 2.53 (dd, 2JHP = 14.1 Hz, 3JHH = 7.7 Hz, 
1H, PCH2), 1.32 (s, 18H, ar-C(CH3)3), 1.31 (s, 18H, ar-C(CH3)3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 180.4, 151.0 (d, JCP = 3.2 Hz), 150.9 (d, JCP = 3.0 Hz), 
141.3, 136.5 (d, JCP = 9.9 Hz), 136.0 (d, JCP = 5.0 Hz), 135.9, 130.1, 128.5, 127.8, 127.6, 127.4, 
127.2, 127.0, 126.1, 125.3, 123.3 (d, JCP = 8.8 Hz), 74.8 (d, JCP = 9.5 Hz), 59.4 (d, JCP = 14.7 Hz), 
35.1, 31.6, 31.3 (d, JCP = 15.7 Hz). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −21.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 3362 (w), 3021 (w), 1599 (m), 1527 (s), 1496 (s), 1446 (m), 1296 (w), 1233 (w), 
1184 (m), 938 (w), 842 (s), 737 (s), 692 (s), 493 (w). 
EA (C44H59N2OPS) calc.: C 76.04, H 8.56, N 4.03; found: C 76.01, H 8.49, N 3.95. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −7.3 (c = 0.92, CHCl3). 
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1-((1S,2R)-3-(bis(3,5-di-tert-Butylphenyl)phosphanyl)-1-((tert-butyldimethylsilyl)oxy)-1-
phenylpropan-2-yl)-3-phenylthiourea (48h) 
OTBDMS
HN
P
NH
S
 
According to general procedure GP4, 1-((1S,2R)-3-(bis(3,5-di-tert-butylphenyl)phosphanyl)-1-
hydroxy-1-phenylpropan-2-yl)-3-phenylthiourea (47h) (53.0 mg, 76.3 µmol), triethylamine 
(15.4 mg, 21.5 µL, 153 µmol), TBDMS triflate (21.2 mg, 18.5 µL, 80.1 µmol), CH2Cl2 (0.9 mL) were 
stirred for six hours and the crude product was purified by column chromatography (SiO2, 
cyclohexane:ethyl acetate (10:1), d x h: 2 x 13 cm) to afford the product 48h (50.0 mg, 62.0 µmol, 
81%) as a white solid. 
 
C50H73N2OPSSi (809.27 g/mol): 
MP: 86-87 °C. 
TLC: Rf = 0.49 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (500 MHz, CD2Cl2): δ/ppm = 7.62 (br s, 1H, NH), 7.52 (d, 3JHH = 8.4 Hz, 2H, ar-H), 7.48 (s, 
1H, ar-H), 7.44-7.36 (m, 3H, ar-H), 7.34-7.19 (m, 6H, ar-H), 7.10-6.98 (m, 4H, ar-H), 6.46 (d, 3JHH 
= 8.6 Hz, 1H, NH), 5.29 (s, 1H, Ph-CH), 4.68-4.54 (m, 1H, NCH), 2.74-2.63 (m, 1H, PCH2), 2.36-
2.23 (m, 1H, PCH2), 1.32 (s, 18H, ar-C(CH3)3), 1.29 (s, 18H, ar-C(CH3)3), 0.76 (s, 9H, SiC(CH3)3), 
0.07 (s, 3H, SiCH3), −0.21 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.5, 151.4 (d, JCP = 7.5 Hz), 151.2 (d, JCP = 6.8 Hz), 
142.5, 136.7, 136.4, 130.7, 128.7, 128.4, 128.4, 127.9, 127.8, 127.4, 127.2, 126.7, 126.2, 124.1, 
123.2, 74.7 (d, JCP = 8.6 Hz), 60.6 (d, JCP = 17.0 Hz), 35.5 (d, JCP = 4.9 Hz), 31.8, 31.8, 26.2, 18.5, 
−4.3. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −22.0. 
IR (ATR): 𝑣𝑣�/cm-1 = 3375 (w), 3183 (w), 2952 (s), 1588 (m), 1496 (s), 1361 (m), 1247 (s), 1093 (m), 
1067 (m), 958 (w), 833 (s), 777 (s), 737 (m), 696 (s), 502 (w), 423 (w). 
EA (C50H73N2OPSSi) calc.: C 74.21, H 9.09, N 3.46; found: C 74.10, H 9.18, N 3.51. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +53.4 (c = 0.64, CH2Cl2). 
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1-((1S,2R)-3-(Diphenylphosphanyl)-1-phenyl-1-((trimethylsilyl)oxy)propan-2-yl)-3-
phenylthiourea (49a) 
OTMS
HN
P
HN
S
 
According to general procedure GP4, 1-((1S,2R)-3-(diphenylphosphanyl)-1-hydroxy-1-phenyl-
propan-2-yl)-3-phenylthiourea (45a) (30.0 mg, 63.8 µmol), DIPEA (24.7 mg, 31.6 µL, 191 µmol), 
TMS triflate (28.3 mg, 23.1 µL, 128 µmol), CH2Cl2 (0.5 mL) were stirred for six hours and the crude 
product was purified by column chromatography (SiO2, cyclohexane:ethyl acetate (100:0 to 10:1), 
d x h: 2 x 17 cm) to afford the product 49a (28.0 mg, 52 µmol, 81%) as a white solid. 
 
C31H35N2OPSSi (584.83 g/mol): 
MP: 56.57 °C. 
TLC: Rf = 0.10 (SiO2, cyclohexane:ethyl acetate (10:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.63 (br s, 2H, ar-H), 7.54 (br s, 1H, NH), 7.47-7.42 (m, 2H, 
ar-H), 7.38-7.32 (m, 6H, ar-H), 7.30-7.23 (m, 3H, ar-H), 7.14-7.04 (m, 7H, ar-H), 6.36 (s, 1H, NH), 
5.30 (s, 1H, Ph-CH), 4.53 (s, 1H, NCH), 2.56-2.47 (m, 1H, PCH2), 2.37-2.29 (m, 1H, PCH2), 0.01 
(s, 9H, Si(CH3)3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.8, 142.2, 137.9, 133.8 (d, JCP = 19.6 Hz), 133.3 (d, 
JCP = 18.8 Hz), 132.6, 129.6, 129.2, 129.1, 129.0, 128.9, 128.5, 128.0, 126.6, 126.4, 117.2 (d, 
JCP = 22.4 Hz), 74.1, 59.9 (d, JCP = 16.7 Hz), 31.0, 0.3. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −24.5. 
IR (ATR): 𝑣𝑣�/cm-1 = 3368 (w), 3171 (w), 2954 (w), 2901 (w), 1504 (s), 1305 (m), 1250 (m), 1214 (s), 
1186 (w), 1152 (w), 1090 (m), 1066 (m), 957 (w), 834 (s), 734 (m), 694 (m), 632 (m), 505 (m). [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +6.4 (c = 0.59, MeOH). 
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1-((1S,2R)-3-(Diphenylphosphanyl)-1-phenyl-1-((triisopropylsilyl)oxy)propan-2-yl)-3-
phenylthiourea (49b) 
OTIPS
HN
P
HN
S
 
According to general procedure GP4, 1-((1S,2R)-3-(diphenylphosphanyl)-1-hydroxy-1-phenyl-
propan-2-yl)-3-phenylthiourea (45a) (35.0 mg, 74.4 µmol), DIPEA (28.8 mg, 36.9 µL, 223 µmol), 
TIPS triflate (47.0 mg, 41.2 µL, 149 µmol), CH2Cl2 (0.5 mL) were stirred for six hours and the crude 
product was purified by column chromatography (SiO2, cyclohexane:ethyl acetate (100:0 to 10:1), 
d x h: 2 x 17 cm) to afford the product 49b (42.0 mg, 67 µmol, 90%) as a white solid. 
 
C37H47N2OPSSi (626.91 g/mol): 
MP: 63-64 °C. 
TLC: Rf = 0.14 (SiO2, cyclohexane:ethyl acetate (10:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = δ 7.86 (s, 1H, NH), 7.51-7.44 (m, 4H, ar-H), 7.38-7.31 (m, 
8H, ar-H), 7.30-7.20 (m, 4H, ar-H), 7.17-7.14 (m, 2H, ar-H), 7.09 (d, 3JHH = 7.6 Hz, 2H, ar-H), 6.03 
(d, 3JHH = 8.7 Hz, 1H, NH), 5.36 (d, 3JHH = 3.4 Hz, 1H, Ph-CH), 4.72 (br s, 1H, NCH), 2.65 (dd, 
2JHP = 13.9 Hz, 3JHH = 5.6 Hz, 1H, PCH2), 2.09 (dd, 2JHP = 13.9 Hz, 3JHH = 9.5 Hz, 1H, PCH2), 1.03-
0.88 (m, 21H, TIPS). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.6, 141.6, 139.1 (d, JCP = 13.5 Hz), 138.8 (d, 
JCP = 12.5 Hz), 136.4, 133.6 (d, JCP = 8.4 Hz), 133.4 (d, JCP = 8.6 Hz), 130.6, 129.3, 129.1, 129.0, 
128.3, 128.1, 127.8, 127.3, 126.1, 74.7, 59.3 (d, JCP = 16.4 Hz), 29.9 (d, JCP = 13.9 Hz), 18.4, 18.3, 
12.9. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −23.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 3371 (w), 3187 (w), 3053 (w), 2941 (m), 2863 (m), 1522 (s), 1495 (s), 1316 (w), 
1242 (m), 1096 (s), 1063 (s), 1025 (m), 881 (m), 840 (w), 734 (s), 692 (s), 574 (w), 496 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C37H47N2OPSSi+: 627.2989 [M+H]+; found: 
627.2988. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −14.3 (c = 0.69, MeOH). 
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1-((1S,2R)-1-(((2,3-Dimethylbutan-2-yl)dimethylsilyl)oxy)-3-(diphenylphosphanyl)-1-
phenylpropan-2-yl)-3-phenylthiourea (49c) 
O
HN
P
HN
S
Si
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with 1-((1S,2R)-3-
(diphenylphosphanyl)-1-hydroxy-1-phenylpropan-2-yl)-3-phenylthiourea (45a) (100 mg, 
213 µmol) and THF (1.5 mL). The corresponding solution was cooled in an ice bath and at 0 °C 
sodium hydride (60% in mineral oil, 20.4 mg, 850 µmol) was added in one portion. The reaction 
mixture was stirred for 30 minutes at 0 °C and then chloro(dimethyl)thexylsilane (57.3 mg, 63.0 µL, 
320 µmol) was added drowise over 5 minutes. The corresponding reaction mixture was stirred for 
16 hours at room temperature and then quenched by water (5 mL). The biphasic mixture was 
extracted with EtOAc (3 x 20 mL) and the combined organic layers were washed with brine 
(20 mL), dried over Na2SO4, filtered, concentrated under vacuum and the crude product was 
purified by column chromatography (SiO2, cyclohexane:ethyl acetate (10:1), d x h: 2 x 13 cm) to 
afford the product 49c (69.9 mg, 114 µmol, 54%) as a white solid.  
 
C36H45N2OPSSi (612.89 g/mol): 
MP: 59-60 °C. 
TLC: Rf = 0.40 (SiO2, cyclohexane:ethyl acetate (10:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.68-7.61 (m, 2H, ar-H), 7.52-7.23 (m, 14H, ar-H), 7.17-
7.06 (m, 4H, ar-H), 6.46 (s, 1H, NH), 5.28 (s, 1H, Ph-CH), 4.59 (s, 1H, nCH), 2.56-2.48 (m, 1H, 
PCH2), 2.44-2.37 (m, 1H, PCH2), 1.51 (p, 3JHH = 6.9 Hz, 1H, CH(CH3)2), 0.79-0.72 (m, 11H, TDS-
CH3), 0.11 (s, 4H, TDS-CH3), −0.21 (s, 3H, TDS-CH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.6, 142.2, 138.0 (d, JCP = 12.8 Hz), 136.4, 133.9 (d, 
JCP = 19.8 Hz), 133.2 (d, JCP = 18.8 Hz), 130.7, 129.5, 129.1, 129.1, 129.0, 128.9, 128.4, 127.9, 
126.8, 126.4, 74.6, 60.1 (d, JCP = 16.9 Hz), 34.4, 31.1 (d, JCP = 15.1 Hz), 25.5, 20.7, 20.5, 19.0, 
18.8, −1.2, −2.1. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −24.4. 
IR (ATR): 𝑣𝑣�/cm-1 = 3369 (w), 3157 (w), 2955 (m), 2864 (w), 1494 (m), 1433 (m), 1376 (w), 
1315 (w), 1249 (m), 1087 (m), 1064 (m), 956 (w), 825 (s), 775 (m), 733 (s), 692 (s), 492 (m). 
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HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C36H45N2OPSSi+: 613.2832 [M+H]+; found: 
613.2833. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +1.7 (c = 0.57, MeOH). 
 
tert-Butyl (4R,5S)-4-((dicyclohexylphosphanyl)methyl)-2,2-dimethyl-5-phenyloxazolidine-
3-carboxylate·BH3 (50) 
O NBoc
PCy2
BH3
 
Under argon atmosphere, a heat gun dried two-necked flask was charged with borane 
dicyclohexylphosphine complex (165 mg, 778 µmol), potassium hydride (95%, 32.9 mg, 778 µmol) 
and THF (2 mL). The corresponding mixture was stirred for two hours at 0 °C and afterwards tert-
butyl (4S,5S)-2,2-dimethyl-4-(((methylsulfonyl)oxy)methyl)-5-phenyloxazolidine-3-carboxylate 
(34) (200 mg, 519 µmol) was added in one portion at 0 °C. The reaction mixture was stirred for 
30 minutes at 0 °C and additional 16 hours at room temperature. Then, water (20 mL) was added 
dropwise to the reaction mixture and the resulting biphasic solution was extracted with EtOAc (3 x 
20 mL). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered, 
concentrated under vacuum and the crude product was purified by column chromatography (SiO2, 
cyclohexane:ethyl acetate (50:1), d x h: 3.5 x 13 cm) to afford the product 50 (187.0 mg, 372 µmol, 
72%) as a white solid. 
 
C29H49BNO3 (501.50 g/mol): 
MP: 150-151 °C. 
TLC: Rf = 0.25 (SiO2, cyclohexane:ethyl acetate (50:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = δ 7.45 (d, 3JHH = 7.0 Hz, 2H, ar-H), 7.34 (t, 3JHH = 7.4 Hz, 
2H, ar-H), 7.28 (t, 3JHH = 7.2 Hz, 1H, ar-H), 5.19 (br s, 1H, Ph-CH), 4.76-4.69 (m, 1H, NCH), 2.24-
1.66 (m, 16H, cy-CH2, cy-CH, PCH2), 1.58 (s, 3H, C(CH3)2), 1.53-1.44 (m, 10H, cy-CH2, cy-CH, 
C(CH3)2), 1.37-1.24 (m, 10. cy-CH2, cy-CH, C(CH3)3), 0.63-−0.15 (br m, 3H, BH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 152.1, 140.9, 128.7, 128.2, 127.8, 81.8, 80.9, 58.1, 
33.8-33.1 (m), 32.7-31.9 (m), 29.3-28.4 (m), 27.9-26.4 (m), 24.5-23.6 (m). 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = 20.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 2930 (m), 2853 (w), 2366 (w), 2337 (w), 1683 (s), 1449 (m), 1364 (s), 1250 (m), 
1170 (m), 1135 (m), 1101 (m), 1061 (m), 1015 (m), 849 (w), 735 (m), 697 (m), 621 (w), 536 (w). 
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HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C29H49BNO3+: 524.3440 [M+Na]+; found: 
524.3449. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −17.0 (c = 0.13, CH2Cl2). 
 
1-((1S,2R)-3-(Dicyclohexylphosphanyl)-1-hydroxy-1-phenylpropan-2-yl)-3-phenyl-
thiourea·BH3 (51) 
OH
HN
P
HN
S
H3B
 
Under argon atmosphere, a heat gun dried two-necked flasked was charged with tert-butyl 
(4R,5S)-4-((dicyclohexylphosphanyl)methyl)-2,2-dimethyl-5-phenyloxazolidine-3-carboxylate BH3 
(50) (259 mg, 516 µmol) and THF (2 mL). Afterwards the reaction mixture was cooled to 0 °C in 
an ice-bath and then at 0 °C concentrated HCl solution (37%, 1.02 g, 0.88 mL, 10.3 mmol) was 
added dropwise to the reaction mixture. After addition, the mixture was stirred for 16 hours at room 
temperature. Then, the crude product was concentrated under vacuum to yield the corresponding 
hydrochloride amino phosphine adduct which was directly used for the next step. 
The crude amino phosphine from the previous step was dissolved in water (3 mL) and CH2Cl2 
(5 mL) followed by phenyl isothiocyanate addition (109 mg, 96.3 µL, 789 µmol). Then, potassium 
carbonate (713 mg, 5.16 mmol) was added over 15 mintues at 0 °C. After addition, the reaction 
mixture was stirred at room temperature for 16 hours. Afterwards the crude product was diluted 
with water (10 mL) and the biphasic mixture was extracted with CH2Cl2 (3 x 20 mL). The combined 
organic layers were washed with brine (20 mL), dried over Na2SO4, concentrated under vacuum 
and the crude product was purified by column chromatography (SiO2, cyclohexane:ethyl acetate 
(4:1), d x h: 3.5 x 23 cm) to afford the product 51 (210 mg, 423 µmol, 82%) as a white solid. 31P-
NMR analysis of the purified product showed that a mixture of borane-protected and free 
phosphine of 1:3 was isolated. The different products were not separated because of similarl Rf 
value. 
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C28H42N2BN2OPS (496.51 g/mol): 
MP: 81-82 °C. 
TLC: Rf = 0.30 (SiO2, cyclohexane:ethyl acetate (4:1)). 
1H NMR (400 MHz, CDCl3) of borane-phosphine: δ/ppm = 7.79-7.57 (br m, 1H, NH), 7.40-7.15 (m, 
8H, ar-H), 6.85 (d, 3JHH = 7.7 Hz, 2H, ar-H), 6.39 (d, 3JHH = 7.5 Hz, 1H, NH), 5.38 (s, 1H, Ph-CH), 
4.78 (s, 1H, NCH), 2.86-2.68 (br m, 1H, OH), 2.34-2.18 (m, 1H, PCH2), 2.06-1.88 (m, 1H, PCH2), 
1.85-1.39 (m, 10H, cy-CH2, cy-CH), 1.31-0.94 (m, 12H, cy-CH2), 0.78-0.16 (br m, 3H, BH3). 
1H NMR (400 MHz, CDCl3) of free phosphine δ/ppm = 7.79-7.57 (br m, 1H, NH), 7.40-7.15 (m, 
8H, ar-H), 7.01 (d, 3JHH = 7.7 Hz, 2H, ar-H), 6.45 (d, 3JHH = 8.1 Hz, 1H, NH), 5.09 (s, 1H, Ph-CH), 
4.65 (s, 1H, NCH), 3.19-3.04 (br m, 1H, OH), 2.06-1.88 (m, 1H, PCH2), 1.85-1.39 (m, 11H, PCH2, 
cy-CH2, cy-CH), 1.31-0.94 (m, 12H, cy-CH2). 
13C{1H} NMR (101 MHz, CDCl3) of the mixture: δ/ppm = 180.2, 179.9, 141.8, 141.2, 136.0, 135.8, 
130.1, 128.5, 128.5, 127.8, 127.5, 127.3, 126.1, 125.7, 125.5, 125.5, 74.7, 72.5, 60.2 (d, 
JCP = 19.1 Hz), 57.8, 33.4 (d, JCP = 10.7 Hz), 33.0 (d, JCP = 11.0 Hz), 32.9, 32.6, 32.3, 30.2 (d, 
JCP = 10.2 Hz), 30.1 (d, JCP = 9.9 Hz), 29.0 (d, JCP = 8.2 Hz), 28.7 (d, JCP = 7.4 Hz), 27.5, 27.5, 
27.4, 27.3, 27.3, 27.2, 27.1, 27.0, 27.0, 26.9, 26.8, 26.7, 26.6, 26.5, 26.1 (d, JCP = 10.7 Hz), 24.2, 
24.0, 21.8, 21.6. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = 19.6 (borane-protected phosphine), −13.5 (free 
phosphine). 
IR (ATR): 𝑣𝑣�/cm-1 = 3364 (w), 2920 (m), 2848 (m), 1595 (w), 1517 (s), 1495 (s), 1446 (m), 1235 (m), 
1180 (m), 1060 (m), 739 (s), 695 (s), 603 (w), 493 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C28H42N2BN2OPS+: 519.2746 [M+Na]+; 
found: 519.2738. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +21.3 (c = 0.81, MeOH). 
 
1-((1S,2R)-1-((tert-Butyldimethylsilyl)oxy)-3-(dicyclohexylphosphanyl)-1-phenylpropan-2-
yl)-3-phenylthiourea (52) 
OTBDMS
HN
P
HN
S
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Under argon atmosphere, a heat-gun dried Schlenk flask was charged with 1-((1S,2R)-3-
(dicyclohexylphosphanyl)-1-hydroxy-1-phenylpropan-2-yl)-3-phenyl-thiourea·BH3 (51) (144 mg, 
290 µmol) and diethylamine (1.42 g, 2.00 mL, 19.4 mmol). Then, the reaction mixture was 
degassed three-times by freeze-pump-thaw method. After degassing, the reaction solution was 
stirred for five days at 55 °C and afterwards the mixture was concentrated under vacuum. The 
corresponding white solid was dissolved in ether (40 mL) and the organic layer was washed with 
water (20 mL), brine (20 mL), dried over Na2SO4, filtered, concentrated under vacuum and the 
crude phosphine was directly used for the next step without any further purification step.  
Under argon atmosphere, a heat-gun dried two-neckeded flask was charged with the crude 
phosphine (140 mg, 290 µmol), CH2Cl2 (2 mL) and the reaction mixture was cooled in an ice-bath. 
At 0 °C, DIPEA (112 mg, 144 µL, 870 µmol) was added followed by dropwise addition of TBDMS 
triflate (81.3 mg, 70.7 µL, 307 µmol) over 10 minutes. After completed addition, the reaction 
mixture was stirred for two hours at 0 °C and 16 hours at room temperature. Then, the mixture 
was concentrated under vacuum and the crude product was purified by column chromatography 
(SiO2, cyclohexane:ethyl acetate (7:1), d x h: 2.5 x 14 cm) to afford the product 52 (87.0 mg, 
146 µmol, 50%) as a white solid. 
 
C34H53N2OPSSi (596.93 g/mol): 
MP: 79-80 °C. 
TLC: Rf = 0.26 (SiO2, cyclohexane:ethyl acetate (7:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.71 (s, 1H, NH), 7.44 (t, 3JHH = 7.6 Hz, 2H, ar-H), 7.33-
7.23 (m, 6H, ar-H), 7.16 (d, 3JHH = 7.2 Hz, 2H, ar-H), 6.39 (s, 1H, NH), 5.26 (s, 1H, Ph-CH), 4.52 (s, 
1H, NCH), 1.82-1.53 (m, 13H, PCH2, cy-CH2, cy-H), 1.33-1.15 (m, 3H, cy-CH2, cy-H), 0.78 (s, 9H, 
SiC(CH3)3), 0.07 (s, 3H, SiCH3), −0.25 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.5, 142.6, 136.7, 130.7, 128.4, 127.9, 126.9, 126.4, 
74.3 (d, 3JCP = 10.1 Hz), 61.0 (d, 2JCP = 19.7 Hz), 34.2 (d, JCP = 12.6 Hz), 33.8 (d, JCP = 13.4 Hz), 
30.9 (d, JCP = 14.2 Hz), 30.7 (d, JCP = 13.0 Hz), 30.2 (d, JCP = 9.9 Hz), 29.8 (d, JCP = 8.8 Hz), 28.2, 
28.0, 28.0, 27.9, 27.8 (d, JCP = 3.2 Hz), 27.1, 26.2, 18.4, −4.2, −4.4. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −14.5. 
IR (ATR): 𝑣𝑣�/cm-1 = 3371 (w), 3169 (w), 2922 (m), 2849 (w), 1496 (s), 1446 (m), 1248 (m), 1183 (w), 
1089 (m), 1064 (m), 958 (w), 835 (s), 776 (s), 744 (m), 696 (s), 557 (w), 504 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C34H53N2OPSSi+: 597.3458 [M+H]+; found: 
597.3460. [𝛼𝛼]𝐷𝐷20 = +37.3 (c = 0.60, MeOH). 
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tert-Butyl (4S,5S)-5-cyclohexyl-2,2-dimethyl-4-(((methylsulfonyl)oxy)methyl)oxazolidine-3-
carboxylate (53) 
O NBoc
OMs
 
An autoclave inlet was charged with tert-butyl (4S,5S)-4-(hydroxymethyl)-2,2-dimethyl-5-
phenyloxazolidine-3-carboxylate (34) (300 mg, 778 µmol), rhodium on activated carbon (5% Rh 
basis, 87 mg) and MeOH (3 mL). Then, the autoclave was pressurized to 5 bar with H2 and the 
reaction mixture stirred for 16 hours at room temperature. Afterwards, the crude mixture was 
filtrated over Celite and concentrated under vacuum. The crude product was purified by flash 
column chromatography (SiO2, cyclohexane:ethyl acetate (3:1), 3.5 x 12 cm) to afford the product 
53 (290 mg, 741 µmol, 95%) as a white solid.  
 
C18H33NO6S (391.52 g/mol):  
MP: 85-86 °C. 
TLC: Rf = 0.56 (SiO2, cyclohexane:ethyl acetate (2:1)) 
1H NMR (400 MHz, DMSO-d6): δ/ppm = δ 4.40-4.31 (br m, 1H, NCH), 4.19 (s, 1H, OCH2), 3.89 (d, 
3JHH = 15.9 Hz, 1H, cy-CH), 3.70 (dd, 3JHH = 8.1 Hz, 2JHH = 4.3 Hz, 1H, OCH2), 3.20 (s, 3H, SCH3), 
1.85 (d, 3JHH = 12.9 Hz, 1H, cy-CH), 1.74-1.67 (m, 2H, cy-CH2), 1.65-1.58 (m, 2H, cy-CH2), 1.49 
(s, 3H, CH3), 1.43 (s, 9H, C(CH3)3), 1.41 (s, 3H, CH3), 1.28-1.06 (m, 4H, cy-CH2), 1.04-0.88 (m, 
2H, cy-CH2). 
13C{1H} NMR (DMSO-d6): δ/ppm = 151.1/150.6*, 93.7/93.3*, 81.2/80.3*, 79.9, 68.1/67.2*, 58.2, 
54.9, 40.6, 36.7, 29.0, 27.9, 26.9, 26.3, 25.9, 25.2, 25.1. [* refers to signal of rotamers] 
IR (ATR): 𝑣𝑣�/cm-1 = 2928 (m), 2851 (w), 1698 (s), 1385 (m), 1361 (s), 1255 (m), 1171 (s), 1115 (m), 
1075 (m), 973 (m), 957 (m), 852 (m), 818 (w), 771 (m), 719 (w), 526 (m). 
EA (C18H27NO6) calc.: C 55.22, H 8.50, N 3.58; found: C 55.23, H 8.24, N 3.71. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +13.6 (c = 0.54, MeOH). 
 
(1S,2R)-2-Amino-1-cyclohexyl-3-(diphenylphosphanyl)propan-1-ol (54) 
OH
NH2
P
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Under argon atmosphere, a heat-gun dried two-necked flask was charged with tert-butyl (4S,5S)-
5-cyclohexyl-2,2-dimethyl-4-(((methylsulfonyl)oxy)methyl)oxazolidine-3-carboxylate (53) 
(250 mg, 639 µmol) and THF (1.7 mL). Then, the reaction mixture was degassed three-times by 
freeze-pump-thaw method. At 0 °C potassium diphenylphosphide solution (0.5 M in THF, 1.66 g, 
1.8 mL, 0.9 mmol) was added dropwise over five minutes and afterwards the mixture was stirred 
two hours at 0 °C and two hours at room temperature. At ambient temperature, aqueous HCl 
(37%, 1.1 mL, 12.8 mmol) was added and then the mixture was stirred at room temperature for 
16 hours. The reaction mixture was adjusted to an alkaline pH (>10) by addition of degassed 
aqueous NaOH (2 M) and then the mixture was extracted with EtOAc (3 x 20 mL). The combined 
organic layers were dried over Na2SO4, filtered, concentrated under vacuum and the crude product 
was purified by flash column chromatography (SiO2, cyclohexane:ethyl acetate (1:5) + 5% NEt3, 
2.5 x 11 cm) to afford the product 54 (210 mg, 615 µmol, 96%) as a white solid. 
 
C21H28NOP (341.19 g/mol): 
MP: 83-84 °C. 
TLC: Rf = 0.33 (SiO2, cyclohexane:ethyl acetate (1:5) + 5% NEt3). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.53-7.29 (m, 10H, ar-H), 3.13 (t, 3JHH = 5.3 Hz, 1H, NCH), 
2.91-2.83 (m, 1H, cy-CH), 2.36 (ddd, 2JHP = 13.8 Hz, 3JHH = 4.2 Hz, 4JHH = 2.7 Hz, 1H, PCH2), 2.09 
(ddd, 2JHP = 13.8 Hz, 3JHH = 9.4 Hz, 4JHH = 2.7 Hz, 1H, PCH2), 1.99 (br s, 2H, NH2), 1.73-1.59 (m, 
4H, cy-CH2), 1.49 (d, 3JHH = 12.8 Hz, 1H, cy-CH), 1.40-1.28 (m, 1H, cy-CH2), 1.23-0.93 (m, 5H, 
cy-CH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 138.8 (d, JCP = 11.5 Hz), 137.9 (d, JCP = 12.3 Hz), 133.2 
(d, JCP = 19.2 Hz), 132.6 (d, JCP = 18.3 Hz), 130.8 (d, JCP = 11.4 Hz), 129.1, 129.1, 129.0, 128.7, 
128.7, 128.7, 128.6, 78.7 (d, JCP = 8.3 Hz), 49.4 (d, JCP = 13.7 Hz), 40.5, 35.4 (d, JCP = 11.9 Hz), 
30.0, 27.8, 26.5, 26.5, 26.2. 
31P NMR (162 MHz, CDCl3) δ/ppm: −22.7. 
IR (ATR): 𝑣𝑣�/cm-1 = 3215 (w), 2922 (m), 2856 (m), 1595 (m), 1429 (m), 1180 (w), 1095 (w), 942 (m), 
815 (w), 733 (s), 691 (s), 514 (m), 472 (s). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C21H28NOP+: 342.1981 [M+H]+; found: 
342.1984. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −20.6 (c = 0.60, MeOH). 
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1-((1S,2R)-3-(Diphenylphosphanyl)-1-hydroxy-1-cyclohexylpropan-2-yl)-3-phenylthiourea 
(55) 
OH
HN
P
HN
S
 
According to general procedure GP1, ((1S,2R)-2-amino-1-cyclohexyl-3-(diphenylphosphanyl)-
propan-1-ol (54) (70.0 mg, 205 µmol), phenyl isothiocyanate (33.9 mg, 30.0 µL, 246 µmol), CH2Cl2 
(1 mL) were stirred for 16 hours and the crude product was purified by column chromatography 
(SiO2, cyclohexane:ethyl acetate (4:1), d x h: 2.5 x 11 cm) to afford the product 55 (75.0 mg, 
157 µmol, 77%) as a white solid. 
 
C28H33N2OPS (476.62 g/mol): 
MP: 80-81 °C. 
TLC: Rf = 0.22 (SiO2, cyclohexane:ethyl acetate (4:1)). 
1H NMR (500 MHz, CDCl3): δ/ppm = 7.61-7.53 (m, 3H, NH, ar-H), 7.47-7.42 (m, 2H, ar-H), 7.42-
7.24 (m, 8H, ar-H), 7.28-7.20 (m, 1H, ar-H), 7.07-7.03 (m, 2H, ar-H), 6.64 (d, 3JHH = 8.3 Hz, 1H, 
NH), 4.78 (br s, 1H, NCH), 3.69 (d, 3JHH = 8.3 Hz, 1H, cy-CH), 2.63 (ddd, 2JHP = 13.8 Hz, 
3JHH = 5.2 Hz, 2JHH  = 2.6 Hz, 1H, PCH2), 2.46 (dd, 2JHP = 13.8, 3JHH = 8.9 Hz, 1H, PCH2), 2.06 (br 
s, 1H, OH), 1.80-1.59 (m, 5H, cy-CH2, cy-CH), 1.28-1.06 (m, 4H, cy-CH2), 0.96-0.77 (m, 2H, cy-
CH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 179.5, 138.5 (d, JCP = 10.7 Hz), 137.0 (d, JCP = 10.5 Hz), 
136.2, 133.2 (d, JCP = 19.2 Hz), 132.8 (d, JCP = 19.1 Hz), 130.2, 129.1, 128.9, 128.7 (d, 
JCP = 4.5 Hz), 128.6 (d, JCP = 4.4 Hz), 127.0, 124.7, 123.8, 76.8, 54.4 (d, JCP = 15.4 Hz), 40.9, 
31.8 (d, JCP = 14.8 Hz), 29.0, 28.9, 26.4, 26.0, 25.9. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −24.5. 
IR (ATR): 𝑣𝑣�/cm-1 = 3234 (w), 2919 (m), 2848 (w), 1594 (w), 1517 (m), 1447 (m), 1316 (w), 
1295 (m), 1238 (m), 1162 (m), 1134 (m), 1076 (w), 1007 (m), 930 (m), 736 (m), 692 (s), 603 (m), 
491 (m), 407 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C28H33N2OPS+: 477.2124 [M+H]+; found: 
477.2131. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −4.0 (c = 0.28, MeOH). 
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1-((1S,2R)-1-((tert-Butyldimethylsilyl)oxy)-1-cyclohexyl-3-(diphenylphosphanyl)propan-2-
yl)-3-phenylthiourea (56) 
OTBDMS
HN
P
HN
S
 
According to general procedure GP4, 1-((1S,2R)-3-(diphenylphosphanyl)-1-hydroxy-1-
cyclohexylpropan-2-yl)-3-phenylthiourea (55) (62.0 mg, 130 µmol), DIPEA (33.6 mg, 43.0 µL, 
260 µmol), TBDMS triflate (41.2 mg, 35.9 µL, 156 µmol), CH2Cl2 (1.4 mL) were stirred for 16 hours 
and the crude product was purified by column chromatography (SiO2, cyclohexane:ethyl acetate 
(5:1), d x h: 2.5 x 11 cm) to afford the product 56 (8.0 mg, 14 µmol, 10%) as a white solid. 
 
C34H47N2OPSSi (590.88 g/mol): 
MP: 65-66 °C. 
TLC: Rf = 0.49 (SiO2, cyclohexane:ethyl acetate (4:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.73-7.64 (m, 2H, ar-H), 7.54 (s, 1H, NH), 7.42-7.34 (m, 7H, 
ar-H), 7.32-7.23 (m, 4H, ar-H), 7.15-7.11 (m, 2H, ar-H), 6.71 (d, 3JHH = 8.3 Hz, 1H, NH), 4.63-4.51 
(m, 1H, OCH), 4.06 (dd, 3JHH = 5.3 Hz, 4JHH = 3.2 Hz, 1H, NCH), 2.70 (dt, 2JHP = 13.4 Hz, 3JHH = 
4.7 Hz, 1H, PCH2), 2.04 (ddd, 2JHP = 13.6 Hz, 3JHH = 10.5 Hz, 4JHH = 4.5 Hz, 1H, PCH2), 1.73-1.65 
(m, 2H, cy-CH2), 1.64-1.56 (m, 1H, cy-CH), 1.18-1.04 (m, 4H, cy-CH2), 0.93-0.80 (m, 4H, cy-CH2), 
0.66 (s, 9H, SiC(CH3)3), 0.03 (s, 3H, SiCH3), 0.00 (s, 3H, SiCH3). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −24.3. 
IR (ATR): 𝑣𝑣�/cm-1 = 3373 (w), 2953 (m), 2926 (m), 2853 (m), 1486 (s), 1344 (m), 1315 (s), 1249 (s), 
1069 (m), 973 (w), 885 (w), 834 (s), 775 (s), 736 (s), 697 (s), 573 (w), 526 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C34H47N2OPSSi+: 591.2989 [M+H]+; found: 
591.2989. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −13.7 (c = 1.00, MeOH).  
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5.2.4 Synthesis of 4th Generation Catalysts 
3-(tert-Butyl) 4-methyl (4S,5S)-2,2,5-trimethyloxazolidine-3,4-dicarboxylate (59) 
O NBoc
OMe
O
 
Under argon atmosphere, a heat-gun dried round-bottomed flask was charged with N-Boc-L-allo-
threonine methyl ester (58) (1.40 g, 6.00 mmol), 2,2-dimethoxypropane (2.55 g, 3.00 mL, 
24.0 mmol), p-toluenesulfonic acid monohydrate (15.4 mg, 0.08 mmol) and toluene (30 mL). Then, 
a Dean-Stark apparatus was attached and the reaction was refluxed for 16 hours. Afterwards the 
reaction mixture was concentrated under vacuum and the crude product was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (5:1), d x h: 3.5 x 13 cm) to afford the product 
59 (1.38 g, 5.06 mmol, 84%) as a yellow oil.  
 
C13H23NO5 (273.33 g/mol): 
TLC: Rf = 0.38 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 4.45-4.38 (m, 1H, OCH), 4.31-4.29 (m, 1H, NCH), 
3.68/3.65* (s, 3H, OCH3), 1.59/1.58* (s, 3H, CH3), 1.45/1.42* (s, 3H, CH3), 1.41/1.33* (s, 9H, 
C(CH3)3), 1.09 (d, 3JHH = 6.3 Hz, 3H, CH3) [* refers to signal of rotamers]. 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 170.4/170.1*, 151.2/150.4*, 93.3/93.1*, 79.9/79.3*, 
71.0/70.7*, 62.8/62.7*, 51.7/51.6*, 27.9/27.8*, 26.4/25.4*, 24.9/24.1*, 15.2/15.1*. 
IR (ATR): 𝑣𝑣�/cm-1 = 1751 (m), 1702 (s), 1454 (w), 1367 (s), 1265 (s), 1168 (m), 1123 (s), 1053 (w), 
979 (w), 737 (s), 704 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C13H23NO5+: 296.1468 [M+Na]+; found: 
296.1472. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −6.6 (c = 0.95, CH2Cl2). 
 
tert-Butyl (4R,5S)-4-(hydroxymethyl)-2,2,5-trimethyloxazolidine-3-carboxylate (60) 
O NBoc
OH
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Under argon atmosphere, a heat-gun dried two-necked flask was charged with LiAlH4 (1M in THF, 
271 mg, 7.14 mL, 7.14 mmol) and then the solution was cooled in an ice-bath. At 0 °C, a solution 
of 3-(tert-butyl) 4-methyl (4S,5S)-2,2,5-trimethyloxazolidine-3,4-dicarboxylate (59) (1.30 g, 
4.76 mmol) in THF (6 mL) was added dropwise over 15 minutes to the LiAlH4 solution via dropping 
funnel. The corresponding mixture was stirred for two hours at 0 °C and then the reaction was 
quenched by slow addition of saturated aqueous NH4Cl solution (10 mL). The aqueous layer was 
extracted with EtOAc (3 x 20 mL), then the combined organic layers were washed with brine 
(20 mL), dried over MgSO4 and concentrated under vacuum. The crude product was purified by 
column chromatography (SiO2, cyclohexane:ethyl acetate (3:1), d x h: 3.5 x 15 cm) to afford the 
product 60 (1.02 g, 4.16 mmol, 87%) as a pale yellow oil.  
 
C12H23NO4 (245.32 g/mol): 
TLC: Rf = 0.35 (SiO2, cyclohexane:ethyl acetate (2:1)). 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 4.63 (dd, 3JHH = 5.8, 3JHH = 4.4 Hz, 1H, OH), 4.21 (quint, 
3JHH = 6.0 Hz, 1H, OCH), 3.74-3.57 (m, 1H, NCH2), 3.51-3.35 (m, 2H, CH2), 1.43-1.37 (m, 15H, 
CH3, C(CH3)3), 1.22 (d, 3JHH = 6.4 Hz, 3H, CH3). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 151.3/151.0*, 91.4/91.3*, 79.1/78.6*, 71.4/71.0*, 
60.6/60.5*, 58.7/58.0*, 28.1/28.0*, 27.7/26.9*, 24.5/23.2*, 14.3. [* refers to signal of rotamers]. 
IR (ATR): 𝑣𝑣�/cm-1 = 1688 (s), 1473 (w), 1363 (s), 1257 (m), 1174 (s), 1129 (m), 1065 (m), 963 (m), 
859 (w), 799 (w), 716 (w), 528 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C12H23NO4+: 268.1519 [M+Na]+; found: 
268.1522. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −11.9 (c = 1.0, CH2Cl2). 
 
tert-Butyl (4R,5S)-2,2,5-trimethyl-4-(((methylsulfonyl)oxy)methyl)oxazolidine-3-carboxylate 
(61) 
O NBoc
OMs
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with tert-butyl (4R,5S)-
4-(hydroxymethyl)-2,2,5-trimethyloxazolidine-3-carboxylate (60) (819 mg, 3.34 mmol), CH2Cl2 
(11 mL) and this mixture was cooled in an ice-bath to 0 °C. Then, triethylamine (845 mg, 1.17 mL, 
8.35 mmol) was added, followed by dropwise addition of methanesulfonyl chloride (497 mg, 
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0.34 mL, 4.34 mmol) over 10 minutes at 0 °C. After addition the mixture was stirred for four hours 
at 0 °C and 16 hours at room temperature. Water (10 mL) was added and the biphasic mixture 
was extracted with CH2CL2 (3 x 10 mL). The combined organic layers were dried over Na2SO4, 
filtered, concentrated under vacuum and the crude product was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (3:1), d x h: 3.5 x 14 cm) to afford the product 
61 (991 mg, 3.06 mmol, 92%) as a colorless oil.  
 
C13H25NO6S (245.32 g/mol): 
TLC: Rf = 0.38 (SiO2, cyclohexane:ethyl acetate (2:1)). 
1H NMR (500 MHz, DMSO-d6): δ/ppm = 4.33-4.21 (m, 2H, OCH, CH2), 4.17-4.07 (m, 1H, CH2), 
4.02-3.93 (m, 1H, NCH), 3.20 (s, 3H, SCH3), 1.49-1.40 (m, 15H, CH3,C(CH3)3), 1.22 (d, 3JHH = 6.5 
Hz, 3H, CH3). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 151.2/150.7*, 92.1/92.0*, 79.8/79.4*, 70.9/70.5*, 
66.1/65.2*, 57.6/57.5*, 36.6/36.5*, 27.9, 27.2/26.4*, 24.3/23.1*, 13.9. [* refers to signal of 
rotamers]. 
IR (ATR): 𝑣𝑣�/cm-1 = 1688 (w), 1421 (m), 1391 (m), 1366 (m), 1264 (s), 1176 (m), 1130 (w), 1066 (w), 
960 (w), 736 (w), 705 (s). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C13H25NO6S +: 346.1295 [M+Na]+; found: 
346.1301. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −21.0 (c = 1.16 CH2Cl2). 
 
(2S,3S)-3-Amino-4-(diphenylphosphanyl)butan-2-ol (62) 
OH
P
NH2
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with tert-butyl (4R,5S)-
2,2,5-trimethyl-4-(((methylsulfonyl)oxy)methyl)oxazolidine-3-carboxylate (61) (401 mg, 
1.24 mmol) and THF (4 mL). Then the reaction mixture was degassed by three freeze-pump-thaw 
cycles. At 0 °C, potassium diphenylphosphide solution (0.5 M in THF, 3.02 g, 3.25 mL, 1.62 mmol) 
was added dropwise over five minutes and afterwards the mixture was stirred two hours at 0 °C 
and two hours at room temperature. At ambient temperature aqueous HCl (37%, 2.58 g, 2.22 mL, 
36.5 mmol) was added and then the mixture was stirred at room temperature for 16 hours. The 
reaction mixture was adjusted to an alkaline pH (>10) by addition of degassed aqueous NaOH 
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(2 M) and then the mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers 
were dried over Na2SO4, filtered, concentrated under vacuum and the crude product was purified 
by column chromatography (SiO2, cyclohexane:ethyl acetate (1:5) + 3% NEt3, d x h: 2.5 x 12 cm) 
to afford the product 62 (173 mg, 0.63 mmol, 51%) as a pale yellow gum. 
 
C16H20NOP (273.32 g/mol): 
TLC: Rf = 0.14 (SiO2, cyclohexane:ethyl acetate (1:5) + 5% NEt3). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.50-7.39 (m, 4H, ar-H), 7.37-7.29 (m, 6H, ar-H), 3.78-
3.67 (m, 1H, OCH), 2.86-2.75 (m, 1H, NCH), 2.32 (dd, 2JHP = 13.8 Hz, 3JHH = 3.3 Hz, 1H, PCH2), 
2.02-1.88 (m, 3H, PCH2*, NH2*), 1.12 (d, 3JHH = 6.4 Hz, 3H, CH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 133.3 (d, JCP = 19.5 Hz), 132.6 (d, JCP = 18.4 Hz), 129.2, 
128.8 (d, JCP = 7.3 Hz), 128.7 (d, JCP = 6.6 Hz), 71.2 (d, JCP = 8.4 Hz), 54.9 (d, JCP = 12.8 Hz), 
34.9 (d, JCP = 12.1 Hz), 20.1. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −23.6. 
IR (ATR): 𝑣𝑣�/cm-1 = 3289 (w), 3203 (w), 1584 (m), 1480 (m), 1433 (s), 1372 (w), 1305 (w), 1095 (m), 
1067 (m), 1026 (w), 922 (w), 740 (s), 697 (s), 508 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C16H20NOP +: 274.1356 [M+H]+; found: 
274.1355. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +44.7 (c = 1.00, CHCl3). 
 
1-((2S,3S)-1-(Diphenylphosphanyl)-3-hydroxybutan-2-yl)-3-phenylthiourea (63) 
OH
HN
P
HN
S
 
According to general procedure GP1, (2S,3S)-3-amino-4-(diphenylphosphanyl)butan-2-ol (62) 
(145 mg, 531 µmol), phenyl isothiocyanate (80.6 mg, 71.3 µL, 584 µmol), CH2Cl2 (2.0 mL) were 
stirred for 16 hours and the crude product was purified by column chromatography (SiO2, 
cyclohexane:ethyl acetate (3:1), d x h: 2.5 x 14 cm) to afford the product 63 (171 mg, 418 µmol, 
79%) as a white solid.  
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C23H25N2OPS (408.50 g/mol): 
MP: 64-65 °C. 
TLC: Rf = 0.25 (SiO2, cyclohexane:ethyl acetate (2:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm: 7.98 (s, 1H, NH), 7.49-7.38 (m, 4H, ar-H), 7.37-7.28 (m, 8H, 
ar-H), 7.25-7.20 (m, 1H, ar-H), 7.11 (d, 3JHH = 7.8 Hz, 2H, ar-H), 6.40 (d, 3JHH = 8.4 Hz, 1H, NH), 
4.70 (s, 1H, OCH), 4.20-3.99 (m, 1H, NCH), 2.57-2.45 (m, 2H, PCH2, OH), 2.30-2.21 (m, 1H, 
PCH2), 1.16 (d, 3JHH = 6.5 Hz, 3H, CH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 180.2, 138.2, 137.3, 136.1, 133.2 (d, JCP = 19.6 Hz), 
132.6 (d, JCP = 18.8 Hz), 130.1, 129.3, 128.9, 128.8 (d, JCP = 5.6 Hz), 128.7 (d, JCP = 5.1 Hz), 
127.0, 124.9, 70.5 (d, JCP = 6.6 Hz), 58.0 (d, JCP = 12.3 Hz), 28.8, 19.2. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −23.6. 
IR (ATR): 𝑣𝑣�/cm-1 = 3357 (w), 3240 (w), 1594 (w), 1520 (s), 1494 (s), 1432 (w), 1314 (m), 1296 (m), 
1237 (m), 1095 (w), 1024 (w), 871 (w), 736 (s), 692 (s), 503 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C23H25N2OPS +: 409.1498 [M+H]+; found: 
409.1503. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +118.8 (c = 0.94, CHCl3). 
 
1-((2S,3S)-3-((tert-Butyldimethylsilyl)oxy)-1-(diphenylphosphanyl)butan-2-yl)-3-phenyl 
thiourea (64) 
OTBDMS
HN
P
HN
S
 
According to general procedure GP4, 1-((2S,3S)-1-(diphenylphosphanyl)-3-hydroxybutan-2-yl)-3-
phenylthiourea (63) (100 mg, 245 µmol), DIPEA (96.3 mg, 123 µL, 745 µmol), TBDMS triflate 
(68.0 mg, 59.0 µL, 257 µmol), CH2Cl2 (2 mL) were stirred for 6 hours and the crude product was 
purified by column chromatography (SiO2, cyclohexane:ethyl acetate (10:1), d x h: 2.5 x 14 cm) to 
afford the product 63 (98.0 mg, 187 µmol, 77%) as a white solid. 
 
C29H39N2OPSSi (522.76 g/mol): 
MP: 50-52 °C. 
TLC: Rf = 0.28 (SiO2, cyclohexane:ethyl acetate (10:1)). 
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1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.96 (s, 1H, NH), 7.53-7.42 (m, 4H, ar-H), 7.39-7.31 (m, 8H, 
ar-H), 7.26-7.21 (m, 1H, ar-H), 7.12 (d, 3JHH = 7.8 Hz, 2H, ar-H), 6.31 (d, 3JHH = 8.9 Hz, 1H, NH), 
4.54 (s, 1H, OCH), 4.18-4.07 (m, 1H, NCH), 2.46-2.30 (m, 2H, PCH2), 1.11 (d, 3JHH = 6.4 Hz, 3H, 
CH3), 0.71 (s, 9H, SiC(CH3)3), −0.01 (s, 3H, SiCH3), −0.19 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 180.1, 139.6, 139.0, 136.7, 133.7 (d, JCP = 19.5 Hz), 
133.1 (d, JCP = 18.9 Hz), 130.5, 129.4, 129.2 (d, JCP = 4.3 Hz), 129.1, 129.0, 127.2, 125.4, 70.5, 
59.2 (d, JCP = 13.3 Hz), 27.8, 26.0, 20.7, 18.3, −5.0, −4.9. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −23.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 3380 (w), 3052 (w), 2926 (w), 2892 (w), 2854 (w), 1590 (s), 1520 (s), 1495 (m), 
1378 (w), 1248 (s), 1138 (m), 1072 (s), 954 (m), 833 (s), 775 (m), 735 (s), 693 (s), 502 (m), 
475 (m). 
EA (C29H39N2OPSSi) calc.: C 66.63, H 7.52, N 5.36; found: C 66.62, H 7.64, N 5.38. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +139.9 (c = 0.63, CH2Cl2). 
 
tert-Butyl (4S,5R)-2,2-dimethyl-4-(((methylsulfonyl)oxy)methyl)-5-phenyloxazolidine-3-
carboxylate (72) 
O NBoc
OMs
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with tert-butyl (4S,5R)-
4-(hydroxymethyl)-2,2-dimethyl-5-phenyloxazolidine-3-carboxylate (71) (750 mg, 2.44 mmol), 
CH2Cl2 (7.8 mL) and this mixture was cooled in an ice-bath to 0 °C. Then, triethylamine (543 mg, 
0.75 mL, 5.37 mmol) was added, followed by dropwise addition of methanesulfonyl chloride 
(363 mg, 0.25 mL, 3.17 mmol) over 10 minutes at 0 °C. After addition, the mixture was stirred for 
four hours at 0 °C and 16 hours at room temperature. Water (10 mL) was added and the biphasic 
mixture was extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were dried over 
Na2SO4, filtered, concentrated under vacuum and the crude product was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (7:1), d x h: 3.5 x 19 cm) to afford the product 
72 (775 mg, 2.01 mmol, 82%) as a colorless gum.  
 
C18H27NO6S (385.48 g/mol):  
TLC: Rf = 0.35 (SiO2, cyclohexane:ethyl acetate (3:1)). 
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1H NMR (500 MHz, DMSO-d6): δ/ppm = 7.47-7.29 (m, 5H, ar-H), 5.41 (d, 3JHH = 5.6 Hz, 1H, Ph-
CH), 4.44-4.33 (m, 1H, CH2), 4.08-3.94 (m, 1H, NCH), 3.76-3.67 (m, 1H, CH2), 2.71/2.66* (s, 3H, 
SCH3), 1.64 (s, 3H, CH3), 1.59/1.58* (s, 3H, CH3), 1.46/1.43* (s, 9H, C(CH3)3). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 151.3/150.7*, 135.0/128.1*, 127.9/126.4*, 
92.7/92.5*, 80.1/79.6*, 76.0/75.5*, 66.2/65.3*, 58.3/58.1*, 35.84/35.7*, 27.9, 27.1/26.3*, 
24.5/23.3*.  
IR (ATR): 𝑣𝑣�/cm-1 = 2979 (w), 2936 (w), 1688 (s), 1456 (m), 1359 (s), 1256 (w), 1172 (s), 960 (m), 
811 (w), 768 (w), 701 (m), 526 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C18H27NO6S+: 408.1451 [M+Na]+; found: 
408.1452. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −5.4 (c = 0.45, MeOH). 
 
tert-butyl ((1S,2S)-3-((tert-Butyldimethylsilyl)oxy)-1-hydroxy-1-phenylpropan-2-yl) 
carbamate (69) 
OH
NHBoc
OTBDMS
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with (1S,2S)-(+)-2-
amino-1-phenyl-1,3-propanediol (32) (3.60 g, 21.5 mmol), MeOH (10 mL) and this mixture was 
cooled in an ice-bath to 0 °C. Then, di-tert-butyldicarbonat (5.16 g, 5.06 mL, 23.7 mmol) was 
added and the corresponding clear reaction solution was stirred for one hour at 0 °C. Afterwards 
the solvent was removed under vacuum and the yellow oil was directly used for the next step. The 
crude was dissolved in DMF (172 mL) and then imidazole (3.22 g, 47.3 mmol) and TBSCl (3.93 g, 
25.8 mmol) was added. After 16 hours the crude was quenched by slow addition of saturated 
aquous NaHCO3 solution (100 mL). The biphasic mixture was extracted with ether (3 x 100 mL) 
and the combined organic layers were washed with brine (3 x 100 mL), dried over Na2SO4, 
concentrated under vacuum and the crude product was purified by column chromatography (SiO2, 
cyclohexane:ethyl acetate (5:1), d x h: 5 x 19 cm) to afford the product 69 (7.20 g, 18.88 mmol, 
88%) as a colorless oil.  
 
C20H35NO4Si (381.59 g/mol):  
TLC: Rf = 0.50 (SiO2, cyclohexane:ethyl acetate (3:1)). 
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1H NMR (400 MHz, CDCl3): δ/ppm = 7.39-7.30 (m, 4H, ar-H), 7.29-7.24 (m, 1H, ar-H), 5.17 (d, 
3JHH = 8.4 Hz, 1H, NH), 5.01 (d, 3JHH = 3.6 Hz, 1H, Ph-CH), 3.86-3.73 (m, 3H, CH2, NCH), 1.37 (s, 
9H, C(CH3)3), 0.93 (s, 9H, SiC(CH3)3), 0.08 (s, 6H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 156.4, 141.4, 128.4, 127.7, 126.2, 79.7, 75.0, 65.1, 56.6, 
28.4, 26.0, 18.3, −5.4. 
IR (ATR): 𝑣𝑣�/cm-1 3436 (m), 2953 (w), 2928 (m), 2883 (w), 2856 (m), 1689 (s), 1495 (s), 1471 (m), 
1390 (m), 1365 (m), 1321 (w), 1252 (s), 1168 (s), 1115 (m), 1069 (m), 1045 (m), 1024 (m), 836 
(s), 777 (s), 738 (w), 699 (w), 669 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C20H35NO4Si +: 504.2228 [M+Na]+; found: 
504.2232. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +13.2 (c = 1.02, MeOH). 
 
tert-Butyl ((1R,2S)-3-((tert-butyldimethylsilyl)oxy)-1-hydroxy-1-phenylpropan-2-yl) 
carbamate (73) 
OH
NHBoc
OTBDMS
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with tert-butyl ((1S,2S)-
3-((tert-butyldimethylsilyl)oxy)-1-hydroxy-1-phenylpropan-2-yl)carbamate (69) (7.10 g, 
18.6 mmol) and THF (180 mL) and this mixture was cooled in an ice-bath to 0 °C. Then, 4-
nitrobenzoic acid (3.72 g, 22.3 mmol) and triphenylphosphine (5.85 g, 22.3 mmol) was added, 
followed by dropwise addition of diisopropyl azodicarboxylate (4.51 g, 4.38 mL, 22.3 mmol) over 
10 minutes at 0 °C. After addition the mixture was stirred for four hours at 0 °C and 16 hours at 
room temperature. Afterwards the reaction mixture was concentrated under vacuum and treated 
with an ether-hexane mixture (1:3, 100 mL). The precipitate was filtered off and the filtrate was 
concentrated under vacuum. The yellow oil was dissolved in MeOH (71 mL) and potassium 
carbonate (5.14 g, 37.2 mmol) was added in one portion. Then, the reaction mixture was stirred 
at room temperature for 80 minutes and then quenched with water (100 mL). The aqueous layer 
was extracted with CH2Cl2 (3 x 200 mL) and the combined organic layers were washed with brine 
(100 mL). The organic layer was dried over Na2SO4, filtered, concentrated under vacuum and the 
crude was triturated with hexane (100 mL) to remove the byproduct 4-nitrobenzoic methyl ester. 
After filtration and concentration of the filtrate the crude product was purified by column 
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chromatography (SiO2, cyclohexane:ethyl acetate (7:1), d x h: 8 x 16 cm) to afford the product 73 
(6.60 g, 17.30 mmol, 93%) as a pale yellow oil.  
 
C20H35NO4Si (381.59 g/mol):  
TLC: Rf = 0.36 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm =7.38-7.33 (m, 4H, ar-H), 7.30-7.24 (m, 1H, ar-H), 5.36 (d, 
3JHH = 8.7 Hz, 1H, NH), 4.94 (dd, 3JHH = 8.5 Hz, 3JHH = 3.9 Hz, 1H, Ph-CH), 4.16 (d, 3JHH = 8.4 Hz, 
1H, OH), 3.87-3.78 (m, 1H, NCH), 3.69-3.63 (m, 2H, CH2), 1.44 (s, 9H, C(CH3)3), 0.91 (s, 9H, 
SiC(CH3)3), 0.05 (s, 3H, SiCH3), 0.04 (s, 3H, SiCH3). 
13C{1H} NMR (126 MHz, CDCl3): δ/ppm = 155.8, 141.7, 128.4, 127.5, 125.8, 79.7, 76.5, 63.2, 55.4, 
28.5, 26.0, 18.3, −5.5. 
IR (ATR): 𝑣𝑣�/cm-1 3448 (m), 2953 (m), 2929 (m), 2884 (w), 2856 (w), 1692 (s), 1495 (s), 1365 (m), 
1251 (s), 1167 (s), 1062 (m), 834 (s), 776 (s), 699 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C20H35NO4Si +: 504.2228 [M+Na]+; found: 
504.2234- [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +11.5 (c = 0.95, MeOH). 
 
tert-Butyl ((5R,6S)-2,2,3,3,9,9,10,10-octamethyl-5-phenyl-4,8-dioxa-3,9-disilaundecan-6-yl) 
carbamate (76) 
OTBDMS
NHBoc
OTBDMS
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged tert-butyl ((1R,2S)-3-
((tert-butyldimethylsilyl)oxy)-1-hydroxy-1-phenylpropan-2-yl)carbamate (73) (1.20 g, 3.14 mmol) 
and DMF (4 mL). Then DMAP (269 mg, 2.20 mmol), imidazole (428 mg, 6.28 mmol) and TBSCl 
(669 mg, 4.40 mmol) was added to the reaction mixture. After stirring for 18 hours at room 
temperature the reaction solution was quenched by addition of water (10 mL) and the 
corresponding aqueous mixture was extracted with MTBE (3 x 30 mL). The combined organic 
layers were washed with brine (3 x 20 mL), dried over Na2SO4, filtered, concentrated under 
vacuum and the crude product was purified by column chromatography (SiO2, cyclohexane:ethyl 
acetate (20:1), d x h: 5 x 16 cm) to afford the product 76 (1.40 g, 2.83 mmol, 90%) as a colorless 
oil.   
EXPERIMENTAL PART            CHAPTER 5 
250 
C26H49NO4Si2 (495.85 g/mol):  
TLC: Rf = 0.38 (SiO2, cyclohexane:ethyl acetate (4:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.35-7.27 (m, 4H, ar-H), 7.25-7.19 (m, 1H, ar-H), 4.87 (d, 
3JHH = 5.1 Hz, 1H, Ph-CH), 4.59 (d, 3JHH = 8.4 Hz, 1H, NCH), 3.89-3.74 (m, 2H, CH2), 3.54-3.44 (m, 
1H, NH), 1.33 (s, 9H, C(CH3)3), 0.88 (s, 18H, SiC(CH3)3), 0.06-0.02 (m, 9H, SiCH3), −0.19 (s, 3H, 
SiCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 155.5, 141.7, 128.0, 127.4, 126.9, 79.0, 74.0, 61.2, 58.2, 
28.5, 26.1, 26.0, 18.4, 18.3, −4.6, −5.0, −5.2, −5.3. 
IR (ATR): 𝑣𝑣�/cm-1 = 2953 (w), 2928 (s), 2884 (w), 2856 (m), 1716 (s), 1493 (s), 1471 (m), 1389 (m), 
1364 (s), 1252 (s), 1170 (s), 1094 (s), 1053 (s), 1027 (m), 1005 (w), 966 (m), 835 (s), 777 (s), 
700 (w), 671 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C26H49NO4Si2+: 518.3092 [M+Na]+; found: 
518.3095. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −14.9 (c = 0.98, MeOH). 
 
tert-Butyl ((1R,2S)-1-((tert-butyldimethylsilyl)oxy)-3-hydroxy-1-phenylpropan-2-yl) 
carbamate (77) 
OTBDMS
NHBoc
OH
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with tert-butyl ((5R,6S)-
2,2,3,3,9,9,10,10-octamethyl-5-phenyl-4,8-dioxa-3,9-disilaundecan-6-yl)carbamate (76) (2.70 g, 
5.45 mmol), pyridine (4.01 g, 4.1 mL, 50.7 mmol), THF (65 mL) and this mixture was cooled in an 
ice-bath to 0 °C. Then HF-Pyridine (70%, 4.51 g, 4.1 mL, 158 mmol) was added dropwise over 
10 minutes at 0 °C and after addition the mixture was stirred for 30 minutes at 0 °C and 3 h at 
room temperature. At 0 °C the reaction mixture was quenched by slow addition of saturated 
aqueous NaHCO3 solution and then the biphasic mixture was extracted with EtOAc (3 x 100 mL). 
The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered, 
concentrated under vacuum and the crude product was purified by column chromatography (SiO2, 
cyclohexane:ethyl acetate (6:1), 3.5 x 23 cm) to afford the product 77 (1.62 g, 4.25 mmol, 78%) 
as a colorless oil.  
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C20H35NO4Si (381.59 g/mol):  
TLC: Rf = 0.52 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.33-7.24 (m, 4H, ar-H), 7.21-7.15 (m, 1H, ar-H), 5.41 (d, 
3JHH = 8.0 Hz, 1H, NH), 5.16-5.10 (m, 1H, Ph-CH), 3.76 (dt, 3JHH = 11.7 Hz, 4JHH = 2.2 Hz, 1H, 
CH2), 3.54-3.49 (m, 1H, NCH), 3.34 (td, 3JHH = 10.9 Hz, 4JHH = 3.7 Hz, 1H, CH2), 2.92 (d, 
3JHH = 10.1 Hz, 1H, OH), 1.39 (s, 9H, C(CH3)3), 0.85 (s, 9H, SiC(CH3)3), 0.00 (s, 3H, SiCH3), 
−0.18 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 155.8, 141.2, 128.5, 127.6, 126.0, 79.7, 77.8, 61.4, 56.7, 
28.6, 26.0, 18.2, −4.8, −5.2. 
IR (ATR): 𝑣𝑣�/cm-1 = 2953 (m), 2928 (m), 2856 (w), 1705 (s), 1490 (s), 1451 (m), 1364 (m), 1249 (s), 
1166 (s), 1102 (m), 1069 (w), 940 (w), 833 (s), 775 (m), 742 (s), 700 (m), 450 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C20H35NO4Si +: 504.2228 [M+Na]+; found: 
504.2232. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −32.1 (c = 0.91, MeOH). 
 
(2S,3R)-2-((tert-Butoxycarbonyl)amino)-3-((tert-butyldimethylsilyl)oxy)-3-phenylpropyl 
methanesulfonate (78) 
OTBDMS
NHBoc
OMs
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with tert-butyl ((1R,2S)-
1-((tert-butyldimethylsilyl)oxy)-3-hydroxy-1-phenylpropan-2-yl) carbamate (77) (599 mg, 
1.57 mmol), CH2Cl2 (5 mL) and this solution was cooled in an ice-bath to 0 °C. Then, triethylamine 
(318 mg, 0.44 mL, 3.14 mmol) was added followed by dropwise addition of methansulfonyl 
chloride (216 mg, 0.15 mL, 1.88 mmol) over 10 minutes at 0 °C. After addition the mixture was 
stirred for 30 minutes at 0 °C and 6 h at room temperature. Afterwards the reaction mixture was 
quenched with water (10 mL) and then the biphasic mixture was extracted with CH2Cl2 (3 x 50 mL). 
The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered, 
concentrated under vacuum and the crude product was purified by column chromatography (SiO2, 
cyclohexane:ethyl acetate (5:1), 3.5 x 19 cm) to afford the product 78 (518 mg, 1.13 mmol, 72%) 
as a colorless gum.  
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C21H37NO6SSi (459.67 g/mol):  
TLC: Rf = 0.52 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.39-7.25 (m, 5H, ar-H), 4.89-4.80 (m, 2H, CH2), 4.42-
4.36 (m, 1H, PH-CH), 4.19 (dd, 3JHH = 10.5 Hz, 2JHH = 3.6 Hz, 1H, NCH), 4.03 (br s, 1H, NH), 
2.95 (s, 3H, SCH3), 1.37 (s, 9H, C(CH3)3), 0.91 (s, 9H, SiC(CH3)3), 0.06 (s, 3H, SiCH3), −0.18 (s, 
3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 155.3, 140.6, 128.5, 128.0, 126.5, 80.0, 74.5, 67.8, 56.2, 
37.6, 28.4, 25.9, 18.3, −4.6, −5.1. 
IR (ATR): 𝑣𝑣�/cm-1 3385 (w), 2954 (m), 2930 (m), 2888 (w), 2857 (m), 1704 (s), 1496 (m), 1455 (m), 
1351 (s), 1251 (s), 1169 (s), 1094 (m), 1048 (m), 966 (m), 927 (m), 835 (s), 776 (s), 700 (s), 
672 (m), 528 (s). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C21H37NO6SSi+: 482.2003 [M+Na]+; found: 
482.2010. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −24.0 (c = 0.14, MeOH). 
 
tert-Butyl (S)-4-((R)-((tert-butyldimethylsilyl)oxy)(phenyl)methyl)-1,2,3-oxathiazolidine-3-
carboxylate 2,2-dioxide (80) 
OTBDMS
BocN
O
S
OO  
Under argon atmosphere, a heat-gun dried two-necked flask was charged with MeCN (7.6 mL), 
CH2Cl2 (7.6 mL), thionyl chloride (755 mg, 460 µL, 6.35 mmol) and the resulting solution was 
cooled in a dry-ice acetone bath. At −78 °C tert-butyl ((1R,2S)-1-((tert-butyldimethylsilyl)oxy)-3-
hydroxy-1-phenylpropan-2-yl)carbamate (77) (969 mg, 2.54 mmol) in MeCN/CH2Cl2/THF 
(13 mL/13 mL/2.5 mL) was added dropwise to the reaction mixture over 45 minutes. After addition 
the mixture was stirred for 10 minutes at −78 °C and then pyridine (1.11 g, 1.13 mL, 14.0 mmol) 
was added over 10 minutes at −78 °C. The reaction solution was slow warmed to room 
temperature and stirred at ambient temperature overnight. Then the reaction mixture was 
concentrated under vacuum and the residue was dissolved in EtOAc (100 mL). The organic layer 
was washed with brine (2 x 50 mL), dried over Na2SO4 and concentrated under vacuum. The 
crude mixture was directly used for the next step. The crude product was dissolved in MeCN 
(5 mL) and then at 0 °C sodium periodate (1.10 g, 5.14 mmol) and ruthenium chloride hydrate 
(7.69 mg, 0.037 mmol) were added. After water addition (5 mL) the resulting blue solution was 
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stirred for one hour at room temperature. Then brine (20 mL) was added and the aqueous layer 
was extracted with ether (3 x 50 mL). The combined organic layers were washed with water 
(50 mL), brine (50 mL), dried over Na2SO4, filtered, concentrated under vacuum and the crude 
product was purified by column chromatography (SiO2, cyclohexane:ethyl acetate (20:1), d x h: 
3.5 x 15 cm) to afford the product 80 (883 mg, 1.99 mmol, 78%) as a white solid.  
 
C20H33NO6SSi (443.60 g/mol):  
TLC: Rf = 0.41 (SiO2, cyclohexane:ethyl acetate (10:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.43-7.34 (m, 4H, ar-H), 7.33-7.27 (m, 1H, ar-H), 5.25 (d, 
3JHH = 2.9 Hz, 1H, Ph-CH), 4.69-4.61 (m, 1H, NCH), 4.34-4.25 (m, 2H, CH2), 1.54 (s, 9H, C(CH3)3), 
0.93 (s, 9H, SiC(CH3)3), 0.12 (s, 3H, SiCH3), −0.11 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 149.2, 139.4, 128.8, 128.3, 126.2, 85.6, 71.9, 65.1, 62.7, 
28.1, 26.0, 18.3, −4.9, −5.1. 
IR (ATR): 𝑣𝑣�/cm-1 = 2963 (w), 2934 (m), 2896 (w), 2860 (m), 1723 (s), 1384 (s), 1315 (s), 1252 (m), 
1192 (s), 1141 (s), 1052 (m), 1026 (m), 968 (m), 832 (s), 792 (m), 744 (m), 705 (s), 654 (m), 
622 (m), 569 (w), 542 (w), 514 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C20H33NO6SSi +: 466.1690 [M+Na]+; found: 
466.1696. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −19.5 (c = 0.85, CH2Cl2). 
 
tert-Butyl ((1R,2R)-1-((tert-butyldimethylsilyl)oxy)-3-(diphenylphosphanyl)-1-phenylpropan 
-2-yl)carbamate (79a) 
OTBDMS
NHBoc
P
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with tert-butyl (S)-4-
((R)-((tert-butyldimethylsilyl)oxy)(phenyl)methyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide 
(80) (250 mg, 0.54 mmol) and THF (3 mL). Then, the reaction mixture was degassed by three 
freeze-pump-thaw cycles. At −78 °C, potassium diphenylphosphide solution (0.5 M, 158 mg, 
1.41 mL, 0.71 mmol) was added dropwise over five minutes and afterwards the mixture was stirred 
one hour at −78 °C and overnight room temperature. At ambient temperature, a mixture of 
degassed H2SO4 (1 M, 3.6 mL) and brine (50%, 11 mL) was added and then the reaction mixture 
was stirred at room temperature for two hours. Then the reaction mixture was adjusted to an 
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alkaline pH (>10) by addition of degassed saturated aqueous Na2CO3 solution and the resulting 
biphasic mixture was extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were dried 
over Na2SO4, filtered, concentrated under vacuum and the crude product was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (20:1), d x h: 2.5 x 13 cm) to afford the product 
79a (172 mg, 0.31 mmol, 58%) as a colorless gum. 
 
C32H44NO3PSi (550.29 g/mol): 
TLC: Rf = 0.32 (SiO2, cyclohexane:ethyl acetate (10:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.33-7.21 (m, 11H, ar-H), 7.17 (t, 3JHH = 7.4 Hz, 2H, ar-H), 
7.07 (d, 3JHH = 7.2 Hz, 2H, ar-H), 5.03 (br s, 1H, Ph-CH), 4.63 (d, 3JHH = 8.5 Hz, 1H, NH), 3.77-
3.64 (m, 1H, NCH), 2.18-2.01 (m, 2H, PCH2), 1.43 (s, 9H, C(CH3)3), 0.94 (s, 9H, SiC(CH3)3), 0.04 
(s, 3H, SiCH3), −0.10 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 155.1, 141.7, 139.4 (d, JCP = 12.4 Hz), 137.2 (d, 
JCP = 12.5 Hz), 133.0 (d, JCP = 19.3 Hz), 132.6 (d, JCP = 18.6 Hz), 128.8, 128.6, 128.5, 128.4, 
128.2, 127.2, 126.3, 79.3, 76.2 (d, JCP = 7.0 Hz), 55.4 (d, JCP = 12.7 Hz), 28.6, 26.3 (d, 
JCP = 12.5 Hz), 26.1, 18.4, −4.6, −5.0. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −22.0. 
IR  (ATR): 𝑣𝑣�/cm-1 = 2954 (m), 2928 (m), 2856 (w), 1704 (s), 1492 (m), 1363 (m), 1251 (m), 
1168 (m), 1100 (m), 1068 (w), 1006 (w), 940 (w), 833 (s), 775 (s), 737 (s), 694 (s), 496 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C32H44NO3PSi+: 550.2901 [M+H]+; found: 
550.2908. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −70.8 (c = 0.91, MeOH). 
 
1-((1R,2R)-1-((tert-Butyldimethylsilyl)oxy)-3-(diphenylphosphanyl)-1-phenylpropan-2-yl)-3-
phenylthiourea (81a) 
OTBDMS
HN
P
HN
S
 
Under argon atmosphere, a heat-gun dried round-bottomed flask was charged with tert-butyl 
((1R,2R)-3-(diphenyl)-1-hydroxy-1-phenylpropan-2-yl)carbamate (79a) (87.4 mg, 0.16 mmol) and 
CH2Cl2 (1.6 mL). The resulting solution was cooled in an ice-water bath. At 0 °C, TFA (1.60 g, 
1.04 mL, 14.0 mmol) was added dropwise and the mixture stirred for four hours at 0 °C and 
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overnight at room temperature. The reaction mixture was adjusted to an alkaline pH (>10) by 
addition of degassed saturated aqueous Na2CO3 solution and extracted with CH2Cl2 (3 x 10 mL). 
The combined organic layers were dried over Na2SO4, filtered, concentrated under vacuum and 
the resulting crude product was directly used for the next step. The crude product was dissolved 
in CH2Cl2 (1.5 mL) and then phenyl isothiocyanate (24.1 mg, 21.3 µL, 0.18 mmol) was added. The 
reaction solution was stirred at room temperature overnight and afterwards concentrated under 
vacuum. The crude product was purified by column chromatography (SiO2, cyclohexane:ethyl 
acetate (8:1), d x h: 2.5 x 17 cm) to afford the product 81a (81.7 mg, 0.14 mmol, 88%) as a white 
solid. 
 
C34H41N2OPSSi (584.83 g/mol): 
MP: 64-65 °C. 
TLC: Rf = 0.44 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 8.15 (br s, 1H, NH), 7.43-7.36 (m, 4H, ar-H), 7.35-7.25 (m, 
10H, ar-H), 7.23-7.17 (m, 4H, ar-H), 7.09 (t, 3JHH = 7.5 Hz, 2H, ar-H), 6.39 (br s, 1H, NH), 5.31 (s, 
1H, Ph-CH), 4.72-4.62 (m, 1H, NCH), 2.26-2.12 (m, 2H, PCH2), 0.78 (s, 9H, SiC(CH3)3), −0.15 (s, 
1H, SiCH3), −0.18 (s, 1H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.3, 141.9, 136.6, 133.4 (d, JCP = 19.3 Hz), 132.8 (d, 
JCP = 18.6 Hz), 130.6, 129.5, 129.2, 129.1 (d, JCP = 2.8 Hz), 129.0 (d, JCP = 3.6 Hz), 128.7, 127.8, 
127.3, 126.5, 125.4, 75.4, 60.2 (d, JCP = 13.0 Hz), 26.4, 26.0, 18.5, −4.4, −5.2. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −23.4. 
IR (ATR): 𝑣𝑣�/cm-1 = 2950 (m), 2926 (m), 2854 (w), 1522 (s), 1494 (s), 1301 (m), 1248 (m), 1098 (m), 
1066 (m), 936 (m), 832 (m), 776 (s), 735 (s), 693 (s), 499 (s). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C34H41N2OPSSi +: 585.2519 [M+H]+; found: 
585.2517. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −156.4 (c = 0.90, CH2Cl2). 
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tert-butyl ((1R,2R)-1-((tert-butyldimethylsilyl)oxy)-3-(di-o-tolylphosphanyl)-1-phenylpropan 
-2-yl)carbamate (79b) 
OTBDMS
NHBoc
P
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with tert-butyl (S)-4-
((R)-((tert-butyldimethylsilyl)oxy)(phenyl)methyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide 
(80) (230 mg, 520 µmol) and THF (2.1 mL). Then, the reaction mixture was degassed by three 
freeze-pump-thaw cycles. At −78 °C, potassium di(o-tolyl)phosphide solution (freshly prepared 
from di(o-tolyl)phosphine (44a) [189 mg, 880 µmol] and potassium hydride [35.4 mg, 880 µmol] in 
THF [1.8 mL]) was added dropwise over five minutes and afterwards the mixture was stirred one 
hour at −78 °C and overnight room temperature. At ambient temperature, a mixture of degassed 
H2SO4 (1 M, 3.5 mL) and brine (50%, 10 mL) was added and then the reaction mixture was stirred 
at room temperature for two hours. The reaction mixture was adjusted to an alkaline pH (>10) by 
addition of degassed saturated aqueous Na2CO3 solution and the resulting biphasic mixture was 
extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were dried over Na2SO4, filtered, 
concentrated under vacuum and the crude product was purified by column chromatography (SiO2, 
cyclohexane:ethyl acetate (30:1), d x h: 2.5 x 14 cm) to afford the product 79b (238 mg, 0.41 mmol, 
80%) as a white gum. 
 
C34H48NO3PSi (577.81 g/mol): 
TLC: Rf = 0.34 (SiO2, cyclohexane:ethyl acetate (20:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.35-7.02 (m, 11H, ar-H), 6.93-6.87 (m, 1H, ar-H), 6.65 (dd, 
3JHH = 7.3 Hz, 4JHH = 3.8 Hz, 1H, ar-H), 5.05 (t, 3JHH = 2.4 Hz, 1H, Ph-CH), 4.55 (d, 3JHH = 8.2 Hz, 
1H, NH), 3.74-3.60 (m, 1H, NCH), 2.41 (s, 3H, ar-CH3), 2.32 (s, 3H, ar-CH3), 2.12-1.96 (m, 2H, 
PCH2), 1.44 (s, 9H, C(CH3)3), 0.95 (s, 9H, SiC(CH3)3), 0.04 (s, 3H, SiCH3), −0.10 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 155.2, 142.9 (d, JCP = 26.3 Hz), 142.3 (d, JCP = 25.9 Hz), 
141.8, 137.6 (d, JCP = 13.4 Hz), 135.6 (d, JCP = 13.3 Hz), 131.2, 131.1, 130.2 (d, JCP = 4.8 Hz), 
130.1 (d, JCP = 5.1 Hz), 128.5, 128.4, 128.1, 127.1, 126.2, 126.1, 79.3, 76.0 (d, JCP = 7.5 Hz), 55.7 
(d, JCP = 13.9 Hz), 28.6, 26.1, 24.7 (d, JCP = 12.4 Hz), 21.4 (d, JCP = 21.6 Hz), 21.2 (d, 
JCP = 21.9 Hz), 18.4, −4.6, −5.0. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −44.1. 
IR  (ATR): 𝑣𝑣�/cm-1 = 2953 (m), 2928 (m), 2856 (w), 1705 (s), 1490 (m), 1451 (m), 1364 (m), 
1249 (m), 1166 (s), 1102 (m), 1069 (m), 940 (w), 833 (s), 775 (s), 742 (s), 700 (m), 450 (w). 
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HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C34H48NO3PSi+: 578.3214 [M+H]+; found: 
578.3221. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −105.3 (c = 0.82, CHCl3). 
 
1-((1R,2R)-1-((tert-Butyldimethylsilyl)oxy)-3-(di-o-tolylphosphanyl)-1-phenylpropan-2-yl)-3-
phenylthiourea (81b) 
OTBDMS
HN
P
HN
S
 
Under argon atmosphere, a heat-gun dried round-bottomed flask was charged with tert-butyl 
((1R,2R)-3-(di-o-tolylphosphanyl)-1-hydroxy-1-phenylpropan-2-yl)carbamate (79b) (145 mg, 
250 µmol) and CH2Cl2 (2.5 mL). The resulting solution was cooled in an ice-water bath. At 0 °C, 
TFA (2.77 g, 1.80 mL, 24.3 mmol) was added dropwise and the mixture stirred for four hours at 
0 °C and overnight at room temperature. The reaction mixture was adjusted to an alkaline pH 
(>10) by addition of degassed saturated aqueous Na2CO3 solution and extracted with CH2Cl2 (3 x 
25 mL). The combined organic layers were dried over Na2SO4, filtered, concentrated under 
vacuum and the resulting crude product was directly used for the next step. The crude product 
was dissolved in CH2Cl2 (1.5 mL) and then phenyl isothiocyanate (38.1 mg, 33.7 µL, 280 µmol) 
was added. The reaction solution was stirred at room temperature overnight and afterwards 
concentrated under vacuum. The crude product was purified by column chromatography (SiO2, 
cyclohexane:ethyl acetate (25:1), d x h: 2.5 x 15 cm) to afford the product 81b (238 mg, 410 µmol, 
80%) as a white solid. 
 
C36H45N2OPSSi (612.89 g/mol): 
MP: 75-76 °C. 
TLC: Rf = 0.29 (SiO2, cyclohexane:ethyl acetate (10:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 9.80 (br s, 1H, NH), 7.47 (d, 3JHH = 7.4 Hz, 2H, ar-H), 7.41-
7.33 (m, 7H, ar-H), 7.32-7.26 (m, 1H, ar-H), 7.24-7.04 (m, 6H, ar-H), 6.84-6.73 (m, 2H, ar-H), 6.30-
6.23 (br m, 1H, NH), 5.46 (s, 1H, Ph-CH), 4.43-4.36 (m, 1H, NCH), 2.37 (s, 3H, ar-CH3), 2.23 (s, 
3H, ar-CH3), 2.07-1.88 (m, 2H, PCH2), 0.86 (s, 9H, SiC(CH3)3), 0.00 (s, 3H, SiCH3), −0.15 (s, 3H, 
SiCH3). 
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13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 179.9, 142.1 (d, JCP = 26.0 Hz), 141.6, 140.9 (d, 
JCP = 25.6 Hz), 138.8, 137.0 (d, JCP = 13.1 Hz), 134.7 (d, JCP = 14.4 Hz), 130.3, 130.2-129.8 (m), 
128.7, 128.5, 128.4, 128.0, 127.1, 126.1 (d, JCP = 17.0 Hz), 125.3, 124.5, 123.2, 74.1 (d, 
JCP = 6.8 Hz), 57.8 (d, JCP = 14.1 Hz), 25.8, 24.0 (d, JCP = 11.9 Hz), 20.8 (d, JCP = 16.1 Hz), 20.6 (d, 
JCP = 16.8 Hz), 17.9, −5.2, −5.3. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −44.5. 
IR (ATR): 𝑣𝑣�/cm-1 = 2950 (m), 2926 (m), 2854 (m), 1589 (w), 1516 (s), 1494 (m), 1449 (m), 
1376 (m), 1248 (s), 1101 (s), 1066 (s), 938 (m), 832 (s), 776 (m), 741 (s), 698 (s), 501 (m), 455 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C36H45N2OPSSi+: 613.2832 [M+H]+; found: 
613.2842 [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −186.0 (c = 0.70, CH2Cl2). 
 
1-((1R,2R)-1-((tert-Butyldimethylsilyl)oxy)-3-(di-o-tolylphosphanyl)-1-phenylpropan-2-yl)-3-
(4-fluorophenyl)thiourea (81c) 
OTBDMS
HN
P
HN
S
F  
Under argon atmosphere, a heat-gun dried round-bottomed flask was charged with tert-butyl 
((1R,2R)-3-(di-o-tolylphosphanyl)-1-hydroxy-1-phenylpropan-2-yl)carbamate (79b) (60.0 mg, 
100 µmol) and CH2Cl2 (1 mL). The resulting solution was cooled in an ice-water bath. At 0 °C, TFA 
(1.02 g, 0.66 mL, 8.90 mmol) was added dropwise and the mixture stirred for four hours at 0 °C 
and overnight at room temperature. The reaction mixture was adjusted to an alkaline pH (>10) by 
addition of degassed saturated aqueous Na2CO3 and extracted with CH2Cl2 (3 x 25 mL). The 
combined organic layers were dried over Na2SO4, filtered, concentrated under vacuum and the 
resulting crude product was directly used for the next step. The crude product was dissolved in 
CH2Cl2 (1 mL) and then 4-fluorophenyl isothiocyanate (17.7 mg, 110 µmol) was added. The 
reaction solution was stirred at room temperature overnight and afterwards concentrated under 
vacuum. The crude product was purified by column chromatography (SiO2, cyclohexane:ethyl 
acetate (20:1), d x h: 2.5 x 12 cm) to afford the product 81c (55.8 mg, 88.0 µmol, 86%) as a white 
solid. 
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C36H44FN2OPSSi (630.88 g/mol): 
MP: 77-78 °C. 
TLC: Rf = 0.20 (SiO2, cyclohexane:ethyl acetate (20:1)). 
1H NMR (400 MHz CD2Cl2): δ/ppm = 8.08 (br s, 1H, NH), 7.42 (d, 3JHH = 7.0 Hz, 2H, ar-H), 7.38-
7.02 (m, 12H, ar-H), 6.91 (t, 3JHH = 7.4 Hz, 2H, ar-H), 6.53 (s, 1H, ar-H), 6.14 (d, 3JHH = 8.3 Hz, 
1H, NH), 5.41 (s, 1H, Ph-CH), 4.61 (br s, 1H, NCH), 2.42 (s, 3H, ar-CH3), 2.30 (s, 3H, ar-CH3), 
2.12-1.98 (m, 2H, PCH2), 0.80 (s, 9H, SiC(CH3)3), -0.10 (s, 3H, SiCH3), −0.15 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.6, 163.0, 160.5, 143.4 (d, JCP = 26.1 Hz), 142.4 (d, 
JCP = 26.1 Hz), 142.0, 137.5 (d, JCP = 12.7 Hz), 135.5 (d, JCP = 12.9 Hz), 132.4, 131.7, 131.1, 
130.7 (d, JCP = 3.2 Hz), 130.6 (d, JCP = 3.4 Hz), 129.1, 129.1, 128.7, 128.0 (d, JCP = 2.5 Hz), 
127.9 (d, JCP = 2.6 Hz), 127.8, 126.7, 126.6, 126.5, 117.4 (d, JCP = 22.8 Hz), 75.2, 60.5 (d, 
JCP = 14.2 Hz), 26.0, 24.7, 21.6 (d, JCP = 14.1 Hz), 21.4 (d, JCP = 14.1 Hz), 18.5, −4.4, −5.1. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −45.4. 
19F{1H} NMR (376 MHz, CD2Cl2): δ/ppm = −114.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 2951 (m), 2926 (m), 2855 (w), 1505 (s), 1469 (m), 1450 (m), 1375 (m), 1217 (s), 
1101 (m), 1066 (s), 938 (m), 832 (s), 776 (s), 743 (s), 700 (m), 509 (m), 454 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C36H45N2OPSSi+: 613.2832 [M+H]+; found: 
613.2842. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −169.8 (c = 0.96, CH2Cl3). 
 
tert-Butyl ((1R,2R)-3-(bis(3,5-dimethylphenyl)phosphanyl)-1-((tert-butyldimethylsilyl)oxy)-
1-phenylpropan-2-yl)carbamate (79c) 
OTBDMS
NHBoc
P
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with tert-butyl (S)-4-
((R)-((tert-butyldimethylsilyl)oxy)(phenyl)methyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide 
(80) (200 mg, 520 µmol) and THF (2 mL). Then the reaction mixture was degassed by three 
freeze-pump-thaw cycles. At −78 °C, potassium bis(3,5-dimethylphenylphosphide solution (freshly 
prepared from bis(3,5-dimethylphenylphosphine (44g) [186 mg, 770 µmol] and potassium hydride 
[30.8 mg, 770 µmol] in THF [2 mL]) was added dropwise over five minutes and afterwards the 
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mixture was stirred one hour at −78 °C and overnight room temperature. At ambient temperature, 
a mixture of degassed H2SO4 (1 M, 4 mL) and brine (50%, 12 mL) was added and then the reaction 
mixture was stirred at room temperature for two hours. The reaction mixture was adjusted to an 
alkaline pH (>10) by addition of degassed saturated aqueous Na2CO3 solution and the resulting 
biphasic mixture was extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were dried 
over Na2SO4, filtered, concentrated under vacuum and the crude product was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (30:1), d x h: 2.5 x 13 cm) to afford the product 
79c (180 mg, 300 µmol, 66%) as a white gum. 
 
C36H52NO3PSi (605.87 g/mol): 
TLC: Rf = 0.53 (SiO2, cyclohexane:ethyl acetate (10:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.35-7.21 (m, 5H, ar-H), 6.94-6.87 (m, 4H, ar-H), 6.70 (d, 
3JHH = 8.0 Hz, 2H, ar-H), 5.06 (s, 1H, Ph-CH), 4.68 (d, 3JHH = 8.1 Hz, 1H, NH), 3.73-3.60 (m, 1H, 
NCH), 2.25 (s, 6H, ar-CH3), 2.16 (s, 6H, ar-CH3), 2.13-2.03 (m, 2H, PCH2), 1.43 (s, 9H, C(CH3)3), 
0.94 (s, 9H, SiC(CH3)3), 0.05 (s, 3H, SiCH3), −0.11 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 155.0, 141.7, 139.1 (d, JCP = 10.8 Hz), 137.8, 137.7, 
137.6, 136.4 (d, JCP = 11.8 Hz), 130.6, 130.4, 130.2, 130.2, 130.0, 127.9, 127.0, 126.2, 79.0, 
75.8 (d, JCP = 6.7 Hz), 55.5 (d, JCP = 12.5 Hz), 28.5, 26.0, 21.3, 21.2, 18.3, −4.7, −5.1. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −22.5. 
IR  (ATR): 𝑣𝑣�/cm-1 = 2947 (m), 2934 (m), 2860 (w), 1711 (s), 1468 (m), 1460 (m), 1370 (m), 
1244 (m), 1109 (s), 1089 (m), 1059 (m), 932 (w), 745 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C34H48NO3PSi+: 606.3527 [M+H]+; found: 
606.3524. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −96.1 (c = 0.92, CHCl3). 
 
1-((1R,2R)-3-(bis(3,5-dimethylphenyl)phosphanyl)-1-((tert-butyldimethylsilyl)oxy)-1-pheny-
lpropan-2-yl)-3-phenylthiourea (81d) 
OTBDMS
HN
P
HN
S
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Under argon atmosphere, a heat-gun dried round-bottomed flask was charged with tert-butyl 
((1R,2R)-3-( bis(3,5-dimethylphenyl)phosphanyl)-1-hydroxy-1-phenylpropan-2-yl)carbamate 
(79c) (135.0 mg, 0.22 mmol) and CH2Cl2 (3 mL). The resulting solution was cooled in an ice-water 
bath. At 0 °C, TFA (2.46 g, 1.59 mL, 21.6 mmol) was added dropwise and stirred for four hours at 
0 °C and overnight at room temperature. The reaction mixture was adjusted to an alkaline pH 
(>10) by addition of degassed saturated aqueous Na2CO3 and extracted with CH2Cl2 (3 x 25 mL). 
The combined organic layers were dried over Na2SO4, filtered, concentrated under vacuum and 
the resulting crude product was directly used for the next step. The crude product was dissolved 
in CH2Cl2 (2 mL) and then phenyl isothiocyanate (33.8 mg, 250 µmol) was added. The reaction 
solution was stirred at room temperature overnight and afterwards concentrated under vacuum. 
The crude product was purified by column chromatography (SiO2, cyclohexane:ethyl acetate 
(20:1), d x h: 2.5 x 14 cm) to afford the product 81d (127 mg, 198 µmol, 89%) as a white solid. 
 
C38H49N2OPSSi (640.94 g/mol): 
MP: 72-73 °C. 
TLC: Rf = 0.47 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (400 MHz CD2Cl2): 8.05 (s, 1H, NH), 7.42-7.23 (m, 8H, ar-H), 7.20-7.13 (m, 2H, ar-H), 
6.93 (t, 3JHH = 7.7 Hz, 4H, ar-H), 6.73 (d, 3JHH = 8.0 Hz, 2H, ar-H), 6.30 (s, 1H, NH), 5.30 (s, 1H, 
Ph-CH), 4.65 (s, 1H, NCH), 2.25 (s, 6H, ar-CH3), 2.18 (s, 6H, ar-CH3), 2.17-2.12 (m, 2H, PCH2), 
0.77 (s, 9H, SiC(CH3)3), −0.15 (s, 3H, SiCH3), −0.18 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.2, 142.0, 138.5 (t, JCP = 7.2 Hz), 136.6, 131.1, 
130.9, 130.7, 130.6, 130.5, 130.4, 128.6, 127.7, 127.3, 126.5, 125.4, 75.4, 60.6 (d, JCP = 13.8 Hz), 
26.0, 21.5 (d, JCP = 7.0 Hz), 18.5, −4.4, −5.1. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −24.2. 
IR (ATR): 𝑣𝑣�/cm-1 = 2950 (m), 2920 (m), 2840 (w), 1500 (s), 1487 (m), 1379 (m), 1216 (s), 1104 (m), 
1062 (s), 936 (m), 837 (s), 771 (s), 747 (s), 710 (m), 511 (m), 436 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C38H50N2OPSSi+: 641.3145 [M+H]+; found: 
641.3153. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −178.8 (c = 0.86, CH2Cl2). 
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tert-Butyl ((1R,2R)-3-(bis(2-methoxyphenyl)phosphanyl)-1-((tert-butyldimethylsilyl)oxy)-1-
phenylpropan-2-yl)carbamate (79d) 
OTBDMS
NHBoc
P
O
O
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with tert-butyl (S)-4-
((R)-((tert-butyldimethylsilyl)oxy)(phenyl)methyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide 
(80) (212 mg, 478 µmol) and THF (2 mL). Then, the reaction mixture was degassed three-times 
by freeze-pump-thaw method. At −78 °C, potassium bis(2-methoxyphenyl)phosphide solution 
(freshly prepared from bis(2-methoxyphenyl)phosphine [200 mg, 812 µmol] and potassium 
hydride [32.6 mg, 813 µmol] in THF [2 mL]) was added dropwise over five minutes and afterwards 
the mixture was stirred one hour at −78 °C and overnight room temperature. At ambient 
temperature, a mixture of degassed H2SO4 (1 M, 4 mL) and brine (50%, 12 mL) was added and 
then the reaction mixture was stirred at room temperature for two hours. The reaction mixture was 
adjusted to an alkaline pH (>10) by addition of degassed saturated aqueous Na2CO3 solution and 
then the biphasic mixture was extracted with CH2Cl2 (3 x 25 mL). The combined organic layers 
were dried over Na2SO4, filtered, concentrated under vacuum and the crude product was purified 
by column chromatography (SiO2, cyclohexane:ethyl acetate (10:1), d x h: 2.5 x 14 cm) to afford 
the product 79d (158 mg, 259 µmol, 54%) as a white gum. 
 
C34H48NO5PSi (609.82 g/mol): 
TLC: Rf = 0.51 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.36 (d, 3JHH = 7.5 Hz, 2H, ar-H), 7.30 (d, 3JHH = 6.8 Hz, 2H, 
ar-H), 7.27 (d, 3JHH = 3.0 Hz, 1H, ar-H), 7.30-7.21 (m, 2H, ar-H), 6.84 (dd, 3JHH = 8.2, 4.2 Hz, 1H, 
ar-H), 6.80-6.74 (m, 3H, ar-H), 6.67 (t, 3JHH = 7.4 Hz, 1H, ar-H), 6.54 (t, 3JHH = 6.9 Hz, 1H, ar-H), 
5.17 (br s, 1H, NH), 4.92 (br s, 1H, Ph-CH), 3.83 (s, 3H, OCH3), 3.68-3.59 (m, 1H, NCH), 3.54 (s, 
3H, OCH3), 2.23-2.09 (m, 2H, PCH2), 1.42 (s, 9H, C(CH3)3), 0.94 (s, 9H, SiC(CH3)3), 0.06 (s, 3H, 
SiCH3), −0.10 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 161.9 (d, JCP = 11.5 Hz), 160.8 (d, JCP = 12.9 Hz), 155.4, 
142.2, 133.3 (d, JCP = 10.3 Hz), 132.9 (d, JCP = 6.3 Hz), 130.4, 129.8, 128.0, 126.9, 126.4, 121.1 (d, 
JCP = 3.5 Hz), 120.9 (d, JCP = 2.6 Hz), 110.2 (d, JCP = 20.1 Hz), 79.0, 75.5 (d, JCP = 7.1 Hz), 56.3 (d, 
JCP = 14.0 Hz), 55.5, 55.4, 28.6, 26.1, 21.8 (d, JCP = 11.3 Hz), 18.5, −4.6, −5.0.  
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −38.8. 
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IR  (ATR): 𝑣𝑣�/cm-1 = 3003 (w), 2929 (w), 2855 (w), 1709 (s), 1584 (w), 1472 (m), 1429 (m), 1365 (w), 
1238 (s), 1164 (s), 1103 (w), 1069 (m), 1023 (m), 942 (m), 834 (m), 749 (s), 701 (w), 496 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C34H48NO5PSi+: 610.3112 [M+H]+; found: 
610.3117. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −55.1 (c = 0.61, CHCl3). 
 
1-((1R,2R)-3-(bis(2-Methoxyphenyl)phosphanyl)-1-((tert-butyldimethylsilyl)oxy)-1-
phenylpropan-2-yl)-3-phenylthiourea (81e) 
OTBDMS
HN
P
HN
S
O
O
 
Under argon atmosphere, a heat-gun dried round-bottomed flask was charged with tert-butyl 
((1R,2R)-3-(bis(2-methoxyphenyl)phosphanyl)-1-((tert-butyldimethylsilyl)oxy)-1-phenylpropan-2-
yl)carbamate (79d) (115.0 mg, 189 µmol), CH2Cl2 (2 mL) and this solution was cooled in an ice-
water bath. At 0 °C, TFA (2.01 g, 1.30 mL, 17.6 mmol) was added dropwise to the reaction mixture 
and then the mixture was stirred for four hours at 0 °C and overnight at room temperature. The 
reaction mixture was adjusted to an alkaline pH (>10) by addition of degassed saturated aqueous 
Na2CO3 and then the mixture was extracted with CH2Cl2 (3 x 25 mL). The combined organic layers 
were dried over Na2SO4, filtered, concentrated under vacuum and the corresponding crude was 
directly used for the next step. The crude mixture was dissolved in CH2Cl2 (2 mL) and then phenyl 
isothiocyanate (28.7 mg, 25.4 µL, 208 µmol) was added. The reaction solution was stirred at room 
temperature overnight and afterwards concentrated under vacuum. The crude product was 
purified by column chromatography (SiO2, cyclohexane:ethyl acetate (20:1), d x h: 2.5 x 14 cm) to 
afford the product 81e (105 mg, 163 µmol, 86%) as a white solid. 
 
C36H45N2O3PSSi (644.89 g/mol): 
MP: 97-98 °C. 
TLC: Rf = 0.47 (SiO2, cyclohexane:ethyl acetate (5:1)). 
1H NMR (400 MHz CD2Cl2): 8.02 (s, 1H, NH), 7.49-7.41 (m, 4H, ar-H), 7.39-7.22 (m, 8H, ar-H), 
6.90-6.70 (m, 5H, ar-H), 6.59-6.54 (m, 1H, ar-H), 6.50 (d, 3JHH = 7.3 Hz, 1H, NH), 5.46 (s, 1H, Ph-
CH), 4.60-4.45 (m, 1H, NCH), 3.71 (s, 3H, OCH3), 3.53 (s, 3H, OCH3), 2.34 (ddd, 2JHP = 15.0 Hz, 
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2JHH = 12.4 Hz, 3JHH = 5.6 Hz, 1H, PCH2), 2.14-2.07 (m, 1H, PCH2), 0.78 (s, 9H, SiC(CH3)3), −0.11 
(s, 3H, SiCH3), −0.17 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 180.0, 162.4 (d, JCP = 11.6 Hz), 161.1 (d, 
JCP = 13.3 Hz), 142.4, 136.8, 133.6 (d, JCP = 11.2 Hz), 133.1 (d, JCP = 6.2 Hz), 130.9, 130.6, 130.2, 
128.5, 127.6, 127.1, 126.5, 125.3, 123.55 (d, JCP = 16.3 Hz), 121.4 (d, JCP = 18.8 Hz), 110.8 (d, 
JCP = 25.6 Hz), 74.9, 61.0 (d, JCP = 15.5 Hz), 55.9, 55.8, 26.0, 22.2 (d, JCP = 9.2 Hz), 18.4, −4.4, 
−5.2. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −37.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 3382 (w), 3167 (w), 2951 (w), 2927 (w), 1521 (m), 1460 (m), 1428 (m), 
1379 (m), 1236 (s), 1177 (w), 1102 (w), 1067 (m), 1023 (m), 940 (w), 832 (m), 748 (s), 699 (s), 
501 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C36H45N2O3PSSi+: 645.2731 [M+H]+; 
found: 645.2742. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −157.4 (c = 0.52, MeOH). 
 
3-(((1R,2R)-1-((tert-butyldimethylsilyl)oxy)-3-(di-o-tolylphosphanyl)-1-phenylpropan-2-yl)-
amino)-4-(phenylamino)cyclobut-3-ene-1,2-dione (83) 
OTBDMS
NH
P
O
O
NH
 
According to general procedure GP3, (1R,2R)-1-((tert-butyldimethylsilyl)oxy)-3-(di-o-tolyl-
phosphanyl)-1-phenylpropan-2-amine (82) (43.3 mg, 209 µmol) in MeOH (5 mL) and 3-(methoxy)-
4-(phenylamino)-3-cyclobutene-1,2-dione (24a) (99.8 mg, 209 µmol) were stirred for four days to 
give the product 83 (75.0 mg, 116 µmol, 55%) as a white solid. 
 
C39H45N2O3PSi (648.85 g/mol): 
MP: >250 °C. 
1H NMR (400 MHz DMSO-d6): δ/ppm = 9.54 (s, 1H, NH), 7.57 (d, 3JHH = 8.9 Hz, 1H, NH), 7.41-
6.98 (m, 19H, ar-H), 6.85 (dd, 3JHH = 7.8 Hz, 4JHH = 3.9 Hz, 1H, ar-H), 4.94 (d, 3JHH = 4.7 Hz, 1H, 
Ph-CH), 4.20-4.05 (m, 1H, NCH), 2.27 (s, 3H, ar-CH3), 2.25 (s, 3H, ar-CH3), 2.48-2.42 (m, 1H, 
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PCH2), 2.13-2.02 (m, 1H, PCH2), 0.85 (s, 9H, SiC(CH3)3), 0.03 (s, 3H, SiCH3), −0.20 (s, 3H, 
SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2): 183.3, 180.4, 168.8, 163.5, 142.0 (d, JCP = 26.1 Hz), 141.2 (d, 
JCP = 25.7 Hz), 140.6, 138.8, 136.5 (d, JCP = 13.2 Hz), 135.0 (d, JCP = 14.0 Hz), 130.6 (d, 
JCP = 7.2 Hz), 130.0 (d, JCP = 4.8 Hz), 129.4, 128.6 (d, JCP = 21.8 Hz), 128.1, 127.6, 126.4, 
126.2 (d, JCP = 3.7 Hz), 122.7, 118.0, 77.5 (d, JCP = 7.4 Hz), 58.1 (d, JCP = 14.0 Hz), 27.3 (d, 
J = 12.9 Hz), 25.7, 20.8 (d, JCP = 14.7 Hz), 20.6 (d, JCP = 15.3 Hz), 17.8, −5.2, −5.1. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −44.3. 
IR (ATR): 𝑣𝑣�/cm-1 = 2853 (w), 1653 (m), 1561 (s), 1535 (s), 1470 (m), 1434 (w), 1251 (w), 1036 (w), 
898 (w), 862 (s), 780 (s), 716 (m), 670 (m), 568 (s), 452 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C39H45N2O3PSi+: 649.3010 [M+H]+; found: 
6439.3002. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −58.2 (c = 0.39, DMSO). 
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5.2.5 Catalyst Evaluation by ESI-MS Back Reaction Screening 
General Procedure for ESI-MS Back Reaction Screening 
A GC-vial was charged with an equimolar mixture of 84a (1186 µg, 5.0 µmol), 84b (1201 µg, 
5.0 µmol) and the organocatalyst (1.0 µmol; 10 mol% based on the total amount of quasi-
enantiomeric substrates 84a and 84b). The mixture was dissolved in CH2Cl2 (0.1 mL) and the 
corresponding solution was stirred for 30 minutes at room temperature. Then, the reaction mixture 
was diluted with CH2Cl2 (1 mL), treated with acetic acid (10 µL) and directly injected into the ESI-
MS spectrometer. 
Overview of Single Catalyst Screening 
Table 50: ESI-MS screening of bifunctional organocatalysts. 
Ar
OH O
OCH3 Ar
OH O
OCD3+
Pcatalyst
 
(10 mol%)
CH2Cl2, RT, 30 min
89b
OCD3
O
OCH3
O
Pcat
Pcat
89a
84b84a
+
+
+
Ar
OH O
OCH3
Pcat
Ar
OH O
OCD3
Pcat
+
88a
88a  
Entry catalyst ESI-MS screening 88a/88b 
ESI-MS screening 
89a/89b 
preparative reaction 
e.r. 
1 19a 48:52 39:61 38:62 
2 19b 31:69 23:77 22:78 
3 19c 32:68 26:74 28:72 
4 19d 40:60 23:77 23:77 
5 19e 40:60 26:74 25:75 
6 19f 35:65 21:79 20:80 
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7 20a 46:54 23:77 23:77 
8 20b 47:53 23:77 23:77 
9 20c 48:52 22:78 24:76 
10 20d 40:60 16:84 17:83 
11 20e 50:50 16:84 14:86 
12 20f 50:50 16:84 16:84 
13 20g 46:54 20:60 21:79 
14 25a 18:82 14:86 12:88 
15 25b 35:65 18:82 19:81 
16 25c 31:69 18:82 18:82 
17 25d 37:63 15:85 14:86 
18 25e 40:60 18:82 19:81 
19 25f 40:60 17:83 15:85 
20 26a 37:63 16:84 17:83 
21 26b 35:65 14:86 14:86 
22 26c 38:62 15:85 11:89 
23 26j 33:67 23:77 25:75 
24 26k 37:63 24:76 25:75 
25 26I 25:75 16:84 16:84 
26 26d 40:60 20:80 20:80 
27 26e 32:68 15:85 15:85 
28 26f 49:51 19:81 18:82 
29 26h 47:53 16:84 16:84 
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30 26m 33:67 18:82 15:85 
31 26g 26:74 16:84 16:84 
32 26l 27:73 12:88 15:85 
33 37 28:72 23:77 24:76 
34 46a 53:47 91:9 90:10 
35 56 60:40 70:30 80:20 
36 45a 51:49 52:48 50:50 
37 49a 72:28 85:15 83:17 
38 49b 50:50 82:18 81:19 
39 49c 70:30 83:17 84:16 
40 46b 66:34 88:12 87:13 
41 46c 81:19 91:9 90:10 
42 46d 60:40 89:11 87:13 
42 46e 65:35 87:13 87:13 
44 46f 60:40 83:17 80:20 
45 48a 73:27 94:6 94:6 
46 48b 72:28 93:7 94:6 
47 48c 60:40 94:6 93:7 
48 48d 85:15 96:4 95:5 
49 48e 86:14 95:5 95:5 
50 48g 75:25 79:21 79:21 
51 48h 73:27 80:20 81:19 
52 52 47:53 50:50 49:51 
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53 64 43:57 13:87 13:87 
54 81a 58:42 93:7 94:6 
55 81b 86:14 95:5 95:5 
56 81c 80:20 95:5 95:5 
57 81d 50:50 71.29 71:29 
58 81e 77:23 89.11 89:11 
59 83 76:24 93:7 92:7 
 
Synthesis of crude catalyst mixture for the first catalyst generation 
Under argon atmosphere a heat-gun dried two-necked flask was charged with (S)-1-(diphenyl-
phosphanyl)-3-phenylpropan-2-amine (18d) (11.0 mg, 34.4 µmol) and CH2Cl2 (200 µL). Then, a 
mixture of phenyl isothiocyanate (1.58 mg, 1.40 µL, 11.7 µmol), 3,5-bis(trifluoromethyl)phenyl 
isothiocyanate (3.18 mg, 2.14 µL, 11.7 µmol) and 4-trifluoromethylphenyl isothiocyanate (2.38 mg, 
11.7 µmol) in CH2Cl2 (100 µL) was added dropwise to the amino phosphine solution. The reaction 
solution was stirred at room temperature overnight and concentrated under vacuum. The resulting 
crude catalyst mixture (524 µg, equal to 10mol% based on the average molecular mass of the 
catalyst mixture) was directly used for ESI-MS back reaction screening following the standard 
protocol for single catalyst screening. 
 
Synthesis of crude catalyst mixture for the second catalyst generation 
Under argon atmosphere a heat-gun dried two-necked flask was charged with (S)-1-(diphenyl-
phosphanyl)-3-phenylpropan-2-amine (3.53 mg, 11.1 µmol), (S)-1-(diphenylphosphanyl)-4-
methylpentan-2-amine (3.16 mg, 11.1 µmol), (S)-1-(diphenylphosphanyl)-3-methylbutan-2-amine 
(3.0 mg, 11.1 µmol) and MeOH (500 µL). Then, 3-(methoxy)-4-(phenylamino)-3-cyclobutene-1,2-
dione (6.74 mg, 33.2 µmol) was added to the reaction mixture and stirred for 48 hours at room 
temperature. The resulting precipitate was filtered off and washed with MeOH to afford the pure 
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catalyst mixture after drying under vacuum. The resulting crude catalyst mixture (463 µg, equal to 
10mol% based on the average molecular mass of the catalyst mixture) was directly used for ESI-
MS back reaction screening following the standard protocol for single catalyst screening. 
Synthesis of crude catalyst mixture for the third catalyst generation 
Step A: Under argon atmosphere a heat-gun dried two-necked flask was charged with (1S,2R)-
2-amino-3-(diphenylphosphanyl)-1-phenylpropan-1-ol (7.71 mg, 23.0 µmol), (1S,2R)-2-amino-3-
(di-o-tolylphosphanyl)-1-phenylpropan-1-ol (8.36 mg, 23.0 µmol), (1S,2R)-2-amino-3-(bis(3,5-di-
methylphenyl)phosphanyl)-1-phenylpropan-1-ol (9.00 mg, 23.0 µmol) and CH2Cl2 (500 µL). Then, 
a mixture of phenyl isothiocyanate (4.76 mg, 4.21 µL, 34.5 µmol) and 4-fluorophenyl 
isothiocyanate (5.28 mg, 34.5 µmol) in CH2Cl2 (100 µL) was added. The reaction solution was 
stirred at room temperature overnight and concentrated under vacuum. The remaining residue 
was directly used for the next step. 
Step B: Under argon atmosphere a heat-gun dried round bottomed flask was charged with the 
crude product mixture from step A, CH2Cl2 (500 µL) and triethylamine (14.0 mg, 19.4 µL, 138 µmol. 
Then, TBDMS triflate (18.2 mg, 15.9 µL, 69.0 µmol) was added dropwise over 5 minutes to the 
reaction mixture at 0 °C. After stirring for two hours at 0 °C and additional four hours at room 
temperature, the mixture was concentrated under vacuum. The crude reaction mixture was 
dissolved in ether (10 mL) and the corresponding organic layer was washed with saturated NH4Cl 
solution (10 mL), saturated NaHCO3 solution (10 mL) and brine (10 mL). The organic layers was 
then dried over Na2SO4, filtered and concentrated under vacuum. The resulting crude catalyst 
mixture (1.86 mg, equal to 10mol% based on the average molecular mass of the catalyst mixture) 
was directly used for ESI-MS back reaction screening following the standard protocol for single 
catalyst screening. 
 
Synthesis of crude catalyst mixture for the fourth catalyst generation 
Step A: Under argon atmosphere a heat-gun dried two-necked flask was charged with tert-butyl 
(S)-4-((R)-((tert-butyldimethylsilyl)oxy)(phenyl)methyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-
dioxide (50 mg, 110 µmol) and THF (1 mL). Then, the reaction mixture was degassed by three 
freeze-pump-thaw cycles. At −78 °C potassium phosphide solution (freshly prepared from a 
mixture di(o-tolyl)phosphine [12.1 mg, 56.5 µmol], diphenylphosphine [12.1 mg, 56.5 µmol], 
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bis(3,5-dimethylphenyl)chlorophosphine [6.9 mg, 28.3 µmol] and potassium hydride [6.8 mg, 
169 µmol] in THF [1.0 mL]) was added dropwise over five minutes and afterwards the mixture was 
stirred for one hour at −78 °C and overnight at room temperature. At ambient temperature, a 
mixture of degassed H2SO4 (1M, 3.6 mL) and brine (50%, 11 mL) was added and the resulting 
mixture was stirred at room temperature for two hours. Then, the reaction mixture was adjusted 
to an alkaline pH (>10) by addition of degassed saturated aqueous Na2CO3 solution and extracted 
with CH2Cl2 (3 x 25 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated under vacuum. The remaining residue was directly used for the next step.  
Step B: Under argon atmosphere a heat-gun dried round bottomed flask was charged with the 
crude product mixture from step A, CH2Cl2 (1 mL) and the resulting solution was cooled in an ice-
water bath. At 0 °C, TFA (1.02 g, 0.66 mL, 8.90 mmol) was added dropwise. After stirring for four 
hours at 0 °C and overnight at room temperature, the reaction mixture was adjusted to an alkaline 
pH (>10) by addition of degassed saturated aqueous Na2CO3 and extracted with CH2Cl2 (3 x 
25 mL). The combined organic layers were dried over Na2SO4, filtered, concentrated under 
vacuum and the residue was directly used for the next step.  
Step C: The crude product mixture from step B was dissolved in CH2Cl2 (1 mL) and then a mixture 
of phenyl isothiocyanate (8.57 mg, 7.6 µL, 62.2 µmol) and 4-fluorophenyl isothiocyanate (9.71 mg, 
62.2 µmol) in CH2Cl2 (200 µL) was added. The reaction solution was stirred at room temperature 
overnight and concentrated under vacuum. The resulting crude catalyst mixture (1.86 mg, equal 
to 10mol% based on the average molecular mass of the catalyst mixture) was directly used for 
ESI-MS back reaction screening following the standard protocol for single catalyst screening. 
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5.2.6 Kinetic Measurements 
Reaction Order in Aldehyde 
A stock solution was prepared by dissolving methyl acrylate (25.8 mg, 27.0 µL, 300 µmol), catalyst 
(1R,2R)-81b (18.4 mg, 30.0 µmol) and mesitylene as internal standard (36.1 mg, 41.5 µL, 
300 µmol) in CD2Cl2 (3.53 mL). 
Under argon atmosphere four different NMR tubes were charged with different amounts of 4-
nitrobenzaldehyde (25 µmol, 0.5 eq. / 50 µmol, 1.0 eq. / 100 µmol, 2.0 eq. / 150 µmol, 3 eq.). 
Then, 0.6 mL of the stock solution (containing 50 µmol methyl acrylate, 1.0 eq.) was added into 
each NMR tube and after shaking the tubes were put into the autosampler of the NMR 
spectrometer. The reaction process at room temperature was tracked by 1H-NMR analysis (every 
30 minutes one 1H-NMR measurement) based on the signals of the methyl ester group of acrylate 
104a (3.73 ppm) and MBH adduct 84a (3.71 ppm).  
Logarithmic plot of the dependence of [acrylate] on the reaction time between 0 to 720 min.
 
Figure 47: Kinetic analysis of the MBH reaction of methyl acrylate with 4-nitrobenzaldehyde.  
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Logarithmic plot of the dependence of [acrylate] on the reaction time between 0 to 60 min. 
 
Figure 48: Kinetic analysis of the MBH reaction of methyl acrylate with 4-nitrobenzaldehyde.  
 
 
Figure 49: Kinetic analysis of the MBH reaction of methyl acrylate with 4-nitrobenzaldehyde between 0 and 60 minutes. 
Double logarithmic plot of the dependence of the reaction rate (kinit) on the initial aldehyde concentration. The data 
points correspond to aldehyde concentrations of 41.7, 83.3, 166.7, and 250.0 mmol/L and a constant acrylate 
concentration of 83.3 mmol/L. Linear fit for 105a: y = 0.9421x –1.8298 (R2 = 0.99), consistent with first order in 105a. 
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Data from Kinetic Measurements 
Table 51: Data from kinetic measurements. 
 with 25 µmol 105a with 50 µmol 105a with 100 µmol 105a with 150 µmol 105a 
time (min) [acrylate] / mmol L−1 [acrylate] / mmol L−1 [acrylate] / mmol L−1 [acrylate] / mmol L−1 
0 83.333 83.3333 83.333 83.333 
30 81.704 80.1382 77.473 74.629 
60 80.774 78.1555 73.323 70.755 
90 79.652 76.4884 71.406 67.037 
120 78.800 75.3241 67.937 63.646 
150 78.098 73.4337 66.607 60.327 
180 77.826 72.4732 64.548 57.986 
210 77.029 71.6556 62.786 55.120 
240 76.362 70.4883 60.575 53.357 
270 75.936  58.269 51.015 
300 75.022 67.7942 56.000 48.998 
330 74.561 66.3440 54.848 47.403 
360 73.685 65.4724 53.301 45.396 
390 73.552 65.1785 52.030 44.016 
420 73.071 63.9079 51.513 43.007 
450 73.057 62.7822 50.112 40.625 
480 72.802 62.7345 48.738 40.423 
510 72.720 62.2378 47.655 39.206 
540 72.660 61.6006 47.032 38.525 
570 72.686 60.9598 46.264 37.610 
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600 72.240 60.5299 45.896 36.396 
630 71.663 60.1776 44.395 35.923 
660 72.129 59.9266 44.493 35.388 
690 71.238 59.3445 43.803 33.758 
720 71.180 58.8217 43.508 33.168 
750 70.974 58.4160 43.157 32.680 
780 70.776 57.4776 42.319 32.538 
810 70.605 56.9575 42.558 31.926 
840 70.688 56.9505 42.555  
870 83.333 57.0109 42.526  
900 83.333 56.8463 42.656 31.022 
930 70.454 56.9953 42.656 30.932 
960 70.362 56.8463 42.630 30.941 
990 70.112 56.9843 42.465 30.978 
1020 70.171 56.9804 42.454 30.972 
1050 70.079 56.9158 42.541 30.855 
1080 70.023 56.8692 42.338  
1110  57.0339 42.413  
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5.2.7 Reaction Scope 
General Procedure for the Asymmetric MBH Reaction 
Under argon atmosphere a heat gun dried GC-vial was charged with activated molecular sieve 
(50 mg), aldehyde (100 µmol), methyl acrylate (200 µmol), phosphine catalyst (10-20 mol%) and 
THF (0.1 mL). The corresponding mixture was stirred at room temperature. The crude mixture 
was concentrated under vacuum and purified by preparative TLC. 
 
Methyl 3-hydroxy-3-(4-nitrophenyl)-2-methylenepropanoate (106a) 
OH O
OCH3
O2N  
1H NMR (400 MHz, CDCl3): δ/ppm = 8.21 (d, 3JHH = 8.8 Hz, 2 H, ar-H), 7.58 (d, 3JHH = 8.8 Hz, 2 H, 
ar-H), 6.40 (s, 1 H, olefinic-H), 5.86 (s, 1 H, olefinic-H), 5.63 (s, 1 H, ar-CH), 3.25 (br s, 1H, OH), 
3.75 (s, 3H, OCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 166.6, 148.7, 147.7, 141.1, 127.5, 123.8, 73.0, 52.4. 
HPLC (Daicel Chiracel IC, heptane/i-PrOH = 90:10, 0.5 mL/min, 25 °C): tR (major) = 22.3 min, 
tR (minor) = 29.1 min, 94% ee (S). 
 
Methyl 3-hydroxy-3-(2-nitrophenyl)-2-methylenepropanoate (106b) 
OH O
OCH3
NO2
 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.92 (d, 3JHH = 8.2 Hz, 1H, ar-H), 7.73 (d, 3JHH = 7.9 Hz, 1H, 
ar-H), 7.62 (t, 3JHH = 7.6 Hz, 1H, ar-H), 7.44 (t, 3JHH = 8.7 Hz, 1H, ar-H), 6.33 (s, 1H, olefinic-H), 
6.18 (s, 1H, 1H, olefinic-H), 5.70 (s, 1H, ar-CH), 3.70 (s, 3H, OCH3), 3.51 (br s, 1H, OH). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 166.5, 148.4, 140.9, 136.2, 133.5, 129.0, 128.8, 126.5, 
124.6, 67.7, 52.2. 
HPLC (Daicel Chiracel OD-H, heptane/i-PrOH = 90:10, 0.5 mL/min, 25 °C): tR (major) = 29.3 min, 
tR (minor) = 36.4 min, 80% ee (S). 
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Methyl 2-((4-cyanophenyl)(hydroxy)methyl)acrylate (106c) 
OH O
OCH3
NC  
1H NMR (400 MHz, CDCl3): δ/ppm = 7.67-7.61 (m, 2H, ar-H), 7.53-7.49 (m, 2H, ar-H), 6.38 (s, 1H, 
olefinic-H), 5.85 (s, 1H, olefinic-H), 5.58 (s, 1H, ar-CH), 3.74 (s, 3H, OCH3), 3.25 (br s, 1H, OH). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 166.6, 146.7, 141.2, 132.4, 127.4, 127.3, 118.8, 111.8, 
73.1, 52.3. 
HPLC (Daicel Chiracel IC, heptane/i-PrOH = 90:10, 0.5 mL/min, 25 °C): tR (major) = 33.4 min, 
tR (minor) = 46.4 min, 92% ee (S). 
 
Methyl-2-((3,5-bis(trifluoromethyl)phenyl)(hydroxy)methyl)acrylate (106d) 
OH O
OCH3
F3C
CF3  
1H NMR (400 MHz, CDCl3): δ/ppm = 7.86 (s, 2H, ar-H), 7.81 (s, 1H, ar-H), 6.43 (s, 1H, olefinic-H), 
5.88 (s, 1H, olefinic-H), 5.65 (s, 1H, ar-CH), 3.76 (s, 3H, OCH3), 3.30 (br s, 1H, OH). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 166.5, 144.2, 140.9, 131.9 (q, JCF = 33.3 Hz), 126.9, 
123.42 (q, JCF = 272.6 Hz), 122.00-121.80 (m), 72.7, 52.4.  
19F{1H} NMR (376 MHz, CDCl3): δ/ppm = −63.8. 
HPLC (Daicel Chiracel OD-H, heptane/i-PrOH = 95:5, 0.5 mL/min, 25 °C): tR (major) = 11.8 min, 
tR (minor) = 10.0 min, 92% ee (S). 
 
Methyl -2-((4-fluorophenyl)(hydroxy)methyl)acrylate (106e) 
OH O
OCH3
F  
1H NMR (400 MHz, CDCl3): δ/ppm = 7.30-7.24 (m, 2H, ar-H), 6.99-6.90 (m, 2H, ar-H), 6.26 (s, 1H, 
olefinic-H), 5.75 (s, 1H, olefinic-H), 5.46 (s, 1H, ar-CH), 3.65 (s, 3H, OCH3), 2.94 (br s, 1H, OH). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 166.8, 163.7, 161.3, 142.0, 137.2 (d, JCF = 3.1 Hz), 
128.5 (d, JCF = 8.3 Hz), 126.2, 115.4 (d, JCF = 21.5 Hz), 72.8, 52.1, 
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19F{1H} NMR (376 MHz, CDCl3): δ/ppm = −114.7. 
HPLC (Daicel Chiracel IC, heptane/i-PrOH = 90:10, 0.5 mL/min, 25 °C): tR (major) = 14.0 min, 
tR (minor) = 25.1 min, 90% ee (S). 
 
Methyl-2-((4-chlorophenyl)(hydroxy)methyl)acrylate (106f) 
OH O
OCH3
Cl  
1H NMR (400 MHz, CDCl3): δ/ppm = 7.31 (s, 4H, ar-H), 6.34 (s, 1H, olefinic-H), 5.83 (s, 1H, 
olefinic-H), 5.52 (s, 1H, ar-CH), 3.73 (s, 3H, OCH3), 2.76 (br s, 1H, OH). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 166.8, 141.8, 139.9, 133.7, 128.7, 128.1, 126.5, 72.9, 
52.2. 
HPLC (Daicel Chiracel IC, heptane/i-PrOH = 90:10, 0.5 mL/min, 25 °C): tR (major) = 15.6 min, 
tR (minor) = 21.9 min, 90% ee (S). 
 
Methyl-2-((4-bromophenyl)(hydroxy)methyl)acrylate (106g) 
OH O
OCH3
Br  
1H NMR (400 MHz, CDCl3): δ/ppm = 7.45-7.34 (m, 2H, ar-H), 7.23-7.15 (m, 2H, ar-H), 6.27 (s, 1H, 
olefinic-H), 5.75 (s, 1H, olefinic-H), 5.44 (s, 1H, ar-CH), 3.66 (s, 3H, OCH3), 2.74 (br s, 1H, OH). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 166.8, 141.7, 140.5, 131.7, 128.4, 126.6, 121.9, 72.9, 
52.2. 
HPLC (Daicel Chiracel IC, heptane/i-PrOH = 90:10, 0.5 mL/min, 25 °C): tR (major) = 14.0 min, 
tR (minor) = 22.0 min, 92% ee (S). 
Methyl-2-(hydroxy(phenyl)methyl)acrylate (106h) 
OH O
OCH3
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1H NMR (400 MHz, CDCl3): δ/ppm = 7.42-7.31 (m, 5H, ar-H), 6.34 (s, 1H, olefinic-H), 5.84 (s, 1H, 
olefinic-H), 5.57 (s, 1H, ar-CH), 3.72 (s, 3H, OCH3), 3.04 (br s, 1H, OH). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 166.0, 142.1, 141.4, 128.6, 128.0, 126.7, 126.3, 73.4, 
52.1. 
HPLC (Daicel Chiracel IC, heptane/i-PrOH = 90:10, 0.5 mL/min, 25 °C): tR (major) = 18.5 min, 
tR (minor) = 34.4 min, 90% ee (S). 
 
Methyl-2-(hydroxy(pyridin-3-yl)methyl)acrylate (106i) 
N
OH O
OCH3
 
1H NMR (400 MHz, CDCl3): δ/ppm = 8.54 (d, 4JHH = 2.2 Hz, 1H, ar-H), 8.45 (dd, 3JHH = 4.9 Hz, 
4JHH = 1.7 Hz, 1H, ar-H), 7.75-7.72 (m, 1H, ar-H), 7.29-7.25 (m, 1H, ar-H), 6.38 (s, 1H, olefinic-H), 
5.94 (s, 1H, olefinic-H), 5.60 (s, 1H, ar-CH), 3.80 (br s, 1H, OH), 3.71 (s, 3H, OCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 166.5, 148.8, 148.3, 141.6, 137.5, 134.8, 126.6, 123.6, 
71.1, 52.2. 
HPLC (Daicel Chiracel IC, heptane/i-PrOH = 70:30, 0.5 mL/min, 25 °C): tR (major) = 23.7 min, 
tR (minor) = 39.7 min, 90% ee (S). 
 
Methyl-2-(furan-2-yl(hydroxy)methyl)acrylate (106j) 
OH O
OCH3
O
 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.37 (dd, 3JHH = 1.8 Hz, 4JHH = 0.9 Hz, 1H, furyl-H), 6.39 (s, 
1H, olefinic-H), 6.33 (dd, 3JHH = 3.3 Hz, 3JHH = 1.8 Hz, 1H), 6.27-6.26 (m, 1H, furyl-H), 5.94 (s, 1H, 
olefinic-H), 5.59 (d, 3JHH = 5.6 Hz, 1H, ar-CH), 3.76 (s, 3H, OCH3), 3.10 (d, 3JHH = 6.5 Hz, 1H, OH). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 166.6, 154.3, 142.5, 139.6, 127.0, 110.6, 107.3, 67.6, 
52.2. 
HPLC (Daicel Chiracel OD-H, heptane/i-PrOH = 90:10, 0.5 mL/min, 40 °C): tR (major) = 18.4 min, 
tR (minor) = 19.3 min, 80% ee (S). 
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Methyl-2-(hydroxy(p-tolyl)methyl)acrylate (106k) 
OH O
OCH3
 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.26 (d, 3JHH = 8.0 Hz, 2H, ar-H), 7.15 (d, 3JHH = 7.9 Hz, 1H, 
ar-H), 6.33 (s, 1H, olefinic-H), 5.85 (s, 1H, olefinic-H), 5.53 (s, 1H, ar-CH), 3.71 (s, 3H, OCH3), 
2.85 (s, 3H, CH3), 2.34 (br s, 1H, OH). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 166.9, 142.2, 138.5, 137.7, 129.3, 126.6, 126.0, 73.2, 
52.0, 21.3. 
HPLC (Daicel Chiracel IC, heptane/i-PrOH = 90:10, 0.5 mL/min, 25 °C): tR (major) = 21.0 min, 
tR (minor) = 36.3 min, 85% ee (S). 
 
Methyl-2-(cyclohexyl(hydroxy)methyl)acrylate (106l) 
OH O
OCH3
 
1H NMR (400 MHz, CDCl3): δ/ppm = 6.24 (s, 1H, olefinic-H), 5.72 (s, 1H, olefinic-H), 4.06 (d, 3JHH 
= 7.4 Hz, 1H, CHOH), 3.77 (s, 3H, OCH3), 2.57 (s, 1H, OH), 2.01-1.90 (m, 1H, CH), 1.79-1.49 (m, 
6H, CH2), 1.28-1.08 (m, 2H, CH2), 1.02-0.91 (m, 2H, CH2).  
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 167.3, 141.1, 126.4, 52.0, 42.5, 30.1, 28.5, 26.5, 26.2, 
26.1. 
HPLC (Daicel Chiracel OD-H, heptane/i-PrOH = 97:3, 0.7 mL/min, 25 °C): tR (minor) = 8.9 min, 
tR (major) = 9.9 min, 30% ee (S).  
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5.3 Asymmetric Cross-Benzoin Reaction 
5.3.1 Synthesis of Morphopline-Based Triazolium Salts 
General Procedure (GP8): Synthesis of triazolium salts 
In the glovebox, a heat-gun dried round-bottomed flask was charged with the lactam (1.0 eq.) and 
CH2Cl2 (5 ml per mmol lactam). Then, trimethyloxonium tetrafluoroborate (1.1 eq. or 1.2 eq.) was 
added in one portion to the reaction mixture. The resulting solution was stirred for 16 hours at 
room temperature. Then, the hydrazine (1.1 eq.) was added in one portion and after stirring for 
four hours at room temperature the reaction flask was taken out of the glovebox and the crude 
mixture was concentrated under vacuum. The resulting solid was dissolved in trimethyl 
orthoformate (8.0 eq. or 50 eq.) and MeCN (only in some cases, 5 mL per mmol lactam) and 
refluxed at 80 °C for six to 48 hours. Afterwards, the crude product was concentrated under 
vacuum and purified by column chromatography. In some cases, an additional purification step 
(recrystallization or second column chromatography) was needed to get the pure product. 
 
(S)-5-(tert-Butyl)-2-(perfluorophenyl)-5,6-dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-2-ium 
tetrafluoroborate (113b) 
O
N
N
N
F F
F
FF
BF4  
According to general procedure GP8, (S)-5-(tert-butyl)morpholin-3-one (112b) (500 mg, 
3.18 mmol) in CH2Cl2 (13 mL) and trimethyloxonium tetrafluoroborate (517 mg, 3.50 mmol) were 
stirred to give of the crude imidate. Then, pentafluorophenylhydrazine (693 mg, 3.50 mmol) was 
added and stirred for six hours. After concentration of the reaction mixture the crude solid was 
dissolved in trimethyl orthoformate (2.78 mL, 2.70 g, 25.4 mmol) and refluxed for 48 hours at 
80 °C. The crude product was purified by column chromatography (SiO2, CH2Cl2:MeOH (70:1), 
d x h: 3.5 x 15 cm) and recrystallization in chloroform to afford the product 113b (470 mg, 
1.08 mmol, 34%) as a white solid.  
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C15H15F5N3O·BF4 (435.10 g/mol): 
MP: 113-114 °C.  
TLC: Rf = 0.47 (SiO2, CH2Cl2:MeOH (10:1)). 
1H NMR (400 MHz, DMSO-d6): δ/ppm = 10.95 (s, 1H, carbene-CH), 5.41 (d, 2JHH = 16.8 Hz, 1H, 
OCH2), 5.04 (d, 2JHH = 16.8 Hz, 1H, OCH2), 4.54-4.48 (m, 2H, CHCH2), 4.01 (dd, 3JHH = 13.3 Hz, 
3JHH = 3.9 Hz, 1H, CHCH2), 1.07 (s, 9H, C(CH3)3). 
13C{1H} NMR (101 MHz, DMSO-d6): δ/ppm = 151.4, 146.8, 64.8, 64.1, 61.4, 35.3, 27.1. 
19F{1H} NMR (376 MHz, DMSO-d6): δ/ppm = −145.2-−145.3 (m), −147.5-−147.6 (m), −148.4, 
−159.9-−160.1 (m). 
IR (ATR): 𝑣𝑣�/cm-1 = 3124 (w), 2969 (w), 2879 (w), 1591 (m), 1539 (s), 1515 (s), 1477 (s), 1212 (w), 
1075 (s), 1036 (s), 987 (s), 908 (m), 845 (m), 736 (m), 522 (w), 460 (w), 443 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C15H15F5N3O+: 348.1130 [M]+; found: 
348.1127. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +4.9 (c = 0.51, MeOH).  
 
General Procedure (GP9): Synthesis of lactams derived from amino alcohols  
Step 1 (only for cases with a cbz-protected amino alcohol): Under argon atmosphere, a heat-gun 
dried round-bottomed flask was charged with cbz-protected amine (1.0 eq). and MeOH (3.3 mL 
per mmol amine). Then, Pd/C (10% Pd basis, 78 mg per mmol amine) was added to the reaction 
mixture and afterwards the argon atmosphere was changed to a hydrogen atmosphere using a 
hydrogen filled balloon. After 16 hours reaction time under an hydrogen atmosphere (balloon), the 
hydrogen atmosphere was changed to a argon atmosphere by bubbling argon through the reaction 
solution. Afterwards, the reaction mixture was filtered over Celite, the Celite cake was washed 
with EtOAc (3 x 3 mL per mmol amine) and after concentration under vacuum the corresponding 
crude amine was isolated without any further purification steps and directly used for the next step. 
Step 2: Under argon atmosphere, a heat-gun dried two-necked flask was charged with the crude 
amine (1.0 eq.) and CH2Cl2 (5 mL per mmol amine). The corresponding solution was cooled in an 
ice-bath and at 0 °C triethylamine (1.3 eq.) was added followed by dropwise addition of 
chloroacetyl chloride (1.1 eq.) over 15 minutes. After complete addition, the reaction was stirred 
for 30 minutes at 0 °C and for further six hours at room temperature. Afterwards saturated aqueous 
NH4Cl solution (5 mL per mmol amine) was added and the biphasic mixture was extracted with 
CH2Cl2 (3 x 5 mL per mmol amine), the combined organic layers were washed with brine (5 mL 
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per mmol amine), dried over Na2SO4, filtered and concentrated under vacuum to yield the 
corresponding chloro acetamide which was directly used for the next step without any further 
purification steps.  
Step 3: Under argon atmosphere a heat-gun dried two-neck flask was charged with the crude 
chloro acetamide (1.0 eq) and THF (5 mL pro chloro acetamide). The corresponding solution was 
cooled in an ice-bath and sodium hydride (60% in mineral oil, 1.5 eq.) was added over one hour 
at 0 °C. After completed addition the reaction was stirred for 30 minutes at 0 °C and further six 
hours at 75 °C. Afterwards, the reaction mixture was quenched by slowly addition of saturated 
aqueous NH4Cl solution (5 mL per mmol chloro acetamide) and then the biphasic mixture was 
extracted with EtOAc (3 x 5 mL per mmol chloro acetamide). The combined organic layers were 
washed with brine (5 mL per mmol chloro acetamide), dried over Na2SO4, filtered and 
concentrated under vacuum. The crude was purified by column chromatography to yield the 
corresponding lactam. 
 
(S)-5-Phenylmorpholin-3-one (112c) 
O
O
N
H
 
According to general procedure GP9, (S)-(+)-2-phenylglycinol (111c) (2.50 g, 18.2 mmol) in 
CH2Cl2 (90 mL), triethylamine (2.39 g, 3.33 mL, 23.7 mmol) and chloroacetyl chloride (2.26 g, 
1.59 mL, 20.0 mmol) were stirred. In the next step the crude chloro acetamide was dissolved in 
THF (90 mL) and sodium hydride (60% in mineral oil, 1.09 g, 24.0 mmol) was added and stirred. 
The crude mixture was purified by column chromatography (SiO2, CH2Cl2:ethyl acetate (2:1), d x 
h: 3.5 x 19 cm) to afford the product 112c (1.67 g, 9.41 mmol, 52%) as a pale yellow solid. 
 
C10H11NO2 (177.20 g/mol): 
MP: 135-136 °C. 
TLC: Rf = 0.32 (SiO2, CH2Cl2:ethyl acetate (2:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.44-7.31 (m, 5H, ar-H), 6.24 (br s, 1H, NH), 4.75 (dd, 
3JHH = 8.3 Hz, 3JHH = 4.2 Hz, 1H, NCH), 4.32 (d, 2JHH = 16.7 Hz, 1H, OCH2), 4.23 (d, 2JHH = 16.7 Hz, 
1H, OCH2), 4.05 (dd, 3JHH = 11.8 Hz, 3JHH = 4.2 Hz, 1H, NCHCH2), 3.56 (dd, 3JHH = 11.8 Hz, 
3JHH = 8.4 Hz, 1H, NCHCH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 169.1, 137.7, 129.1, 128.8, 126.7, 70.3, 67.9, 56.7. 
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IR (ATR): 𝑣𝑣�/cm-1 = 3180 (w), 3045 (w), 2890 (w), 2860 (w), 1668 (s), 1412 (m), 1341 (s), 1314 (m), 
1286 (m), 1122 (s), 1067 (m), 966 (m), 945 (m), 799 (m), 762 (s), 701 (s), 527 (m), 475 (s), 439 (s). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C10H11NO2+: 200.0682 [M+Na]+; found: 
200.0680. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +75.5 (c = 0.98, MeOH).  
 
(S)-2-(Perfluorophenyl)-5-phenyl-5,6-dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-2-ium 
tetrafluoroborate (113c) 
O
N
N
N
F F
F
FF
BF4  
According to general procedure GP8, (S)-3-phenylmorpholine (112c) (571 mg, 3.22 mmol) in 
CH2Cl2 (16 mL) and trimethyloxonium tetrafluoroborate (524 mg, 3.54 mmol) were stirred to give 
of the crude imidate. Then, pentafluorophenylhydrazine (702 mg, 3.54 mmol) was added and 
stirred for four hours. After concentration of the reaction mixture the crude solid was dissolved in 
trimethyl orthoformate (1.41 mL, 1.37 g, 12.9 mmol) and MeCN (16 mL) and refluxed for 18 hours 
at 80 °C. The crude product was purified by recrystallization from chloroform to afford the product 
113c (60 mg, 132 µmol, 4%) as a white solid. 
 
C17H11F5N3O·BF4 (368.08 g/mol): 
MP: 103-104 °C.  
1H NMR (400 MHz, acetone-d6): δ/ppm = 10.37 (s, 1H, carbene-CH), 7.70-7.65 (m, 2H, ar-H), 
7.56-7.46 (m, 3H, ar-H), 6.12 (dd, 3JHH = 7.8 Hz, 3JHH = 4.5 Hz, 1H, NCH), 5.47 (s, 2H, OCH2), 
4.60 (dd, 3JHH = 12.6 Hz, 3JHH = 4.5 Hz, 1H, CHCH2), 4.40 (dd, 3JHH = 12.6 Hz, 3JHH = 7.8 Hz, 1H, 
CHCH2). 
13C{1H} NMR (101 MHz, acetone-d6): δ/ppm = 153.1, 134.4, 131.0, 130.3, 129.1, 69.6, 62.6, 62.2. 
19F{1H} NMR (376 MHz, acetone-d6): δ/ppm = −146.5-−146.7 (m), −149.7-−150.0 (m), −153.5, 
−161.9-−162.1 (m). 
IR (ATR): 𝑣𝑣�/cm-1 = 3114 (w), 1592 (w), 1526 (m), 1377 (w), 1022 (s), 1002 (s), 918 (m), 853 (m), 
702 (w), 518 (w), 474 (m), 462 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C17H11F5N3O+: 368.0817 [M]+; found: 
368.0822. 
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[𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +58.1 (c = 0.58, MeOH).  
 
(S)-5-Cyclohexylmorpholin-3-one (112d) 
O
O
N
H
 
An autoclave inlet was charged with (S)-5-phenylmorpholin-3-one (112c) (400 mg, 2.26 mmol) 
and MeOH (5 mL). To the corresponding mixture Rhodium on alox (5 wt.%, 100 mg) was added 
and this mixture was put in an autoclave. After purging three times with hydrogen the reaction 
mixture was stirred for 16 hours at 10 bar hydrogen pressure. Then, the mixture was filtered 
through Celite and the Celite cake was washed with EtOAc (3 x 10 mL). The crude mixture was 
concentrated under vacuum to yield the product 112d (410 mg, 2.24 mmol, 99%) as a beige solid.  
 
C10H17NO2 (183.25 g/mol): 
MP: 89-90 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 6.22 (s, 1H, NH), 4.18 (d, 2JHH = 16.7 Hz, 1H, OCH2), 4.09 (d, 
2JHH = 16.6 Hz, 1H, OCH2), 3.88 (dd, 3JHH = 11.8 Hz, 3JHH = 4.0 Hz, 1H, NCHCH2), 3.62 (dd, 
3JHH = 11.8 Hz, 7.0 Hz, 1H, NCHCH2), 3.29 (tdd, 3JHH = 6.7 Hz, 3JHH = 4.0 Hz, 3JHH = 1.8 Hz, 1H, 
NCH), 1.83-1.75 (m, 3H, cy-CH, cy-CH2), 1.72-1.67 (m, 2H, cy-CH2), 1.51-1.41 (m, 1H, cy-CH2), 
1.30-1.14 (m, 3H, cy-CH2), 1.08-0.93 (m, 2H, cy-CH2).  
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 169.3, 67.8, 65.9, 56.4, 40.4, 28.8, 28.7, 26.1, 25.9, 25.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 3231 (w), 2928 (m), 2851 (m), 1666 (s), 1635 (m), 1449 (w), 1414 (w), 1358 (m), 
1329 (m), 1121 (m), 1099 (m), 959 (m), 753 (m), 700 (m), 469 (w), 454 (w), 428 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C10H17NO2+: 206.1151 [M+Na]+; found: 
200.1153. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +3.1 (c = 0.89, MeOH).  
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(S)-5-Cyclohexyl-2-(perfluorophenyl)-5,6-dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-2-ium 
tetrafluoroborate (113d) 
O
N
N
N
F F
F
FF
BF4  
According to general procedure GP8, (S)-3-cyclohexylmorpholine (112d) (420 mg, 2.29 mmol) in 
CH2Cl2 (12 mL) and trimethyloxonium tetrafluoroborate (406 mg, 2.75 mmol) were stirred to give 
of the crude imidate. Then, pentafluorophenylhydrazine (544 mg, 2.75 mmol) was added and 
stirred for four hours. After concentration of the reaction mixture the crude solid was dissolved in 
trimethyl orthoformate (2.00 mL, 1.947 g, 18.3 mmol) and MeCN (12 mL) and refluxed for 18 hours 
at 80 °C. The crude product was purified by recrystallization from chloroform to afford the product 
113d (202 mg, 437 µmol, 19%) as a white solid. 
 
C17H17F5N3O·BF4 (374.33 g/mol): 
MP: 115-116 °C.  
TLC: Rf = 0.43 (SiO2, CH2Cl2:MeOH (20:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = δ 10.14 (s, 1H, carbene-CH), 5.12 (d, 2JHH = 16.5 Hz, 1H, 
OCH2), 4.99 (d, 2JHH = 16.4 Hz, 1H, OCH2), 4.55 (dd, 3JHH = 7.0 Hz, 3JHH = 3.2 Hz, 1H, NCH), 
4.32 (d, 3JHH = 13.2 Hz, 1H, CHCH2), 4.20 (dd, 3JHH = 13.0 Hz, 3JHH = 3.5 Hz, 1H, CHCH2), 2.06-
1.96 (m, 1H, cy-CH2), 1.89-1.78 (m, 2H, cy-CH2), 1.75-1.67 (m, 1H, cy-CH2), 1.67-1.54 (m, 2H, 
cy-CH2), 1.35-1.13 (m, 5H, cy-CH, cy-CH2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 151.1, 146.2, 144.9-143.9 (m), 143.1-142.7 (m), 142.3-
141.6 (m), 139.9-138.9 (m), 64.1, 61.8, 61.5, 40.7, 29.3, 28.6, 25.8, 25.7. 
19F{1H} NMR (376 MHz, CDCl3): δ/ppm = −144.59-−144.77 (m), −146.17-−146.35 (m), −152.30, 
−158.87-−159.23 (m). 
IR (ATR): 𝑣𝑣�/cm-1 = 2932 (m), 2857 (w), 1592 (w), 1527 (s), 1451 (m), 1073 (s), 1030 (s), 986 (s), 
881 (w), 852 (m), 731 (w), 678 (w), 522 (m), 460 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C17H17F5N3O+: 374.1286 [M]+; found: 
374.1289. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −16.3 (c = 0.49, MeOH).  
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(S)-6,6-Dimethyl-5-phenylmorpholin-3-one (116a) 
O
O
N
H
 
According to general procedure GP9, (S)-1-amino-2-methyl-1-phenylpropan-2-ol (115a) (1.85 g, 
11.2 mmol) in CH2Cl2 (56 mL), triethylamine (1.47 g, 2.05 mL, 14.6 mmol) and chloroacetyl 
chloride (1.39 g, 980 µL, 12.3 mmol) were stirred. In the next step the crude chloro acetamide was 
dissolved in THF (56 mL) and sodium hydride (60% in mineral oil, 671 mg, 16.8 mmol) was added 
and stirred. The crude mixture was purified by column chromatography (SiO2, CH2Cl2:ethyl acetate 
(5:1), d x h: 3.5 x 19 cm) to afford the product 116a (617 mg, 3.00 mmol, 27%) as a pale yellow 
oil. 
 
C12H15NO2 (205.26 g/mol): 
TLC: Rf = 0.29 (SiO2, CH2Cl2:ethyl acetate (5:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = δ 7.39-7.33 (m, 3H, ar-H), 7.30-7.26 (m, 2H, ar-H), 6.30 (br 
s, 1H, NH), 4.47 (s, 1H, NCH), 4.28 (s, 2H, OCH2), 1.32 (s, 3H, C(CH3)2), 1.06 (s, 3H, C(CH3)2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 169.3, 137.9, 128.7, 128.7, 127.9, 73.5, 64.9, 63.4, 25.6, 
20.0. 
IR (ATR): 𝑣𝑣�/cm-1 = 3222 (w), 2979 (w), 2889 (w), 1660 (s), 1413 (w), 1347 (w), 1151 (w), 1099 (m), 
1073 (m), 698 (s), 464 (m), 425 (s). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C12H15NO2+: 228.1176 [M+Na]+; found: 
228.0995. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +2.0 (c = 0.50, MeOH).  
 
(S)-6,6-Dimethyl-2-(perfluorophenyl)-5-phenyl-5,6-dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]-
oxazin-2-ium tetrafluoroborate (117a) 
O
N
N
N
F F
F
FF
BF4  
According to general procedure GP8, (S)-2,2-dimethyl-3-phenylmorpholine (116a) (571 mg, 
2.78 mmol) in CH2Cl2 (14 mL) and trimethyloxonium tetrafluoroborate (452 mg, 3.06 mmol) were 
stirred to give of the crude imidate. Then, pentafluorophenylhydrazine (606 mg, 3.06 mmol) was 
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added and stirred for four hours. After concentration of the reaction mixture the crude solid was 
dissolved in trimethyl orthoformate (2.43 mL, 2.36 g, 22.2 mmol) and MeCN (14 mL) and refluxed 
for 18 hours at 80 °C. The crude product was purified by two column chromatography (SiO2, 
CH2Cl2:MeOH (100:1), d x h: 3.5 x 23 cm followed by SiO2, cyclohexane:ethyl acetate (1:2), d x 
h: 2.5 x 14 cm)) to afford the product 117a (139 mg, 286 µmol, 10%) as a white solid. 
 
C19H15F5N3O·BF4 (396.34 g/mol): 
MP: 90-91 °C.  
TLC: Rf = 0.43 (SiO2, CH2Cl2:MeOH (20:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 9.81 (s, 1H, carbene-CH), 7.45-7.37 (m, 3H, ar-H), 7.32-
7.28 (m, 2H, ar-H), 5.78 (s, 1H, NCH), 5.31 (d, 2JHH = 17.5 Hz, 1H, OCH2), 5.20 (d, 2JHH = 17.4 Hz, 
1H, OCH2), 1.55 (s, 3H, C(CH3)2), 1.16 (s, 3H, C(CH3)2). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 150.1, 146.9, 144.4-143.4 (m), 141.8-141.1 (m), 140.0-
139.1 (m), 137.4-136.6 (m), 133.8, 130.4, 129.6, 128.2, 75.0, 67.5, 56.6, 24.2, 23.8. 
19F{1H} NMR (376 MHz, CDCl3): δ/ppm = −144.4-−144.6 (m), −145.9-−146.2 (m), −152.3, −158.4-
−158.7 (m). 
IR (ATR): 𝑣𝑣�/cm-1 = 1591 (w), 1514 (s), 1455 (w), 1392 (w), 1375 (w), 1229 (w), 1071 (s), 1004 (s), 
987 (s), 858 (w), 837 (w), 701 (m), 520 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C19H15F5N3O+: 396.1130 [M]+; found: 
396.1131. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +68.4 (c = 0.59, MeOH).  
 
Benzyl ((3S,4R)-4-((tert-butyldimethylsilyl)oxy)-2-hydroxy-2-methylpentan-3-yl)carbamate 
(120a) 
TBDMSO
NHCbz
OH
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with methylmagnesium 
bromide solution (3M in ether, 6.19 g, 5.95 mL, 17.8 mmol) and was cooled in an ice-bath. Then, 
at 0 °C a solution of methyl N-((benzyloxy)carbonyl)-O-(tert-butyldimethylsilyl)-L-threoninate 
(119a) (1.70 g, 4.46 mmol) in ether (17 mL) was added dropwise over 10 minutes to the Grignard 
solution. After addition the reaction was stirred for one hour at 0 °C and further 16 hours at room 
temperature. Afterwards the reaction mixture was quenched by slowly addition of aqueous 
saturated NH4Cl solution (20 mL) at 0 °C. Then, the biphasic mixture was extracted with ether (3 x 
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50 mL), the combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered 
and concentrated under vacuum. The crude mixture was purified by column chromatography 
(SiO2, ethyl acetate:cyclohexane (1:3), d x h: 3.5 x 16 cm) to afford the product 120a (1.55 g, 
4.05 mmol, 91%) as a colorless oil.  
 
C20H35NO4Si (381.59 g/mol): 
TLC: Rf = 0.44 (SiO2, ethyl acetate:cyclohexane (1:3)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.40-7.29 (m, 5H, ar-H), 5.45 (d, 3JHH = 10.1 Hz, 1H, NH), 
5.17 (d, 2JHH = 12.3 Hz, 1H, Ph-CH2), 5.11 (d, 2JHH = 12.3 Hz, 1H, Ph-CH2), 4.47 (qd, 3JHH = 6.2 Hz, 
3JHH = 1.9 Hz, 1H, OCH), 3.54 (s, 1H, OH), 3.39 (dd, 3JHH = 10.1 Hz, 3JHH = 1.9 Hz, 1H, NCH), 
1.34 (s, 3H, C(CH3)2), 1.21 (d, 3JHH = 6.2 Hz, 3H, CHCH3), 1.17 (s, 3H, C(CH3)2), 0.89 (s, 9H, 
SiC(CH3)3), 0.14 (s, 3H, SiCH3), 0.13 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 157.5, 136.8, 128.7, 128.2, 128.1, 73.4, 69.9, 67.0, 61.4, 
27.7, 27.2, 26.0, 21.5, 18.0, −2.9, −4.6. 
IR (ATR): 𝑣𝑣�/cm-1 = 3494 (w), 3445 (w), 2930 (m), 2857 (w), 1723 (s), 1499 (s), 1374 (m), 1303 (m), 
1214 (s), 1165 (m), 1123 (m), 1058 (s), 924 (s), 834 (s), 774 (s), 696 (m), 527 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C20H35NO4Si+: 404.2228 [M+Na]+; found: 
404.2301. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +11.1 (c = 0.38, MeOH).  
 
Benzyl ((3S,4S)-4-((tert-butyldimethylsilyl)oxy)-2-hydroxy-2-methylpentan-3-yl)carbamate 
(120b) 
TBDMSO
NHCbz
OH
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with methylmagnesium 
bromide solution (3M in ether, 7.63 g, 7.33 mL, 22.0 mmol) and was cooled in an ice-bath. Then, 
at 0 °C a solution of benzyl ((3S,4S)-4-((tert-butyldimethylsilyl)oxy)-2-hydroxy-2-methylpentan-3-
yl)carbamate (119b) (2.10 g, 5.50 mmol) in ether (16 mL) was added dropwise over 10 minutes 
to the Grignard solution. After addition the reaction was stirred for one hour at 0 °C and further 
16 hours at room temperature. Afterwards the reaction mixture was quenched by slowly addition 
of aqueous saturated NH4Cl solution (20 mL) at 0 °C. Then, the biphasic mixture was extracted 
with ether (3 x 50 mL), the combined organic layers were washed with brine (20 mL), dried over 
Na2SO4, filtered and concentrated under vacuum. The crude mixture was purified by column 
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chromatography (SiO2, ethyl acetate:cyclohexane (1:3), d x h: 3.5 x 14 cm) to afford the product 
120b (2.09 g, 5.48 mmol, 99%) as a colorless oil.  
 
C20H35NO4Si (381.59 g/mol): 
TLC: Rf = 0.38 (SiO2, ethyl acetate:cyclohexane (1:3)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.30-7.19 (m, 5H, ar-H), 5.16 (d, 3JHH = 9.5 Hz, 1H, NH), 
5.04 (d, 2JHH = 12.2 Hz, 1H, Ph-CH2), 4.99 (d, 2JHH = 12.3 Hz, 1H, Ph-CH2), 4.04-3.97 (m, 1H, 
OCH), 3.75 (s, 1H, OH), 3.38 (dd, 3JHH = 9.4 Hz, 3JHH = 4.2 Hz, 1H, NCH), 1.27 (s, 3H, C(CH3)2), 
1.24 (d, 3JHH = 6.7 Hz, 3H, CHCH3), 1.09 (s, 3H, C(CH3)2), 0.79 (s, 9H, SiC(CH3)3), 0.00 (s, 3H, 
SiCH3), −0.02 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 156.5, 136.7, 128.7, 128.2, 128.1, 73.8, 73.3, 66.9, 62.0, 
28.7, 27.1, 25.9, 22.6, 18.0, −4.0, −4.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 3442 (w), 2930 (m), 2857 (w), 1698 (s), 1509 (m), 1376 (m), 1251 (s), 1090 (s), 
1004 (s), 918 (w), 829 (s), 774 (s), 695 (s), 569 (w), 488 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C20H35NO4Si+: 404.2228 [M+Na]+; found: 
404.2227. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +25.4 (c = 1.06, MeOH).  
 
Benzyl ((2R,3S)-2-((tert-butyldimethylsilyl)oxy)-4-ethyl-4-hydroxyhexan-3-yl)carbamate 
(120c) 
TBDMSO
NHCbz
OH
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with ethylmagnesium 
bromide solution (3M in ether, 3.99 g, 10.1 mL, 30.4 mmol) and was cooled in an ice-bath. Then, 
at 0 °C a solution of methyl N-((benzyloxy)carbonyl)-O-(tert-butyldimethylsilyl)-L-threoninate 
(119a) (2.90 g, 7.60 mmol) in ether (20 mL) was added dropwise over 10 minutes to the Grignard 
solution. After addition the reaction was stirred for one hour at 0 °C and further 16 hours at room 
temperature. Afterwards the reaction mixture was quenched by slowly addition of aqueous 
saturated NH4Cl solution (20 mL) at 0 °C. Then, the biphasic mixture was extracted with ether (3 x 
50 mL), the combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered 
and concentrated under vacuum. The crude mixture was purified by column chromatography 
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(SiO2, ethyl acetate:cyclohexane (1:4), d x h: 3.5 x 21 cm) to afford the product 120c (2.48 g, 
6.07 mmol, 80%) as a colorless oil.  
 
C22H39NO4Si (409.64 g/mol): 
TLC: Rf = 0.53 (SiO2, ethyl acetate:cyclohexane (1:4)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.40-7.29 (m, 5H, ar-H), 5.43 (d, 3JHH = 10.1 Hz, 1H, NH), 
5.16 (d, 2JHH = 12.4 Hz, 1H, Ph-CH2), 5.11 (d, 2JHH = 12.3 Hz, 1H, Ph-CH2), 4.43 (qd, 3JHH = 6.2 Hz, 
3JHH = 1.9 Hz, 1H, OCH), 3.51 (dd, 3JHH = 10.2 Hz, 3JHH = 1.9 Hz, 1H, NCH), 3.43 (s, 1H, OH), 
1.78-1.61 (m, 1H, CH2CH3), 1.61-1.36 (m, 3H, CH2CH3), 0.92-0.90 (m, 3H, CH2CH3), 0.91 (d, 
3JHH = 7.5 Hz, 3H, CH2CH3), 0.88 (s, 9H, SiC(CH3)3), 0.81 (t, 3JHH = 7.6 Hz, 3H, CHCH3), 0.14 (s, 
3H, SiCH3), 0.12 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 157.3, 136.9, 128.6, 128.2, 128.0, 77.8, 70.0, 66.9, 58.0, 
28.2, 26.8, 26.0, 21.3, 18.0, 7.9, 7.7, −2.9, −4.7. 
IR (ATR): 𝑣𝑣�/cm-1 = 3499 (m), 2955 (m), 2858 (w), 1723 (s), 1498 (s), 1462 (m), 1314 (w), 1256 (m), 
1215 (s), 1126 (w), 1058 (s), 936 (s), 883 (m), 835 (s), 775 (s), 735 (m), 695 (m), 497 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C22H39NO4Si+: 432.2541 [M+Na]+; found: 
432.2542. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +20.1 (c = 0.70, MeOH).  
 
Benzyl ((2S,3R)-3-((tert-butyldimethylsilyl)oxy)-1-hydroxy-1,1-diphenylbutan-2-yl)- 
carbamate (120d) 
TBDMSO
NHCbz
OH
Ph Ph
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with phenylmagnesium 
bromide solution (3M in ether, 8.04 g, 8.04 mL, 24.1 mmol) and was cooled in an ice-bath. Then, 
at 0 °C a solution of methyl N-((benzyloxy)carbonyl)-O-(tert-butyldimethylsilyl)-L-threoninate 
(119a) (2.30 g, 6.03 mmol) in ether (17 mL) was added dropwise over 10 minutes to the Grignard 
solution. After addition the reaction was stirred for one hour at 0 °C and further 16 hours at room 
temperature. Afterwards the reaction mixture was quenched by slowly addition of aqueous 
saturated NH4Cl solution (20 mL) at 0 °C. Then, the biphasic mixture was extracted with ether (3 x 
50 mL), the combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered 
and concentrated under vacuum. The crude mixture was purified by column chromatography 
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(SiO2, ethyl acetate:cyclohexane (1:6), d x h: 4.5 x 20 cm) to afford the product 120d (2.48 g, 
6.07 mmol, 80%) as a white solid.   
 
C30H39NO4Si (505.73 g/mol): 
MP: 99-100 °C.  
TLC: Rf = 0.55 (SiO2, ethyl acetate:cyclohexane (1:4)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.60-7.53 (m, 4H, ar-H), 7.35-7.19 (m, 8H, ar-H), 7.18-
7.09 (m, 3H, ar-H), 5.57 (d, 3JHH = 9.9 Hz, 1H, NH), 5.23 (s, 1H, OH), 5.09 (d, 2JHH = 12.6 Hz, 1H, 
OCH2), 4.92 (d, 2JHH = 12.6 Hz, 1H, OCH2), 4.65 (dd, 3JHH = 10.0 Hz, 3JHH = 1.6 Hz, 1H, NCH), 
4.25 (qd, 3JHH = 6.3 Hz, 3JHH = 1.6 Hz, 1H, CHCH3), 1.23 (d, 3JHH = 6.3 Hz, 3H, CHCH3), 0.89 (s, 
9H, SiC(CH3)3), 0.00 (s, 3H, SiCH3), −0.17 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 157.1, 145.8, 144.9, 136.8, 128.6, 128.5, 128.2, 127.9, 
127.7, 127.0, 126.7, 125.4, 125.1, 81.5, 70.7, 66.6, 59.4, 26.1, 21.5, 18.0, −3.0, −4.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 3369 (m), 3028 (w), 2952 (w), 2927 (w), 2858 (w), 1718 (s), 1499 (s), 1450 (m), 
1307 (m), 1257 (m), 1211 (m), 1180 (s), 1069 (s), 939 (s), 870 (m), 836 (m), 749 (s), 696 (s), 597 
(w), 489 (s). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C30H39NO4Si+: 528.2541 [M+Na]+; found: 
528.2546. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +32.8 (c = 0.70, MeOH).  
 
(S)-5-((R)-1-((tert-Butyldimethylsilyl)oxy)ethyl)-6,6-dimethylmorpholin-3-one (121a) 
O
O
N
H
TBDMSO
 
According to general procedure GP9, benzyl ((3S,4R)-4-((tert-butyldimethylsilyl)oxy)-2-hydroxy-
2-methylpentan-3-yl)carbamate (120a) (1.70 g, 4.46 mmol) in MeOH (15 mL) and Pd/C (350 mg) 
were stirred to give of the crude amine as a colorless oil (1.09 g, 4.46 mmol, 98%). 
Then, the crude amine (1.06 g, 4.28 mmol) in CH2Cl2 (22 mL), triethylamine (563 mg, 782 µL, 
5.56 mmol) and chloroacetyl chloride (532 mg, 374 µL, 4.71 mmol) were stirred. In the next step 
the crude chloro acetamide was dissolved in THF (22 mL) and sodium hydride (60% in mineral 
oil, 257 mg, 6.42 mmol) was added and stirred. The crude mixture was purified by column 
chromatography (SiO2, CH2Cl2:ethyl acetate (1:1), d x h: 3.5 x 17 cm) to afford the product 121a 
(895 mg, 3.11 mmol, 73%) as a pale yellow oil. 
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C14H29NO3Si (287.47 g/mol): 
TLC: Rf = 0.40 (SiO2, CH2Cl2:ethyl acetate (1:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 6.24 (s, 1H, NH), 4.16 (d, 2JHH = 17.3 Hz, 1H, OCH2), 4.10 (d, 
2JHH = 17.4 Hz, 1H, OCH2), 3.78 (p, 3JHH = 5.9 Hz, 1H, OCH), 3.17-3.13 (m, 1H, NCH), 1.34 (s, 
3H, C(CH3)2), 1.27-1.23 (m, 6H, C(CH3)2, CHCH3), 0.91 (s, 9H, SiC(CH3)3), 0.11 (s, 3H, SiCH3), 
0.10 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 169.0, 72.1, 67.6, 65.0, 63.0, 27.0, 26.0, 22.8, 20.1, 18.1, 
−3.7, −4.6. 
IR (ATR): 𝑣𝑣�/cm-1 = 3207 (w), 2929 (m), 2889 (m), 2856 (w), 1674 (s), 1427 (w), 1253 (m), 1171 (m), 
1085 (s), 1006 (w), 937 (w), 833 (s), 772 (s), 434 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C14H29NO3Si+: 310.1809 [M+Na]+; found: 
310.1813. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −20.7 (c = 1.73, MeOH).  
 
(S)-5-((S)-1-((tert-Butyldimethylsilyl)oxy)ethyl)-6,6-dimethylmorpholin-3-one (121b) 
O
O
N
H
TBDMSO
 
According to general procedure GP9, benzyl ((3S,4S)-4-((tert-butyldimethylsilyl)oxy)-2-hydroxy-2-
methylpentan-3-yl)carbamate (120b) (1.80 g, 4.72 mmol) in MeOH (16 mL) and Pd/C (400 mg) 
were stirred to give of the crude amine as a colorless oil (1.16 g, 4.67 mmol, 99%). 
Then, the crude amine (1.15 g, 4.65 mmol) in CH2Cl2 (24 mL), triethylamine (612 mg, 850 µL, 
6.05 mmol) and chloroacetyl chloride (578 mg, 407 µL, 5.12 mmol) were stirred. In the next step 
the crude chloro acetamide was dissolved in THF (24 mL) and sodium hydride (60% in mineral 
oil, 279 mg, 6.98 mmol) was added and stirred. The crude mixture was purified by column 
chromatography (SiO2, CH2Cl2:ethyl acetate (1:1), d x h: 3.5 x 18 cm) to afford the product 121b 
(969 mg, 3.37 mmol, 73%) as a white solid. 
 
C14H29NO3Si (287.47 g/mol): 
MP: 56-57 °C.  
TLC: Rf = 0.52 (SiO2, CH2Cl2:ethyl acetate (1:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 6.15 (s, 1H, NH), 4.19 (d, 3JHH = 17.4 Hz, 1H, OCH2), 4.14 (d, 
3JHH = 17.4 Hz, 1H, OCH2), 4.05 (qd, 3JHH = 6.1 Hz, 3JHH = 2.8 Hz, 1H, OCH), 3.19 (t, 3JHH = 3.1 Hz, 
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1H, NCH), 1.40 (s, 3H, C(CH3)2), 1.26 (s, 3H, C(CH3)2), 1.18 (d, 3JHH = 6.1 Hz, 3H, CHCH3), 0.87 (s, 
9H, SiC(CH3)3), 0.07 (s, 3H, SiCH3), 0.06 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 169.2, 70.6, 68.4, 64.0, 63.0, 25.9, 25.2, 24.3, 18.1, 17.6, 
−4.3, −4.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 3357 (w), 2978 (w), 2935 (w), 1637 (s), 1350 (m), 1274 (m), 1164 (m), 1098 (s), 
1077 (m), 1031 (w), 832 (w), 641 (w), 420 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C14H29NO3Si+: 310.1809 [M+Na]+; found: 
310.1812. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −79.4 (c = 0.75, MeOH).  
 
(S)-5-((R)-1-((tert-Butyldimethylsilyl)oxy)ethyl)-6,6-diethylmorpholin-3-one (121c) 
O
O
N
H
TBDMSO
 
According to general procedure GP9, benzyl ((2R,3S)-2-((tert-butyldimethylsilyl)oxy)-4-ethyl-4-
hydroxyhexan-3-yl)carbamate (120c) (2.40 g, 5.86 mmol) in MeOH (19 mL) and Pd/C (550 mg) 
were stirred to give of the crude amine as a colorless oil (1.60 g, 5.81 mmol, 99%). 
Then the crude amine (1.60 g, 4.28 mmol) in CH2Cl2 (29 mL), triethylamine (764 mg, 1.06 mL, 
7.55 mmol) and chloroacetyl chloride (722 mg, 508 µL, 6.39 mmol) were stirred. In the next step 
the crude chloro acetamide was dissolved in THF (29 mL) and sodium hydride (60% in mineral 
oil, 349 mg, 8.72 mmol) was added and stirred. The crude mixture was purified by column 
chromatography (SiO2, CH2Cl2:ethyl acetate (1:1), d x h: 3.5 x 21 cm) to afford the product 121c 
(539 mg, 1.71 mmol, 29%) as a white solid. 
 
C16H33NO3Si (315.53 g/mol): 
MP: 83-84 °C.  
TLC: Rf = 0.33 (SiO2, CH2Cl2:ethyl acetate (1:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 6.56 (s, 1H, NH), 4.09 (d, 2JHH = 17.4 Hz, 1H, OCH2), 4.02 (d, 
2JHH = 17.4 Hz, 1H, OCH2), 3.93 (qd, 3JHH = 6.3 Hz, 3JHH = 4.0 Hz, 1H, OCH), 3.20 (dd, 
3JHH = 4.1 Hz, 3JHH = 2.8 Hz, 1H, NCH), 1.87-1.76 (m, 1H, CH2CH3), 1.78-1.61 (m, 2H, CH2CH3), 
1.41 (dq, 2JHH = 14.7 Hz, 3JHH = 7.4 Hz, 1H, CH2CH3), 1.22 (d, 3JHH = 6.3 Hz, 3H, CHCH3), 0.92-
0.84 (m, 15H, CH2CH3, SiC(CH3)3), 0.09 (s, 3H, SiCH3), 0.08 (s, 3H, SiCH3). 
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13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 170.0, 75.6, 66.9, 62.6, 60.4, 25.9, 25.8, 24.1, 22.3, 18.1, 
7.4, 7.3, −3.7, −4.5. 
IR (ATR): 𝑣𝑣�/cm-1 = 3195 (w), 3073 (w), 2927 (m), 2855 (m), 1673 (s), 1428 (w), 1353 (w), 1252 (m), 
1146 (m), 1086 (s), 972 (m), 935 (w), 831 (s), 771 (s), 702 (w), 491 (w), 439 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C16H33NO3Si+: 316.2302 [M+H]+; found: 
316.2303. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −20.5 (c = 0.82, MeOH).  
 
(S)-5-((R)-1-((tert-Butyldimethylsilyl)oxy)ethyl)-6,6-diphenylmorpholin-3-one (121d) 
O
O
N
H
TBDMSO
Ph
Ph
 
According to general procedure GP9, benzyl ((2S,3R)-3-((tert-butyldimethylsilyl)oxy)-1-hydroxy-
1,1-diphenylbutan-2-yl)-carbamate (120d) (1.80 g, 3.56 mmol) in MeOH (12 mL) and Pd/C 
(278 mg) were stirred to give of the crude amine as a colorless oil (1.30 g, 3.50 mmol, 98%). 
Then, the crude amine (1.28 g, 3.44 mmol) in CH2Cl2 (18 mL), triethylamine (453 mg, 629 µL, 
4.47 mmol) and chloroacetyl chloride (427 mg, 301 µL, 3.78 mmol) were stirred. In the next step 
the crude chloro acetamide was dissolved in THF (18 mL) and sodium hydride (60% in mineral 
oil, 206 mg, 5.16 mmol) was added and stirred. The crude mixture was purified by column 
chromatography (SiO2, CH2Cl2:ethyl acetate (20:1), d x h: 3.5 x 20 cm) to afford the product 121d 
(1.20 g, 2.90 mmol, 84%) as a white solid 
 
C24H33NO3Si (411.61 g/mol): 
MP: 196-197 °C.  
TLC: Rf = 0.27 (SiO2, CH2Cl2:ethyl acetate (20:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.48-7.40 (m, 2H, ar-H), 7.38-7.23 (m, 9H, ar-H, OH), 4.32 (d, 
2JHH = 17.0 Hz, 1H, OCH2), 4.04 (dd, 3JHH = 4.5 Hz, 3JHH = 3.1 Hz, 1H, NCH), 3.96 (d, 
2JHH = 17.0 Hz, 1H, OCH2), 3.85-3.78 (m, 1H, OCH), 0.96 (s, 9H, SiC(CH3)3), 0.94-0.87 (m, 3H, 
CHCH3), 0.08 (s, 3H, SiCH3), 0.00 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 169.9, 143.1, 141.8, 128.8, 128.4, 127.7, 127.5, 127.3, 
126.0, 79.8, 66.8, 63.9, 60.3, 26.0, 23.4, 18.1, −4.0, −4.5. 
IR (ATR): 𝑣𝑣�/cm-1 = 3191 (w), 3082 (w), 2926 (w), 2851 (w), 1681 (s), 1447 (w), 1366 (m), 1250 (m), 
1125 (m), 1068 (m), 965 (m), 862 (s), 831 (m), 769 (s), 696 (s), 622 (w), 508 (w), 462 (m). 
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HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C24H33NO3Si+: 434.2122 [M+Na]+; found: 
434.2121. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −268.9 (c = 1.02, MeOH).  
 
(S)-5-((R)-1-((tert-Butyldimethylsilyl)oxy)ethyl)-6,6-dimethyl-2-(perfluorophenyl)-5,6-
dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-2-ium tetrafluoroborate (122a) 
O
N
N
N
TBDMSO BF4
F
F
F
F
F
 
According to general procedure GP8, (S)-5-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-6,6-dimethyl-
morpholin-3-one (121a) (650 mg, 2.26 mmol) in CH2Cl2 (11 mL) and trimethyloxonium 
tetrafluoroborate (368 mg, 2.49 mmol) were stirred to give of the crude imidate. Then, 
pentafluorophenylhydrazine (492 mg, 2.49 mmol] was added and stirred for four hours. After 
concentration of the reaction mixture the crude solid was dissolved in trimethyl orthoformate 
(2.40 g, 2.48 mL, 22.6 mmol) and refluxed for 20 hours at 80 °C. The crude product was purified 
by column chromatography (SiO2, CH2Cl2:ethyl acetate (2:3), d x h: 3.5 x 16 cm) to afford the 
product 122a (300 mg, 531 µmol, 24%) as a beige solid. 
 
C21H29F5N3O2Si BF4 (478.56 g/mol): 
TLC: Rf = 0.38 (SiO2, CH2Cl2:ethyl acetate (1:3)). 
MP: 76-77 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 10.21 (s, 1H, carbene-CH), 5.06 (d, 2JHH = 17.4 Hz, 1H, 
OCH2), 4.97 (d, 2JHH = 17.5 Hz, 1H, OCH2), 4.68 (s, 1H, CHCH3), 4.50 (qd, 3JHH = 6.4 Hz, 
3JHH = 1.4 Hz, 1H, NCH), 1.53 (s, 3H, C(CH3)2), 1.41 (s, 3H, C(CH3)2), 1.36 (d, 3JHH = 6.7 Hz, 3H, 
CHCH3), 0.75 (s, 9H, SiC(CH3)3), 0.06 (s, 6H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 151.2, 146.5, 145.0-144.2 (m), 142.6-140.7 (m), 140.3-
138.4 (m), 137.4-135.9 (m), 73.7, 67.3, 65.3, 56.5, 25.5, 25.3, 23.4, 22.7, 17.8, −4.3, −4.5. 
19F{1H} NMR (376 MHz, CDCl3) δ/ppm = −144.8-−145.2 (m), −146.0-−146.6 (m), −151.3, 
−158.6-−159.1 (m). 
IR (ATR): 𝑣𝑣�/cm-1 = 2952 (w), 2860 (w), 1663 (s), 1529 (s), 1257 (m), 1235 (w), 1054 (s), 983 (s), 
836 (s), 776 (s), 704 (w), 521 (m). 
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HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C21H29F5N3O2Si+: 478.1944 [M]+; found: 
478.1943. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +15.0 (c = 0.70, MeOH).  
 
(S)-5-((S)-1-((tert-Butyldimethylsilyl)oxy)ethyl)-6,6-dimethyl-2-(perfluorophenyl)-5,6-
dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-2-ium tetrafluoroborate (122b) 
O
N
N
N
TBDMSO BF4
F
F
F
F
F
 
According to general procedure GP8, (S)-5-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-6,6-dimethyl-
morpholin-3-one (121b) (290 mg, 1.01 mmol) in CH2Cl2 (5 mL) and trimethyloxonium 
tetrafluoroborate (164 mg, 1.11 mmol) were stirred to give of the crude imidate. Then, 
pentafluorophenylhydrazine (240 mg, 1.21 mmol) was added and stirred for four hours. After 
concentration of the reaction mixture the crude solid was dissolved in trimethyl orthoformate 
(536 mg, 0.55 mL, 5.05 mmol) and refluxed for 18 hours at 80 °C. The crude product was purified 
by column chromatography (SiO2, CH2Cl2:ethyl acetate (2:3), d x h: 3.5 x 20 cm) to afford the 
product 122b (110 mg, 195 µmol, 19%) as a white solid. 
 
C21H29F5N3O2Si BF4 (478.56 g/mol): 
TLC: Rf = 0.43 (SiO2, CH2Cl2:ethyl acetate (1:3)). 
MP: 171-172 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 9.75 (s, 1H, carbene-CH), 5.12 (d, 2JHH = 17.5 Hz, 1H, OCH2), 
5.04 (d, 2JHH = 17.2 Hz, 1H, OCH2), 4.66 (d, 3JHH = 3.0 Hz, 1H, NCH), 4.42 (qd, 3JHH = 6.2 Hz, 
3JHH = 3.0 Hz, 1H, CHOTBDMS), 1.51 (s, 3H, C(CH3)2), 1.49 (s, 3H, C(CH3)2), 1.00 (d, 
3JHH = 6.2 Hz, 3H, CHCH3), 0.93 (s, 9H, SiC(CH3)3), 0.21 (s, 3H, SiCH3), 0.16 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 149.7, 146.9, 145.6-144.8 (m), 144.1-143.5 (m), 141.5-
140.9 (m), 139.8-138.9 (m), 72.5, 67.6, 66.4, 56.2, 25.8, 24.8, 23.6, 18.1, 18.0, −4.9, −5.1. 
19F{1H} NMR (376 MHz, CDCl3) δ/ppm = −144.9-−145.1 (m), −145.8 (tt, JFF = 21.5 Hz, 
JFF = 4.0 Hz), −152.3, −157.6-−157.9 (m). 
IR (ATR): 𝑣𝑣�/cm-1 = 2953 (w), 2925 (w), 2857 (w), 1529 (s), 1513 (s), 1254 (w), 1227 (w), 1088 (s), 
1072 (s), 1026 (s), 1001 (s), 981 (m), 843 (m), 811 (s), 777 (w), 522 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C21H29F5N3O2Si+: 478.1944 [M]+; found: 
478.1947. 
EXPERIMENTAL PART            CHAPTER 5 
298 
[𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −17.9 (c = 0.40, MeOH).  
 
(S)-5-((R)-1-((tert-Butyldimethylsilyl)oxy)ethyl)-6,6-diethyl-2-(perfluorophenyl)-5,6-dihydro-
8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-2-iumtetrafluoroborate (122c) 
O
N
N
N
TBDMSO BF4
F
F
F
F
F
 
According to general procedure GP8, (S)-5-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-6,6-diethyl-
morpholin-3-one (121c) (400 mg, 1.27 mmol) in CH2Cl2 (7 mL) and trimethyloxonium 
tetrafluoroborate (207 mg, 1.40 mmol) were stirred to give of the crude imidate. Then, 
pentafluorophenylhydrazine (277 mg, 1.40 mmol) was added and stirred for four hours. After 
concentration of the reaction mixture the crude solid was dissolved in trimethyl orthoformate 
(4.85 g, 5.0 mL, 45.7 mmol) and refluxed for 36 hours at 80 °C. The crude product was purified by 
column chromatography (SiO2, CH2Cl2:MeOH (50:1), d x h: 3.5 x 21 cm) followed by 
recrystallization from CH2Cl2/pentane to afford the product 122c (300 mg, 505 µmol, 40%) as a 
pink solid. 
 
C23H33F5N3O2Si BF4 (593.42 g/mol): 
MP: 82-83 °C. 
TLC: Rf = 0.35 (SiO2, CH2Cl2:MeOH (20:1)). 
MP: 177-178 °C.  
1H NMR (400 MHz, CD2Cl2) δ/ppm = 10.27 (s, 1H, carbene-CH), 5.08 (d, 2JHH = 17.7 Hz, 1H, 
OCH2), 4.91 (d, 2JHH = 17.7 Hz, 1H, OCH2), 4.62 (s, 1H, NCH), 4.53 (q, 3JHH = 6.4 Hz, 1H, CHCH3), 
2.03-1.91 (m, 1H, CH2CH3), 1.81-1.54 (m, 3H, CH2CH3), 1.36 (d, 3JHH = 6.3 Hz, 3H, CHCH3), 0.99-
0.93 (m, 6H, CH2CH3), 0.75 (s, 9H, SiC(CH3)3), 0.09 (s, 3H, SiCH3), 0.09 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CD2Cl2) δ/ppm = 152.7, 146.5, 145.2-144.6 (m), 142.6-142.0 (m), 140.5-
139.4 (m), 138.0-137.4 (m), 78.8, 66.3, 65.2, 56.7, 26.1, 25.7, 23.7, 23.2, 18.0, 7.6, 7.0, −4.2, 
−4.3. 
19F{1H} NMR (376 MHz, CD2Cl2) δ/ppm = −145.2-−145.4 (m), −146.2-−146.4 (m), −151.0, −158.8-
−159.1 (m). 
IR (ATR): 𝑣𝑣�/cm-1 = 2949 (w), 2930 (w), 2860 (w), 1529 (m), 1472 (m), 1256 (w), 1061 (s), 1003 (s), 
837 (s), 777 (s), 684 (w), 522 (w). 
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HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C23H33F5N3O2Si+: 506.2257 [M]+; found: 
506.2261. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +8.6 (c = 0.70, MeOH).  
 
(S)-5-((R)-1-((tert-Butyldimethylsilyl)oxy)ethyl)-6,6-dimethyl-2-phenyl-5,6-dihydro-8H-
[1,2,4]triazolo[3,4-c][1,4]oxazin-2-ium tetrafluoroborate (123a) 
O
N
N
N
TBDMSO BF4  
According to general procedure GP8, (S)-5-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-6,6-dimethyl-
morpholin-3-one (121a) (290 mg, 1.01 mmol) in CH2Cl2 (5 mL) and trimethyloxonium tetra-
fluoroborate (164 mg, 1.11 mmol) were stirred to give of the crude imidate. Then, phenylhydrazine 
(120 mg, 110 µL, 1.11 mmol) was added and stirred for four hours. After concentration of the 
reaction mixture the crude solid was dissolved in trimethyl orthoformate (2.35 g, 2.42 mL, 
22.1 mmol) and refluxed for 16 hours at 80 °C. The crude product was purified by column 
chromatography (SiO2, CH2Cl2:MeOH (60:1), d x h: 3 x 23 cm)) to afford the product 123a (280 mg, 
589 µmol, 58%) as a pale yellow solid. 
 
C21H34N3O2Si BF4 (475.41 g/mol): 
MP: 104-105 °C. 
TLC: Rf = 0.29 (SiO2, CH2Cl2:MeOH (20:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 10.17 (s, 1H, carbene-CH), 7.93-7.87 (m, 2H, ar-H), 7.65-
7.55 (m, 3H, ar-H), 5.08 (d, 2JHH = 17.3 Hz, 1H, OCH2), 4.99 (d, 2JHH = 17.3 Hz, 1H, OCH2), 4.64 (d, 
3JHH = 4.4 Hz, 1H, NCH), 4.29 (qd, 3JHH = 6.1 Hz, 3JHH = 4.3 Hz, 1H, CHOTBDMS), 1.50 (s, 3H, 
C(CH3)2), 1.45-1.41 (m, 6H, C(CH3)2, CHCH3), 0.68 (s, 9H, SiC(CH3)3), 0.03 (s, 3H, SiCH3), 
−0.10 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 149.7, 141.1, 134.8, 131.3, 130.6, 120.8, 73.5, 66.8, 
65.3, 56.8, 25.6, 25.4, 23.9, 23.4, 17.7, −4.4, −4.8. 
19F{1H} NMR (376 MHz, CDCl3) δ/ppm = −150.7. 
IR (ATR): 𝑣𝑣�/cm-1 = 2952 (w), 2857 (w), 1668 (w), 1577 (w), 1467 (w), 1405 (w), 1254 (w), 1047 (s), 
983 (s), 915 (m), 835 (s), 772 (s), 682 (m), 518 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C21H34N3O2Si+: 388.2415 [M]+; found: 
388.2418. 
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[𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +25.0 (c = 0.14, MeOH).  
 
(S)-5-((R)-1-((tert-Butyldimethylsilyl)oxy)ethyl)-2-mesityl-6,6-dimethyl-5,6-dihydro-8H-
[1,2,4]triazolo[3,4-c][1,4]oxazin-2-ium tetrafluoroborate (123b) 
O
N
N
N
TBDMSO BF4  
According to general procedure GP8, (S)-5-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-6,6-dimethyl-
morpholin-3-one (121a) (299 mg, 1.04 mmol) in CH2Cl2 (6 mL) and trimethyloxonium tetra-
fluoroborate (169 mg, 1.14 mmol) were stirred to give of the crude imidate. Then, mesitylhydrazine 
(freshly prepared from 1-mesitylhydrazine hydrochloride [214 mg, 1.14 mmol] in ether [5 mL] after 
extraction with saturated aqueous Na2CO3 solution [5 mL]) was added and stirred for four hours. 
After concentration of the reaction mixture the crude solid was dissolved in trimethyl orthoformate 
(2.45 g, 2.49 mL, 22.8 mmol) and refluxed for 18 hours at 80 °C. The crude product was purified 
by column chromatography (SiO2, CH2Cl2:MeOH (50:1), d x h: 3.5 x 23 cm)) to afford the product 
123b (298 mg, 576 µmol, 55%) as a yellow solid. 
 
C24H40N3O4Si BF4 (517.49 g/mol): 
MP: 72-73 °C. 
TLC: Rf = 0.26 (SiO2, CH2Cl2:MeOH (20:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 9.79 (s, 1H, carbene-CH), 7.04 (s, 2H, ar-H), 5.08 (d, 
2JHH = 17.3 Hz, 1H, OCH2), 4.97 (d, 2JHH = 17.3 Hz, 1H, OCH2), 4.73 (s, 1H, NCH), 4.57 (q, 
3JHH = 6.3 Hz, 1H, CHOTBDMS), 2.37 (s, 3H, ar-CH3), 2.07 (s, 6H, ar-CH3), 1.55 (s, 3H, C(CH3)2), 
1.39 (s, 3H, C(CH3)2), 1.34 (d, J = 6.4 Hz, 3H, CHCH3), 0.79 (s, 9H, SiC(CH3)3), 0.12 (s, 3H, 
SiCH3), 0.07 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 151.0, 143.8, 142.6, 135.0, 131.0, 130.0, 73.7, 66.2, 
65.2, 56.7, 53.6, 25.7, 25.5, 23.6, 22.9, 21.4, 17.8, 17.3, −4.2, −4.4. 
19F{1H} NMR (376 MHz, CDCl3) δ/ppm = −150.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 2953 (w), 2928 (w), 2856 (w), 1576 (w), 1459 (w), 1447 (w), 1389 (w), 1254 (w), 
1157 (w), 1053 (s), 1033 (s), 876 (m), 914 (m), 836 (s), 777 (s), 723 (m), 519 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C24H40N3O4Si+: 430.2884 [M]+; found: 
430.2888. 
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[𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −9.0 (c = 0.27, MeOH).  
 
(S)-5-((R)-1-((tert-Butyldimethylsilyl)oxy)ethyl)-6,6-dimethyl-2-(2,4,6-triisopropylphenyl)-
5,6-dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-2-ium tetrafluoroborate (123c) 
O
N
N
N
TBDMSO
BF4  
According to general procedure GP8, (S)-5-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-6,6-dimethyl-
morpholin-3-one (121a) (500 mg, 1.74 mmol) in CH2Cl2 (8 mL) and trimethyloxonium 
tetrafluoroborate (283 mg, 1.91 mmol) were stirred to give of the crude imidate. Then, 1-(2,4,6-
triisopropyl-phenyl)hydrazine (freshly prepared from di-tert-butyl 1-(2,4,6-triisopropylphenyl) 
hydrazine-1,2-dicarboxylate [907 mg, 2.09 mmol] and HCl in dioxane [4M, 4.4 mL, 5.05 g, 
17.4 mmol] in ether [5 mL] after extraction with saturated aqueous Na2CO3 solution [10 mL]) was 
added and stirred for four hours. After concentration of the reaction mixture the crude solid was 
dissolved in trimethyl orthoformate (1.29 g, 1.33 mL, 12.2 mmol) and refluxed for 18 hours at 
80 °C. The crude product was purified by column chromatography (SiO2, cyclohexane:ethyl 
acetate (1:1), d x h: 3.5 x 21 cm)) to afford the product 123c (380 mg, 632 µmol, 36%) as a white 
solid. 
 
C30H52N3O2Si BF4 (514.85 g/mol): 
TLC: Rf = 0.17 (SiO2, cyclohexane:ethyl acetate (1:1)). 
MP: 65-66 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 9.82 (s, 1H, carbene-CH), 7.18 (d, 4JHH = 1.9 Hz, 1H, ar-H), 
7.13 (d, 4JHH = 2.0 Hz, 1H, ar-H), 5.08 (d, 2JHH = 17.3 Hz, 1H, OCH2), 4.97 (d, 2JHH = 17.3 Hz, 1H, 
OCH2), 4.80 (s, 1H NCH), 4.58 (q, 3JHH = 6.4 Hz, 1H, CHOTBDMS), 2.98 (hept, 3JHH = 7.0 Hz, 1H, 
CH(CH3)2), 2.37 (hept, 3JHH = 6.8 Hz, 1H, CH(CH3)2), 2.10 (hept, 3JHH = 6.9 Hz, 1H, CH(CH3)2), 
1.56 (s, 3H, C(CH3)2), 1.40 (s, 3H, C(CH3)2), 1.35-1.27 (m, 12H, C(CH3)2, CHCH3), 1.20 (d, 
3JHH = 6.9 Hz, 3H, CH(CH3)2), 1.16 (d, 3JHH = 6.8 Hz, 3H, CH(CH3)2), 1.14 (d, 3JHH = 6.8 Hz, 3H, 
CH(CH3)2), 0.81 (s, 9H, SiC(CH3)3), 0.14 (s, 3H, SiCH3), 0.09 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 153.9, 150.7, 146.4, 145.1, 144.2, 128.2, 123.1, 122.3, 
73.6, 66.0, 65.2, 56.7, 34.7, 29.1, 29.0, 25.9, 25.6, 25.4, 24.7, 24.3, 24.2, 24.0, 23.9, 23.8, 23.4, 
22.7, 17.8, −4.2, −4.4. 
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19F{1H} NMR (376 MHz, CDCl3) δ/ppm = −151.0. 
IR (ATR): 𝑣𝑣�/cm-1 = 2960 (w), 2939 (w), 1574 (w), 1461 (w), 1253 (w), 1053 (s), 974 (m), 914 (w), 
836 (m), 776 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C30H52N3O2Si+: 514.3823 [M]+; found: 
514.3826. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +15.8 (c = 0.55, MeOH).  
 
(S)-5-((R)-1-((tert-Butyldimethylsilyl)oxy)ethyl)-2-(2,6-dimethoxyphenyl)-6,6-dimethyl-5,6-
dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-2-ium tetrafluoroborate (123d) 
O
N
N
N
TBDMSO
BF4
MeO
MeO
 
According to general procedure GP8, (S)-5-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-6,6-dimethyl-
morpholin-3-one (121a) (650 mg, 2.26 mmol) in CH2Cl2 (15 mL) and trimethyloxonium 
tetrafluoroborate (368 mg, 2.49 mmol) were stirred to give of the crude imidate. Then, 1-(2,6-
dimethoxyphenyl)hydrazine (freshly prepared from di-tert-butyl 1-(2,6-dimethoxyphenyl)-
hydrazine-1,2-dicarboxylate [831 mg, 2.26 mmol] and HCl in dioxane [4M, 4.7 mL, 5.59 g, 
18.8 mmol] in ether [5 mL] after extraction with saturated aqueous Na2CO3 solution [10 mL]) was 
added and stirred for four hours. After concentration of the reaction mixture the crude solid was 
dissolved in trimethyl orthoformate (4.0 mL, 3.88 g, 36.6 mmol) and refluxed for 6 hours at 80 °C. 
The crude product was purified by column chromatography (SiO2, cyclohexane:ethyl acetate (5:1 
to 0:1 after 300 mL), d x h: 3.5 x 23 cm)) to afford the product 123d (538 mg, 1.01 mmol, 45%) as 
a white solid. 
 
C23H38N3O4Si BF4 (448.66 g/mol): 
TLC: Rf = 0.28 (SiO2, ethyl acetate). 
MP: 83-84 °C.  
1H NMR (400 MHz, DMSO-d6) δ/ppm = 10.69 (s, 1H, carbene-CH), 7.65 (t, 3JHH = 8.6 Hz, 1H, 
ar-H), 6.98 (d, 3JHH = 8.6 Hz, 2H, ar-H), 5.08 (s, 2H, OCH2), 4.57 (d, 3JHH = 1.7 Hz, 1H NCH), 
4.48 (qd, 3JHH = 6.3 Hz, 3JHH = 1.8 Hz, 1H, CHOTBDMS), 3.81 (s, 3H, OCH3), 1.46 (s, 3H, C(CH3)2), 
1.31 (s, 3H, C(CH3)2), 1.26 (d, 3JHH = 6.3 Hz, 3H, CHCH3), 0.75 (s, 9H, SiC(CH3)3), 0.07 (s, 3H, 
SiCH3), 0.04 (s, 3H, SiCH3). 
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13C{1H} NMR (101 MHz, DMSO-d6) δ/ppm = 155.2, 149.7, 145.9, 133.7, 112.1, 104.9, 72.8, 65.8, 
64.6, 56.6, 56.0, 25.3, 24.5, 23.6, 22.6, 17.3, −4.7, −4.8. 
19F{1H} NMR (376 MHz, DMSO-d6) δ/ppm = −148.3. 
IR (ATR): 𝑣𝑣�/cm-1 = 2952 (w), 2931 (w), 2855 (w), 1605 (w), 1580 (w), 1486 (s), 1263 (m), 1050 (s), 
1006 (s), 836 (m), 778 (m), 734 (m), 519 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C23H38N3O4Si+: 448.2626 [M]+; found: 
448.2630. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +13.5 (c = 0.90, MeOH).  
 
Methyl N-((benzyloxy)carbonyl)-O-(trimethylsilyl)-L-threoninate (125) 
TMSO
NHCbz
OMe
O
 
Under argon atmosphere, a heat-gun dried round-bottomed flask was charged with N-cbz-L-
threonine methyl ester (124) (2.50 g, 9.17 mmol) and DMF (6 mL). Then, imidazole (1.69 g, 
24.8 mmol), TMS chloride (1.39 g, 1.63 mL, 12.8 mmol) and afterwards the reaction mixture was 
stirred for 48 hours at room temperature. After stirring for 48 hours aqueous HCl solution (1M, 
30 mL) was added to the reaction solution and the corresponding aqueous mixture was extracted 
with ether (3 x 30 mL). The combined organic layers were washed with water, dried over Na2SO4, 
filtered, concentrated under vacuum and the crude mixture was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (3:1), d x h: 5 x 13 cm) to afford the product 125 
(2.96 g, 8.71 mmol, 95%) as a colorless oil.  
 
C16H25NO5Si (339.46 g/mol): 
TLC: Rf = 0.48 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.41-7.30 (m, 5H, ar-H), 5.53 (d, 3JHH = 9.7 Hz, 1H, NH), 
5.14 (s, 2H, Ph-CH2), 4.42 (qd, 3JHH = 6.3 Hz, 3JHH = 1.8 Hz, 1H, OCH), 4.26 (dd, 3JHH = 9.8 Hz, 
3JHH = 1.8 Hz, 1H, NCH), 3.73 (s, 3H, OCH3), 1.20 (d, 3JHH = 6.3 Hz, 3H, CHCH3), 0.05 (s, 9H, 
Si(CH3)3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 171.5, 156.9, 136.4, 128.7, 128.3, 128.3, 68.7, 67.2, 
60.0, 52.4, 21.1, 0.1. 
IR (ATR): 𝑣𝑣�/cm-1 = 3443 (w), 2955 (w), 1724 (w), 1504 (m), 1250 (m), 1203 (m), 1067 (s), 961 (m), 
839 (s), 735 (m), 695 (m), 546 (w), 458 (w). 
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HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C16H25NO5Si+: 362.1394 [M+Na]+; found: 
362.1397. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −30.4 (c = 0.36, MeOH).  
 
Benzyl ((3S,4R)-2-hydroxy-2-methyl-4-((trimethylsilyl)oxy)pentan-3-yl)carbamate (126) 
TMSO
NHCbz
OH
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with ethylmagnesium 
bromide solution (3M in ether, 11.8 g, 11.4 mL, 34.2 mmol) and was cooled in an ice-bath. Then, 
at 0 °C a solution of methyl methyl N-((benzyloxy)carbonyl)-O-(trimethylsilyl)-L-threoninate (125) 
(2.90 g, 8.54 mmol) in ether (24 mL) was added dropwise over 10 minutes to the Grignard solution. 
After addition the reaction was stirred for one hour at 0 °C and further 16 hours at room 
temperature. Afterwards the reaction mixture was quenched by slowly addition of aqueous 
saturated NH4Cl solution (20 mL) at 0 °C. Then, the biphasic mixture was extracted with ether (3 x 
50 mL), the combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered 
and concentrated under vacuum. The crude mixture was purified by column chromatography 
(SiO2, ethyl acetate:cyclohexane (1:4), d x h: 3.5 x 18 cm) to afford the product 126 (2.56 g, 
7.54 mmol, 88%) as a colorless oil.  
 
C17H29NO4Si (339.51 g/mol): 
TLC: Rf = 0.31 (SiO2, ethyl acetate:cyclohexane (1:3)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.39-7.29 (m, 5H, ar-H), 5.49 (d, 3JHH = 10.0 Hz, 1H, NH), 
5.15 (d, 2JHH = 12.3 Hz, 1H, Ph-CH2), 5.12 (d, 2JHH = 12.3 Hz, 1H, Ph-CH2), 4.44 (qd, 3JHH = 6.2 Hz, 
3JHH = 1.9 Hz, 1H, CHCH3), 3.50 (s, 1H, OH), 3.37 (dd, 3JHH = 10.0 Hz, 3JHH = 1.9 Hz, 1H, NCH), 
1.32 (s, 3H, C(CH3)2), 1.19 (d, 3JHH = 6.2 Hz, 3H, CHCH3), 1.17 (s, 3H, C(CH3)2), 0.16 (s, 9H, 
Si(CH3)3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 157.5, 136.8, 128.7, 128.2, 128.1, 73.3, 69.6, 67.0, 61.3, 
27.7, 27.3, 21.2, 0.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 3466 (m), 2965 (m), 2848 (w), 1716 (s), 1448 (s), 1472 (m), 1256 (m), 1225 (s), 
1048 (s), 928 (s), 876 (m), 839 (s), 769 (s), 735 (m), 497 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C17H29NO4Si+: 362.1764 [M+Na]+; found: 
362.1769. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −15.4 (c = 0.46, MeOH).   
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(S)-6,6-Dimethyl-5-((R)-1-((trimethylsilyl)oxy)ethyl)morpholin-3-one (127) 
O
O
N
H
TMSO
 
According to general procedure GP9, methyl N-((benzyloxy)carbonyl)-O-(trimethylsilyl)-L-
threoninate (126) (1.48 g, 4.36 mmol) in EtOAc (14 mL) and Pd/C (340 mg) were stirred to give of 
the crude amine as a colorless oil (891 g, 4.34 mmol, 99%). 
Then, the crude amine (880 mg, 4.28 mmol) in CH2Cl2 (21 mL), triethylamine (563 mg, 782 µL, 
5.56 mmol) and chloroacetyl chloride (532 mg, 374 µL, 4.71 mmol) were stirred. In the next step 
the crude chloro acetamide was dissolved in THF (21 mL) and sodium hydride (60% in mineral 
oil, 257 mg, 6.42 mmol) was added and stirred. The crude mixture was purified by column 
chromatography (SiO2, CH2Cl2:ethyl acetate (2:1), d x h: 3.5 x 25 cm) to afford the product 127 
(90 mg, 367 µmol, 9%) as a white solid. 
 
C11H23NO3Si (245.39 g/mol): 
MP: 96-97 °C. 
TLC: Rf = 0.41 (SiO2, CH2Cl2:ethyl acetate (1:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 6.26 (s, 1H, NH), 4.16 (d, 2JHH = 17.3 Hz, 1H, OCH2), 4.10 (d, 
2JHH = 17.4 Hz, 1H, OCH2), 3.77 (p, 3JHH = 6.1 Hz, 1H, OCH), 3.16 (d, 3JHH = 5.7 Hz, 1H, NCH), 
1.33 (s, 3H, C(CH3)2), 1.25 (d, 3JHH = 6.3 Hz, 3H, CHCH3), 1.23 (s, 3H, C(CH3)2), 0.15 (s, 9H, 
Si(CH3)3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 169.7, 73.2, 66.5, 63.2, 62.3, 24.8, 23.6, 20.2, 2.1. 
IR (ATR): 𝑣𝑣�/cm-1 = 3483 (m), 3212 (w), 2969 (w), 2922 (w), 1664 (s), 1458 (w), 1377 (w), 1338 (m), 
1169 (m), 1117 (s), 1074 (m), 1021 (m), 871 (m), 808 (s), 719 (m), 650 (w), 525 (w), 420 (s). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C11H23NO3Si+: 268.1345 [M+Na]+; found: 
268.1157. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −29.0 (c = 0.14, MeOH).  
 
Benzyl ((3S,4R)-4-(tert-butoxy)-2-hydroxy-2-methylpentan-3-yl)carbamate (131) 
O
NHCbz
OH
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Under argon atmosphere, a heat-gun dried two-necked flask was charged with methylmagnesium 
bromide solution (3M in ether, 14.9 g, 14.4 mL, 43.2 mmol) and was cooled in an ice-bath. At 0 °C, 
a solution of methyl N-((benzyloxy)carbonyl)-O-(tert-butyl)-L-threoninate (130) (3.49 g, 
10.8 mmol) in ether (28 mL) was added dropwise over 10 minutes to the Grignard solution. After 
addition the reaction was stirred for one hour at 0 °C and further 16 hours at room temperature. 
Afterwards the reaction mixture was quenched by slowly addition of aqueous saturated NH4Cl 
solution (20 mL) at 0 °C. Then, the biphasic mixture was extracted with ether (3 x 50 mL), the 
combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and 
concentrated under vacuum. The crude mixture was purified by column chromatography (SiO2, 
ethyl acetate:cyclohexane (1:3), d x h: 3.5 x 17 cm) to afford the product 131 (2.68 g, 8.28 mmol, 
77%) as a colorless oil.  
 
C18H29NO4 (323.43 g/mol): 
TLC: Rf = 0.33 (SiO2, ethyl acetate:cyclohexane (1:3)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.40-7.29 (m, 5H, ar-H), 5.49 (d, 3JHH = 10.2 Hz, 1H, NH), 
5.16 (d, 2JHH = 12.3 Hz, 1H, Ph-CH2), 5.11 (d, 2JHH = 12.3 Hz, 1H, Ph-CH2), 4.35 (qd, 3JHH = 6.1 Hz, 
3JHH = 2.1 Hz, 1H, OCH), 3.40 (dd, 3JHH = 10.3 Hz, 3JHH = 2.1 Hz, 1H, NCH), 1.33 (s, 3H, C(CH3)2), 
1.26 (s, 9H, OC(CH3)3), 1.21 (d, 3JHH = 6.1 Hz, 3H, CHCH3), 1.15 (s, 3H, C(CH3)2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 157.4, 136.8, 128.6, 128.2, 128.1, 74.9, 73.2, 69.5, 66.9, 
62.1, 29.6, 27.8, 27.4, 20.7. 
IR (ATR): 𝑣𝑣�/cm-1 = 3450 (w), 2974 (m), 2937 (w), 1718 (s), 1499 (s), 1371 (m), 1309 (w), 1291 (w), 
1215 (s), 1060 (s), 937 (s), 735 (s), 695 (s), 502 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C18H29NO4+: 346.1989 [M+Na]+; found: 
346.1990. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +3.8 (c = 1.59, MeOH).  
 
(S)-5-((R)-1-(tert-Butoxy)ethyl)-6,6-dimethylmorpholin-3-one (132) 
O
O
N
H
O
 
According to general procedure GP9, benzyl ((3S,4R)-4-(tert-butoxy)-2-hydroxy-2-methylpentan-
3-yl)carbamate (131) (2.60 g, 8.04 mmol) in MeOH (26 mL) and Pd/C (600 mg) were stirred to 
give of the crude amine as a pale yellow oil (1.50 g, 7.93 mmol, 99%). 
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Then, the crude amine (1.40 g, 7.40 mmol) in CH2Cl2 (28 mL), triethylamine (973 mg, 1.35 mL, 
9.62 mmol) and chloroacetyl chloride (919 mg, 647 µL, 8.14 mmol) were stirred. In the next step 
the crude chloro acetamide was dissolved in THF (28 mL) and sodium hydride (60% in mineral 
oil, 444 mg, 11.1 mmol) was added and stirred. The crude mixture was purified by column 
chromatography (SiO2, CH2Cl2:ethyl acetate (1:1), d x h: 3.5 x 20 cm) to afford the product 132 
(895 mg, 3.11 mmol, 73%) as a white solid. 
 
C12H23NO3 (229.32 g/mol): 
MP: 46-47 °C. 
TLC: Rf = 0.31 (SiO2, CH2Cl2:ethyl acetate (1:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = δ 6.47 (s, 1H, NH), 4.13 (d, 2JHH = 17.3 Hz, 1H, OCH2), 4.07 (d, 
2JHH = 17.3 Hz, 1H, OCH2), 3.49 (dq, 3JHH = 7.9 Hz, 3JHH = 6.0 Hz, 1H, OCH), 3.13 (dd, 
3JHH = 7.8 Hz, 3JHH = 1.3 Hz, 1H, NCH), 1.33 (s, 3H, C(CH3)2), 1.25 (s, 3H, C(CH3)2), 1.23 (d, 
3JHH = 6.0 Hz, 3H, CHCH3), 1.21 (s, 9H, OC(CH3)3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 168.6, 75.2, 72.3, 66.8, 64.2, 62.9, 28.8, 27.5, 22.7, 19.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 3239 (w), 2973 (m), 2936 (w), 1671 (s), 1485 (w), 1363 (m), 1287 (m), 1194 (s), 
1169 (s), 1080 (s), 989 (w), 919 (w), 851 (m), 806 (m), 488 (w), 461 (w), 422 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C12H23NO3+: 252.1570 [M+Na]+; found: 
252.1567. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −15.5 (c = 1.47, MeOH).  
 
Methyl (2S,3R)-2-(((benzyloxy)carbonyl)amino)-3-hydroxy-3-phenylpropanoate (135) 
OH
NHCbz
OMe
O
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with L-threo-
phenylserine (134) (950 mg, 5.24 mmol) and MeOH (9.5 mL). The reaction mixture was cooled in 
an ice-bath and at 0 °C thionyl chloride (686 mg, 418 µL, 5.76 mmol) was added dropwise to the 
mixture and after addition the reaction mixture was refluxed for 16 hours. Afterwards the crude 
was concentrated under vacuum and directly used for the next step without further purification 
steps.  
The crude hydrochloride salt was dissolved in THF (20 mL) and then DIPEA (1.36 g, 1.73 mL, 
10.5 mmol) was added to the mixture. At 0 °C, benzyl chloroformate (983 mg, 874 µL, 5.76 mmol) 
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was added dropwise to the reaction solution over 10 minutes. Afterwards the mixture was stirred 
for 16 hours at room temperature and then aqueous HCl solution (1M, 30 mL) was added. The 
biphasic mixture was extracted with EtOAc (3 x 30 mL), the combined organic layers were washed 
with water (30 mL), brine (30 mL), dried over Na2SO4, filtered and concentrated under vacuum. 
The crude mixture was purified by column chromatography (SiO2, cyclohexane:ethyl acetate (1:1), 
d x h: 3.5 x 21 cm) to afford the product 135 (1.63 g, 4.96 mmol, 95%) as a white solid.  
 
C18H19NO5 (329.35 g/mol): 
MP: 102-103 °C. 
TLC: Rf = 0.52 (SiO2, cyclohexane:ethyl acetate (1:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.40-7.22 (m, 10H, ar-H), 5.66 (s, 1H, NH), 5.27 (s, 1H, OfCH), 
4.99 (s, 2H, Ph-CH2), 4.61 (d, 3JHH = 9.3 Hz, 1H, NCH), 3.75 (s, 3H, OCH3), 2.97 (s, 1H, OH). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 171.3, 156.4, 139.7, 136.3, 128.6, 128.3, 128.2, 128.0, 
126.0, 73.7, 67.1, 60.0, 52.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 3398 (m), 1752 (s), 1697 (s), 1510 (s), 1450 (m), 1326 (m), 1254 (m), 1205 (s), 
1095 (w), 1053 (s), 981 (w), 933 (w), 798 (w), 773 (w), 740 (m), 700 (s), 569 (m), 468 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C18H19NO5+: 352.1155 [M+Na]+; found: 
352.1156. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −29.1 (c = 0.80, MeOH).  
 
Methyl (2S,3R)-2-(((benzyloxy)carbonyl)amino)-3-((tert-butyldimethylsilyl)oxy)-3-phenyl-
propanoate (136) 
TBDMSO
NHCbz
OMe
O
 
Under argon atmosphere, a heat-gun dried round-bottomed flask was charged with methyl 
(2S,3R)-2-(((benzyloxy)carbonyl)amino)-3-hydroxy-3-phenylpropanoate (135) (1.60 g, 
4.86 mmol) and DMF (5 mL). Then, imidazole (662 mg, 9.72 mmol), DMAP (404 mg, 3.30 mmol), 
TBDMS chloride (1.03 g, 6.8 mmol) and afterwards the reaction mixture was stirred for 48 hours 
at room temperature. After stirring for 48 hours aqueous HCl solution (1M, 30 mL) was added to 
the reaction solution and the corresponding aqueous mixture was extracted with ether (3 x 30 mL). 
The combined organic layers were washed with water, dried over Na2SO4, filtered, concentrated 
under vacuum and the crude mixture was purified by column chromatography (SiO2, 
EXPERIMENTAL PART            CHAPTER 5 
309 
cyclohexane:ethyl acetate (4:1), d x h: 3.5 x 20 cm) to afford the product 136 (1.07 g, 2.41 mmol, 
50%) as a colorless oil.  
 
C24H33NO5Si (443.62 g/mol): 
TLC: Rf = 0.44 (SiO2, cyclohexane:ethyl acetate (4:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.50-7.40 (m, 10H, ar-H), 5.67 (d, 3JHH = 9.8 Hz, 1H, OCH), 
5.47 (d, 3JHH = 2.1 Hz, 1H, NH), 5.13 (s, 2H, Ph-CH2), 4.64 (dd, 3JHH = 9.8 Hz, 3JHH = 2.2 Hz, 1H, 
NCH), 3.93 (s, 3H, OCH3), 1.02 (s, 9H, SiC(CH3)3), 0.13 (s, 3H, SiCH3), 0.00 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 170.9, 156.2, 140.5, 136.5, 128.6, 128.3, 128.2, 128.2, 
128.0, 126.3, 74.8, 67.0, 61.3, 52.6, 25.8, 18.2, −4.5, −5.4. 
IR (ATR): 𝑣𝑣�/cm-1 = 3251 (w), 2952 (w), 2929 (w), 2856 (w), 1727 (s), 1498 (s), 1253 (s), 1201 (s), 
1094 (m), 1060 (s), 1027 (m), 1005 (m), 833 (s), 776 (s), 696 (s), 557 (w), 485 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C24H33NO5Si+: 466.2020 [M+Na]+; found: 
466.2026. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −36.2 (c = 0.52, MeOH).  
 
Benzyl ((1R,2S)-1-((tert-butyldimethylsilyl)oxy)-3-hydroxy-3-methyl-1-phenylbutan-2-yl)-
carbamate (137) 
TBDMSO
NHCbz
OH
 
Under argon atmosphere a heat-gun dried two-neck flask was charged with methylmagnesium 
bromide solution (3M in ether, 3.12 g, 3.00 mL, 9.00 mmol) and was cooled in an ice-bath. Then, 
at 0 °C a solution of methyl (2S,3R)-2-(((benzyloxy)carbonyl)amino)-3-((tert-butyldimethyl-silyl)-
oxy)-3-phenyl-propanoate (136) (998 mg, 2.25 mmol) in ether (7 mL) was added dropwise over 
10 minutes to the Grignard solution. After addition, the reaction was stirred for one hour at 0 °C 
and further 16 hours at room temperature. Afterwards the reaction mixture was quenched by 
slowly addition of aqueous saturated NH4Cl solution (10 mL) at 0 °C. Then the biphasic mixture 
was extracted with ether (3 x 20 mL), the combined organic layers were washed with brine 
(10 mL), dried over Na2SO4, filtered and concentrated under vacuum. The crude product was 
purified by column chromatography (SiO2, ethyl acetate:cyclohexane (1:4), d x h: 3.5 x 17 cm) to 
afford the product 137 (909 mg, 2.05 mmol, 91%) as a colorless oil.  
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C25H37NO2Si (443.66 g/mol): 
TLC: Rf = 0.31 (SiO2, cyclohexane:ethyl acetate (3:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.29-7.10 (m, 10H, ar-H), 5.46 (d, 3JHH = 10.1 Hz, 1H, OCH), 
5.16 (d, 3JHH = 1.8 Hz, 1H, NH), 4.86 (d, 2JHH = 12.4 Hz, 1H, Ph-CH2), 4.80 (d, 2JHH = 12.4 Hz, 1H, 
Ph-CH2), 3.46 (dd, 3JHH = 10.1 Hz, 3JHH = 1.7 Hz, 1H, NCH), 3.14 (s, 1H, OH), 1.36 (s, 3H, C(CH3)2), 
1.14 (s, 3H, C(CH3)2), 0.82 (s, 9H, SiC(CH3)3), 0.00 (s, 3H, SiCH3), −0.42 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 156.6, 141.5, 136.9, 128.6, 128.1, 127.9, 127.6, 127.0, 
126.8, 75.1, 73.6, 66.7, 62.9, 27.9, 27.3, 26.1, 18.1, −3.6, −4.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 3438 (w), 2953 (m), 2929 (m), 2889 (w), 2857 (w), 1710 (s), 1497 (s), 1454 (m), 
1298 (m), 1255 (s), 1213 (s), 1048 (s), 1001 (m), 833 (s), 775 (s), 747 (m), 697 (s), 576 (m), 
540 (m), 483 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C25H37NO2Si+: 466.2384 [M+Na]+; found: 
466.2388. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −47.1 (c = 1.01, MeOH).  
 
(S)-5-((R)-((tert-Butyldimethylsilyl)oxy)(phenyl)methyl)-6,6-dimethylmorpholin-3-one (138) 
O
O
N
H
TBDMSO
 
According to general procedure GP9, benzyl ((1R,2S)-1-((tert-butyldimethylsilyl)oxy)-3-hydroxy-
3-methyl-1-phenylbutan-2-yl)-carbamate (137) (745 mg, 1.68 mmol) in MeOH (7 mL) and Pd/C 
(144 mg) were stirred to give of the crude amine as a colorless oil (520 mg, 1.68 mmol, 100%). 
Then, the crude amine (520 mg, 1.68 mmol) in CH2Cl2 (9 mL), triethylamine (221 mg, 307 µL, 
2.18 mmol) and chloroacetyl chloride (209 mg, 147 µL, 1.85 mmol) were stirred. In the next step 
the crude chloro acetamide was dissolved in THF (9 mL) and sodium hydride (60% in mineral oil, 
101 mg, 2.52 mmol) was added and stirred. The crude mixture was purified by column 
chromatography (SiO2, CH2Cl2:ethyl acetate (2:1), d x h: 3.5 x 18 cm) to afford the product 138 
(414 mg, 1.18 mmol, 71%) as a beige solid. 
 
C19H31NO3Si (349.55 g/mol): 
MP: 84-85 °C.  
TLC: Rf = 0.50 (SiO2, CH2Cl2:ethyl acetate (2:1)). 
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1H NMR (400 MHz, CDCl3) δ/ppm = 7.38-7.27 (m, 5H, ar-H), 6.43 (s, 1H, NH), 4.43 (d, 
3JHH = 7.8 Hz, 1H, OCH), 4.16 (d, 2JHH = 17.4 Hz, 1H, OCH2), 4.14 (d, 2JHH = 17.4 Hz, 1H, OCH2), 
3.58 (dd, 3JHH = 7.8 Hz, 3JHH = 1.1 Hz, 1H), 1.29 (s, 3H, C(CH3)2), 0.87 (s, 9H, SiC(CH3)3), 0.68 (s, 
3H, C(CH3)2), 0.05 (s, 3H, SiCH3), −0.36 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 169.2, 141.0, 129.0, 128.9, 127.7, 75.2, 71.9, 65.1, 62.9, 
26.9, 25.9, 19.6, 18.2, −4.2, −4.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 3400 (w), 2929 (w), 2887 (w), 2956 (w), 1674 (s), 1428 (w), 1364 (w), 1320 (w), 
1255 (m), 1100 (m), 1066 (m), 1003 (w), 833 (s), 775 (s), 700 (s), 571 (w), 509 (w), 422 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C19H31NO3Si+: 372.1965 [M+Na]+; found: 
372.1965. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −10.3 (c = 0.41, MeOH).  
 
(S)-5-((R)-((tert-Butyldimethylsilyl)oxy)(phenyl)methyl)-6,6-dimethyl-2-(perfluorophenyl)-
5,6-dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-2-ium tetrafluoroborate (139) 
O
N
N
N
F F
F
FF
TBDMSO
BF4  
According to general procedure GP8, (S)-5-((R)-((tert-butyldimethylsilyl)oxy)(phenyl)methyl)-6,6-
dimethylmorpholin-3-one (138) (270 mg, 772 µmol) in CH2Cl2 (4 mL) and trimethyloxonium 
tetrafluoroborate (126 mg, 849 µmol) were stirred to give of the crude imidate. Then, 
pentafluorophenylhydrazine (168 mg, 849 µmol) was added and stirred for six hours. After 
concentration of the reaction mixture the crude solid was dissolved in trimethyl orthoformate 
(655 mg, 676 µL6.18 mmol) and refluxed for 48 hours at 80 °C. The crude product was purified 
by column chromatography (SiO2, CH2Cl2:MeOH (1:60), d x h: 3.5 x 15 cm) to afford the product 
139 (89 mg, 142 µmol, 18%) as a beige solid. 
 
C26H31F5N3O2Si·BF4 (627.43 g/mol): 
MP: 70-71 °C.  
TLC: Rf = 0.48 (SiO2, CH2Cl2:MeOH (20:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 8.91 (s, carbene-CH), 7.49-7.32 (m, 3H, ar-H), 7.25-7.22 (m, 
2H, ar-H), 5.39 (d, 3JHH = 2.8 Hz, 1H, TDMSOCH), 5.17 (d, 2JHH = 17.5 Hz, 1H, OCH2), 5.04 (d, 
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2JHH = 17.4 Hz, 1H, OCH2), 4.77 (d, 3JHH = 2.8 Hz, 1H, NCH), 1.59 (s, 3H, C(CH3)2), 1.41 (s, 3H, 
C(CH3)2), 0.81 (s, 9H, SiC(CH3)3), 0.04 (s, 3H, SiCH3), −0.22 (s, 3H, SiCH3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 150.8, 146.4, 144.3-144.2 (m), 141.7-141.6 (m), 139.3, 
137.1-136.7 (m), 129.5, 126.6, 111.0-110.6 (m), 73.8, 71.9, 68.4, 56.7, 25.9, 25.8, 25.7, 23.6, 
18.1, −4.0, −4.4. 
19F{1H} NMR (376 MHz, CDCl3) δ/ppm = −144.0-−144.1 (m), −145.5-−145.6 (m), −151.9, −157.7-
−157.9 (m). 
IR (ATR): 𝑣𝑣�/cm-1 = 2930 (w), 2858 (w), 1588 (w), 1514 (m), 1473 (w), 1258 (m), 1071 (s), 1003 (s), 
886 (m), 837 (s), 778 (m), 756 (m), 703 (m), 540 (w), 520 (w).  
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C26H31F5N3O2Si+: 540.2100 [M]+; found: 
540.2105. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −30.5 (c = 0.40, MeOH).  
 
(R)-5-Benzhydrylmorpholin-3-one (144) 
O
O
N
H
 
According to general procedure GP9, (R)-2-amino-3,3-diphenylpropan-1-ol (143) (1.32 g, 
5.79 mmol) in CH2Cl2 (29 mL), triethylamine (762 mg, 1.06 mL, 7.53 mmol) and chloroacetyl 
chloride (719 mg, 507 µL, 6.37 mmol) were stirred. In the next step the crude chloro acetamide 
was dissolved in THF (29 mL) and sodium hydride (60% in mineral oil, 347 mg, 8.69 mmol) was 
added and stirred. The crude mixture was purified by column chromatography (SiO2, CH2Cl2:ethyl 
acetate (2:1), d x h: 3.5 x 23 cm) to afford the product 144 (1.09 g, 4.08 mmol, 70%) as a white 
solid 
 
C17H17NO2 (267.33 g/mol): 
MP: 122-123 °C.  
TLC: Rf = 0.38 (SiO2, CH2Cl2:ethyl acetate (2:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.41-7.22 (m, 10H, ar-H), 5.93 (s, 1H, NH), 4.39-4.32 (m, 1H, 
CHPh2), 4.22 (d, 2JHH = 16.7 Hz, 1H, OCH2), 4.15 (d, 2JHH = 16.7 Hz, 1H, OCH2), 3.96 (d, 
3JHH = 11.1 Hz, 1H, NCH), 3.79 (dd, 3JHH = 12.0 Hz, 3JHH = 3.7 Hz, 1H, NCH2), 3.53 (dd, 
3JHH = 12.0 Hz, 3JHH = 6.8 Hz, 1H, NCH2). 
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13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 168.7, 140.2, 139.5, 129.6, 129.2, 128.2, 127.8, 127.7, 
127.5, 68.1, 67.3, 55.2, 54.4. 
IR (ATR): 𝑣𝑣�/cm-1 = 3188 (w), 3109 (w), 2998 (w), 2870 (w), 1676 (s), 1544 (m), 1494 (m), 1317 (w), 
1119 (s), 964 (m), 895 (m), 782 (m), 702 (m), 634 (m), 536 (s), 428 (s). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C17H17NO2+: 290.1151 [M+Na]+; found: 
290.1150. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −24.5 (c = 0.62, MeOH).  
 
(S)-5-Benzhydryl-2-(perfluorophenyl)-5,6-dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-2-ium 
tetrafluoroborate (145) 
O
N
N
N
F F
F
FF
BF4  
According to general procedure GP8, (S)-3-benzhydrylmorpholine (144) (580 mg, 2.17 mmol) in 
CH2Cl2 (11 mL) and trimethyloxonium tetrafluoroborate (385 mg, 2.60 mmol) were stirred to give 
of the crude imidate. Then, pentafluorophenylhydrazine (473 mg, 2.39 mmol) was added and 
stirred for four hours. After concentration of the reaction mixture the crude solid was dissolved in 
trimethyl orthoformate (1.84 g, 1.90 mL, 17.4 mmol) and MeCN (11 mL) and refluxed for 18 hours 
at 80 °C. The crude product was purified by column chromatography (SiO2, pentane:ether (1:1), 
d x h: 2.5 x 12 cm)) followed by recrystallization from ether to afford the product 145 (160 mg, 
293 µmol, 14%) as a white solid. 
 
C24H17F5N3O·BF4 (458.41 g/mol): 
TLC: Rf = 0.52 (SiO2, pentane:ether (1:1)). 
MP: 224-225 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 8.66 (s, 1H, carbene-CH), 7.49-7.45 (m, 2H, ar-H), 7.43-
7.30 (m, 8H, ar-H), 5.66 (dd, 3JHH = 11.8 Hz, 4JHH = 2.6 Hz, 1H, Ph-CH), 5.29 (d, 3JHH = 16.7 Hz, 
1H, OCH2), 5.07 (d, 3JHH = 16.7 Hz, 1H, OCH2), 4.46 (d, 3JHH = 11.8 Hz, 1H, NCH), 4.25 (dd, 
3JHH = 12.9 Hz, 4JHH = 2.8 Hz, 1H, CHCH2), 4.17 (d, 3JHH = 12.8 Hz, 1H, CHCH2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 150.4, 145.5, 138.3, 137.9, 130.3, 129.8, 129.3, 129.1, 
128.5, 128.4, 128.2, 128.2, 127.8, 65.0, 62.2, 60.4, 54.3. 
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19F{1H} NMR (376 MHz, CDCl3) δ/ppm = −143.9-−144.2 (m), −145.2-−145.5 (m), −152.2, −157.8-
−158.1 (m). 
IR (ATR): 𝑣𝑣�/cm-1 = 3132 (w), 1591 (m), 1527 (s), 1445 (w), 1113 (m), 1030 (s), 996 (s), 850 (m), 
751 (w), 701 (s), 631 (m), 519 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C24H17F5N3O+: 458.1286 [M]+; found: 
458.1290. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +28.0 (c = 0.29, MeOH).  
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5.3.2 Synthesis of Piperidine-Based Triazolium Salts 
(S)-6-(Hydroxydiphenylmethyl)piperidin-2-one (150) 
ON
HHO
 
Under argon atmosphere, a two-necked flask was charged with methyl (R)-6-oxopiperidine-2-
carboxylate (149) (1000 mg, 6.36 mmol) and THF (6 mL). Then, the corresponding solution was 
cooled in an ice-bath and at 0 °C phenylmagnesium bromide solution (3M in ether, 8.48 g, 8.48 mL, 
25.4 mmol) was added dropwise over 15 minutes to the reaction mixture. After complete addition 
the mixture was stirred for 16 hours at room temperature. Then, the reaction solution was 
quenched by slowly addition of saturated aqueous NH4Cl solution (20 mL). The biphasic mixture 
was extracted with EtOAc (3 x 50 mL) and then the combined organic layers were washed with 
brine, dried over Na2SO4, filtered and concentrated under vacuum. The crude mixture was purified 
by recrystallization in EtOH to yield the product 149 (923 mg, 3.28 mmol, 52%) was as a white 
solid.  
 
C18H19NO2 (281.35 g/mol): 
MP: 139-140 °C.  
TLC: Rf = 0.19 (SiO2, cyclohexane:ethyl acetate (1:2)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.52-7.47 (m, 2H, ar-H), 7.40-7.35 (m, 2H, ar-H), 7.32-
7.26 (m, 2H, ar-H), 7.24-7.17 (m, 3H, ar-H), 7.16-7.10 (m, 1H, ar-H), 5.65 (s, 1H, NH), 4.39 (dd, 
3JHH = 9.8 Hz, 3JHH = 4.9 Hz, 1H, NCH), 2.58 (s, 1H, OH), 2.39-2.30 (m, 1H, CH2), 2.23-2.12 (m, 
1H, CH2), 1.85-1.76 (m, 1H, CH2), 1.64-1.52 (m, 2H, CH2), 1.48-1.42 (m, 1H, CH2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 174.0, 143.9, 142.9, 129.3, 128.4, 128.0, 127.2, 126.0, 
125.5, 78.7, 59.4, 31.7, 22.7, 20.0. 
IR (ATR): 𝑣𝑣�/cm-1 = 3394 (w), 3339 (w), 3059 (w), 2944 (w), 2869 (w), 1666 (s), 1493 (w), 1473 (w), 
1448 (w), 1394 (w), 1361 (w), 1329 (w), 1308 (w), 1181 (w), 1126 (w), 1065 (w), 996 (w), 964 (w), 
748 (m), 698 (m), 663 (w), 634 (w), 546 (w). 
EA (C18H19NO2) calc.: C 76.84, H 6.81, N 4.98; found: C 76.78, H 6.86, N 5.24. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −188.6 (c = 0.54, CHCl3).  
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(S)-6-(Fluorodiphenylmethyl)piperidin-2-one (153) 
ON
HF
 
Under argon atmosphere, a two-necked flask was charged with (S)-6-(hydroxydiphenyl-methyl)-
piperidin-2-one (150) (574 mg, 2.04 mmol) and CH2Cl2 (19 mL). Then, the corresponding solution 
was cooled in an ice-bath and at 0 °C DAST (658 mg, 539 µL, 4.08 mmol) was added dropwise 
over 15 minutes to the reaction mixture. After complete addition the mixture was stirred for 
16 hours at room temperature. Then, the reaction solution was quenched by slowly addition of 
saturated aqueous NaHCO3 solution (20 mL) at 0°C. The biphasic mixture was extracted with 
CH2Cl2 (3 x 50 mL) and then the combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated under vacuum. The crude mixture was purified by column 
chromatography (SiO2, cyclohexane:ethyl acetate (1:1) to CH2Cl2/MeOH (10:1), d x h: 3.5 x 10 cm) 
to afford the product 153 (544 mg, 1.92 mmol, 94%) as an orange oil. 
 
C18H18FNO (283.35 g/mol): 
TLC: Rf = 0.44 (SiO2, CH2Cl2:ethyl acetate (10:4)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.52-7.47 (m, 2H, ar-H), 7.43-7.26 (m, 8H, ar-H), 5.63 (s, 1H, 
NH), 4.46-4.32 (m, 1H, NCH), 2.45-2.36 (m, 1H, CH2), 2.35-2.24 (m, 1H, CH2), 1.96-1.87 (m, 1H, 
CH2), 1.73-1.62 (m, 3H, CH2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 172.8, 140.4 (d, JCF = 23.3 Hz), 139.7 (d, JCF = 23.9 Hz), 
129.3 (d, JCF = 1.7 Hz), 128.8 (d, JCF = 1.5 Hz), 128.6, 128.2, 125.2 (d, JCF = 9.9 Hz), 124.8 (d, 
JCF = 9.8 Hz), 98.5 (d, JCF = 187.5 Hz), 58.7 (d, JCF = 22.6 Hz), 31.5, 22.9 (d, JCF = 3.6 Hz), 19.9. 
19F{1H} NMR (376 MHz, CDCl3) δ/ppm = −170.0. 
IR (ATR): 𝑣𝑣�/cm-1 = 3390 (w), 3059 (w), 3029 (w), 2944 (w), 2876 (w), 1655 (s), 1449 (m), 1299 (m), 
1160 (w), 1078 (w), 962 (w), 740 (s), 694 (s), 500 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C18H18FNO+: 306.1265 [M+Na]+; found: 
306.1266. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −63.2 (c = 0.30, MeOH).  
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(S)-5-(Fluorodiphenylmethyl)-2-(perfluorophenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-
a]pyridin-2-ium tetrafluoroborate (154) 
N
N
N
F F
F
FF
BF4
F
 
According to general procedure GP8, (S)-6-(fluorodiphenylmethyl)piperidin-2-one (153) (530 mg, 
1.87 mmol) in CH2Cl2 (10 mL) and trimethyloxonium tetrafluoroborate (304 mg, 2.06 mmol) were 
stirred to give of the crude imidate. Then, pentafluorophenylhydrazine (407 mg, 2.06 mmol) was 
added and stirred for four hours. After concentration of the reaction mixture the crude solid was 
dissolved in trimethyl orthoformate (1.59 g, 1.64 mL, 15.0 mmol) and MeCN (10 mL) and refluxed 
for 18 hours at 80 °C. The crude product was purified by two column chromatography (SiO2, 
CH2Cl2:MeOH (100:1), d x h: 3.5 x 21 cm followed by SiO2, cyclohexane:ethyl acetate (1:1), d x 
h: 3.5 x 23 cm)) to afford the product 154 (139 mg, 286 µmol, 10%) as a yellow solid. 
 
C25H18F6N3·BF4 (474.43 g/mol): 
TLC: Rf = 0.40 (SiO2, CH2Cl2:MeOH (20:1)). 
MP: 80-81 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = δ 8.31 (s, 1H, carbene-CH), 7.55-7.48 (m, 2H, ar-H), 7.48-
7.44 (m, 2H, ar-H), 7.39 (t, 3JHH = 7.6 Hz, 4H, ar-H), 7.36-7.27 (m, 2H, ar-H), 6.12 (ddd, 
3JHF = 29.3 Hz, 3JHH = 6.6 Hz, 3JHH = 3.7 Hz, 1H, NCH), 3.17-3.00 (m, 2H, CH2), 2.37-2.18 (m, 3H, 
CH2), 1.98-1.83 (m, 1H, CH2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 155.7, 144.9, 138.5 (d, JCF = 20.7 Hz), 138.2 (d, 
JCF = 17.6 Hz), 129.9 (d, JCF = 2.2 Hz), 129.7, 129.3 (d, JCF = 1.7 Hz), 129.0, 128.7, 124.7 (d, 
JCF = 11.0 Hz), 124.5 (d, JCF = 10.0 Hz), 100.9 (d, JCF = 188.0 Hz), 62.1 (d, JCF = 19.1 Hz), 22.7, 
20.8, 16.3 (d, JCF = 5.5 Hz). 
19F{1H} NMR (376 MHz, CDCl3) δ/ppm = −144.0-−144.3 (m), −145.6 (t, JFF = 21.7 Hz), −152.5, 
−157.7-−158.0 (m), −167.1. 
IR (ATR): 𝑣𝑣�/cm-1 = 2976 (w), 1586 (m), 1515 (s), 1476 (w), 1450 (w), 1235 (w), 1072 (s), 1052 (s), 
1032 (s), 992 (s), 843 (m), 748 (m), 697 (s), 646 (m), 635 (m), 520 (m), 466 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C25H18F6N3+: 474.1399 [M]+; found: 
474.1404. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −1.0 (c = 0.29, MeOH).   
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(R)-6-(Hydroxydiphenylmethyl)piperidin-2-one (164a) 
ON
HHO
 
Under argon atmosphere, a two-necked flask was charged with methyl (S)-6-oxopiperidine-2-
carboxylate (163) (1.59 g, 10.1 mmol) and THF (6 mL). Then, the corresponding solution was 
cooled in an ice-bath and at 0 °C phenylmagnesium bromide solution (3M in ether, 7.36 g, 13.5 mL, 
40.57 mmol) was added dropwise over 15 minutes to the reaction mixture. After complete addition 
the mixture was stirred for 16 hours at room temperature. Then the reaction solution was 
quenched by slowly addition of saturated aqueous NH4Cl solution (20 mL). The biphasic mixture 
was extracted with EtOAc (3 x 50 mL) and then the combined organic layers were washed with 
brine, dried over Na2SO4, filtered and concentrated under vacuum. The crude mixture was purified 
by recrystallization in EtOH to yield the product 164a (1.96 g, 6.97 mmol, 69%) was as a white 
solid.  
 
C18H19NO2 (281.35 g/mol): 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.59-7.55 (m, 2H, ar-H), 7.47-7.43 (m, 2H, ar-H), 7.37 (t, 
3JHH = 7.7 Hz, 2H, ar-H), 7.32-7.24 (m, 3H, ar-H), 7.23-7.18 (m, 1H, ar-H), 5.80 (s, 1H, NH), 
4.47 (dd, 3JHH = 9.7 Hz, 3JHH = 5.0 Hz, 1H, CH), 2.81 (br s, 1H, OH), 2.45-2.38 (m, 1H, CH2), 2.31-
2.19 (m, 1H, CH2), 1.93-1.84 (m, 1H, CH2), 1.72-1.49 (m, 3H, CH2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 174.3, 143.8, 142.7, 129.3, 128.5, 128.1, 127.2, 126.0, 
125.5, 78.7, 59.5, 31.6, 22.7, 20.0. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +185.3 (c = 0.51, CHCl3).  
 
(R)-6-(bis(3,5-Difluorophenyl)(hydroxy)methyl)piperidin-2-one (164b) 
ON
HHO
F
F
F F  
Under argon atmosphere, a heat-gun dried two-necked flask was charged with magnesium 
(450 mg, 18.6 mmol) and THF (20 mL). Afterwards 1-bromo-3,5-difluorobenzene (2.39 g, 1.42 mL, 
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12.4 mmol) was added dropwise to the magnesium and then the Grignard formation was started 
by heating with the heat gun. After the start the reaction mixture was stirred for four hours at 50 °C.  
Under argon atmosphere, a second two-necked flask was charged with methyl (R)-6-
oxopiperidine-2-carboxylate (163) (485 mg, 3.09 mmol) and THF (1 mL). Then, the corresponding 
solution was cooled in an ice-bath and at 0 °C the freshly prepared Grignard reagent was added 
dropwise over 15 minutes to the reaction mixture. After complete addition the mixture was stirred 
for 16 hours at room temperature. Then the reaction solution was quenched by slowly addition of 
saturated aqueous NH4Cl solution (20 mL). The biphasic mixture was extracted with EtOAc (3 x 
50 mL) and then the combined organic layers were washed with brine, dried over Na2SO4, filtered 
and concentrated under vacuum. The crude mixture was purified by recrystallization in EtOH to 
yield the product 164b (844 mg, 2.39 mmol, 77%) was a white solid.  
 
C18H15F4NO2 (353.32 g/mol): 
MP: >250 °C.  
1H NMR (400 MHz, DMSO-d6) δ/ppm = 7.40-7.33 (m, 2H, ar-H), 7.30-7.23 (m, 2H, ar-H), 7.16-
7.04 (m, 2H, ar-H), 6.32 (s, 1H, ar-H), 5.94 (s, 1H, ar-H), 4.68 (dd, 3JHH = 8.8 Hz, 3JHH = 5.4 Hz, 
1H, NCH), 2.22-2.00 (m, 2H, CH2), 1.83-1.73 (m, 1H, CH2), 1.63-1.35 (m, 3H, CH2). 
13C{1H} NMR (101 MHz, DMSO-d6) δ/ppm = 171.6, 163.8 (d, JCF = 13.4 Hz), 163.5 (d, 
JCF = 13.3 Hz), 161.3 (d, JCF = 13.0 Hz), 161.1 (d, JCF = 13.4 Hz), 148.9, 148.8, 148.7, 148.6, 
109.6 (d, JCF = 26.4 Hz), 108.8 (d, JCF = 26.5 Hz), 103.2, 102.9, 102.7, 102.4, 102.2, 78.0, 57.3, 
31.3, 22.4, 19.3. 
19F{1H} NMR (376 MHz, DMSO-d6) δ/ppm = −108.9, −109.2. 
IR (ATR): 𝑣𝑣�/cm-1 = 3369 (w), 2950 (w), 1664 (m), 1620 (m), 1593 (s), 1439 (s), 1301 (m), 1116 (s), 
981 (s), 855 (s), 786 (w), 145 (s), 604 (w), 510 (m), 458 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C18H15F4NO2+: 376.0931 [M+Na]+; found: 
376.0934. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +86.5 (c = 0.58, MeOH).  
 
(R)-6-Benzhydrylpiperidin-2-one (165a) 
ON
H
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Under argon atmosphere, a heat-gun dried two-necked flask was charged with (R)-6-
(hydroxydiphenylmethyl)piperidin-2-one (164a) (1.08 g, 3.85 mmol) and CH2Cl2 (44 mL). Then, at 
−20 °C, triethylsilane (2.24 g, 3.20 mL, 19.3 mmol) was added followed by dropwise addition of 
boron trifluoride diethyl etherate (ca. 48% BF3, 3.42 g, 3.11 mL, 11.56 mmol) over 15 minutes to 
the reaction mixture. After complete addition the reaction mixture was stirred for three hours at 
room temperature followed by a second addition of triethylsilane (3.58 g, 5.12 mL, 30.82 mmol) 
and boron trifluoride diethyl etherate (ca. 48% BF3, 9.11 g, 8.29 mL, 30.82 mmol) at −20 °C. 
Afterwards, the reaction mixture stirred for 36 hours at room temperature and then it was 
quenched by slowly addition of saturated aqueous NaHCO3 (50 mL) at 0 °C. The corresponding 
biphasic mixture was extracted with CH2Cl2 (3 x 50 mL) and the combined organic layers were 
washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The crude mixture was 
purified by column chromatography (SiO2, CH2Cl2:ethyl acetate (7:3), d x h: 3.5 x 25 cm) to afford 
the product 165a (807 mg, 3.04 mmol, 79%) as a white solid.  
 
C18H19NO (265.36 g/mol): 
MP: 239-240 °C.  
TLC: Rf = 0.25 (SiO2, CH2Cl2:ethyl acetate (7:3)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.31-7.08 (m, 10H, ar-H), 5.63 (s, 1H, NH), 4.08 (td, 
3JHH = 10.3 Hz, 3JHH = 4.1 Hz, 1H, NCH), 3.68 (d, 3JHH = 10.6 Hz, 1H, CHPh2), 2.39-2.29 (m, 1H, 
CH2), 2.27-2.16 (m, 1H, CH2), 1.88-1.77 (m, 1H, CH2), 1.75-1.67 (m, 1H, CH2), 1.66-1.54 (m, 1H, 
CH2), 1.34-1.21 (m, 1H, CH2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 172.3, 141.1, 140.2, 129.5, 129.0, 128.3, 127.9, 127.7, 
127.2, 59.1, 56.1, 31.5, 27.9, 20.0. 
IR (ATR): 𝑣𝑣�/cm-1 = 3397 (M9, 3335 (m), 2955 (w), 2932 (w), 1662 (s), 1448 (m), 1396 (m), 
1305 (w), 1189 (m), 1066 (w), 996 (w), 964 (m), 779 (w), 750 (s), 695 (s), 661 (m), 633 (s), 605 (m), 
543 (s), 465 (w), 429 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C18H19NO+: 266.1383 [M+H]+; found: 
266.1382. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +90.0 (c = 0.51, MeOH).  
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(R)-6-(Dicyclohexylmethyl)piperidin-2-one (166) 
ON
H
 
An autoclave inlet was charged with (R)-6-benzhydrylpiperidin-2-one (165a) (401 mg, 1.51 mmol) 
and MeOH (9 mL). To the corresponding mixture rhodium on alox (5 wt.%, 200 mg) was added 
and this mixture was put in an autoclave. After purging three times with hydrogen the reaction 
mixture was stirred for 16 hours at 10 bar hydrogen pressure. Then the mixture was filtered 
through Celite and the Celite cake was washed with EtOAc (3 x 10 mL). The crude mixture was 
concentrated under vacuum to yield the product 166 (415 mg, 1.50 mmol, 99%) as a beige solid.  
 
C18H31NO (277.45 g/mol): 
MP: 118-119 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 5.55 (s, 1H, NH), 3.60 (dd, 3JHH = 10.5 Hz, 3JHH = 3.7 Hz, 1H, 
NCH), 2.44-2.34 (m, 1H, CH2), 2.33-2.21 (m, 1H, CH2), 1.94-1.84 (m, 1H, CH2), 1.79-1.48 (m, 
15H, CH2, cy-CH2, cy-CH, CHCy2), 1.29-1.01 (m, 10H, CH2, cy-CH2, cy-CH, CHCy2), 1.00-0.95 (m, 
1H, CH2, cy-CH2, cy-CH, CHCy2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 172.6, 53.9, 53.7, 37.4, 37.0, 32.9, 32.3, 32.0, 31.9, 31.4, 
27.7, 27.1, 27.1, 27.0, 27.0, 26.6, 26.5, 20.7. 
IR (ATR): 𝑣𝑣�/cm-1 = 3199 (w), 3050 (w), 2918 (m), 2846 (w), 1594 (w), 1521 (s), 1495 (s), 1432 (w), 
1309 (m), 1241 (m), 1179 (m), 1092 (w), 1050 (w), 738 (s), 692 (s), 494 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C18H31NO+: 300.2298 [M+Na]+; found: 
300.2297. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +6.9 (c = 0.31, MeOH).  
 
(R)-5-Benzhydryl-2-(perfluorophenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-2-ium 
tetrafluoroborate (167) 
N
N
N
F F
F
FF
BF4  
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According to general procedure GP8, (R)-6-benzhydrylpiperidin-2-one (165a) (400 mg, 
1.51 mmol) in CH2Cl2 (8 mL) and trimethyloxonium tetrafluoroborate (289 mg, 1.96 mmol) were 
stirred to give of the crude imidate. Then, pentafluorophenylhydrazine (328 mg, 1.66 mmol) was 
added and stirred for four hours. After concentration of the reaction mixture the crude solid was 
dissolved in trimethyl orthoformate (1.84 g, 1.90 mL, 17.4 mmol) and MeCN (7 mL) and refluxed 
for 18 hours at 80 °C. The crude product was purified by column chromatography (SiO2, 
CH2Cl2:MeOH (30:1), d x h: 2.5 x 12 cm)) followed by recrystallization from ether/CH2Cl2 to afford 
the product 167 (246 mg, 453 µmol, 30%) as a white solid. 
 
C25H19F5N3·BF4 (543.24 g/mol): 
MP: 97-98 °C.  
TLC: Rf = 0.32 (SiO2, CH2Cl2:MeOH (20:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 8.46 (s, 1H, carbene-CH), 7.51-7.44 (m, 2H, ar-H), 7.44-
7.36 (m, 6H, ar-H), 7.35-7.29 (m, 2H, ar-H), 5.78 (dt, 3JHH = 11.8 Hz, 3JHH = 3.5 Hz, 1H, Ph-CH), 
4.31 (d, 3JHH = 11.4 Hz, 1H, NCH), 3.40-3.26 (m, 1H, CH2), 3.20-3.06 (m, 1H, CH2), 2.29-2.02 (m, 
4H, CH2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 154.2, 144.6, 144.2-143.35 (m), 141.9-141.2 (m), 139.7-
139.1 (m), 139.0, 138.7, 137.3-136.2 (m), 130.1, 129.6, 128.8, 128.6, 128.1, 128.0, 60.9, 55.7, 
24.2, 21.1, 14.7. 
19F{1H} NMR (376 MHz, CDCl3) δ/ppm = −144.1-−144.3 (m), −146.1-−146.3 (m), −152.4, −158.0-
−158.6 (m). 
IR (ATR): 𝑣𝑣�/cm-1 = 3123 (w), 1584 (m), 1514 (s), 1452 (w), 1299 (w), 1237 (w), 1048 (s), 913 (w), 
842 (m), 705 (s), 630 (w), 519 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C25H19F5N3+: 456.1494 [M]+; found: 
456.1496. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −67.4 (c = 0.58, MeOH).  
 
(R)-5-(Dicyclohexylmethyl)-2-(perfluorophenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]-
pyridin-2-ium tetrafluoroborate (168) 
N
N
N
F F
F
FF
BF4  
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According to general procedure GP8, (R)-6-(dicyclohexylmethyl)piperidin-2-one (166) (400 mg, 
1.44 mmol) in CH2Cl2 (8 mL) and trimethyloxonium tetrafluoroborate (277 mg, 1.87 mmol) were 
stirred to give of the crude imidate. Then, pentafluorophenylhydrazine (314 mg, 1.58 mmol) was 
added and stirred for four hours. After concentration of the reaction mixture the crude solid was 
dissolved in trimethyl orthoformate (1.07 g, 1.11 mL, 10.1 mmol) and MeCN (8 mL) and refluxed 
for 16 hours at 80 °C. The crude product was purified by two column chromatography (SiO2, 
CH2Cl2:MeOH (30:1), d x h: 3.5 x 24 cm followed by SiO2, cyclohexane:ethyl acetate (1:1), d x h: 
2.5 x 16 cm)) to afford the product 168 (155 mg, 279 µmol, 19%) as a white solid. 
 
C25H31F5N3·BF4 (468.54 g/mol): 
TLC: Rf = 0.43 (SiO2, CH2Cl2:MeOH (20:1)). 
MP: 92-93 °C.  
1H NMR (400 MHz, CDCl3) δ/ppm = 10.07 (s, 1H, carbene-CH), 4.93-4.82 (m, 1H, NCH), 3.36- 
3.24 (m, 1H, CH2), 2.93 (dd, 3JHH = 17.7 Hz, 3JHH = 5.8 Hz, 1H, CH2), 2.31-2.17 (m, 2H, CH2), 2.11-
1.98 (m, 1H, CH2), 1.97-1.83 (m, 5H, CH2, cy-CH2), 1.81-1.60 (m, 9H, cy-CH, cy-CH2), 1.32-
1.03 (m, 12H, cy-CH2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 155.3, 144.9, 144.8-144.24 (m), 142.4-141.6 (m), 139.6-
139.1 (m), 137.3-136.5 (m), 61.7, 51.5, 37.2, 37.1, 34.2, 32.8, 30.6, 30.3, 27.1, 27.0, 26.8, 26.7, 
26.3, 26.1, 23.9, 21.8, 17.9. 
19F{1H} NMR (376 MHz, CDCl3) δ/ppm = −145.4-−145.6 (m), −146.4-−146.7 (m), −152.5 (s), 
−158.89 (t, 3JFF = 22.3 Hz). 
IR (ATR): 𝑣𝑣�/cm-1 = 2925 (m), 2853 (w), 1589 (m), 1528 (m), 1515 (w), 1446 (w), 1396 (w), 
1351 (m), 1075 (s), 1055 (s), 1033 (s), 1004 (s), 909 (w), 793 (w), 521 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C25H31F5N3+: 468.2433 [M]+; found: 
468.2433. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +53.7 (c = 0.55, MeOH).  
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5.3.3 Preparative Cross-Benzoin Reaction 
General Procedure for the Asymmetric Cross-Benzoin Reaction 
Under argon atmosphere, a heat-gun dried GC-vial was charged with benzaldehyde (0.10 mmol), 
hydrocinnamaldehyde (0.15 mmol), triazolium salt (0.02 mmol) and CH2Cl2 (0.1 mL). Then, the 
reaction mixture was treated with DIPEA (0.1 mmol) and stirred for 16 hours at room temperature. 
Afterwards the crude mixture was concentrated under vacuum and purified by preparative TLC.  
 
Determination of the chemoselectivity: 
The chemoselectivity of the cross-benzoin reaction was determined by 1H-NMR analysis of the 
crude mixture based on the signals of the benzylic proton of benzoin (5.95 ppm) and benzylic 
proton of the cross-benzoin product (5.05 ppm). 
 
Determination of the enantiomeric excess: 
HPLC (Daicel Chiracel IC, heptane/i-PrOH = 95:5, 0.5 mL/min, 40 °C): tR (major) = 18.5 min, 
tR (minor) = 34.4 min. 
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5.4 Synthesis of Iridium Complexes derived from chiral 
bidentate NHC-Phosphine Ligands 
5.4.1 Synthesis of Chiral Bidentate NHC-Phosphine Ligands 
(S)-5-(((Methylsulfonyl)oxy)methyl)-2-phenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-
ium tetrafluoroborate (174) 
N
N
N
MsO BF4  
According to general procedure GP8, (S)-(5-oxopyrrolidin-2-yl)methyl methanesulfonate (173) 
(504 mg, 2.61 mmol) in CH2Cl2 (17 mL) and trimethyloxonium tetrafluoroborate (425 mg, 
2.87 mmol) were stirred to give of the crude imidate. Then, phenylhydrazine (310 mg, 285 µL, 
2.87 mmol) was added and stirred for four hours. After concentration of the reaction mixture the 
crude solid was dissolved in trimethyl orthoformate (4.04 g, 4.17 mL, 38.1 mmol) and MeCN 
(8 mL) and refluxed for 16 hours at 80 °C. The crude product was purified by two column 
chromatography (SiO2, CH2Cl2:MeOH (20:1), d x h: 5 x 13 cm) to afford the product 174 (806 mg, 
2.11 mmol, 81%) as a yellow gum. 
 
C13H16N3O3S BF4 (381.16 g/mol): 
TLC: Rf = 0.48 (SiO2, CH2Cl2:MeOH (10:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 10.06 (s, 1H, carbene-CH), 7.85-7.77 (m, 2H, ar-H), 7.66-
7.56 (m, 3H, ar-H), 5.01-4.94 (m, 1H, CH2OMs), 4.55 (dd, 3JHH = 12.2 Hz, 4JHH = 4.1 Hz, 1H, 
CH2OMs), 3.41-3.20 (m, 2H, CH2), 3.16-3.10 (m, 2H, CH2), 3.09 (s, 3H, SO2CH3), 2.88-2.75 (m, 
1H, CH). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 163.3, 137.8, 136.1, 131.7, 130.8, 121.7, 69.5, 60.3, 
38.0, 30.0, 22.4. 
19F{1H} NMR (376 MHz, CD2Cl2): δ/ppm = −150.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 3133 (w), 3033 (w), 2942 (w), 1690 (w), 1591 (m), 1352 (s), 1173 (s), 1033 (s), 
970 (s), 811 (m), 761 (m), 687 (m), 522 (s). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C13H16N3O3S+: 294.0907 [M]+; found: 
294.0911. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −31.4 (c = 0.98, MeOH).   
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(S)-5-(Bromomethyl)-2-phenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium 
tetrafluoroborate (176) 
N
N
N
Br BF4  
According to general procedure GP8, (S)-5-(bromomethyl)pyrrolidin-2-one (175) (178 mg, 
1.00 mmol) in CH2Cl2 (7 mL) and trimethyloxonium tetrafluoroborate (163 mg, 1.10 mmol) were 
stirred to give of the crude imidate. Then, phenylhydrazine (114 mg, 104 µL, 1.05 mmol) was 
added and stirred for four hours. After concentration of the reaction mixture the crude solid was 
dissolved in trimethyl orthoformate (5.21 g, 5.37 mL, 49.1 mmol) and refluxed for 16 hours at 
80 °C. The crude product was purified by two column chromatography (SiO2, CH2Cl2:MeOH 
(30:1), d x h: 3.5 x 16 cm) to afford the product 176 (321 mg, 877 µmol, 88%) as a beige solid. 
 
C12H13N3Br BF4 (365.96 g/mol): 
MP: 112-113 °C. 
TLC: Rf = 0.49 (SiO2, CH2Cl2:MeOH (10:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 10.11 (s, 1H, carbene-CH), 7.87-7.81 (m, 2H, ar-H), 7.67-
7.56 (m, 3H, ar-H), 5.39 (dq, 3JHH = 8.3 Hz, 3JHH = 3.8 Hz, 1H, NCH), 4.22 (dd, 3JHH = 12.0 Hz, 
4JHH = 3.8 Hz, 1H, CH2Br), 3.85 (dd, 3JHH = 12.0 Hz, 4JHH = 3.5 Hz, 1H, CH2Br), 3.49-3.33 (m, 1H, 
CH2), 3.31-3.21 (m, 1H, CH2), 3.19-3.07 (m, 1H, CH2), 2.82-2.70 (m, 1H, CH2). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 163.4, 137.2, 136.1, 131.6, 130.8, 121.4, 61.1, 34.8, 
32.6, 22.5. 
19F{1H} NMR (376 MHz, CD2Cl2): δ/ppm = −151.3. 
IR (ATR): 𝑣𝑣�/cm-1 = 3137 (w), 3109 (w), 1685 (w), 1592 (m), 1520 (m), 1385 (w), 1221 (m), 1019 (s), 
761 (s), 684 (s), 651 (m), 519 (m), 487 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C12H13N3Br+: 278.0287 [M]+; found: 
278.0291. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −29.2 (c = 0.98, MeOH).  
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(S)-5-((Diphenylphosphanyl)methyl)pyrrolidin-2-one (178) 
N
H
O
P
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with (S)-(5-
oxopyrrolidin-2-yl)methyl methanesulfonate (173) (334 mg, 1.73 mmol) and THF (3 mL). Then, 
the reaction mixture was degassed by three freeze-pump-thaw cycles. At 0 °C, potassium 
diphenylphosphide solution (0.5M, 5.19 mL, 4.82 g, 2.60 mmol) was added dropwise over five 
minutes and afterwards the mixture was stirred overnight at room temperature. At ambient 
temperature water (10 mL) was added and then the resulting biphasic mixture was extracted with 
EtOAc (3 x 25 mL). The combined organic layers were dried over Na2SO4, filtered, concentrated 
under vacuum and the crude product was purified by column chromatography (SiO2, MeOH:ethyl 
acetate (1:50), d x h: 3.5 x 13 cm) to afford the product 178 (286 mg, 1.01 mmol, 58%) as a white 
solid. 
 
C17H18NOP (283.31 g/mol): 
MP: 98-99 °C. 
TLC: Rf = 0.45 (SiO2, EtOAc:MeOH (50:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.49-7.40 (m, 4H, ar-H), 7.40-7.29 (m, 6H, ar-H), 5.89 (s, 
1H, NH), 3.65 (p, 3JHH = 6.7 Hz, 1H, NCH), 2.37-2.18 (m, 5H, PCH2, CH2), 1.91-1.79 (m, 1H, CH2). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 177.7, 138.4 (d, JCP = 12.1 Hz), 133.5, 133.2 (d, 
JCP = 19.4 Hz), 131.1 (d, JCP = 11.4 Hz), 129.5 (d, JCP = 6.6 Hz), 129.2 (d, JCP = 5.6 Hz), 52.6 (d, 
JCP = 17.5 Hz), 36.9 (d, JCP = 14.3 Hz), 30.6, 29.5 (d, JCP = 8.8 Hz). 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −23.3. 
IR (ATR): 𝑣𝑣�/cm-1 = 3226 (br m), 3069 (w), 3048 (w), 2955 (w), 1681 (s), 1432 (m), 1343 (w), 
1277 (m), 1253 (m), 1184 (m), 1065 (m), 963 (w), 890 (w), 742 (s), 682 (s), 515 (m), 492 (m), 
465 (s), 421 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C17H18NOP+: 306.1018 [M+Na]+; found: 
306.1020. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −3.6 (c = 0.97, MeOH).  
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(S)-5-((Diphenylphosphanyl)methyl)pyrrolidin-2-one BH3 complex (174) 
N
H
O
P
BH3  
Under argon atmosphere, a heat-gun dried two-necked flask was charged with borane 
diphenylphosphine complex (173) (540 mg, 2.70 mmol) and THF (4 mL). At 0 °C, sodium hydride 
(95%, 68.2 mg, 2.70 mmol) was added to the reaction solution and the resulting reaction mixture 
was stirred for 45 minutes at 0 °C. Afterwards (S)-(5-oxopyrrolidin-2-yl)methyl methanesulfonate 
(386 mg, 2.00 mmol) was added to the red reaction solution and then stirred for 30 minutes at 
0 °C and further two hours at room temperature. After full conversion (TLC test) the reaction 
mixture was quenched with water (10 mL) and then the resulting biphasic mixture was extracted 
with EtOAc (3 x 25 mL). The combined organic layers were washed with brine (20 mL), dried over 
Na2SO4, filtered, concentrated under vacuum and the crude product was purified by column 
chromatography (SiO2, MeOH:ethyl acetate (1:40), d x h: 3.5 x 14 cm) to afford the product 174 
(582 mg, 1.96 mmol, 98%) as a white gum. 
 
C17H18NOP·BH3 (297.14 g/mol): 
TLC: Rf = 0.51 (SiO2, EtOAc:MeOH (25:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.75-7.62 (m, 4H, ar-H), 7.58-7.43 (m, 6H, ar-H), 5.99 (br s, 
1H, NH), 3.95-3.85 (m, 1H, NCH), 2.55 (td, 3JHH = 13.9 Hz, 3JHH = 3.5 Hz, 1H, PCH2), 2.48-2.37 (m, 
1H, CH2), 2.37-2.19 (m, 3H, PCH2, CH2), 1.86-1.68 (m, 1H, CH2), 1.45-0.58 (br m, 3H, BH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 177.1, 132.4 (d, JCP = 9.4 Hz), 132.0, 131.9, 131.8 (d, 
JCP = 3.0 Hz), 129.3 (d, JCP = 2.1 Hz), 129.2 (d, JCP = 2.0 Hz), 50.1 (d, JCP = 1.6 Hz), 34.1 (d, 
JCP = 35.2 Hz), 29.9, 29.8 (d, J = 10.4 Hz). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −11.8 (br s). 
IR (ATR): 𝑣𝑣�/cm-1 = 3222 (w), 3055 (w), 2377 (m), 1688 (s), 1435 (m), 1414 (w), 1281 (w), 1261 (w), 
1106 (m), 1058 (m), 887 (w), 735 (s), 690 (s), 592 (s), 472 (s). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C17H18NOP·BH3+: 320.1349 [M+Na]+; 
found: 320.1352. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +13.0 (c = 1.00, MeOH).  
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(S)-5-((Diphenylphosphanyl)methyl)-2-phenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-
ium tetrafluoroborate (177) 
N
N
N
P BF4
 
In the glovebox a heat-gun dried round-bottom flask was charged with (S)-5-((diphenyl-
phosphanyl)methyl)pyrrolidin-2-one BH3 complex (180) (200 mg, 673 µmol) and CH2Cl2 (4.7 mL). 
Then, trimethyloxonium tetrafluoroborate (109 mg, 740 µmol) was added in one portion to the 
reaction mixture. The resulting solution was stirred for 16 hours at room temperature. Then, the 
hydrazine (80.0 mg, 73.4 µL, 740 µmol) was added in one portion and after stirring for four hours 
at room temperature the reaction flask was taken out of the glovebox and the crude mixture was 
concentrated under vacuum. The resulting solid was dissolved in triethyll orthoformate (1.78 g, 
2.00 mL, 12.0 mmol) and refluxed at 115 °C for six to 90 minutes. Afterwards, the crude product 
was purified by two column chromatography (SiO2, CH2Cl2:MeOH (50:1), d x h: 2.5 x 15 cm) to 
afford the product 177 (248 mg, 526 µmol, 78%) as a pale yellow gum. 
 
C24H23N3P BF4 (471.25 g/mol): 
MP: 71-72 °C. 
TLC: Rf = 0.28 (SiO2, CH2Cl2:MeOH (20:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 9.72 (s, 1H, carbene-CH), 7.70-7.64 (m, 2H, ar-H), 7.60-
7.53 (m, 3H, ar-H), 7.52-7.45 (m, 4H, ar-H), 7.41-7.32 (m, 3H, ar-H), 7.28-7.21 (m, 2H, ar-H), 7.18-
7.10 (m, 1H, ar-H), 5.26-5.12 (m, 1H, NCH), 3.41 (ddd, 2JHP = 17.4 Hz, 2JHH = 9.6 Hz, 3JHH = 6.0 Hz, 
1H, PCH2), 3.28-3.15 (m, 1H, PCH2), 3.13-3.02 (m, 2H, CH2), 2.95-2.82 (m, 2H, CH2). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 162.4, 137.3, 136.7 (d, JCP = 11.4 Hz), 136.5 (d, 
JCP = 9.3 Hz), 135.8, 134.0 (d, JCP = 21.4 Hz), 132.8 (d, JCP = 19.1 Hz), 131.4, 130.7, 130.4, 129.8, 
129.5, 129.5, 129.4, 121.1, 60.5 (d, JCP = 17.2 Hz), 34.2 (d, JCP = 2.6 Hz), 34.0 (d, JCP = 3.6 Hz), 
22.7 (d, JCP = 4.7 Hz). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −28.0. 
19F{1H} NMR (376 MHz, CDCl3): δ/ppm = −151.0. 
IR (ATR): 𝑣𝑣�/cm-1 = 2923 (w), 2854 (w), 1662 (w), 1589 (w), 118 (w), 1050 (s), 976 (m), 875 (w), 
741 (s), 694 (s), 505 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C24H23N3P+: 384.1624 [M]+; found: 
384.1627. 
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[𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −6.8 (c = 0.58, MeOH).  
 
General Procedure (GP10): Synthesis of phosphine-NHC triazolium BArF salts 
In the glovebox, a heat-gun dried round-bottomed flask was charged with the phosphine lactam 
(1.0 eq.) and CH2Cl2 (7 ml per mmol lactam). Then, trimethyloxonium tetrafluoroborate (1.1 eq.) 
was added in one portion and the resulting solution was stirred for 16 hours at room temperature. 
Then, the hydrazine (1.1 eq.) was added in one portion and after stirring for four hours at room 
temperature the reaction flask was taken out of the glovebox and the crude mixture was treated 
with sodium BArF (1.5 eq.). After stirring for 16 hours, the reaction mixture was fitered over a pad 
of silica gel and the pad was washed with CH2Cl2/MeOH (20:1) solution. The crude solution was 
concentrated under vacuum and then the resulting gum was dissolved in triethyl orthoformate 
(17.8 eq.) and refluxed at 115 °C for 90 minutes. Afterwards, the crude product was concentrated 
under vacuum and purified by column chromatography.  
 
(S)-5-((Diphenylphosphanyl)methyl)-2-phenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-
ium BArF (181a) 
N
N
N
P BArF
 
According to general procedure GP10, (S)-5-((diphenylphosphanyl)methyl)pyrrolidin-2-one BH3 
complex (180) (100 mg, 337 µmol) in CH2Cl2 (2.4 mL) and trimethyloxonium tetrafluoroborate 
(57.7 mg, 371 µmol) were stirred to give of the crude imidate. Then, phenylhydrazine (40.1 mg, 
36.8 µL, 371 µmol) was added and stirred for four hours. Afterwards, the reaction solution was 
treated with sodium BArF (448 mg, 506 µmol) and stirred for 16 hours at room temperature. After 
concentration of the reaction mixture and filtration over silica gel the crude gum was dissolved in 
triethyl orthoformate (889 mg, 988 µL, 6.00 mmol) and refluxed for 90 minutes at 115 °C. The 
crude product was purified by column chromatography (SiO2, CH2Cl2:MeOH (100:1), d x h: 2.5 x 
18 cm) to afford the product 181a (316 mg, 253 µmol, 75%) as a pale yellow solid.  
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C24H23N3P BArF (1247.66 g/mol): 
MP: 52-53 °C. 
TLC: Rf = 0.40 (SiO2, CH2Cl2:MeOH (50:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 9.30 (s, 1H, carbene-CH), 7.73 (s, 8H, ar-H), 7.67-7.59 (m, 
5H, ar-H), 7.56 (s, 4H, ar-H), 7.58-7.47 (m, 3H, ar-H), 7.48-7.36 (m, 7H, ar-H), 4.90-4.78 (m, 1H, 
NCH), 3.42 (ddd, 2JHP = 17.8 Hz, 2JHH = 9.4 Hz, 3JHH = 5.1 Hz, 1H, PCH2), 3.34-3.20 (m, 1H, CH2), 
3.20-3.06 (m, 1H, CH2), 2.92 (dd, 3JHP = 14.5 Hz, 3JHH = 4.2 Hz, 1H), CH2, 2.88-2.74 (m, 1H, CH2), 
2.63 (ddd, 2JHP = 14.3 Hz, 2JHH = 9.2 Hz, 3JHH = 3.4 Hz, 1H, PCH2). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 163.3, 162.8 (q, JCF = 49.8 Hz), 161.8 (q, JCF = 49.7 Hz), 
135.4, 135.1 (d, JCP = 15.0 Hz), 134.9 (d, JCP = 9.7 Hz), 133.7 (d, JCP = 20.4 Hz), 132.8, 132.7, 
132.6, 131.3, 130.9 (d, JCF = 69.2 Hz), 129.7-129.5 (m), 129.4-129.1 (m), 125.2 (q, JCF = 272.5 Hz), 
121.4, 118.3-117.8 (m), 61.3 (d, JCP = 16.8 Hz), 35.8 (d, JCP = 8.6 Hz), 34.7 (d, JCP = 17.1 Hz), 
22.6. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −26.4. 
19F{1H} NMR (376 MHz, CD2Cl2): δ/ppm = −62.3. 
IR (ATR): 𝑣𝑣�/cm-1 = 1352 (m), 1271 (s), 1111 (s), 885 (m), 837 (m), 743 (w), 711 (w), 680 (m), 
668 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C24H23N3P+: 384.1624 [M]+; found: 
384.1631. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −6.6 (c = 0.62, MeOH).  
 
(S)-5-((Diphenylphosphanyl)methyl)-2-mesityl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-
ium BArF (181b) 
N
N
N
P
BArF
 
According to general procedure GP10, (S)-5-((diphenylphosphanyl)methyl)pyrrolidin-2-one BH3 
complex (180) (100 mg, 337 µmol) in CH2Cl2 (2.4 mL) and trimethyloxonium tetrafluoroborate 
(57.7 mg, 371 µmol) were stirred to give of the crude imidate. Then, mesitylhydrazine (freshly 
prepared from 1-mesitylhydrazine hydrochloride [69.2 mg, 371 µmol] in ether [5 mL] after 
extraction with saturated aqueous Na2CO3 solution [5 mL]) was added and stirred for four hours. 
EXPERIMENTAL PART            CHAPTER 5 
332 
Afterwards, the reaction solution was treated with sodium BArF (448 mg, 506 µmol) and stirred for 
16 hours at room temperature. After concentration of the reaction mixture and filtration over silica 
gel the crude gum was dissolved in triethyl orthoformate (889 mg, 988 µL, 6.00 mmol) and refluxed 
for 90 minutes at 115 °C. The crude product was purified by column chromatography (SiO2, 
CH2Cl2:MeOH (100:1), d x h: 2.5 x 20 cm) to afford the product 181b (371 mg, 288 µmol, 85%) as 
a pale yellow gum. 
 
C27H29N3P BArF (1289.74 g/mol): 
TLC: Rf = 0.45 (SiO2, CH2Cl2:MeOH (50:1)). 
 
(S)-2-(2,6-Dimethoxyphenyl)-5-((diphenylphosphanyl)methyl)-6,7-dihydro-5H-pyrrolo[2,1-
c][1,2,4]triazol-2-ium BArF (181c) 
N
N
N
P
BArF
MeO
MeO
 
According to general procedure GP10, (S)-5-((diphenylphosphanyl)methyl)pyrrolidin-2-one BH3 
complex (180) (290 mg, 976 µmol) in CH2Cl2 (7 mL) and trimethyloxonium tetrafluoroborate 
(159 mg, 1.07 mmol) were stirred to give of the crude imidate. Then, 1-(2,6-
dimethoxyphenyl)hydrazine (freshly prepared from di-tert-butyl 1-(2,6-dimethoxyphenyl)-
hydrazine-1,2-dicarboxylate [432 mg, 1.17 mmol] and HCl in dioxane [4M, 2.90 g, 2.44 mL, 
9.76 mmol] in ether [5 mL] after extraction with saturated aqueous Na2CO3 solution [10 mL]) was 
added and stirred for four hours. Afterwards, the reaction solution was treated with sodium BArF 
(1.30 g, 1.46 mol) and stirred for 16 hours at room temperature. After concentration of the reaction 
mixture and filtration over silica gel the crude gum was dissolved in triethyl orthoformate (2.82 g, 
3.18 mL, 17.4 mmol) and refluxed for 90 minutes at 115 °C. The crude product was purified by 
column chromatography (SiO2, CH2Cl2:MeOH (100:1), d x h: 3.5 x 10 cm) to afford the product 
181c (240 mg, 183 µmol, 19%) as a yellow solid. 
 
C26H27N3O2P BArF (1307.71 g/mol): 
MP: 61-62 °C. 
TLC: Rf = 0.57 (SiO2, CH2Cl2:MeOH (50:1)). 
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1H NMR (400 MHz, CD2Cl2): δ/ppm = 9.26 (s, 1H, carbene-CH), 7.73 (s, 9H, ar-H), 7.59-7.51 (m, 
7H, ar-H), 7.47-7.38 (m, 7H, ar-H), 6.75 (d, 3JHH = 8.6 Hz, 2H, ar-H), 4.78-4.67 (m, 1H, NCH), 3.81 
(s, 6H, ar-OCH3), 3.36 (ddd, 2JHP = 17.6, 3JHH = 9.3 Hz, 4JHH = 4.8 Hz, 1H, PCH2), 3.29-3.19 (m, 
1H, CH2), 3.14-3.00 (m, 1H, CH2), 2.87 (ddd, 2JHP = 14.2 Hz, 3JHH = 4.9 Hz, 4JHH = 1.0 Hz, 1H, 
PCH2), 2.77-2.56 (m, 2H, CH2). 
13C{1H} NMR (101 MHz, CD2Cl2) δ/ppm = 162.3 (q, JCF = 50.0 Hz), 162.2, 155.8, 140.9, 135.4, 
134.8, 133.7 (d, JCP = 20.3 Hz), 132.8 (d, JCP = 19.2 Hz), 131.0, 130.4, 129.9 (d, JCP = 7.7 Hz), 
129.7 (d, JCP = 7.4 Hz), 129.7-129.5 (m), 129.4-129.1 (m), 125.2 (q, JCF = 272.5 Hz), 121.1, 118.2-
117.9 (m), 113.1, 105.1, 60.9 (d, JCP = 18.1 Hz), 57.0, 36.0 (d, JCP = 8.4 Hz), 34.8 (d, 
JCP = 17.3 Hz), 22.6. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −25.7. 
19F{1H} NMR (376 MHz, CD2Cl2) δ/ppm = −62.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 2169 (w), 2140 (w), 1586 (w), 1351 (m), 1275 (m), 1166 (m), 1047 (s), 873 (m), 
667 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C26H27N3O2P+: 444.1835 [M]+; found: 
444.1843. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −2.5 (c = 0.72, MeOH).  
 
(S)-2-(tert-Butyl)-5-((diphenylphosphanyl)methyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]-
triazol-2-ium BArF (181d) 
N
N
N
P
BArF
 
According to general procedure GP10, (S)-5-((diphenylphosphanyl)methyl)pyrrolidin-2-one BH3 
complex (180) (100 mg, 337 µmol) in CH2Cl2 (2.5 mL) and trimethyloxonium tetrafluoroborate 
(57.7 mg, 371 µmol) were stirred to give of the crude imidate. Then, tert-butylhydrazine (freshly 
prepared from tert-butylhydrazine hydrochloride [54.6 mg, 438 µmol] in ether [2 mL] after 
extraction with saturated aqueous Na2CO3 solution [3 mL]) was added and stirred for four hours. 
Afterwards, the reaction solution was treated with sodium BArF (448 mg, 506 µmol) and stirred for 
16 hours at room temperature. After concentration of the reaction mixture and filtration over silica 
gel the crude gum was dissolved in triethyl orthoformate (889 mg, 1.00 mL, 6.00 mmol) and 
refluxed for 90 minutes at 115 °C. The crude product was purified by column chromatography 
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(SiO2, CH2Cl2:MeOH (100:1), d x h: 2.5 x 20 cm) to afford the product 181d (278 mg, 226 µmol, 
67%) as a yellow gum. 
 
C22H27N3P BArF (1227.67 g/mol): 
TLC: Rf = 0.35 (SiO2, CH2Cl2:MeOH (50:1)). 
1H NMR (400 MHz, CD2Cl2) δ/ppm = 8.75 (s, 1H, carbene-CH), 7.64 (s, 8H, ar-H), 7.47 (s, 4H, ar-
H), 7.44-7.30 (m, 10H, ar-H), 4.68-4.54 (m, 1H, NCH), 3.24-3.15 (m, 1H, CH2), 3.10-3.02 (m, 1H, 
CH2), 3.01-2.91 (m, 1H, CH2), 2.71 (dd, 2JHP = 14.4 Hz, 3JHH = 4.7 Hz, 1H, PCH2), 2.67-2.57 (m, 
1H, CH2), 2.52 (ddd, 2JHP = 14.4 Hz, 3JHH = 8.9 Hz, 4JHH = 2.4 Hz, 1H, PCH2), 1.52 (s, 9H, C(CH3)3). 
13C{1H} NMR (101 MHz, CD2Cl2) δ/ppm = 162.8 (q, JCF = 49.6 Hz), 162.8, 161.8 (d, JCP = 49.7 Hz), 
135.6 (d, JCP = 8.4 Hz), 135.4, 134.5 (d, JCP = 13.7 Hz), 133.5 (d, JCP = 20.3 Hz), 132.8 (d, 
JCP = 19.2 Hz), 130.8 (d, JCF = 45.4 Hz), 129.9 (d, JCP = 7.8 Hz), 129.8 (d, JCP = 7.3 Hz), 129.7-
129.4 (m), 129.3-129.1 (m), 125.2 (q, JCF = 272.4 Hz), 121.1, 118.2-117.9 (m), 66.0, 60.7 (d, 
JCP = 18.1 Hz), 36.0 (d, JCP = 8.9 Hz), 34.4 (d, JCP = 17.0 Hz), 29.0, 22.4. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −26.0. 
19F{1H} NMR (376 MHz, CD2Cl2) δ/ppm = −62.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 1352 (s), 1272 (s), 1113 (s), 930 (m), 885 (w), 743 (w), 711 (m), 667 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C22H27N3P+: 364.1937 [M]+; found: 
364.1942. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −2.6 (c = 0.44, MeOH).  
 
(S)-5-((di-o-Tolylphosphanyl)methyl)pyrrolidin-2-one BH3 complex (182a) 
N
H
O
P
BH3
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with borane di(o-
tolyl)phosphine complex (371 mg, 1.63 mmol) and THF (2 mL). At 0 °C, sodium hydride (95%, 
41.1 mg, 1.63 mmol) was added to the reaction solution and the resulting reaction mixture was 
stirred for 45 minutes at 0 °C. Afterwards (S)-(5-oxopyrrolidin-2-yl)methyl methanesulfonate (173) 
(242 mg, 1.25 mmol) was added to the red reaction solution and then stirred for 30 minutes at 
0 °C and further two hours at room temperature. After full conversion (TLC test) the reaction 
mixture was quenched with water (10 mL) and then the resulting biphasic mixture was extracted 
with EtOAc (3 x 25 mL). The combined organic layers were washed with brine (20 mL), dried over 
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Na2SO4, filtered, concentrated under vacuum and the crude product was purified by column 
chromatography (SiO2, MeOH:ethyl acetate (1:30), d x h: 3.5 x 20 cm) to afford the product 182a 
(342 mg, 1.05 mmol, 84%) as a white solid. 
 
C19H22NOP·BH3 (325.20 g/mol): 
MP: 100-101 °C. 
TLC: Rf = 0.44 (SiO2, EtOAc:MeOH (30:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 7.85-7.71 (m, 2H, ar-H), 7.49-7.38 (m, 2H, ar-H), 7.40-
7.31 (m, 2H, ar-H), 7.23-7.14 (m, 2H, ar-H), 5.57 (s, 1H, NH), 4.02-3.88 (m, 1H, NCH), 2.70-
2.52 (m, 2H, PCH2, CH2), 2.35-2.17 (m, 3H, PCH2, CH2), 2.05 (s, 5H, ar-CH3), 1.86-1.75 (m, 1H, 
CH2), 1.42-0.76 (br m, 3H, BH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 177.6, 142.7, 142.5, 142.2 (d, JCP = 8.3 Hz), 142.0 (d, 
JCP = 6.0 Hz), 132.9 (d, JCP = 9.5 Hz), 132.7 (d, JCP = 9.7 Hz), 131.9 (d, JCP = 2.5 Hz), 130.4 (d, 
JCP = 5.0 Hz), 129.0 (d, JCP = 3.2 Hz), 127.0 (d, JCP = 11.0 Hz), 126.8 (d, JCP = 11.0 Hz), 126.4, 
50.0, 35.5 (d, JCP = 14.6 Hz), 29.9, 29.4 (d, JCP = 8.6 Hz), 21.5, 21.2. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −12.4 (br s). 
IR (ATR): 𝑣𝑣�/cm-1 = 2381 (w), 1687 (s), 1450 (m), 1279 (m), 1199 (w), 1131 (w), 1062 (m), 743 (s), 
593 (w), 491 (m), 456 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C19H22NOP+: 334.1331 [M+Na]+; found: 
334.1333. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −11.2 (c = 0.91, MeOH).  
 
(S)-5-((di-o-Tolylphosphanyl)methyl)-2-phenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-
2-ium BArF (183a) 
N
N
N
P BArF
 
According to general procedure GP10, (S)-5-((di-o-tolylphosphanyl)methyl)pyrrolidin-2-one BH3 
complex (182a) (100 mg, 308 µmol) in CH2Cl2 (2.2 mL) and trimethyloxonium tetrafluoroborate 
(52.7 mg, 339 µmol) were stirred to give of the crude imidate. Then, phenylhydrazine (36.6 mg, 
33.6 µL, 339 µmol) was added and stirred for four hours. Afterwards, the reaction solution was 
treated with sodium BArF (409 mg, 462 µmol) and stirred for 16 hours at room temperature. After 
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concentration of the reaction mixture and filtration over silica gel the crude gum was dissolved in 
triethyl orthoformate (812 mg, 903 µL, 5.48 mmol) and refluxed for 90 minutes at 115 °C. The 
crude product was purified by column chromatography (SiO2, CH2Cl2:MeOH (100:1), d x h: 2.5 x 
24 cm) to afford the product 183a (330 mg, 259 µmol, 84%) as a yellow gum. 
 
C26H27N3P BArF (1275.71 g/mol): 
TLC: Rf = 0.43 (SiO2, CH2Cl2:MeOH (60:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 9.18 (s, 1H, carbene-CH), 7.73 (s, 8H, ar-H), 7.68-7.57 (m, 
5H, ar-H), 7.56 (s, 4H, ar-H), 7.34-7.16 (m, 8H, ar-H), 4.94-4.83 (m, 1H, NCH), 3.42 (ddd, 
2JHP = 17.7 Hz, 2JHH = 9.3 Hz, 3JHH = 4.7 Hz, 1H, PCH2), 3.33-3.23 (m, 1H, CH2), 3.20-3.10 (m, 1H, 
CH2), 2.90-2.80 (m, 2H, CH2), 2.62 (ddd, 2JHP = 14.5 Hz, 3JHH = 8.8 Hz, 4JHH = 3.7 Hz, 1H, PCH2), 
2.46 (s, 3H, ar-CH3), 2.40 (s, 3H, ar-CH3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 163.3, 162.3 (q, JCF = 50.0 Hz), 143.4 (d, JCP = 27.4 Hz), 
142.8 (d, JCP = 26.7 Hz), 135.4, 135.2 (d, JCP = 11.6 Hz), 133.8 (d, JCP = 7.8 Hz), 133.4 (d, 
JCP = 9.4 Hz), 132.7, 131.9, 131.5 (d, JCP = 5.5 Hz), 131.3, 131.1, 130.7, 130.5, 129.7-129.2 (m), 
125.2 (q, JCF = 272.5 Hz), 121.4, 118.2-117.9 (m), 61.4 (d, JCP = 18.3 Hz), 35.9 (d, JCP = 9.3 Hz), 
33.4 (d, JCP = 17.1 Hz), 22.6, 21.7 (d, JCP = 12.9 Hz), 21.5 (d, JCP = 12.4 Hz). 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −48.0. 
19F{1H} NMR (376 MHz, CD2Cl2): δ/ppm = −62.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 1609 (w), 1588 (w), 1352 (s), 1271 (s), 1113 (s), 885 (m), 838 (m), 745 (m), 
711 (m), 681 (m), 668 (m), 449 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C26H27N3P+: 412.1937 [M]+; found: 
412.1941. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −16.6 (c = 0.87, MeOH).  
 
(S)-5-((Dicyclohexylphosphanyl)methyl)pyrrolidin-2-one BH3 complex (182b) 
N
H
O
P
BH3  
Under argon atmosphere, a heat-gun dried two-necked flask was charged with borane 
dicyclohexylphosphine complex (714 mg, 3.37 mmol) and THF (6 mL). At 0 °C, sodium hydride 
(95%, 85.1 mg, 3.37 mmol) was added to the reaction solution and the resulting reaction mixture 
was stirred for 45 minutes at 0 °C. Afterwards (S)-(5-oxopyrrolidin-2-yl)methyl methanesulfonate 
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(173) (500 mg, 2.59 mmol) was added to the red reaction solution and then stirred for 30 minutes 
at 0 °C and further two hours at room temperature. After full conversion (TLC test) the reaction 
mixture was quenched with water (10 mL) and then the resulting biphasic mixture was extracted 
with EtOAc (3 x 25 mL). The combined organic layers were washed with brine (20 mL), dried over 
Na2SO4, filtered, concentrated under vacuum and the crude product was purified by column 
chromatography (SiO2, MeOH:ethyl acetate (1:30), d x h: 3.5 x 12 cm) to afford the product 182b 
(147 mg, 477 µmol, 18%) as a white gum. 
 
C17H30NOP·BH3 (309.24 g/mol): 
TLC: Rf = 0.43 (SiO2, EtOAc:MeOH (20:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 6.31 (br s, 1H, NH), 3.95-3.85 (m, 1H, NCH), 2.45-2.23 (m, 
3H, PCH2, CH2), 1.93-1.59 (m, 15H, CH2, cy-CH2), 1.42-1.17 (m, 10H, CH2, cy-CH2), 0.80-
−0.08 (m, 3H, BH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = 177.1, 51.3, 32.7 (d, JCP = 32.6 Hz), 31.9 (d, 
JCP = 33.5 Hz), 30.1, 30.0, 27.4, 27.1, 26.9, 26.9, 26.8, 26.8 (d, JCP = 5.2 Hz), 26.6, 26.5 (d, 
JCP = 2.7 Hz), 26.4 (d, JCP = 2.8 Hz), 26.0. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = 21.8 (br s). 
IR (ATR): 𝑣𝑣�/cm-1 = 3251 (m), 2910 (s), 2844 (s), 1742 (s), 1709 (s), 1397 (m), 1243 (s), 1200 (w), 
1126 (w), 1079 (w), 1057 (s), 999 (m), 962 (w), 927 (s), 681 (m), 527 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C17H30NOP·BH3+: 332.2291 [M+Na]+; 
found: 332.2286. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +25.4 (c = 0.95, MeOH).  
 
(S)-5-((di-Cyclohexyl)-2-phenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium BArF 
(183b) 
N
N
N
P BArF
 
According to general procedure GP10, (S)-5-((dicyclohexylphosphanyl)methyl)pyrrolidin-2-one 
BH3 complex (182b) (100 mg, 323 µmol) in CH2Cl2 (2.3 mL) and trimethyloxonium 
tetrafluoroborate (52.6 mg, 355 µmol) were stirred to give of the crude imidate. Then, 
phenylhydrazine (38.4 mg, 35.2 µL, 355 µmol) was added and stirred for four hours. Afterwards, 
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the reaction solution was treated with sodium BArF (429 mg, 85 µmol) and stirred for 16 hours at 
room temperature. After concentration of the reaction mixture and filtration over silica gel the crude 
gum was dissolved in triethyl orthoformate (957 mg, 1.06 mL, 6.46 mmol) and refluxed for 
120 minutes at 115 °C. The crude product was purified by column chromatography (SiO2, 
CH2Cl2:MeOH (100:1), d x h: 2.5 x 20 cm) to afford the product 183b (267 mg, 212 µmol, 66%) as 
a yellow solid. 
 
C24H35N3P BArF (1259.76 g/mol): 
MP: 59-60 °C. 
TLC: Rf = 0.38 (SiO2, CH2Cl2:MeOH (50:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 10.25 (s, 1H, carbene-CH), 7.72 (s, 8H, ar-H), 7.69-7.64 (m, 
5H, ar-H), 7.56 (s, 4H, ar-H), 5.07-4.94 (m, 1H, NCH), 3.45-3.06 (m, 3H, PCH2, CH2), 2.77-2.61 (m, 
1H, CH2), 2.44-2.29 (m, 1H, CH2), 2.25-2.07 (m, 1H, CH2), 1.98-1.56 (m, 11H, cy-CH2, cy-CH2), 
1.46-1.14 (m, 11H, cy- CH2, cy-CH). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 163.0, 161.8 (q, JCF = 49.9 Hz), 137.1, 135.4, 131.3 (d, 
JCP = 1.9 Hz), 129.7-129.4 (m), 129.4-129.1 (m), 125.2 (q, JCF = 272.4 Hz), 121.5, 121.4, 121.1, 
118.2-117.8 (m), 59.5, 37.5 (d, JCP = 7.7 Hz), 33.4 (d, JCP = 32.4 Hz), 32.0 (d, JCP = 33.2 Hz), 27.6, 
27.2, 27.0 (d, JCP = 2.4 Hz), 26.9, 26.7 (d, JCP = 6.4 Hz), 26.2, 22.4 (d, JCP = 5.1 Hz). 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = −13.4. 
19F{1H} NMR (376 MHz, CD2Cl2): δ/ppm = −62.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 2934 (w), 2858 (w), 1352 (s), 1272 (s), 1112 (s), 885 (m), 837 (m), 758 (w), 
711 (m), 681 (m), 668 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C24H35N3P+: 396.2563 [M]+; found: 
396.2569. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −5.6 (c = 0.42, MeOH).  
 
(S)-5-((di-tert-Butylphosphanyl)methyl)pyrrolidin-2-one BH3 complex (182c) 
N
H
O
P
BH3  
Under argon atmosphere, a heat-gun dried two-necked flask was charged with borane di(tert-
butyl)phosphine complex (1.0 g, 6.25 mmol) and THF (10 mL). At 0 °C, sodium hydride (95%, 
158 mg, 6.25 mmol) was added to the reaction solution and the resulting reaction mixture was 
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stirred for 45 minutes at 0 °C. Afterwards (S)-(5-oxopyrrolidin-2-yl)methyl methanesulfonate (173) 
(929 mg, 4.81 mmol) was added to the red reaction solution and then stirred for 30 minutes at 
0 °C and further two hours at room temperature. After full conversion (TLC test) the reaction 
mixture was quenched with water (20 mL) and then the resulting biphasic mixture was extracted 
with EtOAc (3 x 25 mL). The combined organic layers were washed with brine (20 mL), dried over 
Na2SO4, filtered, concentrated under vacuum and the crude product was purified by column 
chromatography (SiO2, MeOH:ethyl acetate (1:50), d x h: 3.5 x 22 cm) to afford the product 182c 
(734 mg, 2.85 mmol, 59%) as a white solid. 
 
C13H26NOP·BH3 (257.16 g/mol): 
MP: 197-198 °C. 
TLC: Rf = 0.25 (SiO2, EtOAc:MeOH (40:1)). 
1H NMR (400 MHz, CDCl3): δ/ppm = 6.49 (s, 1H), 4.02-3.90 (m, 1H, NCH), 2.47-2.22 (m, 3H, 
PCH2, CH2), 2.00-1.93 (m, 1H, CH2), 1.83-1.63 (m, 2H, CH2), 1.29-1.21 (m, 18H, PC(CH3)3), 0.86-
0.07 (br m, 3H, BH3). 
13C{1H} NMR (101 MHz, CDCl3): δ/ppm = δ 177.1, 51.9, 32.8 (d, JCP = 26.8 Hz), 32.0 (d, 
JCP = 27.5 Hz), 30.1, 30.1 (d, JCP = 10.2 Hz), 27.9, 27.8, 26.3 (d, JCP = 26.0 Hz). 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = 39.8 (br s). 
IR (ATR): 𝑣𝑣�/cm-1 = 3198 (w), 2969 (w), 2902 (w), 2385 (m), 2351 (m), 1706 (s), 1649 (m), 1467 (m), 
1369 (m), 1282 (m), 1076 (s), 1021 (m), 741 (m), 629 (s), 547 (w), 493 (s), 461 (m), 416 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C12H13N3Br+: 280.1974 [M+Na]+; found: 
280.1976. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +22.6 (c = 0.95, MeOH).  
 
(S)-5-((di-tert-Butyl)-2-phenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium BArF (183c) 
N
N
N
P BArF
 
According to general procedure GP10, (S)-5-((di-tert-butylphosphanyl)methyl)pyrrolidin-2-one 
BH3 complex (182c) (301 mg, 1.17 mmol) in CH2Cl2 (9 mL) and trimethyloxonium tetrafluoroborate 
(190 mg, 1.29 mmol) were stirred to give of the crude imidate. Then, phenylhydrazine (139 mg, 
128 µL, 1.29 mmol) was added and stirred for four hours Afterwards, the reaction solution was 
treated with sodium BArF (429 mg, 85 µmol) and stirred for 16 hours at room temperature. After 
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concentration of the reaction mixture and filtration over silica gel the crude gum was dissolved in 
triethyl orthoformate (3.47 g, 3.85 mL, 23.4 mmol) and refluxed for 120 minutes at 115 °C. The 
crude product was purified by two column chromatography (SiO2, CH2Cl2:MeOH (100:1), d x h: 
2.5 x 17 cm) to afford the product 183c (380 mg, 315 µmol, 27%) as a pale yellow gum. 
 
C20H31N3P BArF (1207.68 g/mol): 
TLC: Rf = 0.60 (SiO2, CH2Cl2:MeOH (50:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 9.97 (s, 1H, carbene-CH), 7.64 (s, 8H, ar-H), 7.63-7.51 (m, 
5H, ar-H), 7.47 (s, 4H, ar-H), 4.77-4.67 (m, 1H, NCH), 3.35-3.04 (m, 4H, PCH2, CH2), 2.67-2.53 (m, 
1H, CH2), 2.14 (dd, 2JHP = 15.4 Hz, 3JHH = 3.8 Hz, 1H, PCH2), 1.74-1.63 (m, 1H, CH2), 1.14 (d, 
2JHP = 12.0 Hz, 9H, PC(CH3)3), 0.98 (d, 2JHP = 12.2 Hz, 9H, PC(CH3)3). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 163.1, 162.3 (q, JCF = 49.8 Hz), 135.4 (d, JCP = 5.0 Hz), 
132.6, 131.3, 129.6 (q, JCF = 5.8 Hz), 129.3 (q, JCF = 5.8 Hz), 125.2 (q, JCF = 272.4 Hz), 121.5, 
118.3-117.8 (m), 64.1 (d, JCP = 20.6 Hz), 36.3 (d, JCP = 7.9 Hz), 32.8 (d, JCP = 17.3 Hz), 32.1 (d, 
JCP = 15.5 Hz), 29.6 (d, JCP = 12.4 Hz), 29.4 (d, JCP = 12.7 Hz), 28.1 (d, JCP = 9.0 Hz), 22.2. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = 16.3. 
19F{1H} NMR (376 MHz, CD2Cl2): δ/ppm = −62.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 2958 (w), 1469 (w), 1352 (s), 1271 (s), 1112 (s), 885 (m), 838 (m), 757 (w), 
712 (m), 681 (m), 668 (m), 448 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C20H31N3P+: 344.2250 [M]+; found: 
344.2248. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −10.1 (c = 0.66, MeOH).  
 
General Procedure (GP11): Synthesis of iridium-complexes 
In the glovebox, a heat-gun dried round-bottomed flask was charged with the triazolium salt 
(1.0 eq), chloro(1,5-cyclooctadiene)iridium(I) dimer (0.5 eq.) and THF (30 ml per mmol lactam). 
Then, potassium tert-butoxide (1.2 eq.) was added in one portion and the reaction mixture was 
stirred for 16 hours at room temperature. After concentration under reduced pressure, the crude 
product was purified by column chromatography.  
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Iridium complex 184 
P
Ir
N
N
N BArF
 
According to general procedure GP11, (S)-5-((diphenylphosphanyl)methyl)-2-phenyl-6,7-dihydro-
5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium BArF (181a) (34.9 mg, 28.0 µmol), chloro(1,5-cyclo-
octadiene)iridium(I) dimer (9.4 mg, 14.0 µmol) in THF (0.9 mL) and potassium tert-butoxide 
(3.77 mg, 33.6 µmol) were stirred for 16 hours at room temperature. The crude product was 
purified by column chromatography (SiO2, CH2Cl2:pentane (4:1), d x h: 2.5 x 13 cm) to afford the 
product 184 (14.3 mg, 9.00 µmol, 33%) as a red solid. 
 
C32H34IrN3P BArF (1610.19 g/mol): 
MP: 101-102 °C. 
TLC: Rf = 0.48 (SiO2, CH2Cl2:pentane (4:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.80-7.54 (m, 22H, ar-H), 7.50-7.45 (m, 3H, ar-H), 7.31-
7.24 (m, 2H, ar-H), 4.98-4.82 (m, 2H, olefinic-CH), 4.64 (t, 3JHH = 7.2 Hz, 1H, olefinic-CH), 3.69 (p, 
3JHH = 7.1 Hz, 1H, olefinic-CH), 3.31-3.13 (m, 3H, PCH2, CH2), 3.06 (ddd, 2JHP = 14.8 Hz, 
3JHH = 11.5 Hz, 3JHH = 3.5 Hz, 1H, PCH2), 2.70-2.60 (m, 1H, CH2), 2.61-2.41 (m, 2H, CH2), 2.21-
2.00 (m, 3H, CH2, CH), 1.77-1.47 (m, 4H, CH2).  
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 168.8 (d, JCP = 11.0 Hz), 162.3 (q, JCF = 49.8 Hz), 160.0, 
139.6, 135.6 (d, JCP = 13.2 Hz), 135.4, 134.0, 133.4, 133.1, 131.9 (d, JCP = 2.6 Hz), 131.5 (d, 
JCP = 9.8 Hz), 130.8, 130.2 (d, JCP = 10.9 Hz), 130.0, 129.7 (d, JCP = 10.4 Hz), 129.4-129.1 (m), 
125.6, 125.2 (q, JCF = 272.4 Hz), 121.1, 118.3-117.7 (m), 91.4 (d, J = 8.8 Hz), 87.2 (d, 
JCP = 13.6 Hz), 85.4, 82.1, 57.7 (d, JCP = 2.2 Hz), 35.7 (d, JCP = 4.2 Hz), 35.0, 34.9, 33.9, 33.6, 
27.8 (d, JCP = 7.4 Hz), 21.3. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = 16.6. 
19F{1H} NMR (376 MHz, CD2Cl2): δ/ppm = −62.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 2945 (w), 1352 (s), 1273 (s), 1114 (s), 885 (w), 838 (w), 744 (m), 711 (m), 
681 (m), 518 (w), 448 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C32H34IrN3P+: 684.2114 [M]+; found: 
684.2085. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +17.0 (c = 0.11, CH2Cl2).  
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Iridicum complex 185a 
P
Ir
N
N
N
BArF
 
According to general procedure GP11, (S)-5-((diphenylphosphanyl)methyl)-2-mesityl-6,7-dihydro-
5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium BArF (181b) (40.0 mg, 31.0 µmol), chloro(1,5-cyclo-
octadiene)iridium(I) dimer (10.4 mg, 15.5 µmol) in THF (1 mL) and potassium tert-butoxide 
(4.17 mg, 37.2 µmol) were stirred for 16 hours at room temperature. The crude product was 
purified by column chromatography (SiO2, CH2Cl2:pentane (3:1), d x h: 2.5 x 13 cm) to afford the 
product 185a (22.0 mg, 14.0 µmol mmol, 46%) as a red solid. 
 
C39H55IrN3P BArF (1721.84 g/mol): 
TLC: Rf = 0.58 (SiO2, CH2Cl2:pentane (4:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.76-7.68 (m, 7H, ar-H), 7.68-7.62 (m, 2H, ar-H), 7.61-
7.35 (m, 11H, ar-H), 7.03 (s, 2H, ar-H), 5.12-5.02 (m, 1H, olefinic-CH), 4.86-4.74 (m, 1H, olefinic-
CH), 4.18-4.08 (m, 1H, olefinic-CH), 3.80 (p, 3JHH = 7.1 Hz, 1H, olefinic-CH), 3.27-3.12 (m, 3H, 
PCH2, CH2), 2.95 (ddd, 2JHP = 14.9 Hz, 3JHH = 12.5, 3JHH = 2.9 Hz, 1H, PCH2), 2.60-2.42 (m, 2H, 
CH2), 2.36 (s, 3H, ar-CH3), 2.31-2.17 (m, 2H, CH2), 2.16 (s, 3H, ar-CH3), 2.11-1.98 (m, 2H, CH2), 
1.93 (s, 3H, ar-CH3), 1.81-1.68 (m, 1H, CH), 1.69-1.49 (m, 4H, CH2). 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = 13.8. 
19F{1H} NMR (376 MHz, CD2Cl2): δ/ppm = −62.9. 
 
Iridium complex 185b 
P
Ir
N
N
N
BArF
OMe
MeO  
According to general procedure GP11, (S)-2-(2,6-dimethoxyphenyl)-5-((diphenyl-
phosphanyl)methyl)-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium BArF (181c) (150 mg, 
115 µmol), chloro(1,5-cyclooctadiene)iridium(I) dimer (38.6 mg, 57.5 µmol) in THF (2.5 mL) and 
potassium tert-butoxide (113 mg, 138 µmol) were stirred for 16 hours at room temperature. The 
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crude product was purified by column chromatography (SiO2, CH2Cl2:pentane (4:1), d x h: 2.5 x 
13 cm) to afford the product 185b (85.0 mg, 53.0 µmol, 46%) as a red solid. 
 
C34H38IrN3O2P BArF (1607.11 g/mol): 
MP: 103-104 °C.  
TLC: Rf = 0.49 (SiO2, CH2Cl2:pentane (4:1)). 
1H NMR (400 MHz, CD2Cl2) δ/ppm = 7.77-7.69 (m, 10H, ar-H), 7.60-7.43 (m, 11H, ar-H), 7.30-
7.22 (m, 2H, ar-H), 6.72 (d, 3JHH = 2.9 Hz, 1H, ar-H), 6.70 (d, 3JHH = 3.2 Hz, 1H, ar-H), 5.23-5.13 (m, 
1H, olefinic-CH), 4.95-4.84 (m, 1H, olefinic-CH), 4.10-4.00 (m, 2H, olefinic-CH), 3.83 (s, 3H, ar-
OCH3), 3.54 (s, 3H, ar-OCH3), 3.29-3.19 (m, 1H, NCH), 3.19-3.10 (m, 2H, CH2), 3.11-3.06 (m, 1H, 
PCH2), 3.01 (ddd, 2JHP = 14.8 Hz, 3JHH = 11.9 Hz, 4JHH = 3.2 Hz, 1H, PCH2), 2.59-2.48 (m, 2H, 
CH2), 2.33-2.04 (m, 4H, CH2), 1.74-1.60 (m, 3H, CH2), 1.56-1.44 (m, 1H, CH2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = δ 170.2, 162.3 (q, JCF = 49.8 Hz), 159.1, 157.5, 157.1, 
135.9 (d, JCP = 12.8 Hz), 135.4, 133.0, 132.7 (d, JCP = 2.5 Hz), 131.8, 131.7, 131.6, 129.8 (d, 
JCP = 11.0 Hz), 129.6 (q, JCF = 5.8 Hz), 129.5 (d, JCP = 10.1 Hz), 129.3 (q, JCF = 5.8 Hz), 125.2 (q, 
JCF = 272.5 Hz), 118.3-117.6 (m), 104.8 (d, JCP = 4.5 Hz), 91.2 (d, JCP = 12.3 Hz), 89.7 (d, 
JCP = 9.8 Hz), 83.6, 77.2, 58.0, 56.7 (d, JCP = 14.8 Hz), 34.9 (d, JCP = 12.6 Hz), 34.6, 34.2, 33.8 (d, 
JCP = 32.3 Hz), 29.2, 28.3, 21.1. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = 14.6. 
19F{1H} NMR (376 MHz, CD2Cl2) δ/ppm = −62.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 2950 (w), 1604 (w), 1484 (w), 1352 (m), 1273 (s), 1111 (s), 885 (m), 838 (m), 
780 (w), 742 (w), 711 (m), 681 (m), 518 (w), 494 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C34H38IrN3O2P+: 744.2327 [M]+; found: 
744.2327. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −16.0 (c = 0.20, CH2Cl2).  
 
Iridium complex 185c 
P
Ir
N
N
N BArF
 
According to general procedure GP11, (S)-2-(tert-butyl)-5-((diphenylphosphanyl)methyl)-6,7-
dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium BArF (181d) (80.0 mg, 65.2 µmol), chloro(1,5-cyclo-
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octadiene)-iridium(I) dimer (21.9 mg, 32.6 µmol) in THF (1.5 mL) and potassium tert-butoxide 
(8.78 mg, 78.2 µmol) were stirred for 16 hours at room temperature. The crude product was 
purified by column chromatography (SiO2, CH2Cl2:pentane (2:1), d x h: 2.5 x 23 cm) to afford the 
product 185c (74.0 mg, 48.0 µmol, 74%) as an orange solid. 
 
C30H38IrN3P BArF (1659.97 g/mol): 
MP: 129-130 °C. 
TLC: Rf = 0.25 (SiO2, CH2Cl2:pentane (2:1)). 
1H NMR (400 MHz, CD2Cl2): δ/ppm = 7.74 (s, 8H, ar-H), 7.57 (s, 4H, ar-H), 7.54-7.40 (m, 8H, ar-
H), 7.21-7.13 (m, 2H, ar-H), 5.04 (t, 3JHH = 7.0 Hz, 1H, olefinic-CH), 4.97-4.82 (m, 2H, olefinic-CH), 
4.34 (p, 3JHH = 7.3 Hz, 1H, olefinic-CH), 3.24-2.94 (m, 5H, PCH2, CH2), 2.76-2.50 (m, 3H, CH2), 
2.20-1.96 (m, 4H, CH2), 1.88-1.76 (m, 1H, CH), 1.69 (s, 9H, C(CH3)3), 1.57-1.44 (m, 2H, CH2). 
13C{1H} NMR (101 MHz, CD2Cl2): δ/ppm = 168.6 (d, JCP = 12.2 Hz), 162.8 (q, JCP = 49.5 Hz), 
158.3, 135.57-135.18 (m), 134.2 (d, JCP = 49.1 Hz), 133.0, 132.1, 131.7-131.5 (m), 131.2 (d, 
JCP = 9.7 Hz), 130.0 (d, JCP = 10.9 Hz), 129.8-129.5 (m), 129.4-129.2 (m), 129.0, 125.2 (q, 
JCF = 272.4 Hz), 121.1, 118.4-117.8 (m), 88.2 (d, JCP = 6.4 Hz), 84.2, 82.6, 79.8 (d, JCP = 17.9 Hz), 
62.7, 58.0 (d, JCP = 2.9 Hz), 37.5, 33.8 (d, JCP = 12.9 Hz), 33.5 (d, JCP = 10.1 Hz), 31.9, 30.3, 26.9, 
26.7, 21.1. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = 19.1. 
19F{1H} NMR (376 MHz, CD2Cl2) δ/ppm = −62.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 2952 (w), 2926 (w), 1352 (s), 1275 (s), 1157 (m), 1118 (s), 886 (w), 837 (w), 
744 (m), 697 (m), 681 (m), 667 (m), 522 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C30H38IrN3P+: 664.2428 [M]+; found: 
664.2416. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −12.5 (c = 0.53, CH2Cl2).  
 
Iridium complex 185d 
P
Ir
N
N
N
BArF
 
According to general procedure GP11, (S)-5-((di-o-tolylphosphanyl)methyl)-2-phenyl-6,7-dihydro-
5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium BArF (183a) (40.1 mg, 31.4 µmol), chloro(1,5-cyclo-
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octadiene)iridium(I) dimer (10.5 mg, 15.7 µmol) in THF (1 mL) and potassium tert-butoxide 
(5.16 mg, 37.7 µmol) were stirred for 16 hours at room temperature. The crude product was 
purified by column chromatography (SiO2, CH2Cl2:pentane (5:2), d x h: 1.5 x 16 cm) to afford the 
product 185d (15.7 mg, 10.0 µmol, 32%) as a red solid. 
 
C38H53IrN3P BArF (1708.53 g/mol): 
MP: 99-100 °C.  
TLC: Rf = 0.78 (SiO2, CH2Cl2:pentane (5:1)). 
1H NMR (400 MHz, CD2Cl2) δ/ppm = 8.45 (dd, 3JHP = 17.2 Hz, 3JHH = 7.5 Hz, 1H, ar-H), 7.76-
7.68 (m, 10H, ar-H), 7.62-7.58 (m, 3H, ar-H), 7.58-7.50 (m, 5H, ar-H), 7.50-7.37 (m, 4H, ar-H), 
7.16 (t, 3JHH = 7.6 Hz, 1H, ar-H), 6.80 (dd, 4JHP = 12.5, 3JHH = 7.8 Hz, 1H, ar-H), 4.97-4.85 (m, 2H, 
olefinic-CH), 4.54-4.45 (m, 1H, olefinic-CH), 3.53 (p, 3JHH = 7.1 Hz, 1H, olefinic-CH), 3.32-3.18 (m, 
1H, PCH2), 3.18-3.12 (m, 2H, PCH2, CH2), 3.01-2.91 (m, 1H, CH2), 2.80 (s, 3H, ar-CH3), 2.63-
2.35 (m, 4H, CH2), 2.22-2.14 (m, 1H, CH2), 2.14 (s, 3H, ar-CH3), 2.07-2.01 (m, 1H, CH2), 1.80-
1.70 (m, 1H, CH), 1.66-1.46 (m, 4H, CH2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 168.5, 162.3 (q, JCF = 50.0 Hz), 159.7, 142.8, 142.2 (d, 
JCP = 30.6 Hz), 139.8, 135.4, 133.9, 133.6, 132.7 (d, JCP = 8.3 Hz), 132.3, 130.8, 129.9, 129.6, 
129.3, 129.0, 126.8, 125.8, 125.2 (q, JCF = 272.5 Hz), 121.1, 118.2-117.8 (m), 89.5 (d, 
JCP = 8.3 Hz), 85.2, 84.8, 83.1, 56.8, 36.0, 35.8, 34.9 (d, JCP = 12.2 Hz), 31.7, 27.3, 27.1, 23.3, 
21.2. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = 20.0. 
19F{1H} NMR (376 MHz, CD2Cl2) δ/ppm = −62.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 2931 (w), 1352 (m), 1273 (s), 1115 (s), 981 (w), 886 (w), 838 (w), 754 (w), 
712 (m), 681 (m), 464 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C38H38IrN3P+: 712.2429 [M]+; found: 
712.2437. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −140.0 (c = 0.40, CH2Cl2).  
 
Iridium complex 185e 
P
Ir
N
N
N
BArF
 
EXPERIMENTAL PART            CHAPTER 5 
346 
According to general procedure GP11, (S)-5-((di-cyclohexyl)-2-phenyl-6,7-dihydro-5H-
pyrrolo[2,1-c][1,2,4]triazol-2-ium BArF (183b) (80.0 mg, 63.5 µmol), chloro(1,5-cyclo-
octadiene)iridium(I) dimer (21.3 mg, 31.8 µmol) in THF (1.4 mL) and potassium tert-butoxide 
(8.55 mg, 76.2 µmol) were stirred for 16 hours at room temperature. The crude product was 
purified by column chromatography (SiO2, CH2Cl2:pentane (3:1), d x h: 1.5 x 13 cm) to afford the 
product 185e (30.0 mg, 19.0 µmol, 30%) as a red solid. 
 
C32H46IrN3P BArF (1559.15 g/mol): 
TLC: Rf = 0.70 (SiO2, CH2Cl2:pentane (4:1)). 
1H NMR (400 MHz, CD2Cl2) δ/ppm = 7.93-7.87 (m, 2H, ar-H), 7.73 (s, 8H, ar-H), 7.59-7.52 (m, 7H, 
ar-H), 5.49 (t, 3JHH = 7.2 Hz, 1H, olefinic-CH), 4.83-4.74 (m, 1H, olefinic-CH), 4.45-4.31 (m, 1H, 
olefinic-CH), 4.10-3.98 (m, 1H, olefinic-CH), 3.25-3.07 (m, 4H, NCH, PCH2, CH2), 2.79-2.71 (m, 
1H, CH2), 2.60-2.44 (m, 2H, PCH2, CH2), 2.35-2.23 (m, 2H, cy-CH2), 2.19-1.91 (m, 7H, cy-CH2, 
cy-CH), 1.90-1.78 (m, 4H, cy-CH2), 1.75-1.63 (m, 3H, cy-CH2, cy-CH), 1.61-1.50 (m, 2H, cy-CH2), 
1.44-1.14 (m, 10H, cy-CH2), 1.13-0.99 (m, 1H, cy-CH2), 0.98-0.89 (m, 1H, cy-CH2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 169.4 (d, JCP = 10.6 Hz), 162.3 (q, JCF = 49.8 Hz), 159.8, 
139.5, 135.4, 130.2, 129.8, 129.7-129.4 (m), 129.4-129.1 (m), 125.2 (q, JCF = 272.3 Hz), 124.3, 
121.1, 118.2-117.90 (m), 87.6 (d, JCP = 7.1 Hz), 86.6, 80.7, 80.5 (d, JCP = 14.7 Hz), 57.4, 37.8, 
37.7 (d, JCP = 23.8 Hz), 36.0, 34.7 (d, JCP = 10.2 Hz), 32.1 (d, JCP = 27.6 Hz), 30.9, 30.1, 29.5, 
27.5-26.9 (m), 26.7, 26.6, 26.5, 22.6 (d, JCP = 28.2 Hz), 21.2. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = 23.6. 
19F{1H} NMR (376 MHz, CD2Cl2) δ/ppm = −62.9. 
IR (ATR): 𝑣𝑣�/cm-1 = 2960 (w), 1352 (m), 1272 (s), 1163 (m), 1121 (s), 885 (m), 837 (w), 713 (m), 
681 (m), 667 (m), 580 (w), 445 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C32H46IrN3P+: 696.3055 [M]+; found: 
696.3057. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −16.0 (c = 0.26, CH2Cl2).  
 
Iridium complex 185f 
P
Ir
N
N
N
BArF
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According to general procedure GP11, (S)-5-((di-tert-butyl)-2-phenyl-6,7-dihydro-5H-pyrrolo[2,1-
c][1,2,4]triazol-2-ium BArF (185f) (200 mg, 166 µmol), chloro(1,5-cyclo-octadiene)iridium(I) dimer 
(55.8 mg, 83.0 µmol) in THF (3.7 mL) and potassium tert-butoxide (163 mg, 199 µmol) were stirred 
for 16 hours at room temperature. The crude product was purified by column chromatography 
(SiO2, CH2Cl2:pentane (2:1), d x h: 1.5 x 16 cm) to afford the product 185f (89.0 mg, 59.0 µmol, 
36%) as a red solid. 
 
C28H42IrN3P BArF (1507.07 g/mol): 
MP: 160-161 °C. 
TLC: Rf = 0.33 (SiO2, CH2Cl2:pentane (3:1)). 
1H NMR (400 MHz, CD2Cl2) δ/ppm = 8.07-7.99 (m, 2H, ar-H), 7.73 (s, 8H, ar-H), 7.58-7.52 (m, 7H, 
ar-H), 5.90 (t, 3JHH = 7.3 Hz, 1H, olefinic-CH), 4.69 (q, 3JHH = 7.6 Hz, 1H, olefinic-CH), 4.51-4.36 (m, 
2H, olefinic-CH), 3.26-3.09 (m, 4H, NCH, CH2), 2.74 (dd, 2JHP = 15.8 Hz, 3JHH = 7.5 Hz, 1H, PCH2), 
2.68-2.48 (m, 2H, CH2), 2.26 (ddd, 2JHP = 15.0 Hz, 3JHH = 8.7 Hz, 4JHH = 3.8 Hz, 1H, PCH2), 2.09-
1.88 (m, 3H, CH2), 1.66-1.50 (m, 4H, CH2), 1.46 (d, 3JHP = 13.5 Hz, 9H, PC(CH3)3), 1.40-1.26 (m, 
4H, CH2), 1.13 (d, 3JHP = 13.8 Hz, 9H, PC(CH3)3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 169.1 (d, JCP = 9.8 Hz), 162.3 (q, JCF = 49.9 Hz), 159.5, 
139.4, 135.4, 130.0, 129.7, 129.7-129.4 (m), 129.4-129.1 (m), 125.2 (q, JCF = 272.4 Hz), 123.9, 
121.1, 118.3-117.8 (m), 114.8, 88.0, 83.5 (d, JCP = 6.6 Hz), 81.8, 75.7 (d, JCP = 15.4 Hz), 57.5, 
39.4 (d, JCP = 16.6 Hz), 37.7 (d, JCP = 4.1 Hz), 36.8 (d, JCP = 18.7 Hz), 36.3, 34.6 (d, JCP = 9.5 Hz), 
30.9 (d, JCP = 4.8 Hz), 30.3 (d, JCP = 3.6 Hz), 27.1, 26.1 (d, JCP = 2.7 Hz), 24.3 (d, JCP = 22.6 Hz), 
21.2. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = 47.7. 
19F{1H} NMR (376 MHz, CD2Cl2) δ/ppm = −62.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 2958 (w), 1352 (m), 1272 (s), 1164 (m), 1120 (s), 885 (w), 827 (m), 713 (m), 
681 (m), 667 (m), 444 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C28H42IrN3P+: 644.2741 [M]+; found: 
644.2752. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −13.0 (c = 0.06, CH2Cl2).  
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(S)-6-((Diphenylphosphanyl)methyl)piperidin-2-one BH3 complex (186) 
N
H
O
P
BH3
 
Under argon atmosphere, a heat-gun dried two-necked flask was charged with borane 
diphenylphosphine complex (377 mg, 1.89 mmol) and THF (3 mL). At 0 °C, sodium hydride (95%, 
47.6 mg, 1.89 mmol) was added to the reaction solution and the resulting reaction mixture was 
stirred for 45 minutes at 0 °C. Afterwards (S)-(6-oxopiperidin-2-yl)methyl methanesulfonate (156) 
(301 mg, 1.45 mmol) was added to the red reaction solution and then stirred for 30 minutes at 
0 °C and further two hours at room temperature. After full conversion (TLC test) the reaction 
mixture was quenched with water (10 mL) and then the resulting biphasic mixture was extracted 
with EtOAc (3 x 25 mL). The combined organic layers were washed with brine (20 mL), dried over 
Na2SO4, filtered, concentrated under vacuum and the crude product was purified by column 
chromatography (SiO2, MeOH:ethyl acetate (1:60), d x h: 3.5 x 15 cm) to afford the product 186 
(389 mg, 1.25 mmol, 86%) as a white gum. 
 
C18H20NOP·BH3 (311.17 g/mol): 
TLC: Rf = 0.28 (SiO2, EtOAc:MeOH (50:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 7.75-7.62 (m, 4H, ar-H), 7.57-7.42 (m, 6H, ar-H), 6.14 (br s, 
1H, NH), 3.79-3.69 (m, 1H, NCH), 2.58-2.45 (m, 1H, PCH2), 2.44-2.18 (m, 3H, PCH2, CH2), 1.98-
1.76 (m, 2H, CH2), 1.72-1.57 (m, 1H, CH2), 1.52-1.41 (m, 1H, CH2), 1.32-0.63 (br m, 3H, BH3). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 171.5, 132.4 (d, JCP = 9.4 Hz), 132.0 (d, JCP = 9.3 Hz), 
131.9, 131.9 (d, JCP = 2.5 Hz), 129.4 (d, JCP = 3.8 Hz), 129.3 (d, JCP = 3.9 Hz), 128.8 (d, 
JCP = 2.4 Hz), 128.2, 49.0 (d, JCP = 2.4 Hz), 34.2 (d, JCP = 34.8 Hz), 31.3, 30.9 (d, JCP = 8.8 Hz), 
19.5. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −11.3 (br s). 
IR (ATR): 𝑣𝑣�/cm-1 = 3346 (w), 3055 (w), 2948 (w), 2872 (w), 2378 (m), 1655 (s), 1435 (s), 1335 (m), 
1305 (m), 1106 (m), 1061 (s), 998 (w), 823 (w), 735 (s), 690 (s), 594 (m), 497 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C18H20NOP·BH3+: 334.1506 [M+Na]+; 
found: 334.1512. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = +5.8 (c = 1.00, MeOH).  
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(S)-5-((Diphenylphosphanyl)methyl)-2-phenyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-
a]pyridin-2-ium BArF (187) 
N
N
N
P BArF
 
According to general procedure GP10, (S)-5-((dicyclohexylphosphanyl)methyl)pyrrolidin-2-one 
BH3 complex (186) (100 mg, 321 µmol) in CH2Cl2 (2.3 mL) and trimethyloxonium tetrafluoroborate 
(55.0 mg, 353 µmol) were stirred to give of the crude imidate. Then, phenylhydrazine (38.2 mg, 
35.0 µL, 353 µmol) was added and stirred for four hours. Afterwards, the reaction solution was 
treated with sodium BArF (427 mg, 482 µmol) and stirred for 16 hours at room temperature. After 
concentration of the reaction mixture and filtration over silica gel the crude gum was dissolved in 
triethyl orthoformate (957 mg, 1.06 mL, 6.46 mmol) and refluxed for 120 minutes at 115 °C. The 
crude product was purified by column chromatography (SiO2, CH2Cl2:MeOH (50:1), d x h: 2.5 x 
21 cm) to afford the product 187 (302 mg, 241 µmol, 75%) as a pale yellow gum. 
 
C25H25N3P BArF (1251.69 g/mol): 
TLC: Rf = 0.45 (SiO2, CH2Cl2:MeOH (10:1)). 
1H NMR (400 MHz, CDCl3) δ/ppm = 9.41 (s, 1H, carbene-CH), 7.69 (s, 8H, ar-H), 7.62-7.40 (m, 
12H, ar-H), 7.39-7.29 (m, 7H, ar-H), 4.55-4.45 (m, 1H, NCH), 3.11-2.95 (m, 2H, CH2), 2.77 (dd, 
2JHP = 14.7 Hz, 3JHH = 4.8 Hz, 1H, PCH2), 2.62 (ddd, 2JHP = 14.8 Hz, 3JHH = 8.0 Hz, 4JHH = 2.5 Hz, 
1H, PCH2), 2.32-2.08 (m, 3H, CH2), 1.97-1.82 (m, 1H, CH2). 
13C{1H} NMR (101 MHz, CDCl3) δ/ppm = 161.7 (q, JCF = 49.8 Hz), 154.3, 135.9 (d, JCP = 17.0 Hz), 
134.9, 134.5 (d, JCP = 7.7 Hz), 134.2 (d, JCP = 9.3 Hz), 133.9, 133.1 (d, JCP = 20.3 Hz), 132.2 (d, 
JCP = 18.7 Hz), 130.8, 130.3, 129.7 (d, JCP = 7.8 Hz), 129.4 (d, JCP = 7.4 Hz), 129.2 (q, 
JCF = 5.8 Hz), 128.9 (q, JCF = 5.8 Hz), 128.7, 128.6, 124.7 (q, JCF = 272.6 Hz)., 120.4, 117.6 (d, 
JCP = 5.1 Hz), 57.0 (d, JCP = 16.7 Hz), 35.1 (d, JCP = 18.2 Hz), 28.9 (d, JCP = 8.7 Hz), 21.3, 16.8. 
31P{1H} NMR (162 MHz, CDCl3): δ/ppm = −25.4. 
19F{1H} NMR (376 MHz, CDCl3) δ/ppm = −62.4. 
IR (ATR): 𝑣𝑣�/cm-1 = 2972 (w), 2951 (w), 1677 (w), 1352 (s), 1272 (s), 1117 (s), 1087 (s), 885 (m), 
837 (m), 742 (m), 711 (m), 680 (s), 668 (s), 448 (w). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C25H25N3P+: 398.1781 [M]+; found: 
398.1787. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −16.1 (c = 1.19, MeOH).  
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Iridium complex 188 
P
Ir
N
N
N
BArF
 
According to general procedure GP11, (S)-5-((diphenylphosphanyl)methyl)-2-phenyl-5,6,7,8-
tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-2-ium BArF (187) (120 mg, 95.1 µmol), chloro(1,5-
cyclooctadiene)-iridium(I) dimer (31.9 mg, 47.6 µmol) in THF (2.1 mL) and potassium tert-butoxide 
(12.8 mg, 114 µmol) were stirred for 16 hours at room temperature. The crude product was purified 
by column chromatography (SiO2, CH2Cl2:pentane (5:1), d x h: 2.5 x 13 cm) to afford the product 
188 (87.0 mg, 56.0 µmol mmol, 59%) as an orange solid. 
 
C33H36IrN3P BArF (1693.98 g/mol): 
MP: 81-82 °C. 
TLC: Rf = 0.56 (SiO2, CH2Cl2:pentane (5:1)). 
1H NMR (400 MHz, CD2Cl2) δ/ppm = 7.83-7.65 (m, 12H, ar-H), 7.61-7.50 (m, 10H, ar-H), 7.51-
7.41 (m, 3H, ar-H), 7.25-7.14 (m, 2H, ar-H), 5.18-5.05 (m, 1H, olefinic-CH), 4.99-4.88 (m, 2H, 
olefinic-CH), 3.49 (p, 3JHH = 7.1 Hz, 1H, olefinic-CH), 3.29-3.17 (m, 1H, CH2), 3.03 (dt, 
2JHP = 17.0 Hz, 3JHH = 4.8 Hz, 1H, PCH2), 2.96-2.80 (m, 2H, CH2), 2.67 (dd, 2JHP = 15.5 Hz, 
3JHH = 6.7 Hz, 1H, PCH2), 2.61-2.46 (m, 2H, CH2), 2.47-2.36 (m, 1H, CH2), 2.26-2.04 (m, 4H, CH2), 
1.99-1.86 (m, 1H, CH), 1.78-1.50 (m, 4H, CH2). 
13C{1H} NMR (101 MHz, CD2Cl2) δ/ppm = 174.8 (d, JCP = 12.2 Hz), 162.8 (q, JCF = 49.8 Hz), 152.5, 
139.1, 135.4, 135.2 (d, JCP = 13.1 Hz), 133.6, 133.2-132.8 (m), 131.9, 131.7 (d, JCP = 2.6 Hz), 
131.4, 131.2 (d, JCP = 9.7 Hz), 130.4, 130.2 (d, JCP = 10.8 Hz), 130.1-129.8 (m), 129.8, 129.7, 
129.8-129.5 (m), 129.4-129.2 (m), 129.1-128.9 (m), 125.2 (q, JCF = 272.4 Hz), 124.6, 121.1, 
118.6-117.3 (m), 91.5 (d, JCP = 8.0 Hz), 86.5, 86.1 (d, JCP = 14.2 Hz), 82.8, 57.0 (d, JCP = 4.0 Hz), 
36.4 (d, JCP = 4.0 Hz), 35.7, 33.3 (d, JCP = 37.1 Hz), 29.7 (d, JCP = 12.5 Hz), 27.4, 22.5, 17.7. 
31P{1H} NMR (162 MHz, CD2Cl2): δ/ppm = 11.5. 
19F{1H} NMR (376 MHz, CD2Cl2) δ/ppm = −62.8. 
IR (ATR): 𝑣𝑣�/cm-1 = 2923 (w), 1353 (s), 1274 (s), 1116 (s), 885 (w), 838 (w), 744 (m), 712 (m), 
681 (m), 522 (m). 
HRMS (ESI (+), 3600 V, 180 °C, MeOH): (m/z) calc. for C33H36IrN3P+: 698.2272 [M]+; found: 
698.2281. [𝜶𝜶]𝑫𝑫𝟐𝟐𝟐𝟐 = −68.0 (c = 0.05, CH2Cl2).  
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5.4.2 Hydrogenation of Model Substrates 
General Procedure: Hydrogenation at elevated pressure (50 bar) 
A glas vial (13 x 40 mm) containing a magnetic stirring bar was charged with the model substrate 
(0.1 mmol) and CH2Cl2 (0.2 mL). Then, the iridium complex (1 mol%) was added to the reaction 
solution and after placing the vial in the autoclave it was purged and pressurized with hydrogen 
gas (50 bar). After stirring for four hours at room temperature the hydrogen atmosphere was 
released and the crude product was concentrated under vacuum. The crude mixture was 
dissolved with ether, filtered through a short plug of silica gel, eluting with pentane/ether (1:1) and 
concentrated under vacuum. The crude product was analyzed by GC and HPLC analysis.  
 
(E)-1,2-Diphenyl-1-propene (189) 
1.0 mol% [Ir-cat.]
50 bar H2
CH2Cl2
 
(0.2 M), RT, 2 h
∗
189 190  
Conversion determination by GC: 
GC(Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C·min−1, 250 °C/10 
min): tR = 18.3 min (190), tR = 21.4 min (189). 
Enantiomeric excess determination by HPLC:  
HPLC (Daicel Chiracel OJ, heptane/i-PrOH = 99:1, 0.5 mL/min, 25 °C): 
tR ((R)-190) = 14.7 min, tR ((S)-190) = 24.2 min. 
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(E)-2-(4-Methoxyphenyl)-2-butene (192) 
1.0 mol% [Ir-cat.]
50 bar H2
CH2Cl2
 
(0.2 M), RT, 2 hMeO
∗
MeO
191 192  
Conversion determination by GC: 
GC(Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C·min−1, 250 °C/10 
min): tR = 12.1 min (192), tR = 14.8 min (191). 
Enantiomeric excess determination by HPLC:  
HPLC (Daicel Chiracel OD-H, heptane, 0.5 mL/min, 25 °C):  
tR ((S)-192) = 14.0 min, tR ((R)-192) = 15.8 min. 
 
1-(But-1-en-2-yl)-4-methoxybenzene (194) 
1.0 mol% [Ir-cat.]
50 bar H2
CH2Cl2
 
(0.2 M), RT, 2 hMeO
∗
MeO
193 194  
Conversion determination by GC: 
GC(Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C·min−1, 250 °C/10 
min): tR = 12.1 min (194), tR = 13.1 (193). 
Enantiomeric excess determination by HPLC:  
HPLC (Daicel Chiracel OD-H, heptane, 0.5 mL/min, 25 °C):  
tR ((S)-194) = 14.0 min, tR ((R)-194) = 15.8 min. 
 
6-Methoxy-1-methyl-3,4-dihydronaphthalene (196) 
1.0 mol% [Ir-cat.]
50 bar H2
CH2Cl2
 
(0.2 M), RT, 2 hMeO
∗
MeO
195 196  
Conversion determination by GC: 
GC(Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C·min−1, 250 °C/10 
min): tR = 17.1 min (196), tR = 18.4 min (195). 
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Enantiomeric excess determination by HPLC:  
HPLC (Daicel Chiracel OD-H, heptane, 0.5 mL/min, 25 °C):  
tR ((R)-196) = 25.7 min, tR ((S)-196) = 33.6 min. 
 
(E)-Ethyl 3-phenylbut-2-enoate (198) 
1.0 mol% [Ir-cat.]
50 bar H2
CH2Cl2
 
(0.2 M), RT, 2 h
CO2Et
* CO2Et
197 198  
Conversion determination by GC: 
GC(Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C·min−1, 250 °C/10 
min): tR = (197), tR = (198). 
Enantiomeric excess determination by HPLC:  
HPLC (Daicel Chiracel OD-H, heptane/i-PrOH = 99:1, 0.5 mL/min, 25 °C):  
tR ((R)-198) = 11.1 min, tR ((S)-198) = 21.1 min. 
 
(E)-2-Methyl-3-phenylprop-2-en-1-ol (200) 
1.0 mol% [Ir-cat.]
50 bar H2
CH2Cl2
 
(0.2 M), RT, 4 h
OH
*
OH
199 200  
Conversion determination by GC: 
GC(Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C·min−1, 250 °C/10 
min): tR = 14.3 min (200), tR = 16.0 min (199). 
Enantiomeric excess determination by HPLC:  
HPLC (Daicel Chiracel OD-H, heptane/i-PrOH = 95:5, 0.5 mL/min, 40 °C):  
tR ((R)-200) = 15.3 min, tR ((S)-200) = 17.6 min. 
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N-(1-Phenylethylidene)-aniline (202) 
1.0 mol% [Ir-cat.]
50 bar H2
CH2Cl2
 
(0.2 M), RT, 4 h
N
*
N
H
201 202  
Conversion determination by GC: 
GC(Macherey-Nagel Optima 5-Amin, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/8 min, 
5 °C·min−1, 250 °C/10 min): tR = 12.6 min (202), tR = 13.1 min (201). 
Enantiomeric excess determination by HPLC:  
HPLC (Daicel Chiracel OD-H, heptane/i-PrOH = 99:1, 0.5 mL/min, 40 °C):  
tR ((S)-202) = 22.2 min, tR ((R)-202) = 29.5 min. 
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6. Appendix 
6.1 List of Abbreviations 
Ac    acetyl 
ACDC    asymmetric counteranion directed catalysis 
AcOH    acetic acid 
aq.    aqueous 
Ar    aryl 
BArF    tertrakis[3,5-bis(trifluoro-methyl)phenyl]borate 
BH    Baylis-Hillman 
BINAP    2,2’-bis(diphenylphosphino)-1,1’-binapthyl 
Bn    benzyl 
BOC    tert-butoxylcarbonyl 
br    broad 
Bu    butyl 
°C    Grad Celsius 
c    concentration 
CAC    chloroacetyl chloride 
calc.    calculated 
cat.     Catalyst 
Cbz    carboxybenzyl 
CH2Cl2    dichloromethane 
COD    cycloocta-1,5-diene 
conv.    Conversion 
CSA    camphorsulfonic acid 
Cy    cyclohexyl 
d    day(s) or doublet (NMR) 
DAST    (dimethylamino)sulfur trifluoride 
DABCO   1,4-diazabicyclo[2.2.2]octan 
DCC    N,N’-dicyclohexylcarbodiimide 
DIAD    diisopropyl azodicarboxylate 
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DIPEA    N,N-diisopropylethylamine  
DMAP    N,N-4-(dimethylamino)pyridine  
DMF    dimethylformamide 
DMP    2,2-dimethoxypropane 
DMSO    dimethyl sulfoxide 
E    opposite 
EA    elemental analysis 
ee    enantiomeric excess 
eq.    equivalent(s) 
ESI    electrospray ionization 
Et    ethyl 
EtOH    ethanol 
GC    gas chromatography 
h    hour(s) 
HFIP    hexafluoro-2-propanol 
HPLC    high performance liquid chromatography 
Hz    Hertz 
i-Pr    2-propyl 
J    coupling constant 
K    Kelvin (NMR)  
KIE    kinetic isotope effect 
M    molar [mol/L] or metal 
m    multiplet (NMR) or medium (IR) 
MBH    Morita-Baylis-Hillman 
MP    melting point 
m/z    mass-to-charge ratio 
Me    methyl 
MeOH    methanol 
Mes    mesitylene 
min    minute(s) 
mL    milliliter 
MS    mass spectrometry or molecular sieves 
NADH    nicotinamide adenine dinucleotide 
n.d.    not determined 
NHC    N-heterocyclic carbene 
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NMR    nuclear Overhauser enhancement spectroscopy  
Nu    nucleophile 
o    ortho 
o-Tol    ortho-tolyl 
p    para 
p-TsOH   para-toluenesulfonic acid 
PC    propylene carbonate 
Ph    phenyl 
PHOX    phosphino-oxazoline 
PhNCS   phenyl isothiocyanate 
ppm    parts per million 
q (NMR)   quartet 
quint (NMR)   quintet 
rac.    Racemic 
RDS    rate-determining step 
Rf    retention factor 
RT    room temperature 
s    singlet (NMR) or strong (IR) 
sat.    saturated 
sec.    second(s) 
T    time 
t (NMR)   triplet 
t or tert    tertiary 
TRIP (R)-3,3'-bis(2,4,6-triisopropylphenyl)-1,1'-binaphthyl-2,2'-diyl 
hydrogenph osphate 
TBAF    tetrabutylammonium fluoride 
TBDMS   tert-butyldimethylsilyl 
TDS    dimethylthexylsilyl 
TFA    trifluoroacetic acid 
THF    tetrahydrofurane 
TIPS    triisopropylsilyl 
TLC    thin layer chromatography 
TMS    trimethylsilyl 
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8. Summary 
The general aim of this doctoral thesis was the development and synthesis of different chiral 
bifunctional phosphines as catalysts for the asymmetric Morita-Baylis-Hillman reaction. Moreover, 
the mechanism of the reaction was investigated using the back reaction screening technology. 
In chapter two, the synthesis of four different catalyst generations starting from commercially 
available amino acids was described (Figure 20). The effect of the chiral backbone, the H-bond 
donor moiety and the phosphine residue on the enantioselectivity of the MBH reaction was 
investigated by evaluating these catalysts.   
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Figure 50: Overview about synthesized catalyst generations.  
Moreover, the potential of mass spectrometric back reaction screening for the evaluation of 
catalysts for asymmetric MBH reactions was demonstrated. Screening of 62 bifunctional 
phosphines has led to an efficient catalyst for the reaction of methyl acrylate with aldehydes, 
showing improved enantioselectivity and scope compared to previously reported catalysts (Figure 
21). Finally, the back reaction screening protocol was successfully extended to multi-catalyst 
screening of crude catalyst mixtures containing up to six bifunctional phosphines.  
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Figure 51: Evaluation of chiral bifunctional phosphines by back reaction screening.  
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In addition, the results from back reaction screening and additional kinetic studies have provided 
evidence that the enantioselectivity is determined in the C–C bond-forming step which is turnover-
limiting. 
In chapter three, the synthesis of two different catalyst classes is described in chapter three 
(Figure 31). For morpholine-based precatalysts, the effects of the chiral backbone, the N-residue 
on the triazolium ring and the substituents next to the stereogenic center on the chemo- and 
enantioselectivity of the cross-benzoin reaction were investigated. Moreover, for piperidine-based 
triazolium salts the effect of the chiral backbone and the impact of an additional hydrogen-bonding 
subunit on the outcome of the cross-coupling of aldehydes was studied.  
O
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Figure 52: Catalyst classes for the asymmetric cross-benzoin reaction.  
Only threonine-derived morpholine-based precatalysts gave good results in terms of chemo- and 
enantioselectivity. For NHC-catalyst 122a (R = Me) and 122c (R = Et) good chemo selectivities 
and reactivities were obtained, indicating the importance of the N-pentafluoro phenyl residue on 
the triazolium unit. Moreover, for catalyst 122c higher enantioselectivity was achieved by installing 
a N-mesyl group such as in catalyst 123b (Figure 53).  
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Figure 53: New possible NHC-precatalyst for the asymmetric cross-benzoin reaction. 
In chapter four, the synthesis of eight new chiral bidentate NHC-phosphine ligands and the 
formation of the corresponding iridium complexes is described in chapter four (Figure 45). The 
influence of each structural unit (N-residue on the triazolium ring, P-residues, size of fused-ring 
system) on the asymmetric hydrogenation of model substrates was investigated. Unfortunately, 
with unfunctionalized olefins only low conversions and low enantioselectivities were achieved for 
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most ligands. Only catalyst 185c, with an N-alkyl group at the triazolium unit showed high reactivity 
towards unfunctionalized alkenes. On the other hand, alkenes with functional groups such as a 
hydroxy or ester group and an imine were suitable substrates for the hydrogenation reaction but 
only low to moderate enantioselectivities were observed. The best rests were obtained with 
catalyst 185e, which gave high conversion and moderate enantioselectivities in the reduction of 
allylic alcohol 199 (>99% conversion, 50% ee) and of imine 201 (>99% conversion, 64% ee). 
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Figure 54: Iridium complexes derived from chiral bidentate NHC-phosphine ligands.  
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